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Abstract
ABSTRACT
Pluripotent human embryonic stem cells (hESCs) are a valuable tool for clinical therapies,
drug testing and investigation of developmental pathways. Recently, over-expression of four
pluripotency-associated genes (OCT4, NANOG, SOX2, and LlN28) has proven sufficient to
reprogram differentiated cells into pluripotent stem cells, potentially alleviating the need for
human embryos to isolate hESCs and opening new avenues for the investigation of
pluripotency.
This project aimed to generate an in vitro model system to study the epigenetic mechanisms
regulating pluripotency transcription factors. hESCs were differentiated into fibroblasts
(hESC-Fib) and subsequently reprogrammed to induced pluripotency stem cells (iPSCs) by
lentiviral over-expression of human OCT4, NANOG, SOX2 and LlN28. iPSC colonies were
positively identified by live staining with the surface marker TRA-1-81 and expanded in
culture. They were then further differentiated into a fibroblast line to allow comparison with
hESC-Fib. All cells in the model system shared the same genotype and were cultured under
similar conditions, enabling unbiased analysis of epigenetic characteristics.
DNA methylation analysis of key pluripotency-genes such as OCT4, SOX2, NANOG, and
REX1 by bisulfite sequencing, revealed that these were hypomethylated in hESCs and
iPSCs, and hypermethylated in their fibroblast derivatives. A gradual increase in the number
of CpGs gaining DNA methylation was observed when hESCs and iPSCs were
differentiated into fibroblasts, while TaqMan real-time PCR and fluorescence staining
revealed that expression of these genes was inversely related to the levels of DNA
methylation in their promoters. The master pluripotency regulators OCT4, SOX2 and
NANOG all showed differential methylation in their OCT/SOX binding regions, suggesting a
common regulatory mechanism between them. This is, to our knowledge, the first report for
SOX2 differential methylation in human non-cancerous cells. Reactivation of REX1 was not
found to be necessary for the reprogramming of hESC-Fib to iPSCs, calling for re-evaluation
of its role in human pluripotency.
Based on the observation that the DNA methylation levels of pluripotency genes were
higher in fibroblast cell lines compared to hESCs and iPSCs, we hypothesised that
reduction in DNA methylation could render differentiated cells more permissive to
reprogramming. Stable knock-downs of the DNA methyltransferases (DNMTs) DNMT1 and
DNMT3A were, thus, performed in hESC-Fib. Knock-down of DNMT1, the most abundant
DNMT in hESC-Fib, resulted in global reduction of DNA methylation levels as determined by
restriction digests with methylation specific enzymes. Reprogramming of hESC-Fib carrying
a DNMT1 knock-down showed a 40% reduction in generation of iPSC colonies compared to
untreated controls, perhaps owing to the delay in progression of S phase in the cell cycle
caused by DNMT1 knock-down. In contrast, knock-down of DNMT3A resulted in a >80%
increase in iPSC colony formation, potentially indicating differences in mechanism of action
and specificity between the two DNMT enzymes.
Through this study, we have gained new insights into the epigenetic mechanisms underlying
cell phenotype and provided the foundation for further improving reprogramming efficiency.
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Abbreviation Description
% Per cent
AP Alkaline phosphatase
ATP Adenosine triphosphate
BLlS Biotin-Ienti clone 15
bp Base pairs
BSA Bovine serum albumin
BSC Biological safety cabinet
ChiP Chromatin immunoprecipitation
COBRA Combined bisulfite restriction analysis
DAPI Di-amino phenyl-indole
DMEM Dublecco's (Modified Eagle's) minimal essential medium
DMR Differentially methylated region
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DNMT DNA methyltransferase
dNTP Deoxyribonucleotide triphosphate
Dn Di-thio-threitol
EB Embryoid body
EDTA Ethylenediaminetetraacetic acid
ESC Embryonic stem cell
FBS Foetal bovine serum
FC Flow cytometry
FGF Fibroblast growth factors
FITC Fluorescein iso-thiocyanate
FSA Fibroblast surface antigen
GFP Green fluorescence protein
HAT Histone acetyltransferase
HDAC Histone de-acetylase
HEK Human embryonic kidney
hESC Human embryonic stem cell
ICM Inner cell mass
ICR Imprinting control region
IMS Industrial methylated spirit
iPSC Induced pluripotency stem cell
IRES Internal ribosome entry side
KD Knock-down
KSR Knock-out serum replacement
LTR Long terminal repeat
MEF Mouse embryonic fibroblast
mESC Mouse embryonic stem cell
miRNA Micro-RNA
mMSc Mouse mesenchymal stem cell
mNSC Mouse neural stem cell
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GENE SYMBOLS
Abbreviation Full name
AFP Alpha-fetoprotein
Bmil B lymphoma Mo-MLV insertion region 1
BMP4 Bone morphogenic protein 4
BRGl Brahma·-related gene 1
CARMl Co-activator associated arginine methyltransferase 1
CD Cluster of differentiation
CDHl Cadherin 1
CDKN1C Cyclin-dependent kinase inhibitor 1C
Chdl Chromodomain helicase DNA-binding protein 1
Coup-tf I & II Chicken ovalbumin upstream promoter transcription factor I & II
DAPKl Death-associated protein kinase 1
Dmapl DNA methyltransferase-associate protein 1
DNMT1, 3A, 3B & 3L DNA methyltransferase 1, 3A, 3B & 3L
DotlL Disruptor of telomeric silencing
Eed Embryonic ectoderm development
EHMTl Euchromatic histone methyltransferase 1
EHOX ESC-paired-like homeobox-containing
ESRl Estrogen receptor1
Esrrb Estrogen-related receptor beta
EzhZ Enhancer of zeste homologue 2
FBX1S F-box containing protein 15
FGF4 Fibroblast growth factor 4
FOXD3 Forkhead box D3
FSA Fibroblast surface antigen
GABRB3 Gamma aminobutyric acid receptor sub-unit beta 3
GATA4, 5& 6 Recognise GAIA motif in gene promoters
GenS General control of amino-acid synthesis protein 5
GCNF Germ cell nuclear factor
GNAS.l XLas Guanine alphas protein 1 complex locus
GTLZ Gene trap locus 2
HDACl Histone de-acetylase 1
hGDF3 Human growth-differentiation factor 3
HICl Hypermethylated in cancer 1
HMGZA High mobility group 2A
HPl Heterochromatin protein 1
HPRT Hypoxanthine-guanine phosphoribosyltransferase
IGFZ Insulin-like growth factor 2
Jmjdla, Ze & 3 Jumonji domain-containing protein la, 2c and 3
KLF4 Kruppel-like factor 4
Kv Voltage-gated potassium channel
LEFTB Left-right determination factor B
LIF Leukaemia inhibitory factor
Lrhl Liver receptor homolog 1
MBP3 Methyl-binding protein 3
MGMT Methyl-guanine DNA methyltransferase
MLL Myeloid/lymphoid leukaemia
Mtal Metastasis-associated 1
MYOG Myogenin
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NANOG From Tir Na Nog (=Iand of the ever young)
NESP55 Neuroendocrine secretory protein 55
OCT4 Octamer 4 (aka POU5F1 for POU class 5 forkhead box 1)
P4HB Prolyl-4-hydroxylase B
PEG1 & 10 Paternally expressed gene 1 & 10
PODXL Podocalyxin-like
PTPN6 Protein tyrosine phosphatase non-receptor type 6
RASSFl Ras association domain-containing protein 1
Rbp2 Retinol binding protein 2 (aka Jarid1a for Jumonji AT-rich interactive domain la)
REXl Reduced expression 1
Ringlb Really interesting new gene (RING)-finger protein
Rxbr Retinoid x receptor beta
Sfl Steroidogenic factor 1 (aka Nr5a1)
SLC22A18 Solute carrier family 22 member 18
SNRPN Small nuclear ribonucleiprotein polypeptide N
SOX2 Sex-determining region Y (SRY)-related high mobility group (HMG) box 2
SSEA Stage-specific embryonic antigen
Suz12 Suppressor of zeste homologue 12
TBN Taube nuss (=deaf nut)
TDGFl Teratocarcinoma-derived growth factor 1 (aka crypto-1)
TERT Telomere reverse transcriptase
TlMP3 Tissue inhibitor of metalloproteinases 3
TP73 Tumour protein 73
UTFl Undifferentiated ESCtranscription factor 1
UTX Ubiquitously transcribed tetraricopeptide repeat, X chromosome
VCAM-l Vascular cell adhesion molecule 1
TGF5 Transforming growth factor
Pax6 Paired box gene 6
GENE NOMENCLATURE
According to current guidelines from the Human Genome Nomenclature Committee
(http://www.gene.ucl.ac.uklnomenclature/). abbreviations for human genes are capitalized
and italicized, while their respective proteins are capitalized but not italicized. Mouse gene
and protein nomenclature follows gUidelines from the current Mouse Genome Nomenclature
Committee (http://www.informatics.jax.org/mgihome/nomen/), based on which gene
abbreviations are written with a capitalized first letter and subsequent lower case letters, all
italicized. Abbreviations for mouse proteins have the same gene symbol but are not
italicized.
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1. INTRODUCTION
1.1 THESIS RATIONALE & OBJECTIVES
Pluripotent human embryonic stem cells (hESCs) were first derived from the inner cell mass
(ICM) of human blastocysts (Thomson et al. 1998). hESCs have the remarkable potential to
self-renew indefinitely and differentiate into the three embryonic germ layers, which can
potentially give rise to all types of cells in the adult body (Reubinoff et al. 2000). More recently,
over-expression of four pluripotency-associated genes (OCT4, SOX2, and KLF4 & e-MYC
or NANOG & LlN28) in differentiated somatic cells was proven sufficient to induce
reprogramming towards pluripotent ESC-like cells (induced-pluripotency stem cells, iPSCs;
Takahashi et al. 2007; Yu et al. 2007b), and has opened new avenues for investigation of
the pluripotent cell state.
The pluripotent state is largely dependent on the actions of transcription factors such as
OCT4, NANOG, SOX2 and KLF4. These genes are considered as "master regulators" that
hold pivotal roles in maintaining pluripotent characteristics, and are at the top of a
transcriptional hierarchy that regulates the expression of over 300 genes in hESCs (Boyer et
al. 2005; Babaie et al. 2007). The activation and silencing of pluripotency-related genes in
undifferentiated and differentiated cell lineages also involves a range of epigenetic
mechanisms that act in concert to maintain local chromatin in an open or closed
conformation (reviewed by Minard et al. 2009).
Limited studies in mouse ESCs (mESCs) have shown that key pluripotency transcription
factors, such as Oet4, can be themselves subject to epigenetic regulation (Azuara et al.
2006; Feldman et a/. 2006). However, the epigenetic factors that determine whether
piuripotency-associated genes are expressed or silenced in differentiated cell types are
almost unknown in human cells. Moreover, the exact epigenetic processes associated with
activating or repressing/silencing the human pluripotent state are poorly understood.
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This thesis aimed to investigate some of the epigenetic mechanisms associated with the
transcriptional activity of key pluripotency genes in hESCs and iPSCs, as well as during
transition of cell phenotype from a pluripotent to a differentiated state and during
reprogramming to iPSCs. Chapter 3 of this thesis created a model cell system where hESCs
were differentiated into a fibroblast cell line, which was subsequently reprogrammed to
iPSCs by lentiviral over-expression of human OCT4, NANOG, SOX2 and LlN28. The iPSCs
were then further differentiated into fibroblasts, so that undifferentiated hESCs and iPSCs,
and derived-fibroblast cells originated from one hESC line, shared the same genotype and
were cultured under similar conditions, to minimise experimental variation that could affect
the analysis of epigenetic gene regulation (Figure 1.1).
Differentiation
hESCs
iPSCs
hESC-Fibroblasts
iPS-Fibroblasts
Differentiation
Figure 1.1- Model system for studying the epigenetic mechanisms of pluripotency in hESCsand iPSCs
Model system of cells having the same genotype, but different phenotypes. This system was generated from
HUES7 hESCsin order to study the epigenetic mechanisms associated with pluripotency maintenance,
differentiation and reprogramming.
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In chapter 4, this model cell system was used to characterise gene and protein expression
profiles of the key pluripotency factors OCT4, NANOG, SOX2, KLF4, LlN28, DNMT3B and
REX1 during differentiation and reprogramming, and in the pluripotent and fibroblast-
differentiated states. The epigenetic mechanisms associated with expression, repression
and re-activation of key pluripotency factors were also investigated, by analysing the DNA
methylation profiles and histone modifications associated with regulatory regions of each
gene.
Through the generation of hESC and hESC-derived fibroblast lines carrying shRNA-
mediated knock-down of the DNA methyltransferases DNMT1 and DNMT3A, chapter 5 of
this thesis aimed to investigate the effects of epigenetic manipulation on cell phenotype, cell
cycle progression, DNA methylation of imprinted and tumour suppressor genes, and finally,
test the hypothesis that knock-down of DNA methyltransferases in hESC-derived fibroblasts
would enable faster or more efficient re-activation of pluripotency factors during iPSC
generation.
The remaining introduction to this thesis will be concerned with the known culture
techniques and characteristics of cell-types comprising the model cell system described in
Figure 1.1, as well as with the transcription-factor and epigenetic networks associated with
the pluripotent and differentiated cell phenotypes.
1.2 HUMAN EMBRYONIC STEM CELLS
1.2.1 Origins and derivation of hESCs
Pluripotent hESCs were first isolated via immunosurgical procedures from the ICM of pre-
implantation embryos, at the blastocyst stage (Thomson et al. 1998). hESCs have the
capacity to remain in an undifferentiated state and self-renew indefinitely or, in the presence
of appropriate stimulating factors, differentiate into cell types derived from endoderm,
mesoderm and ectoderm (Reubinoff et al. 2000). This potential, known as pluripotency,
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makes hESCs a powerful tool for regenerative medicine, drug screening and investigation of
early human developmental pathways (Odorico et al. 2001; Smith 2001; Anke et al. 2006;
Cervera and Stojkovic 2007).
It is estimated that, since 1998, over 400 hESC lines have been generated, mostly from
embryos derived from in vitro fertilized oocytes, using whole blastocysts, isolated ICM,
morula stage or developmentally arrested embryos (reviewed by Brimble et al. 2004; Zhang
et al. 2006). Blastomere biopsy technologies also enabled hESC isolation from a single
blastomere (Klimanskaya et al. 2006). While most laboratories fail to detail the number or
quality of oocytes/embryos needed to generate a hESC line, Cowan et al. (2004) reported
that 286 cleaved embryos (6 to 12 cell stage) and 58 blastocysts were used to derive 17
new hESC lines, demonstrating a 5% success rate in the derivation process.
1.2.2 Characterisation of hESCs
In order to standardise the characterisation of independently derived hESCs lines, a set of
minimum criteria have been proposed (reviewed by Hoffman and Carpenter 2005) which
include the expression of hESC-specific surface markers and transcription factors. The
proposed minimum criteria of what defines a hESC line are outlined below:
* Expression of factors associated with the pluripotent state (e.g. OCT4, NANOG)
* Expression of surface markers associated with the pluripotent state (e.g. TRA-1-
81ITRA-1-60, SSEA4/SSEA3)
* Karyotype stability over extended undifferentiated culture
* Functional telomerase expression
* Ability to differentiate into lineages from all three embryonic germ layers, either by
teratoma formation after injection into immunodeficient mice or by in vitro
differentiation via embryoid body formation (see sections 1.2.4 and 3.1.2).
- 4
PhD~Tkhe=s~is--------------------------------------------S~C~h-OO~I-Of~C~I~in~ic-a~IS~c~ie-n-ce-s
ElenaMatsa The University of Nottingham
Chapter 1- Introduction
Even though fulfilment of these criteria is important for determining whether hESCs possess
self-renewal and differentiation capacities, some hESC lines lack extensive characterisation,
especially in terms of teratoma formation, telomerase activity and karyotype stability (Chung
et al. 2008). This problem is being addressed by the International Stem Cell Initiative (ISCI)
which has launched an extensive study comparing 59 hESC lines, in order to further define
hESC characteristics (Adewumi et al. 2007).
1.2.3 In vitro culture of human hESCs
1.2.3.1 Feeder cells
hESCs were originally cultured on mouse embryonic fibroblast (MEF) feeders, in medium
containing 20% foetal bovine serum (FBS), and passaged by manual dissection (Thomson
et al. 1998). This method remains widely used to date and allows undifferentiated culture of
hESCs, as assessed by morphology and phenotype (Reubinoff et al. 2000; Heins et al.
2004). The colony-like growth of hESCs on MEFs offers the advantage of positively-
selecting undifferentiated colonies to expand by manual dissection at each passage (Bigdeli
et al. 2008). However, this culture method is particularly laborious, requiring specialised
skills and time (Bigdeli et al. 2008). Automated dissection of hESC colonies, achieved using
Laser Microdissection and Pressure Catapulting (LMPC; Terstegge et al. 2009), has
alleviated some of the manual labour requirements, but still involves the use of specialised
equipment and is considered to be a subjective process since only a few colonies are
propagated at each passage, based only on their morphological characteristics. Propagating
whole populations of hESCs to the next passage has been achieved via enzymatic
dissociation of hESC colonies (e.g. using collagenase IV, trypsin or dispase), which however
yields variable-sized colonies and leads to increased karyotype instability (reviewed by
Grandela and Wolvetang 2007; Heng et al. 2007).
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Moreover, the use of animal feeder cells (Le. MEFs) for hESC culture increases the risk of
infection by retroviruses or other animal pathogens (Amit et al. 2004; Martin et al. 2005).
Immunogenic epitopes such as N-glycolylneuraminic acid non-human sialic acid can be
transferred from MEFs or FBS to hESCs, increasing the possibility of an immune reaction
upon potential hESC transplantation to humans, and hindering reliable and reproducible
hESC research (Skottman and Hovatta 2006). Human fibroblast cells, derived from foreskin,
placenta, adult marrow stroma and hESCs have been used as feeders for hESCs to replace
animal feeders (Richards et al. 2002; Richards et al. 2003; Xu et al. 2004; Genbacev et al.
2005; Inzunza et al. 2005; Skottman et al. 2006). Despite their human origin, human feeder
cells are still often cultured in FBS-containing media prior to their use in hESC culture and
therefore carry a slight risk for hESC xeno-infection.
1.2.3.2 Culture media
Culture of hESCs in 20% FBS is subject to inconsistencies due to batch-to-batch variations
in commercially available FBS (reviewed in Skottman and Hovatta 2006). This contributed
towards the use of defined serum replacement (KnockOut Serum Replacement, KSR:
Invitrogen; Richards et al. 2002; Koivisto et al. 2004) which could sustain undifferentiated
culture of hESCs when supplemented with 4ng/ml of the paracrine signalling molecule,
basic-FGF (bFGF or FGF2; Amit et al. 2000; Inzunza et al. 2005). However, KSR still
contained some products of animal origin, such as AlbuMAX (lipid enriched bovine serum
albumin; Unger et al. 2008). Treatment with bFGF and Activin A, Nodal, or Noggin,
(members of the TGF-13 signalling pathway) was able to support undifferentiated in vitro
culture of hESCs in serum-free and feeder-free conditions (Vallier et al. 2005; Xu et a/.
2005), through inactivation of SMAD1 and 5, which are responsible for hESCs differentiation
towards mesoderm, stabilisation of NANOG expression and inhibition of apoptosis (James
et al. 2005; li et a/. 2007b; Vallier et al. 2009a). These observations formed the foundation
of formulating chemically-defined media that could sustain and potentially-standardize hESC
PhD Thesis
Elena Matsa
6
School of Clinical Sciences
The University of Nottingham
Chapter 1- Introduction
cultures. Examples of chemically defined media include; mTeSR™1 Maintenance Medium
from StemCell Technologies and STEMPRO® ESCs culture medium from Invitrogen
(Ludwig et al. 2006a; Ludwig et al. 2006b; Wang et al. 2007; Swistowski et al. 2009).
However, chemically-defined, commercially available media are very costly, a feature that
can limit their use for everyday research. Also, they rely on the use of artificial Matrigel™
surfaces (see section 1.2.3.3) which are derived from animal sources (Kleinman and Martin
2005).
1.2.3.3 Feeder-freeculture surfaces
In order to alleviate the need for feeder cells, hESCs have been cultured on natural or
artificial matrices that are synthesised by extra-cellular matrix components (e.g. Matrigel™
and human laminin). Matrigel™ is the most commonly used surface for feeder-free hESC
culture. It supports the growth of numerous hESC lines passaged either by trypsin, dispase
or collagenase IV enzymes, and cultured either in MEF-conditioned medium with KSR and
bFGF, or in defined media (Xu et al. 2001; Ludwig et al. 2006b; Braam et al. 2008a).
However, Matrigel™ is expensive and has limited shelf-life. Cheaper, more stable, easy-to-
handle and defined surfaces for hESC culture have been developed recently, and include
oxygen plasma etched tissue culture polystyrene (PE-TCPS) or thermo-responsive co-
polymer coated surfaces (Loh et al. 2009; Mahlstedt et al. 2010). Nevertheless, these
surfaces could only support hESC culture in MEF-conditioned medium with KSR and bFGF,
and failed to support undifferentiated culture in defined media. Also, defined surfaces are
still not commercially available (Loh et al. 2009; Mahlstedt et al. 2010).
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1.2.4 In vitro differentiation of hESCs
1.2.4.1 Differentiation via embryoid body formation
hESCs can differentiate in vitro into cell types representative of the three embryonic germ
layers via formation of three-dimensional 3D aggregates, known as embryoid bodies (EBs;
reviewed by Andres et al. 2009).
One method by which EBs can be generated is the manual dissection or enzymatic
treatment of hESC colonies with collagenase IV, trypsin or dispase, followed by suspension
culture in non-adhesive surfaces, using 15-20% FBS (Itskovitz-Eldor et al. 2000; Kehat et al.
2001). However, suspension cultures generate EBs with significant size variation (3 to 1000
cells) due to variable size and dissociation of starting hESC colonies, thus introducing
considerable inconsistency to differentiation towards desired lineages (Kehat et al. 2001; Ng
et al. 2005b; Pal and Khanna 2007). Moreover, contaminating MEFs have the potential to
interfere with the differentiation process by competing for cell-cell interactions as well as
insulating communication between hESCs (Weitzer 2006).
Other methods, such as the formation of hanging drops with a defined numbers of cells,
allow more uniform formation of EBs, but are not amenable to scale-up and have been more
successful in mESCs than hESCs (Reubinoff et al. 2000; Baharvand et al. 2006; Burridge et
al. 2007). Large-scale production of EBs has been achieved via the use of spinner flasks
and bioreactors (Schroeder et al. 2005), but often results in agglomeration of EBs (Cameron
et al. 2006). Forced aggregation of a defined number of hESCs by centrifugation in ultralow-
attachment U96-well plates or silicon etched 384-well plates enables formation of EBs with
a controllable size (Ng et al. 2005a; Ungrin et al. 2008), but is excessively costly. Forced
aggregation in untreated V-96 plates (Burridge et al. 2007) is a cost effective method for the
generation of EBs with uniform and controllable size, following simple and reproducible
procedures (Burridge et al. 2007).
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1.2.4.2 Differentiation via non-embryoid body methods
hESCs can also be induced to differentiate in monolayer cultures with defined growth
factors added to the medium or by co-culture with differentiated cell types of a relevant
lineage (reviewed by Andres et al. 2009). For example, treatment of monolayer hESC
cultures with Activin A and BMP4, or co-culture with END-2 mouse visceral endoderm cells
have been shown to induce differentiation and facilitate formation of cardiomyotes
(Mummery et al. 2003; Yao et al. 2006). Equally, co-culture with mouse foetal liver-derived
stromal cells facilitated differentiation towards haematopoietic lineages (Ma et al. 2007).
Even though monolayer differentiation uniformly exposes cells to components of the culture
medium, it is believed that differentiation towards some lineages might require the cell-cell
or cell to extra-cellular matrix interactions that are provided by the formation of 3D EB
aggregates (Andres et al. 2009).
1.2.4.3 Small molecules and paracrine factors affecting hESCdifferentiation
Small soluble molecules such as 5-aza-2'-deoxycytidine and ascorbic acid have been
shown to influence differentiation of hESCs towards cardiomyocytes or haematopoietic
lineages (Passier et al. 2005; Yoon et al. 2006; Ma et al. 2007). Moreover, Activin A in
combination to Wnt3a signalling have been associated with differentiation of hESCs towards
hepatic lineages (Hay et al. 2008; Sadhana et al. 2008), while Activin A and BMP4 can
promote formation of cardiac lineages (Laflamme et al. 2007). An elaborate study by Vallier
et al. (2009c) has determined that BMP4 signalling induces hESCs to differentiate towards
primitive endoderm and trophectoderm, BMP4 in combination to Activin and bFGF induce
mesoderm differentiation, and finally inhibition of Activin/nodal signalling leads to the
formation of neuroectoderm.
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1.2.4.4 Culture system used in this thesis
Since hESCs cultured for this thesis were used only for research purposes, refraining from
animal products was of a lesser significance. Therefore, chemically defined medium was not
used, to reduce the cost of experimentation. In this thesis, hESCs were cultured on
Matrigel™-coated plastic surfaces, using KSR and bFGF-containing medium that had been
conditioned on MEF feeders. Cells were passaged enzymatically using trypsin. This culture
system has been shown to sustain a stable karyotype in hESCs following prolonged
passaging (Denning et al. 2006) and also provided several advantages for the work carried
out in this thesis; 1) it permitted the use of defined numbers of hESCs for forced
aggregation, which was the selected differentiation system used in this thesis as it enabled
standardisation of differentiation procedures (Burridge et al. 2007) and direct comparison
between fibroblast cells derived from hESCs and iPSCs (see section 3.1.1). This culture
system also enabled precise cell counts for 2) the formation of growth curves and 3) for
efficient genetic modification by shRNA-mediated gene knock-down experiments performed
in chapter 5 (Braam et al. 2008a).
1.3 TRANSCRIPTION FACTOR NETWORKS ASSOCIATED WITH PLURIPOTENCY
The pluripotent phenotype of hESCs is sustained by a complex network of transcription
factors (TFs; Boyer et al. 2005), that can act either to repress differentiation-specific genes
or stimulate factors which actively maintain pluripotency. This section will discuss the
mechanisms of TF-regulation over gene expression and pluripotency maintenance.
1.3.1 Regulation of gene expression by transcription factors
Initiation of transcriptional activity in eukaryotic genes is dependent on the accessibility of
regulatory regions in gene promoters to the RNA Polymerase II (Pol II) transcriptional
machinery (Ptashne and Gann 1997). Regulatory regions in gene promoters fall within three
categories; the core promoter, the proximal enhancer and the distal enhancer (Figure 1.2).
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Elements of the core promoter sequence attract binding of transcriptional pre-initiation
complexes (PIC) and general transcription factors (GTFs, e.g. TATA binding proteins TFIIA.
B, D), whereas the proximal and distal enhancers attract "activator" or repressor" TFs.
Transcriptional "activator" or "repressor" TFs affect gene expression either by direct
interaction with components of the core promoter or with co-regulators (also known as
transcription-associated factors, TAFs) which in turn interact directly with Pol II, GTFs or
nucleosome remodelling and histone modifying enzymes (section 1.5.1) that can change the
chromatin compaction of the promoter and improve the accessibility of Pol II to the core
promoters (reviewed by Fuda et al. 2009). Transcriptional enhancer elements can be
located upstream or downstream the transcription start site (TSS) and can modulate gene
expression independently of their orientation (Vise I et al. 2009).
Activator or repressor TF-proteins contain conserved DNA binding motifs (e.g. forkhead,
OCT/SOX, zing-finger, helix-loop-helix, and POU motifs) that enable association with
promoter regulatory regions based on compatibility to the DNA sequence (Reid et al. 2010).
Transcription factors are stimulated to bind DNA based on developmental or environmental
signalling, transmitted by hormones or morphogenic molecules (e.g. thyroxin, retinoic acid;
reviewed by Cosma 2002).
Co-regulator
___.--t---....~
Distal enhancer Proximal
enhancer -37 -31 -26 -2 +4+18 +28 +32
BRE iTATAi ilnd iMTEi DPE I
Core promoter
Figure 1.2- Transcription regulatory interactions
General transcription factors (GTFs, light blue) bind to specific sequences in gene promoters (B recognition
element (BRE), TATA box (TATA), initiator (Inr), motif ten element (MTE) or downstream promoter element
(DPE)), located within close proximity to the transcription start site (TSS, black arrow). Activator or repressor
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transcription factors (orange and yellow) bind the proximal and distal enhancers, and can interact with GTFs
(green arrows), TATAbinding protein (TBP,dark blue) or RNApolymerase II (Pol II, red) to enhance or repress
gene transcription. Activator or repressor transcription factors also interact with co-regulators which in turn
either interact with the general transcription machinery or chromatin-modifying factors (blue arrows; Fudaet
01.2009)
1.3.2 Master regulators of pluripotency
The establishment and maintenance of pluripotency in mouse and human ESCs is regulated
by a complex network of transcription factors, in which over 300 different genes are involved
(Boyer et al. 2005; Orkin 2005; Kim et al. 2008a). In this network, the transcription factors
OCT4 (also known as POU5F1), NANOG and SOX2 stand out for the significance of their
contribution to pluripotency establishment and maintenance, and are considered to be
master regulators at the top of the pluripotency network (Boyer et al. 2006; Wang et al.
2006; Babaie et al. 2007; Masui et al. 2007). Chromatin immuno-precipitation studies have
revealed that OCT4, SOX2, and NANOG TFs occupy hundreds of gene promoters in mouse
and human ESCs (Boyer et al. 2005; Chen et al. 2008b) and mostly bind within ±2kb of the
TSS in mESCs (Liu et al. 2008b). In some cases, these TFs co-localise on promoter
regions, suggesting that they might act in protein complexes to regulate gene expression
(Kim et al. 2008a). Binding of Oct4, Sox2 and Nanog TFs is enriched in genes involved in
developmental processes (Kim et al. 2008a). RNA interference (RNAi, see section 5.1.2)
studies have shown that these master pluripotency-regulating TFs can contribute to
suppressing the expression of differentiation genes, such as MyoO, GA TA6 and TGF5, as
well as promoting the expression of pluripotency-associated genes, such as Fbx15, R£X1,
LEFTB and TOGF1 (Ivanova et al. 2006; Babaie et al. 2007). Moreover, OCT4, SOX2 and
NANOG have been shown to function collaboratively to regulate each other's expression,
and can also regulate their own expression by auto regulatory feedback loops (OkumUra-
Nakanishi et al. 2005; Rodda et al. 2005; Chen and Zhong 2008).
Another factor that is considered to be at the top of the ESC transcriptional hierarchy, at
least in mESCs, is Klf4 (Li et al. 2005; Jiang et al. 2008). Klf4 also exhibits auto regulatorY
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abilities, making this a common feature between key ESC genes (Figure 1.3). Klf4 co-
occupies numerous gene promoters in mESCs, together with Oct4, Nanog and Sox2 (Loh et
al. 2006; Chen and Zhong 2008), but shares the majority of its targets with Nanog (Loh et el.
2006; Jiang et al. 2008) and acts as an enhancer of Oct4 and Sox2 in the regulation of
developmental processes (Liu et al. 2008b).
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Figure 1.3- Transcriptional regulatory circuit between master pluripotency regulators
Transcription factors at the top of mouse and human ESCtranscriptional hierarchy (OCT4, NANOG, SOX2 and
KLF4) exhibit auto-regulatory abilities, unlike downstream regulators of pluripotency, such as REX1. Arrows
point to the factor being transcriptionally regulated (modified from Chen and Zhong 2008).
1.3.3 Expression and roles of master pluripotency regulators in
determining cell phenotype
1.3.3.1 OCT4
OCT4 is expressed in mouse and human totipotent and pluripotent cells in ,the ICM, ESCs
and embryonic carcinoma cells (ECs; reviewed by Koestenbauer et al. 2006). Deletion of
Oct4 in mouse embryos has been shown to prevent normal formation of the ICM (NichOlS et
al. 1998), while its knock-down in mESCs leads to trophectoderm differentiation through up-
regulation of Cdx2 (Niwa et al. 2000; Niwa et al. 2005). Oct4 over-expression in mESCs
results in differentiation towards primitive endoderm and mesoderm (Niwa et al. 2000). In
hESCs, OCT4 down-regulation was shown to promote differentiation towards endoderm and
mesoderm lineages, while its up-regulation resulted in differentiation towards endoderm
(Rodriguez et al. 2007).
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1.3.3.2 NANOG
NANOG is expressed in mouse and human ICM, ESCs and ECs, while in the mouse,
expression is also detected in morula-stage embryos (reviewed by Koestenbauer et al.
2006). Loss of Nanog is lethal in mouse embryos at the blastocyst stage (Mitsui et al. 2003),
and its down-regulation in mouse and human ESCs results in loss of pluripotency and
induction of endoderm, trophectoderm, mesoderm and neural crest cell marker expression
(Hyslop et al. 2005; Ivanova et al. 2006). Over-expression of Nanog in mESCs has been
shown to enable the maintenance of pluripotency even in the absence of extrinsic LlF
treatment that is usually necessary to sustain mESC cultures (Mitsui et al. 2003). In hESCS,
NANOG over-expression enables feeder-free growth in unconditioned medium (Darr et al.
2006).
1.3.3.3 SOX2
SOX2 is expressed in the mouse and human morula, ICM, ESCs and ECs (reviewed by
Koestenbauer et al. 2006). This TF is also expressed in the neural plate during
embryogenesis (Zappone et al. 2000; Miyagi et al. 2004) and in neural stem cells in the
adult organism, albeit from an alternative regulatory region (Miyagi et al. 2006). Despite its
somewhat widespread expression and role in neurogenesis (Graham et al. 2003; Ferri et al.
2004) SOX2 plays a major role in pluripotency maintenance; its deletion is lethal for mouse
embryos which do not develop an epiblast, while knock-down in mouse and human ESCS
leads to loss of self-renewal capacity and differentiation towards trophectoderm (Avilion et
al. 2003; Ivanova et al. 2006; Li et al. 2007a; Fong et al. 2008).
1.3.3.4 KLF4
KLF4 expression has a more widespread tissue distribution as it has been detected in the
gut, epithelial cells, keratinocytes as well as mouse and human ESCs (Garrett-Sinha et al.
1996; Shields et al. 1996; Aasen et al. 2008). Klf4 has a major role in chromatin remodelling
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and interacts with Klf2 and Klf5 to maintain mESC identity by supporting their self-renewal
capacity (Li et al. 2005). Klf4 also co-operates with Oct4 and Sox2 to induce activation of
Lefty1, which in turn promotes Oct4 and Sox2 expression (Nakatake et al. 2006). Klf4
depletion in mESCs leads to differentiation and up-regulation of lineage commitment genes
such as Brachyury (T) and Cdx2 (Jiang et al. 2008).
1.3.4 Downstream regulators of pluripotency
Despite the hierarchical significance of OCT4, NANOG, SOX2 and KLF4 TFs in the
establishment and maintenance of pluripotency, other factors such as LlN28, DNMT3B and
REX1 have been implicated in the transcriptional network of mouse and human ESCs
(Adewumi et al. 2007; Kim et al. 2008a). These factors, often referred to as "downstream
regulators" of pluripotency, are among the most highly expressed transcripts in ESCs, and
are expressed at almost undetectable levels in differentiated cell types (Richards et al.
2004; Enver et al. 2005; Adewumi et al. 2007; Viswanathan et al. 2008). Some down-steam
regulators of pluripotency, such as Rex1, assist in the maintenance of pluripotency bY
suppressing lineage commitment genes (e.g. Pax6; Darr and Benvenisty 2009; Scotland et
al. 2009), while others, such as TDGF1 can actively maintain pluripotency by promoting self-
renewal (Babaie et al. 2007; Xu et al. 2009a; Table 1.1).
1.4 MICRO RNAs AND THEIR ROLE IN PLURIPOTENCY AND DIFFERENTIATIOlf
Micro-RNAs (miRNAs) are non-coding 21-nucleotide RNA molecules capable of binding to
and causing the degradation of endogenous mRNAs via the RNAi pathway (see section
5.1.2; Valencia-Sanchez et al. 2006; Kim et al. 2009d). miRNAs of the miR-290, miR-302
and miR-17-95 families have been detected at elevated levels in mESCs and are believed
to promote rapid proliferation and maintenance of self-renewal (Wang et al. 2008b). other
miRNAs have been implicated in differentiation (reviewed in Bosnali et al. 2009), including
miRNAs of the let-7 family, which are suppressed in ESCs by the pluripotency factor LlN28
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(Newman et a/. 2008). Let-7 miRNAs are up-regulated upon differentiation, repressing cell-
cycle regulators, such as CQC25A and CDK6 (Johnson et al. 2007), and growth promoting
factors, such as RAS, HMG2A and c-MYC (Johnson et al. 2005). Moreover, miRNA-145
represses the 3' untranslated region (UTR) of OCT4, SOX2 and KLF4, leading to
translational inhibition of these genes and to differentiation (Xu et al. 2009c).
Table 1.1- Roles of downstream pluripotency TFs in the maintenance of self-renewal and differentiation
ESCs=embryonic stem cells, ECs=embryonic carcinoma cells, EGs= embryonic germ cells, ICM= Inner cell mass
Gene Expression Function References
Stimulates production of histone H2a mRNA involved Yu et al. 2007a;
in co-ordinating ESCproliferation, stimulates post- Newman et al. 2008;LlN28 ESCs,ECs transcriptional OCT4 expression, blocks processing of Darr and Benvenisty
2009; Qiu et al. 2009;
let-7 miRNAs which promote differentiation Xu and Huang 2009
-
Regulated by Nanog and Sox2. Dispensable for self- Thompson and Gudas
REXl ESCs,ECs, EGs renewal in ESCs,prevents differentiation to 2002; Shi et al. 2006;
endoderm Scotland et al. 2009
DNMT38 ICM, ESCs,ECs
Dispensable for self-renewal in ESCs,necessary for Jackson et al. 2004;
differentiation and silencing of Oct4 & Nanog Tsumura et al. 2006
C-MYC ESCs,ECs Promotes self renewal in ESCs Cartwright et al. 2005
c
Highly expressed in ESCs& ECs, regulated by c-Myc, Armstrong et al.ro
TERT E ESCs,ECs 2000; Armstrong et
::J supports self-renewal
s: 01.2005
'0 Regulated by Oct4, co-receptor of Nodal, stimulates
TDGFl
c
ro ESCs,ECs
self-renewal in ESCs Babaie et al. 2007Q)
V)
::J Blastocyst, Regulated by Oct4 and Sox2, delays or blocks Okuda et al. 1998;UTFl 0E ESCs,ECs, EGs differentiation Nishimoto et al. 2005
FOXD3 Blastocyst, Interacts with Oct4, necessary for generation of Hanna et al. 2002;
f- ESCs,ECs pluripotent cell populations in embryos Laslett et al. 2003
T8N ICM, ESCs,ECs, Essential for survival of ICM cells in mouse Voss et al. 2000
F8X15 ICM, ESCs,ECs
Interacts with Oct4 and Sox2. Dispensable for self-
Tokuzawa et al. 2003
renewal in ESCs
hGDF3 ESCs,ECs High expression levels in ESCs& ECs Adewumi et al. 2007
Prevents differentiation to haematopoietic,
EHOX ESCs endothelial and cardiac markers upon differentiation Jackson et al. 2002
I--- in ESCs
I----GA8R83 ESCs,ECs High expression levels in ESCs& ECs Adewumi et al. 2007
LEFT8 hESCs Regulated by Oct4, high expression levels in ESCs Babaie et al. 2007;Sun et al. 2007
Esrrb Interacts with Oct4 and Nanog, promotes Zhang et al. 2008
establishment of self-renewal and pluripotency
mESCs Supports self-renewal & inhibits differentiation upon
Ronin LlF removal in mESCs, through epigenetic silencing of Dejosez et al. 2008
'----
lineage commitment factors
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1.5 EPIGENETIC CONTROL OF GENE EXPRESSION
Complex organisms, such as humans, contain a variety of cell-types that are all derived
from a single genome (Holliday 1994; Lynch 2004). Divergent cell phenotypes are
determined by expression of unique sets of genes in each cell-type, a trait that is to some
extent dependent on a range of heritable covalent modifications of the DNA and associated
histone proteins, known as epigenetic modifications (Hemberger et al. 2009; Ho and
Crabtree 2010; Law and Jacobsen 2010). Epigenetic modifications can affect the
expression of individual genes by altering chromatin architecture, and thus changing the
accessibility of Pol II to gene promoters (reviewed by Cairns 2009).
1.5.1 Chromatin remodelling and histone modifications
1.5.1.1 Chromatin organisation
In order to fit within a nucleus, eukaryotic genomic DNA is compacted more than 10,000
times by histone proteins (Figure 1.4.A). 147bp of super helical DNA are wrapped around a
histone octamer, composed of two H2A-H2B dimers and two molecules of each H3 and H4,
to form a nucleosome (Luger 2003). The point at which DNA enters and exits a nucleosome
is occupied by "linker" H1 molecules. Nucleosomes line up to form 11nm fibres, which are
further compacted into 30nm fibres that give rise to the highly ordered structure known as
chromatin (Sparmann and van Lohuizen 2006).
Chromatin condensation varies at different areas of the genome, in a manner that is related
to gene activity; actively transcribed genes are usually located within chromatin with an
open conformation, known as euchromatin, whereas silenced genes are found within
densely compacted chromatin, known as heterochromatin (Gilbert et a/. 2004). Repetitive
sequences, such as centromeres and telomeres, are permanently associated with
heterochromatic regions (constitutive heterochromatin) whereas developmentally regulated
genes become associated with heterochromatin depending on cell type or stage of the cell
cycle (facultative heterochromatin; Woodcock and Dimitrov 2001). Heterochromatic regions
17
PhD Thesis
Elena Matsa
School a/Clinical Sciences
The University of Nottingham
Chapter 1- Introduction
tend to assemble at the nuclear lamina (Figure 1.4.8), while transcriptionally active
euchromatic regions are clustered towards the interior of the nucleus and interact via
chromosome loops (cis) or bridges (trans; Lanctot et al. 2007a; Guelen et al. 2008). This 3D
chromatin topography forms "transcriptional factories", which regulate gene expression by
facilitating interactions between distal regulatory elements and target genes (reviewed by
Gondor and Ohlsson 2009).
A Chromosome B f'-
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Figure 1.4- Chromatin organisation and regulation of gene expression
A. Genetic information within eukaryotic nuclei is assembled into chromosomes, in which the DNA double
helix is wrapped around nucleosomes forming a "beads on string" structure that is subsequently folded into
higher order chromatin (Sparmann and van Lohuizen 2006). B. Radial organisation of chromosome territories
(eT) within nuclei that facilitates chromatin cross-talk. The relative positions of chromosomes in the
interphase nucleus depend on the proportion of genes and A+T content (Gondor and Ohlsson 2009). C.
Histone proteins within the nucleosome have long, flexible amino-terminal domains (tails) in which a number
of amino-acids are targets of covalent modification, such as acetylation (Ac), methylation (Me),
phosphorylation (P), and ubiquitilation (Ub). Histone modifications affect the dynamic chromatin structure
and are associatedwith alterations in gene transcriptional activity (Sparmann and van Lohuizen 2006).
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1.5.1.2 Chromatin remodelling
Chromatin remodelling enzymes facilitate nucleosome re-positioning or ejection in order to
"cover" or uncover" regulatory elements located in gene promoters (Cairns 2005). Such
chromatin remodelling enzymes include the ATP-dependent SWI/SNF complex (usually
associated with gene activation) and the ISWI complex (associated with gene silencing),
which catalyse nucleosome disassembly or sliding along the DNA (Fazzio and Tsukiyama
2003). Also, incorporation of different histone isoforms into the nucleosome affects the
covalent attraction between DNA and histone proteins, leading to altered nucleosome
compaction and, therefore, accessibility to the transcriptional machinery (reviewed by Cairns
2009). Constitutive heterochromatin, facultative heterochromatin and euchromatin
preferentially associate with the histone 3 variants H3.1, H3.2 or H3.3, respectively (Hake
and Allis 2006). Moreover, the histone 2A variant H2A.Z is enriched in euchromatic regions
(Zhang et al. 2005), whereas Macro-H2A is often found in the inactive X chromosome and is
thought to promote gene silencing by inhibition of TF binding and chromatin remodelling
(Changolkar and Pehrson 2006; Buschbeck and Di Croce 2010).
1.5.1.3 Histone modifications
The protruding termini of histone proteins, and especially the amino termini of H3 and H4
and the amino and carboxy termini of H2A, H2B and H1 histones, are susceptible to a
number of covalent modifications such as methylation, acetylation, phosphorylation,
ubiquitilation, sumoylation, glycosylation, and biotinilation (reviewed in Kouzarides 2007;
Table 1.2). Histone modifications have important roles in the regulation of gene activation or
repression by maintaining the dynamic equilibrium of chromatin structure (Li 2002;
Margueron et al. 2005; Turek-Plewa and Jagodzinski 2005). For example, lack of
acetylation on histone 4 lysine 16 (H4K16Ac) attracts binding of the ISWI complex to gene
promoters, which in turn facilitates gene silencing (Corona et al. 2002). Also, histone 3
lysine 9 methylation (H3K9me), catalyzed by G9a methyltransferase (Tachibana et al. 2001)
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is believed to be important in the recruitment of heterochromatin protein 1 (HP1), which
compacts chromatin structure and establishes long term transcriptional repression (Boulias
and Talianidis 2004). Histone acetylation is typically associated with active transcription and
open chromatin architecture (Kurdistani and Grunstein 2003; Margueron et al. 2005; Table
1.2; Figure 1.4.C), whereas histone methylation has a more diverse effect on transcriptional
activity. For example, H3K9 methylation is associated with repressed gene activity (tri-
methylation of this residue found in heterochromatic regions and di- & mono- methylation
found in silent euchromatic regions), whereas H3K4 methylation is exclusively associated
with transcriptionally active genes (reviewed by Martin and Zhang 2005; Shilatifard 2008).
Ubiquitilation can be associated with transcriptional activation or repression, dependent on
its- interaction with other histone modifications. This is exemplified by co-operation of
H3K9me, H3K27me and H2AK199 ubiquitilation (H2AK199Ub) in silencing of the inactive X-
chromosome (Senner and Brockdorff 2009), in contrast to H2BK120Ub which interacts with
transcriptional activators, and H3K4me and H3K79me, to promote early steps of
transcriptional initiation (Weake and Workman 2008).
Table 1.2- Classes of histone modifications and examples of enzymes catalysing each modification
Red:: repressive mark, associated with gene silencing, green= activating mark, associated with gene
expression. List not exhaustive (modified from Berger 2007; Kouzarides 2007).
Modification Histone Amino-acid Enzyme Function
H2A KS
"iii
H2B K12,K1S ~ CBPjP300
:J:
K4,K18 -III
K9,K14, K18 QJ PCAFjGCNSIII
III
H3 K14 ~ TlP60QJ
-K14,K23 III ScSAS3e
Acetylation III Transcription,KS6 ~ ScRTT109....I DNA repair,
KS, K12 >- HATl....
replication,QJ
KS,K8 u CBPjP300III
condensationQJ PCAFjGCNS-H4 KS, K8,K12, K16 c::
0
KS,K8,K12 .... HBOlIII
K16 :I: ScSAS3:--------
H4 K16 SirT2
De-acetylation
K
Histone de-acetylases (HDAC)
-
class I, II and III
-
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Trithorax (Trx) group proteins;
K4 Mlll, Mll2, Mll3, Mll4, Mll5,
III SEllA, SEllB, ASHl, Sc/Sp SEll
.
Q.I
III Suv39H1, Suv39H2, G9a,111
"-
ESET/SETDB1, Riz1, EuHTMase/GlP,K9 Q.I
-
III
I: Cll8, SpClr4 Transcription,111
"- Pr-SET 7/8, SUV4 20H1, SUV420H2, DNA repairH3 ..
Methylation K20 >-
.r:. SpSet9..
Q.I
Polyeomb group (PeG) proteins;
K27 EQ.I EZH2, SUZ12, EEDI:
K36 0 SET2, NSD1, SYMD2..
• !!!
K79 :I: DOll, Sc/Sp DOll
R2, R17, R26 CARMl
H4 R3 PRMT4, PRMT5
Transcription
K4 lSD1, Rbp2
III JMJD1A, JHDM2a, JHDM2b,Q.I
-
III .....
K9 Q.I 111
~ I:
JMJD2A/JMJDM3A, JMJD2B,1:-
De-methylation o > JMJD2C/GASC1, JMJD2DH3 .. .r:. := ·ro Transcription
.!!! ~ .C' E
JHDM1a, JHDM1b,:I: E o 0
K36
Q.I E"tl JMJD2A/JMJDM3A,0 ::J
.....
JMJD2C/GASC1
H2B 514 MSll Transcription,
Phosphorylation
T3 Haspin DNA repair,
H3
528 MSK1, MSK2 chromosome
H4 51 CKII condensation
Ubiquitilation H2A
K119 Bmi/Ring1A Transcription,
H2B K120 RNF20/RNF40 DNA repair
Sumoylation
H2A K126
K6, K7
UBC9 Transcription
H2B
1.5.1.4 Regulation of pluripotency and differentiation by chromatin remodelling
Regulation of the pluripotent cell phenotype by chromatin remodelling and histone
modifications has mostly been studied in mESCs, whereas information from hESCs is
scarce. mESCs are actively dividing cells, with a uniquely high transcriptional activity (Efroni
et al. 2008) that correlates to increased formation of open chromatin structures compared to
differentiated cells (Azuara et al. 2006). Formation of euchromatic regions is associated with
high expression of the chromatin remodelling enzyme, Chd1, which is believed to promote
transcriptional activity by incorporation of the histone 3 variant H3.3 (section 1.5.1.2) into
nucleosomes (McKittrick et al. 2004). Chd1 associates with the pluripotency regulators
Oct4, Nanog and Sox2 and promotes their transcriptional activity, and thus the maintenance
of self-renewal in mESCs (Sims et al. 2007; Chen et al. 2008a; Gaspar-Maia et al. 2009).
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mESCs also have a unique embryonic isoform of the SWI/SNF-related chromatin
remodelling complex~ Baf (esBAF), whose ATPase-subunit, Brg1, shares common gene
targets with the key ESC TFs Oct4, Sox2 and Nanog (Ho et al. 200gb). esBAF is believed to
be necessary for the maintenance of pluripotency and self-renewal in mESCs by
suppressing lineage commitment genes, such as Fgf5 and EphrinB4 (Ho et al. 200ga).
Upon differentiation of mouse and human ESCs, chromatin compaction increases
(Meshorer and Misteli 2006), and is associated with increased expression of HP1 (Bartova
et al. 2008).
1.5.1.5 Regulation of pluripotency and differentiation by histone modifications
mESCs have been characterised with elevated levels of histone acetylation, which also
facilitate the high transcriptional activity observed in mESCs (Efroni et al. 2008). The histone
acetyltransferase Tip60/p400 is believed to be recruited to the promoters of active genes in
mESCs, and have an essential role in the maintenance of mESC identity (Fazzio et al.
2008). p300 and Gcn5 HATs also have important roles in embryonic development,
demonstrated by their co-localisation with the master pluripotency regulators Oct4, Sox2
and Nanog in mESCs (Chen et al. 2008b). Further histone modifications implicated in the
maintenance of pluripotency and transition of cell phenotype from a pluripotent to a
differentiated state are outlined in Table 1.3.
Table 1.3-Histone modifying enzymes associated with pluripoteney and differentiation
Red= repressive mark, associated with gene silencing, green= activating mark, associated with gene
expression. * PRC= Polycomb repressive complex
Class Enzyme Function References
Suz12, Eed,
Catalyse H3K27me3, interact with Oct4 and Faust et al. 1998; O'Carroll
Polyeomb PRC2* Ezh2
Sox2, essential for early embryogenesis and et al. 2001; Pasini et al.
Group ESCdifferentiation 2007
(PeG) Essential for early embryogenesis & proper de Napoles et al. 2004;
PRC1* Ringlb
maintenance of self-renewal in ESCs Stock et al. 2007; van der
. Stoop et al. 2008
Trithorax Group MLL
Catalyses H3K4me3. Essential for neuronal Ayton and Cleary 2001; Lim
(Trx) complex (Mill) & haematopoietic differentiation et al. 2009; Madan et al.(MilS) 2009
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H3K9 methylation. Required for repression Tachibana et al. 2002;
G9a of key pluripotency genes during mESC Feldman et al. 2006;
differentiation Epsztejn-Litman et al. 2008
- Rbp2 H3K4me3 de-methylation. Represses Pasini et al. 2007; Lopez-
(JaridIa) developmental regulators in mESCs Bigaset al. 2008
H3K79 methylation. Dispensable for self-
DotH
renewal in mESCs. Necessary for early Barry et al. 2009; Jacinto et
differentiation, where its deficiency leads to 0/.2009
proliferative arrest in G2/M-phase
Jarid2 Associates with and inhibits PCR2 Shen et al. 2009
Jmjd l a, H3K9 de-methylation. Deletion leads to loss Loh et al. 2007
Methylation Jmjd2c of pluripotency. Prevent H3K9me in Nanog
H3K27me3 de-methylation. Repression in Agger et al. 2007; Hong et
mESCs leads to differentiation towards al. 2007; Lanet al. 2007;
Jmjd3, UTX
neural lineages. Needed for resolution of
Leeet al. 2007; Xiang et al.
2007; Burgold et al. 2008;
bivalent domains in differentiation Senet al. 2008
Catalyses H3R26me2, H3R17me2. Required
for self renewal & pluripotency. Deletion
Torres-Padilla et al. 2007;
CARMI down-regulates Oct4 & Sox2, over
expression up-regulates Nanog & resists
Wu et al. 2009a
differentiation
PaflC
Maintains H3K4me3 in promoters of Oct4
Ding et al. 2009
and Nanog
Associated with transcriptional repression
Ma and Schultz 2008;
HDACI and heterochromatin formation during
differentiation
Weichert et al. 2008
Part of the alternative NuRD complex,
Mtal
NODE, which associates with Oct4 and
Liang et al. 2008
Acetylation Nanog in ESCs.Deletion in mESCs leads to
reactivation of differentiation factors
Tip60/p400 Associated with transcriptional activity &
Fazzioet al. 2008
complex maintenance of mESC identity
p300,GcnS
Essential roles during development. p300
Chen et al. 2008b
associated with Oct4, Sox2 and Nanog
Worth noting is that mouse and human ESCs are enriched in "bivalent" chromatin domains,
which are promoter regions associated with both the activating mark, H3K4me3, and the
silencing mark, H3K27me3 (Pan et al. 2007; Kim et al. 2008a). Genes associated with
bivalent domains in ESCs are inactive, but poised for quick reactivation upon differentiation
(Figure 1.5). A poised epigenetic state in ESCs is found in genes necessary for lineage .
commitment, such as TFs of the Sox, Fox, Pax, Irx, and Pou gene families and
developmental regulators, such as Ikaras, Math1, Npas3, Meis2, and Pax2 (Bernstein et al.
2006). Upon differentiation, lineage commitment genes lose one of the two epigenetic
marks, and either become activated or stably repressed, depending on the lineage of
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differentiation (Mikkelsen et al. 2007; Pan et al. 2007). Gene promoters that lack bivalent
domains can be a~sociated with one or none of the two epigenetic marks, while those
promoters that lack both H3K4me3 and H3K27me3 have a tendency to be regulated by
DNA methylation (Fouse et al. 2008).
Development ..,
r41gulator pne
1[5·eell Lymphocyte
Early embryonic
(e.g.Ocr4) .Lm_c. Expressed TIc*
Hematopoietic
(e.g.lkaros) rt.nc "pn',,""
Bivalent chromatin I
Neural-associ'ated
(e.g. Mati11) 1I
I
I
___________________ J
~ H3K9ac
H3K4me
H3K27me
Figure 1.5- Bivalent domains in ESCs
In human and mouse ESCsthe promoters of a range of transcriptionally inactive genes are associated with the
opposing histone marks, H3K27me3 (associated with gene silencing) and H3K4me3 (associated with gene
activation). Bivalent histone conformation denotes silenced genes that are poised for quick activation upon
differentiation. During differentiation, bivalent domains are resolved, leading to transcriptional activation of
tissue-specific genes (e.g. activation of Ikaros upon differentiation towards lymphocytes) and silencing of loci
associated with alternative developmental pathways (e.g. Mathl in this example). Pluripotency-associated
genes such as Oct4 also become repressed upon differentiation (adapted from Spivakov and Fisher 2007).
1.5.2 DNA methylation
DNA methylation is a reaction that involves the addition of methyl groups to 5' cytosine
residues of CpG dinucleotides on DNA strands, using S-adenosyl-L-methionine (AdoMet) as
a donor for the methyl groups (Gruenbaum et al. 1981; Figure 1.6). This epigenetic
modification is catalysed by the DNA methyltransferase (DNMT; section 1.5.2.2) family of
enzymes and has been associated with transcriptional silencing (section 1.5.2.1).
CpG dinucleotides represent 0.83-0.99% of the human and mouse genomes. Depending on
cell-type, -60-90% of cytosine residues in CpG sites are methylated (Zhao and Zhang
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2006), with the majority of methylated cytosines being located within heterochromatic regions,
such as repetitive ~nd transposable elements (reviewed by Brenner and Fuks 2006). Non-
methylated CpG sites are usually clustered in CpG islands, which are regions of 2!500bp in
length with CpG content 2!55%, often located in gene promoters and exons (Takai and
Jones 2002). DNA methylation changes at CpG islands can impact on transcriptional
activity, for example of genes located on the inactive X-chromosome or developmentally
regulated genes (Saxonov et al. 2006). In humans, -50-70% of gene promoters are
associated with CpG islands (Marino-Ramirez et al. 2004).
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Figure 1.6- Addition of methyl groups to DNA cytosine residues
Methyl groups are added to 5' cytosine residues of CpG dinucleotides on DNA strands, using S-adenosyl-L-
methionine as a donor for the methyl groups. Following donation of a methyl group, S-adenosyl-L-methionine
is converted to S-adenosyl-L-homocysteine (modified from Gruenbaum et al. 1981).
1.5.2.1 Gene silencing by DNA methylation
DNA methylation is associated with silencing of transposable elements, as a defence
mechanism against disruption of surrounding. genes, as well as silencing of repetitive DNA
sequences at pericentromeric and telomeric regions that is required to maintain genomic
stability (reviewed by Wilson et al. 2007). Gene silencing by DNA methylation has also been
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implicated in X-chromosome inactivation (Yen et al. 2007), genomic imprinting (Hore et al.
2007; see section 1.5.2.5), DNA replication timing (Ting et al. 2004; Unterberger et al.
2006), global shaping and maintenance of developmental patterning (Ehrlich 2003; Cavalli
2006), and tissue-specific gene expression (reviewed by Brena et al. 2006). Each cell type
is thought to have a unique DNA methylation "fingerprint" or tissue-specific differential DNA
methylation (T-DMR) that extends from imprinting and X-chromosome inactivation, to gene
promoters, exons, introns, transposons and repetitive elements (Yang et al. ; Illingworth et
al. 2008).
Repression of transcriptional activity by DNA methylation is believed to be achieved via
three possible mechanisms (Figure 1.7); 1) inhibition of TF binding to their specific promoter
sites when these have been methylated, 2) co-operation with chromatin-remodelling
complexes that condense chromatin architecture and prevent Pol II and GTFs from binding
to promoter regions and initiating transcription, or 3) co-operation with histone modifications
via methyl-binding proteins to alter chromatin structure to its condensed, inactive form
(reviewed by Vaissiere et al. 2008). In cases of transcriptional silencing through co-
operation with chromatin remodelling and histone modification enzymes, it is unclear
whether DNA methylation acts as the primary or secondary event (Vaissiere et al. 2008).
Whereas some histone modifications can confer a poised or transcriptionally repressed
promoter state (section 1.5.1.5), DNA methylation has been associated with more
permanent silencing of gene expression (Feldman et al. 2006; Fouse et al. 2008; Mohn et
al. 2008).
26
PhD Thesis
Elena Matsa
School a/Clinical Sciences
The University a/Nottingham
Chapter 1- Introductlon
B
Silenced gene
c
Silenced gene
D
Silenced gene
Figure 1.7- Regulation of gene silencing by DNAmethylation
A. Active gene promoters can be associated with unmethylated CpGsites, acetylation of histone tails and an
open chromatin conformation that allow transcription factor (TF) binding to regulatory elements. Promoters
containing methylated CpGscan inhibit gene transcription by B. blocking TF binding to promoter regions, C.
promoting heterochromatin formation through histone de-acetylation and chromatin remodelling complexes,
or D. association of methyl-binding proteins (such as MeCP2jMBP2) with methylated cytosines, that in turn
recruit histone de-acetylases (HDAC) that create a non-permissive chromatin state for TFs. Black and white
circles represent methylated and unmethylated CpGs,respectively. Yellow stars represent histone acetylation
(modified from Vaissiere et al. 2008).
1.5.2.2 De novo and maintenance DNA methylation
The global levels of DNA methylation undergo cycles of methylation and de-methylation
events (Figure 1.8), during gametogenesis from primordial germ cells (PGCs) and during
embryonic development (reviewed by Li 2002). Global de-methylation during
embryogenesis occurs at the 4-8 cell stage in human embryos (Fulka et al. 2004) and at the
2-8 cell stage in mouse and sheep embryos (Young and 8eaujean 2004; Yang et al. 2007):
By the blastocyst stage, global DNA methylation levels increase (Fulka et al. 2004), mostly
due to de novo DNA methylation (Figure 1.9) catalysed by the DNA methyltransferase
(DNMT) enzymes DNMT3A and DNMT38. Another enzyme of the DNMT3 family; DNMT3L,
interacts with and stimulates the action of DNMT3A and 38, but has no methyltransferase
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activity itself (Chedin et al. 2002; Suetake et al. 2004; Gowher et al. 2005). De novo DNMTs
catalyse the addition of methyl groups on CpG sites that were previously unmethylated
(Chen et al. 2003), and are thought to have a preference for binding to T-DMRs (Hattori et
al. 2004). The mechanisms by which de novo DNMTs establish DNA methylation patterns
during development are not well understood (Nimura et al. 2006), even though recent
evidence suggests that establishment of methylation patterns at imprinted loci and
transposable elements during gametogenesis might be associated with binding of DNMT3L
to unmethylated H3K4 tails, which recruit DNMT3A for de novo methylation (reviewed by
Law and Jacobsen 2010). Several other repressive histone modifications, such as
H3K27me and H3K9me - catalysed by Ezh2 and G9a, have been shown to attract binding
of DNMT3A and 3B to the DNA and promote DNA methylation (reviewed by Jones and
Liang 2009). Suv39/h1-catalysed H3K9me is specifically associated with Dnmt3b
recruitment to pericentromeric repeats (Lehnertz et al. 2003).
Once established, DNA methylation patterns are maintained at every cycle of DNA
replication by the "maintenance" methyltransferase, DNMT1 (Figure 1.9). DNMT1 catalyses
the addition of methyl groups to CpG sites on newly synthesised DNA strands (Leonhardt et
al. 1992; Pradhan et al. 1999) after being recruited to the replication fork by the proliferating
cell nuclear antigen (PCNA) and the ubiquitin-like homeodomain & ring-finger domain 1
protein (UHRF1), an enzyme that has a high affinity for binding hemi-methylated DNA
(Bostick et al. 2007).
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Figure 1.8- Cycles of DNA methylation and de-methylation during early embryonic development
DNA methylation levels during germ-cell and early embryonic development in methylated imprinted genes
(black), unmethylated imprinted genes (grey), and non-imprinted DNA sequences of the maternally (red) and
paternally (blue) inherited alleles. The horizontal and vertical axes, and the relative levels of DNAmethylation
are not drawn to scale (Reik and Walter 2001).
De novo methylated DNA
A Unmethylated DNA
DNMT3A
DNMT38
DNA
replication
•
Herni-rnethvlated :
DNA
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Fullymethylated DNA
Figure 1.9- De novo and maintenance DNA methylation
A. De novo DNA methylation is carried out by the DNA methyltransferase enzymes DNMT3A and DNMT3B,
and it is responsible for establishing DNA methylation patterns during early development. B. Model depicting
maintenance DNA methylation during DNA replication. DNMTl is proposed to be recruited to the replication
fork through interactions with the proliferating cell nuclear antigen (peNA) and ubiquitin-like homeodomain &
ring-finger domain 1 protein (UHRF1),which specifically interacts with hemimethylated DNA. DNMTl acts to
maintain DNA methylation patterns by restoring hemimethylated DNA to a fully methylated state. Black and
White circles represent methylated and unmethylated DNA, respectively (Law and Jacobsen2010).
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1.5.2.3 Overlapping functions of de novo and maintenance DNA methyltransferases
A lot of evidence has emerged challenging the distinct roles that have been assigned to the
de novo and maintenance methyltransferases, and supporting that DNMTs might have over-
lapping roles (Liang et al. 2002). Observations that over-expression of DNMT1 in somatic
cells results in hyper-methylation of DNA (Vertino et al. 1996; Biniszkiewicz et al. 2002)
come in contrast to the notion that DNMT1 can only copy the methylation pattern of a parent
DNA strand (Szyf 2003). Equally, evidence from mESCs with knock-out of Dnmt3a and
Dnmt3b enzymes suggests that Dnmt1 expression is not sufficient to maintain DNA
methylation at repetitive sequences such as intracisternal A-particle (lAP) repeats, major
and minor satellite elements, transposons, and centromeric and pericentromeric regions
(Table 1.5). It is, therefore, proposed that de novo DNMTs might be necessary to maintain
DNA methylation at highly methylated regions of DNA (i.e. repeat sequences), to which they
could be attracted through association with histone modifications, such as H3K9me, that are
frequently found at repetitive sequences (Jones and Liang 2009).
1.5.2.4 Active DNA de-methylation
Even though DNA methylation patterns can be established and maintained by DNA
methyltransferase enzymes, little evidence is available about how DNA de-methylation
occurs during gametogenesis and embryonic development (Figure 1.8), and is mostly based
on studies from mouse embryos. Since enzymes with de-methylase activity have not been
identified so far in mammals, it has been suggested that reduction of global DNA
methylation during early development occurs via passive mechanisms, either in the absence
of DNMTs or by their exclusion from the nucleus during phases of de-methylation (reviewed
by Ooi and Bestor 2008). However, the speed by which some de-methylation events occur,
such as the de-methylation of the paternal genome within hours of fertilisation (Oswald et al.
2000), suggests that de-methylation takes place via active mechanisms that occur
independently to DNA replication (Szyf 2003).
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It has been proposed that active de-methylation might occur through glycosylation of
methyl-cytosine residues, catalysed by meCG glycosylase enzymes (Zhu et al. 2000).
However, this mechanism is not favourable at early stages of embryonic development since
it introduces damage to the DNA, which would constantly need to be repaired. Other groups
have shown that the methylated-DNA binding protein, MBD2, possesses DNA de-methylase
activity in vitro (Hendrich and Bird 1998; Bhattacharya et al. 1999; Ramchandani et al.
1999), but in vivo evidence for this remains controversial (Hendrich et a/. 2001; Detich et al.
2002). Even more controversially, the de novo methyltransferases DNMT3A and DNMT3B
have been shown to possess de-methylase activities through their ability to de-aminate meC
residues to T, and C residues to U during transcription of DNA (Kangaspeska et a/. 2008;
Metivier et a/. 2008), though it remains unclear whether the efficiency of de-amination is
compatible with the timing of reported de-methylation events (Ooi and Bestor 2008).
1.5.2.5 Genomic imprinting
Expression of genes located on autosomal chromosomes occurs from both the maternally
and paternally inherited alleles (bi-allelic expression), except in "imprinted" genes, that are
only expressed from one of the two alleles (mono-allelic expression; Ferguson-Smith and
Surani 2001). Over 50 imprinted genes have been identified in the human genome, most of
which are clustered in chromosomes 7, 11, 15 and 20 (Morison et al. 2005; Table 1.4).
Mono-allelic expression at these genes can be established following global genomic de-
methylation either during gametogenesis (germline imprints) or during embryogenesis
(somatic imprints; Reik and Walter 2001; Surani 2001). Even though the exact mechanism
of imprint establishment is poorly understood, silencing of the inactive allele has been
associated with increased DNA methylation at imprinting control regions (lCR) and
differentially methylated regions (DMR) located within the promoter regions of imprinted
genes (Reik and Waiter 2001; Constancia et al. 2004). Increased DNA methylation at the
silenced allele has also been associated with enrichment of the repressive histone marks
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H3K9me & K27me, while H3 & H4 acetylation have been associated with the unmethylated,
active alleles (Hu et al. 2000; Grandjean et al. 2001; Fournier et al. 2002; Lewis et al. 2004).
Table 1.4- Human imprinted genes
ARR= antisense regulatory region (Thorvaldsen et al. 1998; Yang et al. 1998; Buiting et al. 1999; Fitzpatrick et
al. 2002; Lin et al. 2003; Williamson et al. 2004; Morison et al. 2005; Williamson et al. 2006).
Imprinted Chromosome
Transcripts
Expressed Imprint
Imprint locusgene/cluster locus allele establishment
ARHI - paternal - -
DIRAS3
lp31
- paternal germline promoter
TP73 lp36 - maternal germline promoter
NAP1LS 4q22 - paternal germ line promoter
ZACl 6q24 Isoform 1 paternal germline promoter
IGF2R 6q25 - maternal - -
GRB10 7pll - paternal germ line intron CGI2
PEG10
paternal germ line PEG10PEG10
SGCE promoter7q21
DLXS - maternal -
-
CPM -
-
maternal
germlineKLF14 promoter
MEST/PEGl 7q32 MESTITl
MEST isoform 1 paternal germline MEST promoter
MEST isoform 2
CTNNA3 10q22 - maternal -
-
INPPSF V2 10q26 - paternal germline promoter
WTl llp13 - paternal germline ARR DMR
PHLDA2
SLC22A18
SLC22A1LS maternal KCNQ10Tl
KCNQl
CDKN1C germline promoter
KCNQl (KvDMR)
llp15 KCNQ10Tl paternal
H19 maternal germline intergenic DMR
promoter
IGF2/H19 IGF2
paternal somatic DMRO
intron DMR2
IGF2AS
-
-
GTL2/MEG3 maternal somatic GTL2 promoter
DKLl/DI03 14q32 DLKl
paternal germline
0013 intergenic DMR
NON - promoter,
SNURF/SNRPN
SNRPN paternal
germline15qll -
IPW
ATP10C maternal -
-
PEG3 19q13 - paternal germ line promoter
NESP
maternal
somatic NESP55
GNAS
germline lA promoterGNAS 20q13 Exon lA
GNASXLas paternal
germ line XL/NESPAS
NESPAS promoter
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1.5.2.6 DNA methylation defects during mammalian development and human
disease
DNA methylation is an essential process for mammalian development, demonstrated by
observations that Dnmt3a defects result in underdeveloped offspring and lead to death by
four weeks after birth, while Dnmt1 or 3b defects are lethal in mouse embryos at E14.5-18.5
(Kaneda et al. 2004; Ueda et al. 2006). Dnmt3b-l- mouse embryos also exhibit defects in
neural tube development (Okano et al. 1999). Disruption of the de novo methyltransferase,
Dnmt31, results in global hypo-methylation and developmental arrest by E8.5, as well as
defective spermatogenesis and failure to establish maternal DNA methylation imprints in
oocytes (reviewed by Gopalakrishnan et al. 2008). In humans, mutations in DNMT38 have
been associated with ICF (immunodeficiency, centromere instability, facial disruption)
syndrome, mental retardation, and developmental delay (Hansen et al. 1999; Jin et al.
2008).
Global genomic hypo-methylation (especially at repetitive regions and transposable
elements) and tissue-specific hyper-methylation (e.g. in tumour-suppressor genes) are
regarded as hallmarks of cancer, whereas loss of mono-allelic expression at imprinted loci
has also been to linked disorders such as the Prader-Willil Angelman syndromes, Beckwith-
Wiedermann syndrome, Albrights hereditary osteodystrophy, Pseudohypothyroidism type 1a
and 1b, and cancer (Robertson 2005; Feinberg 2007; Jelinic and Shaw 2007).
1.5.2.7 Regulation of pluripotency and differentiation by DNA methylation
As development and differentiation proceed, the global DNA methylation signatures of
pluripotent and differentiated cells become distinctively different (Bibikova et al. 2006; Fouse
et al. 2008; Ball et a/. 2009). Using Iliumina® universal bead arrays, Bibikova et al. (2006)
demonstrated that the DNA methylation profiles of 14 independently isolated hESC lines
Were clearly distinguished from those of somatic and cancer cells. They produced a list of
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49 CpG sites from 40 genes, including imprinted and differentially methylated genes, tumour
suppressor genes, oncogenes, and genes involved in cell cycle regulation, differentiation,
apoptosis and DNA damage repair, which contributed the most to the unique hESC DNA
methylation signature. More recently, genome-wide DNA methylation analysis by next
generation bisulfite sequencing demonstrated that 286 regions, mostly in promoter clusters
and CpG islands, were hypomethylated in hESCs compared to differentiated cells, whereas
the overall level of DNA methylation (mostly in repeat sequences and transposons) was
higher in hESCs (Laurent et al. 2010). Closer examination revealed that pluripotency
associated TFs, such as OCT4 and KLF4, were hypo-methylated in hESCs (see section
4.1.1), in contrast to several lineage-commitment genes, such as TCF3, that were hyper-
methylated in hESCs (Meissner et al. 2008; Brunner et al. 2009; Laurent et al. 2010).
DNMT knock-out studies in mESCs have shown that loss of Dnmt1 expression and/or
combined knock-out Dnmt3a & Dnmt3b resulted in reduced global DNA methylation,
especially evident at repeat elements (summarised in Table 1.5). Overall, knock-down of
DNMTs in mESCs did not affect self-renewal or other undifferentiated characteristics (e.g.
expression of Oct4), but did impair differentiation, especially in cases of combined knock-out
(Shen et al. 2006). Dnmt3a and Dnmt3b were shown to co-operate in the methylation of
Oct4 and Nanog in differentiating mESCs, since knock-out of these two enzymes resulted in
abnormal differentiation and failure to silence Oct4 and Nanog (Jackson et al. 2004).
Interestingly, hESCs also have uniquely high cytosine methylation at CpA residues of the
DNA. CpA methylation is found at similar patterns to CpG methylation (across the genome
and gene regions, but reduced at gene promoters; Laurent et al. 2010). However, the
functional significance of this type of methylation in ESCs is not well understood.
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Table 1.5- Roles of DNA methyltransferase enzymes in mouse and human ESCs
KO= knock-out, DKO= double knock-out, TKD= triple knock-out
Cell type Gene Treatment Effect Papers
Chen et 0/.
Hypo-methylation in 236 methylation sites, 52-84% 2003; Hattori
reduction in global methylation, hypo-methylation at eta/.2004;
repetitive elements & imprinted loci, telomere Jackson et 0/.
KO elongation, reduced differentiation ability 2004; Li et 0/.2007e
Dnmtl Hattori et 0/.
Reduced differentiation ability. Initial establishment 2004; Gonzalo
of Oct4 and Nanog methylation gradually lost et 0/. 2006; Li
et 0/. 2007e
Over- Hyper-methylation at repetitive sequences (lAP, Jackson et 0/.
expression centromeres), loss if imprinting (lgf2 & H19) 2004
Dnmt3a KO
Partial methylation of Oct4 & Nanog upon
differentiation. No effect on other processes studied Biniszkiewiez
Partial methylation of Oct4 & Nanog upon et 0/.2002
Dnmt3b KO differentiation. No effect on other processes studied
Chen et 0/.
Hypo-methylation in 236 methylation sites (same as 2003; HattoriIII eta/.2004;u in Dnmtl KO), near loss in global methylationVI Jackson et 0/.w
E 2004
Viable cells with normal alkaline phosphatase and
Oct4 expression. Progressive DNA hypo-methylation
Dnmt3a-
DKO
between passages 5 t075 at repeat sequences (lAP, Hattori et 0/.
3b major and minor satellite repeats at centromeric and 2004
pericentromeric regions) and individual genes (H19,
/gf2, Pegl, Snrpn). Increased histone acetylation
Chen et 0/.
Abnormal differentiation and failure to methylate/ 2003; Jackson
silence Oct4 & Nanog. Increased histone acetylation et 0/.2004;Gonzalo et 0/.
2006
No change in undifferentiated characteristics.
Maintenance of normal chromosome numbers,
Dnmtl,
pericentromeric heterochromatin domains marked
TKO with H3K9me & HPl. Severe global DNA hypo- Li et 0/. 2007e3a &3b
methylation at repeat sequences (lAP,
peri centromeric major satellite repeats,
retroelements) and individual genes (lgf2, Snrpn),
u Differentiation OCT4, CPTlA & SPAG6 gene promoters associatedVI DNMT3A to neural Shen et al.,w
with DNMT3A during differentiation 2006 HMGs:
progenitors
1.5.2.8 Regulation of pi uri potency-associated TFs by epigenetic modifications
Transcription factors that are key for the maintenance of a pluripotent phenotype in ESCs
(section 1.3) are themselves regulated by epigenetic modifications. As mentioned earlier,
OCT4 and KLF4, but also NANOG, are hypo-methylated in their transcriptionally active
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states in ESCs, and hyper-methylated in differentiated cell types, indicating that
transcriptional activity of pluripotency-regulators is inversely related to enrichment of DNA
methylation in their promoters (Meissner et al. 2008; Brunner et al. 2009; Laurent et al.
2010). Also, it has been suggested that silencing of Oct4 during differentiation of mESCs
occurs via a carefully orchestrated step-wise process that involves G9a-mediated H3K9
methylation (Feldman et al. 2006; Epsztejn-Litman et al. 2008). Further details about the
regulation of pluripotency genes by epigenetic modifications will be discussed later, in
section 4.1.1.
1.6 DIFFERENCES BETWEEN HUMAN AND MOUSE ESCs
Animal models have been the backbone of biological research for several years. Their
extensive use has enabled the investigation and understanding of human disease, and has
lead to the development of novel therapeutic drugs for human conditions (Tsumura et al.
2006). Nevertheless, due to divergent evolution, several dissimilarities exist between
humans and model organisms, including differences in gene regulation and gene
expression, protein structure and activity, protein interactions, and consequently, differences
in their response towards toxins and drugs (reviewed in Olson et al. 2000; Chakraborty et al.
2009; Shively and Clarkson 2009).
Substantial differences have also been observed between human and mouse ESCs ,
regarding their transcriptional profiles, culture conditions and expression of surface markers.
For example, the genome-wide transcriptional profile of mESCs is only 13-55% similar to
that of hESCs (reviewed in Pound et al. 2004; Dixit and Boelsterli 2007; Shanks et al. 200,9).
Moreover, mESCs require exogenous treatment with LlF and BMP4 molecules to maintain
their pluripotency in vitro, and express the surface antigen SSEA 1 in their pluripotent state
(Sato et al. 2003; Abeyta et al. 2004; Wei et al. 2005). In contrast, hESC in vitro culture is
independent of LlF and BMP4 signalling, and SSEA 1 is expressed only when cells are
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differentiated. In their pluripotent state, hESCs express the surface antigens SSEA4,
SSEA3, TRA-.1-81 and TRA-1-60 (Chambers 2004; Rao 2004). mESCs and hESCs also
exhibit considerably different sensitivities to treatment with chemicals or drugs, such as 5-
aza-cytidine, which is toxic to hESCs even at small doses, but is tolerable in mESCs and
promotes their differentiation towards endothelial cells (Pera et al. 2000; Boiani and Scholer
2005; Adewumi et al. 2007).
Mouse ESCs derived from the epiblast instead of the ICM (known as epiblast stem cells,
EpiSCs; Brons et al. 2007) show more similarity to hESCs in terms of morphology, and do
not require extrinsic LlF or BMP signalling to self-renew in vitro (Tesar et al. 2007). Instead,
similar to hESCs, the maintenance of self-renewal in EpiSCs is associated with Activin
AlNodal signalling, while early differentiation stages are associated with BMP4 signalling
(Vallier et al. 2009c). EpiSCs also show increased similarity to hESCs in the regulation of
gene expression by piuripotency-associated TFs, such as Oct4 (Tesar et al. 2007).
Even though mESC-based studies have provided valuable information about the epigenetic
regulation of the pluripotent cell state (sections 1.5.1.4, 1.5.1.5 and 1.5.2.7), limited
information is available for hESCs or EpiSCs. Also, despite the increased similarity between
hESCs and EpiSCs, divergent evolution might still have contributed to yet uncharacterised
differences between these two cell types. Developing human models to study the regulation
of pluripotency and differentiation is of paramount significance towards understanding
human development and disease. Therefore, this study has developed a hESC-based
model cell system (Figure 1.1) in order to investigate the epigenetic mechanisms that
regulate key piuripotency-associated genes and affect the transition of cell phenotype from
a pluripotent to a differentiated state and vice-versa.
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1.7 DIFFERENCES BETWEEN hESC LINES
1.7.1 Variation in transcriptional profiles
Since the initial isolation of hESCs from human blastocysts in 1998 (Thomson et al. 1998),
well over 400 additional hESC lines have been derived (Brimble et al. 2004). hESC lines
share a range of characteristics, such as morphology, and expression of the pluripotency-
associated factors OCT4, NANOG, and SOX2 (reviewed by Allegrucci and Young 2007).
However, they also exhibit a number of dissimilarities concerning their proliferation rate,
which has been shown to range between 24-48 hours (Hoffman and Carpenter 2005), and
the relative expression levels of piuripotency-associated factors (Amit et al. 2000; Cowan et
al. 2004; Zeng et al. 2004; Sjogren-Jansson et al. 2005). It is suggested that a range of
"pluripotency states" might exist which could allow differentiation towards the three
embryonic germ layers (Carpenter et al. 2003; Rho et al. 2006; Adewumi et al. 2007), but
confer some differentiation bias, since even a two-fold change in the levels of OCT4 can
favour differentiation towards endoderm or mesoderm in hESCs (Rodriguez et al. 2007).
Indeed, an extensive study by Osafune et al. (2008) demonstrated that certain hESC lines
preferentially differentiate towards ectodermal (HUES6), endodermal (HUES8) or
mesodermal lineages (HUES3). Some of the differences observed between hESC lines
have been accounted by genotype variation (reviewed by Allegrucci and Young 2007).
However, transcriptional diversity among different passages of the same hESC line
suggests that culture-related effects and methodological differences can also affect hESC
phenotype (Cowan et al. 2004; Skottman et al. 2005).
1.7.2 Variation in epigenetic profiles
Current methods used for ESCs culture can induce stable and heritable changes in the
epigenome of hESCs. Such evidence has been provided by Allegrucci et al. (2007), who
showed that the global DNA methylation levels in hESCs differ considerably between
independently derived cell lines. Even though some differences might be due to genetic
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variation (Richards et al. 2004), Allegrucci et al. were able to show that the greatest
alterations in the DNA methylome, at least under the conditions tested, occurred during the
earliest passages of hESC in vitro culture, with further changes being introduced upon
prolonged culture or when cells were transferred from MEF feeders to feeder-free culture on
Matrigel™. The epigenetic alterations introduced to hESCs due to in vitro manipulations
were stably inherited to their differentiated derivatives (Allegrucci et al. 2007).
Further differences in the epigenetic characteristics of hESCs have been demonstrated by
Kim et al. (2007), who showed variation in the allele-specific expression of imprinted genes
in 22 different hESC lines and associated these differences to changes in DNA methylation.
Similar results were published by the International Stem Cell Initiative (Adewumi et al.
2007), Rugg-Gunn et al. (2007), and Sun et al. (2006), who also reported imprinting
variation between samples of the same hESC line, analysed at different passages. Tumour
suppressor genes, such as RASSF1 and PTPN6, have also exhibited accumulation of
aberrant DNA methylation in hESC cultures (Maitra et al. 2005). Moreover, epigenetic
characteristics associated with differentiation, such as the % DNA methylation of OCT4 and
NANOG, were shown to vary when hESCs were differentiated either by retinoic acid or cell
clumps (Yeo et al. 2007).
X-chromosome inactivation (XCI) is another epigenetic trait exhibiting variation among
hESC lines. XCI is one of the first measurable epigenetic changes that occur in the early
mammalian embryo, and is thought to take place during the same time as differentiation into
the three germ layers (Monk and Harper 1979). Some hESC lines (HUES1, HUES9 and
HUES14) show the ability to carry out XCI upon in vitro differentiation, when others seem to
have already inactivated one X-chromosome in their pluripotent states (HUES5 and HES-3)
or to be completely incapable of XCI (HUES6, HUES12, HES-2, H7 and H9; Silva et al.
2008). Considering the importance of XCI in embryogenesis, adult physiology, brain function
and social skill development, as well as in cancer, correct dosage of X-chromosome genes
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is vital for cellular integrity and human development (Tomkins et al. 2002; Ganesan et a/.
2005; Skuse 2005; Cutter et al. 2006).
Together, these findings challenge current culture techniques as well as the overall ability of
hESCs to serve as a model for developmental epigenetic studies without careful prior
characterisation (Allegrucci et al. 2007). By generating a single-genotype model cell system
(Figure 1.1), maintaining the same culture conditions between pluripotent cell lines (hESCs
& iPSCs, section 1.2.4.4) and using the same protocols to generate and culture fibroblast
differentiated cells from hESCs and iPSCs (section 3.1.1), this study aimed to eliminate the
factor of genetic variation and limit any changes in cell phenotype due to culture-induced
effects, in order to enable unbiased analysis of the epigenetic regulation mechanisms
associated with key pluripotency-genes.
1.8 REPROGRAMMING SOMATIC CELLS INTO A PLURIPOTENT STATE
The limited supply of human oocytes/embryos for the derivation of hESCs, as well as ethical
considerations surrounding the need for human embryos to isolate hESCs have, thus far,
limited the use of hESCs or their differentiated derivatives in research and in the clinic
(Cervera and Stojkovic 2007). Alternative sources of pluripotent cells have, therefore, been
sought after, mostly relying on reprogramming somatic cells to an ESC-like state. Techniques
such as somatic cell nuclear transfer (SCNT), fusion of somatic cells with ESCs, or treatment
of somatic cells with ESC or amphibian oocyte and egg extracts were able to reprogram
differentiated cells to an ESC-like state (reviewed by Alberio et al. 2006), but suffered from
dependence on animal products, need for oocytes or generation of tetraploid cells, which
would still be controversial if used in humans (reviewed by Hochedlinger and Jaenisch
2006; Figure 1.10).
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1.8.1 Generation of induced-pluripotency stem cells
Extensive characterisation of the transcription factor networks that regulate pluripotency
enabled, in 2006, the reprogramming of differentiated mouse fibroblasts to an ESC-like state
(Takahashi and Yamanaka 2006). Initially, twenty-four candidate TFs were tested for their
ability to induce pluripotency when they were retrovirally over-expressed in mouse
fibroblasts. Four of these factors; Oct4, Sox2, KIf4 and c-myc, were found to be necessary
and sufficient for inducing pluripotency in differentiated cells. Soon after this discovery, it
emerged that the same four factors, as well as combination of the TFs OCT4, SOX2,
NANOG and LlN28 could induce pluripotency in human differentiated fibroblasts (Ok ita et al.
2007; Yu et al. 2007b). Reprogramming somatic cells by over-expression of defined TFs
can potentially alleviate the need for human embryos to isolate ESCs. It also opens new
Possibilities for treatments in regenerative medicine using autologous patient cells that could
be isolated from tissues such as the skin, using non-invasive procedures (Amabile and
Meissner 2009).
SCNT Cell fusion Cell
explantation
~
Cell extracts Defined TFs
III
cu No animal
.!!! Reproductive CustomisedE In vitro reprogramming products or0 cloning ESCs
....
oocytes~
III
cu
Inefficient, Insertionalb.O Abnormal Fusedcells are Limited to No functionale
~
offspring ethics, tetraploid (4n) germ cells reprogramming mutagenesis byiQ
.c: human eggs virusu
Figure 1.10- Strategies used to induce reprogramming of somatic cells
Somatic cell nuclear transfer (SCNT)involves the injection of a somatic-cell nucleus into an enucleated egg,
which upon transfer to a surrogate mother can give rise to offspring, or upon explantation in culture can give
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rise to genetically matched ESCs.Cell fusion of somatic cells with ESCsresults in the generation of hybrids that
show all features of pluripotent ESCs.Explantation of somatic cells in culture selects for immortal cell lines
that may be pluripotent or multipotent, but hasso far only given rise to spermatogonial stem cells. Treatment
with cell extracts from ESCsor animal oocytes induces reactivation of some pluripotency-associated
transcription factors (TFs)but does not induce complete reprogramming. Over-expression of defined TFs in
somatic cells enables complete reprogramming to iPSCs(modified from Jaenischand Young 2008).
1.8.1.1 Identification and characterisation of reprogrammed iPSCs
In the first experiments performed to generate iPSCs, potentially reprogrammed cells were
selected based on re-activation of the pluripotency-associated factor Fbx15 (Takahashi and
Yamanaka 2006). Despite having an ESC-like morphology, cells selected based on Fbx15
expression had notably different transcriptional and epigenetic profiles to mESCs, and could
not contribute to the formation of chimeras (Takahashi and Yamanaka 2006). In subsequent
experiments, selection of putative iPSC colonies was based on Nanog reactivation (Okita et
al. 2007), and resulted in the formation of cell colonies that were morphologically
indistinguishable from mESCs, demonstrated ESC-like proliferation rates and telomere
length, had similar transcriptional and DNA methylation profiles to ESCs, and could
contribute to the formation of germ-line chimeras (Ok ita et al. 2007; Marion et al. 2009b).
Oct4-based selection was used equally successfully to isolate iPSC colonies from MEFs
(Wernig et al. 2007), and human fibroblasts (Yu et al. 2007b).
In order to enable selection of iPSC colonies based on Nanog or OCT4 expression,
fibroblast cells had to be genetically engineered to carry gene-targeted GFP cassettes
expressed under the endogenous Nanog or Oct4/0CT4 promoters. However, for the
therapeutic application of iPSCs, non-engineered somatic cells would need to be used.
Meissner et al. (2007) demonstrated isolation of iPSCs from genetically unmodified somatic
cells based on morphological characteristics. Nonetheless, colony identification in the
absence of a selection marker depends on personal experience and is, thus, subjective.
Extensive characterisation of hESCs-surface markers, identified that fully reprogrammed
iPSCs could be selected based on reactivation of TRA-1-81 (Figure 1.11; Chan et al. 2009).
Non-reprogrammed somatic cells and "partially reprogrammed" cell colonies emerging
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during iPSC generation (see section 1.B.1.2) did not express TRA-1-B1, but some did
express the hESC-surface marker SSEA4, therefore rendering this marker as inappropriate
for the identification of fully reprogrammed iPSCs. Even though early in vitro identification of
putative iPSCs could be performed based on colony morphology, size and TRA-1-B1
expression (Chan et al. 2009), these were not enough to confirm full reprogramming.
Further criteria that are necessary for the selection of bona fide iPSCs have been reviewed
by Maherali and Hochedlinger (200B), and are outlined below:
* Morphological similarity to ESCs
* Reactivation of endogenous pluripotency factors (e.g. OCT4, NANOG, SOX2)
* Reactivation of ESC-specific surface antigens (e.g. TRA-1-B1)
* Functional telomerase expression
* Repression of viral transgene expression
* Epigenetic similarity to ESCs in the promoters of pluripotency factors, X-
chromosome reactivation in female lines, and formation of bivalent histone domains
(see section 1.B.3)
* Ability to differentiate into lineages from all three embryonic germ layers
Maherali and Hochedlinger (200B) suggested that the differentiation potential of iPSCs
should be assessed by the highest stringency test possible, which in mice means; germ-line
transmission following blastocyst chimerism, and in humans; teratoma formation (reviewed
by Daley et a/. 2009).
1.8.1.2 Partially reprogrammed colonies formed during iPSe generation
Partially reprogrammed colonies represent an intermediate state between iPSCs and the
somatic cell type used for reprogramming (Figure 1.11). They are considered to originate
from somatic cells that either do not incorporate all four iPSC factors, incorporate all factors
but do not express some of them or expressed them at the wrong levels (Papapetrou et a/.
2009). Some partially reprogrammed colonies generated from mouse fibroblasts express
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the mESC-surface marker, SSEA 1, but not Oct4 or Nanog, and down-regulate fibroblast-
specific gene~. more readily than they activate mESC-specific genes (Sridharan et al. 2009).
Partially reprogrammed colonies generated from human differentiated cells can express the
hESC-surface marker SSEA4, but lack TRA-1-B1 expression and show persistent
expression of viral transgenes (Subramanyam and Blelloch 2009). Overall, partially
reprogrammed colonies show incomplete re-activation of endogenous pluripotency genes
as well as incomplete silencing of differentiation genes and viral transgenes. Also, the DNA
methylation and histone modification characteristics of partially reprogrammed colonies are
in an intermediate state between iPSCs and the somatic cell-type used for reprogramming
(section 1.B.3; Takahashi and Yamanaka 2006; Mikkelsen et a/. 200B).
CD13-
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Figure 1.11- Distinguishing fully reprogrammed iPSCs from partially reprogrammed cells
Phase images (20x magnification) and marker expression of fully reprogrammed (Type III) and partially
reprogrammed (Type I & II) cell colonies generated from hESC-derived fibroblasts following transduction with
retroviruses over-expressing OCT4, SOX2, KLF4 and c-MYC. Fully reprogrammed bona fide iPSCs reactivate
both the TRA-1-81/TRA-1-60 and SSEA4 hESC-surface markers, and silence viral transgenes and differentiation
genes (CD13; modified from Chan et al. 2009; Subramanyam and Blelloch 2009).
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1.8.1.3 Molecular events during iPSe generation
Two studies have attempted to investigate the molecular mechanisms that underline
reprogramming of somatic cells to iPSCs, by using doxycycline-inducible viral vectors to
perform time-course analysis of pluripotency gene re-activation in mouse fibroblasts
(Brambrink et al. 2008; Stadtfeld et al. 2008b). Flow cytometry analysis showed that down-
regulation of Thy1, a surface antigen expressed in fibroblasts and other differentiated cell
types (Rege and Hagood 2006), was one of the first events to occur during reprogramming
(Stadtfeld et al. 2008b; Figure1.12). Alkaline phosphatase (AP) was the first mESC marker
to be reactivated upon iPSC formation (day 3 post doxycycline treatment; Brambrink et al.
2008). Expression of the mESC-surface marker, SSEA 1, was observed on day 9 post-
doxycycline treatment, whereas Oct4- and Nanog-driven GFP expression were expressed
several days later, between days 11-16 post-doxycycline treatment. Transgene expression
was required for a minimum period of 8-12 days, in order to allow completion of the
reprogramming process, but continued transgene expression up to day 21 post-doxycycline
treatment enhanced the formation of iPSC colonies (Brambrink et al. 2008). Reactivation of
endogenous genes, such as Sox2, and X-chromosome reactivation were shown to correlate
with the period when cells became independent of doxycycline-induced transgene
expression (Stadtfeld et al. 2008b). These experiments demonstrate that generation of
iPSCs follows a defined sequence of events, where viral mediated over-expression of
pluripotency factors brings about the silencing of differentiation genes, and then the re-
activation of endogenous pluripotency factors, which in turn make the transgenes
dispensable. However, the exact details of how endogenous pluripotency factors become
reactivated during iPSC generation remain undefined.
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Figurel.12- Sequential activation of pluripotency markers during reprogramming to iPSCs
Kinetics of pluripotency marker reactivation during reprogramming of mouse fibroblasts to iPSCs, by lentiviral
over-expression of Oct4, Sox2, Klf4 and c-myc. Alkaline phosphatase and SSEAl are reactivated 3-9 days post
lentiviral transduction (PTD), whereas endogenous Oct4 and Nanog protein reactivation was detected 2 weeks
PTD. Expression of lentiviral transgenes was necessary for approximately 2 weeks to initiate iPSC formation
(Jaenisch and Young 2008).
1.8.2 The role of reprogramming TFs in the induction of pluripotency
ChiP and microarray analysis performed by Sridharan et al. (2009) revealed that the iPSC
TFs; Oct4, Sox2, Klf4 and c-Myc, occupy similar gene promoters in mESCs and mouse
iPSCs (-87% similarity). Some gene promoters are occupied by all four iPSC factors, while
others are bound by combinations of three or two, or just one factor. Genes associated with
Oct4, Sox2 and Klf4 in the absence of c-Myc are mostly involved in transcriptional control of
development (e.g. Lefty2, Foxh1) and show the highest increase in expression upon
reprogramming of mouse fibroblasts to iPSCs, which correlates with loss of the repressive
mark H3K27me3 and enrichment of the activating mark H3K4me3 0Nei et al. 2009), as well
as a decrease in DNA methylation (Doi et al. 2009). However, genes bound individually by
Oct4, Sox2, or Klf4 are not activated as strongly or become repressed (e.g. lineage
commitment genes), indicating that transcriptional activation might be achieved by GO-
operation of the three master pluripotency regulators (Figure 1.13). Genes associated with
c-Myc alone or in combination with other factors are mostly involved in metabolic processes
(e.g. control of translation, RNA splicing, cell cycle, and energy production). c-Myc is,
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therefore, thought to be necessary for enhancing the early steps of reprogramming by up-
regulating the metabolic program of the pluripotent state (Sridharan et al. 2009).
Observations that iPSCs can be derived in the absence of c-Myc, or by over-expression of
Oct4 and Sox2 alone (nevertheless at very low efficiency, see Table 3.2) indicate that not all
iPSC factors are required for reprogramming. Also, replacement of KLF4 and c-MYC by
NANOG and LlN28 for the generation of iPSCs from human fibroblasts (Yu et al. 2007b; Jia
et al. 2010) indicates that different molecular pathways can lead to reprogramming or that
the functions of KLF4 and c-MYC overlap with those of NANOG and LlN28 (reviewed by
Hochedlinger and Plath 2009). Indeed, LlN28 appears to positively regulate c-MYC though
inhibition of let-7 miRNAs that can target c-MYC for degradation, suggesting that the two
TFs might induce iPSC generation via similar mechanisms (Kumar et al. 2007; Viswanathan
et al. 2008). Also, LlN28 might promote reprogramming by directly activating translation of
OCT4 mRNA (Qiu et al. 2009).
Nonetheless, the exact pathway of somatic cell reprogramming by defined TFs is largely
unknown. It is suggested that exogenous TFs might down-regulate lineage commitment
genes and "jump-start" the re-activation of endogenous pluripotency- TFs by triggering the
auto-regulatory feed-back loops that control their expression (section 1.3.2). Equally,
exogenous TFs could induce iPSC formation by triggering the activation of differentiation
antagonists, or altering chromatin architecture to an open conformation that would be
permissive to reactivation of the ESC-transcriptional machinery (reviewed by Hochedlinger
and Plath 2009).
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Figure 1.13- Possible roles of key pluripotency-regulators in the generation of iPSCs
A. Co-binding of Oct4, Sox2 and Klf4 to gene promoters together with other transcription factors (TFs),
including Nanog and Esrrb, recruit co-activators such as the histone acetyltransferase (HAT) p300, thus
promoting transcriptional activity in genes necessaryfor self-renewal. B. Genes bound be either Oct4, Sox2or
Klf4 are often repressed through recruitment of histone de-acetylases (HDAC)and histone methyltransferases
of the Polycomb complex group (PcG).C. In collaboration with other TFs,c-Myc is suggested to activate the
basic energy, proliferation and metabolism program of the mESC-state(adapted from Hochedlinger and Plath
2009)
1.8.3 Epigenetic characteristics of iPSCs
Both mouse and human iPSCs show hypo-methylation in the promoter regions of
pluripotency regulators such as OCT4, NANOG and REX1, compared to the somatic cells
.
they were derived from (Takahashi et al. 2007; Mikkelsen et al. 2008; Park et al. 2008c; Doi
et al. 200~). mESCs also show re-establishment of histone protein "bivalent domains"
(section 1.5.1.5) in the promoter regions of lineage-specific genes, such as Pax5, Sox1 and
Nkx2.2 (Mikkelsen et al. 2007; Wernig et al. 2007) and reactivation of the silent X-
chromosome in female lines, which is associated with reduced Ezh2-catalysed H3K27me3
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(Maherali et al. 2007). However, recent analysis of DNA methylation at 2,020 CpG islands,
using padlock-probes, revealed that although iPSCs and hESCs were clustered together
based on their DNA methylation signatures, they also had subtle yet noticeable differences,
with iPSCs being overall more methylated than hESCs (Deng et al. 2009). Similar results
were provided by Lagarkova et al. (2010) who compared the DNA methylation profiles of
hESCs to iPSCs derived from umbilical vein endothelial cells. Imprinted genes, such as
H19, KCNQ10T1, PEG3, GTL2 and IGF2, also showed aberrant DNA methylation and
allele-specific expression in iPSCs (Pick et al. 2009). Therefore, even though in vitro
reprogramming by defined factors can re-assign the epigenetic identity of somatic cells to an
ESC-like state, the severe effects of aberrant epigenetic characteristics on human health
(see section 1.5.2.6) suggest that further investigation into the epigenetic signatures of
iPSCs is necessary before their use can safely be transferred to the clinic.
1.8.3.1 Improving the generation of iPSCs via epigenetic manipulations
The efficiency of iPSC generation has been manipulated by treatment of somatic cells with
small molecules capable of affecting DNA methylation or histone modifications (Table 1.6).
Treatment of MEFs with 5-azacytidine, a DNA methyltransferase inhibitor molecule, was
shown to enhance reprogramming efficiency by 10-fold (Huangfu et al. 2008a), while
treatment of the same cells with the HDAC inhibitors; valporic acid (VPA), suberoylanilide
hydroxamic acid (SAHA), or trichostatin A (TSA) was also shown to improve the efficiency of
iPSC generation (Huangfu et al. 2008a). VPA had the most profound effect, as it enabled a
100-fold improvement of the reprogramming process (Huangfu et al. 2008a). Treatment of
human fibroblasts with this molecule enabled a 10 to 20-fold increase in iPSC production,
and also allowed iPSCs to be generated when fibroblasts were transduced with OCT4 and
SOX2 alone (Huangfu et a/. 2008b). Treatment with the small molecule BIX-01294, a G9a
inhibitor capable of significantly reducing H3K9 methylation (Kubicek et al. 2007) enabled
reprogramming of mouse neural progenitor cells by infection with Oct4 and KIf4 alone (Shi
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et al. 2008). Moreover, treatment of partially reprogrammed granular colonies generated
during reprogr::amming of MEFs, with siRNAs or shRNAs against the DNA methyltransferase
DNMT1 was shown to enable full reprogramming of these colonies into iPSes (Mikkelsen et
al. 2008). Despite their success in improving the efficiency of iPSe generation, most
chemical compounds used to date to improve iPSe-generation efficiency have a broad
specificity, affecting all types of DNA methylation or all histone de-acetylation enzymes,
therefore providing little information about the exact mechanism by which they impact on
reprogramming efficiency.
Table 1.6- Small molecules used to manipulate iPSegeneration
0= OCT4, s= SOX2, K= KLF4, c= c-MYC
Treatment Function
Vector & Cell type Effect References
transgenes
Increased iPSC generation by 10-fold.
S-alacytidine DNMT Combination with the glucocorticoid
(S-ala) inhibitor Retrovirus OSKC Dexamethasone improved s-aza effect
by a further 2.6-fold
Valporic acid Increased iPSC generation by >100-fold
Huangfu et(VPA) Retrovirus OSK MEFs Improved iPSC generation by SO-fold
Suberoylanilide
a/.2008a
HDAC
Hydroxamic
inhibitor
acid (SAHA) Retrovirus OSKC Increased iPSC generation efficiency
Trichostatin A
(TSA)
S-alacytidine DNMT Dox-inducible 2nd(S-ala) inhibitor lentivirus OSKC generation Partially reprogrammed iPSC become Mikkelsen
Dnmtl DNMT siRNA/shRNA MEFs
fully reprogrammed et 0/.2008
enzyme
Chromatin Gaspar-
Chdl shRNA MEFs Inhibits iPSC generation Maia et 0/.
remodelling
2009
Retrovirus SKC Mouse
BIX-01294
G9a Neural Increased iPse generation efficiency
inhibitor Retrovirus OK Progenitors Shi et 0/.
Retrovirus KC
L-channel Combination of RG108 or BayK8644 with
20Q8
BayK8644 or
calcium Retrovirus OK MEFs BIX-01294 further improved iPSC
RGI08
agonist generation efficiency
Valporic acid
Retrovirus aSK Human
Huangfu etHDAC Fibroblasts Increased iPSC generation by 10-20 fold(VPA) inhibitor Retrovirus OS (BJ, HDF) a/.2008b
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1.8.4 Differentiation of iPSCs
iPSCs generated form mouse and human fibroblasts have been differentiated to a variety of
cell types, including cardiomyocytes, neurons, macrophages, T-cells, neurospheres, B-cells,
adipocytes, osteoblasts and retina cells (Maherali et al. 2007; Hirami et a/. 2009; Katsuhisa
et al. 2009). Haematopoietic progenitors generated from iPSCs have so far been used in
mouse models to rescue sickle cell anaemia symptoms (Hanna et al. 2007), while neural
iPSC-derivatives have been used in rat models to improve symptoms of Parkinson's
disease (Wernig et al. 2008b). Human iPSC-derived cardiomyocytes as well as hepatocytes
and vascular cells have been extensively characterised and were found to have similar
properties to their ESC-derived equivalents (Gai et al. 2009; Song et al. 2009; Taura et a/.
2009; Yokoo et al. 2009), demonstrating that hESCs and iPSCs share common
differentiation potentials. hESCs and iPSCs were also shown to rely on the same signalling
pathways for differentiation into extra-embryonic tissues, neuroectoderm and mesendoderm
(Vallier et a/. 2009b). In this thesis, iPSCs were differentiated into fibroblasts (see section
3.1.1) in order to determine whether they could "circle" back to the same cell phenotype that
they were derived from (Figure 1.1) or whether the "parent" hESC-derived fibroblasts would
have different gene expression and epigenetic regulation of pluripotency-associated TFs
compared to iPSC-derived fibroblasts.
1.9 THESIS PERSPECTIVE
Gene expression is regulated by complex interactions between transcription factors and
epigenetic modifications, which ultimately lead to gene activation or repression/silencing by
changing the availability of gene promoter regions to binding of the Pol II transcriptional
machinery (section 1.3.1). Over-expression of a defined set of transcription factors in
differentiated cells is sufficient to trigger reactivation of endogenous pluripotency genes and
transition the differentiated cell phenotype to an ESC-like state (section 1.8.1). However, the
mechanisms of endogenous TF reactivation are not well understood, and it is unknown
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whether a change in cell phenotype is induced by the viral transgenes or if it occurs as a
consequence of endogenous TF reactivation. Repression/ silencing of the same TFs can
lead to differentiation of pluripotent hESCs and iPSCs, therefore raising the question of how
key pluripotency-associated TFs become activated or repressed to enable a change in cell
phenotype. The mechanisms of endogenous pluripotency-associated TF activation and
repression/ silencing were subject to investigation in chapters 4 and 5 of this thesis. Chapter
4 also investigated whether TFs in iPSCs reach the same epigenetic state as hESCs and
whether they use the same mechanisms to repress piuripotency-associated TFs upon
phenotype transition to fibroblasts. Chapter 5 was concerned with demonstrating that
altering the epigenetic modifications associated with pluripotency genes in differentiated
cells to a more ESC-like state can facilitate gene reactivation and improve the overall
reprogramming to iPSCs.
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2 MATERIALS AND METHODS
2.1 CEll CULTURE
All cell culture experiments were performed in a type II Biological Safety Cabinet, and cells
were incubated at 37°C, 5% C02, in a humidified atmosphere. Bright field and fluorescence
images of live cells were captured using a Nikon ECLIPSE TE2000-S inverted microscope.
2.1.1 Media
All media were filter sterilized though a O.21Jmfilter (Sartorius: 16532K) and were warmed-
up to 37°C before use.
Table 2.1- Composition of media used for cell culture
MEF/HEK293
BGK
DIFF
2.1.2 Isolation of mouse embryonic fibroblasts (MEFs)
MEFs were isolated from mouse embryos and used either to condition BGK medium for
feeding hESCs or as feeder cells for manual passaging of hESCs.
Pregnant female CD1 mice (Charles River Laboratories), at day 13.5 of gestation, were
sacrificed by cervical dislocation and placed in a type I Biological Safety Cabinet. An initial
horizontal incision was made on the abdomen skin and, using forceps and scissors, and a
cut was made on the peritoneum to expose the uterine horns, which were removed and
dipped in IMS. The horns were then placed in a Petri dish containing PBS (GIBCO
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Invitrogen: 14190), where each embryo was dissected out and decapitated, and visceral
tissue was removed. The embryos from each pregnant mouse were placed in a 50ml
Universal tube containing fresh PBS and were transferred from the dissection room to a
stem cell culture suite. There, the embryos were placed in a 90mm Petri dish containing
1.5ml of 0.25% Trypsin (GIBCO Invitrogen: 25200-072) and were thoroughly sliced using a
scalpel. The embryos were transferred to a 250ml container, where the volume of trypsin
was topped up to 2ml per embryo. They were then vortexed and incubated in a 37°C water
bath for 5 minutes. This was repeated until the embryos appeared to be homogenized.
Following homogenization, 4ml of MEF medium, supplemented with 1x penicillin and
streptomycin (GIBCO Invitrogen: 15870-063), were added per embryo. The suspension was
shaken vigorously and vortexed again, and then allowed to stand at room temperature for 1
minute. The cells were transferred to a fresh container, leaving any sedimented tissue
behind, and were aliquoted to 175cm2 tissue culture flasks (NUNC: 156502) at a density
equivalent to 2 embryos per flask. The volume in the flasks was topped up to 30ml using
MEF medium, supplemented with penicillin and streptomycin. The flasks were stored in a
humidified 37°C, 5% CO 2 incubator (Heraeus HERAcell 150). The next day, the medium
was replaced with fresh MEF medium without penicillin or streptomycin, and cells were
cultured until confluent. Cells were then cryopreserved in Dimethyl Sulfoxide (OMSO;
SIGMA: 02650), at a density of 3 vials per 175cm2 flask.
2.1.3 Growth and passage of MEFs
A cryopreserved vial (Nunc CryoTube Vials; NUNC: 343958) of MEFs was removed from
the liquid nitrogen storage tank and was mixed with 10ml of MEF medium. The cell
suspension was centrifuged (SIGMA 3-16 Mid-bench centrifuge; SIGMA: 10270) at 200xg
for 5 minutes to remove DMSO. Following centrifugation, the supernatant was removed, and
the cells were re-suspended in 15ml of MEF medium and transferred to a 75cm2 culture
flask (NUNC: 153732). They were then placed in a 37°C incubator for 1-3 days or until
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confluent, depending on the MEF batch. Once the flask was confluent, the MEF medium
was aspirated. The cells were washed with 15ml of PBS and treated with 1.5ml of 0.05%
trypsin (GIBCO: 25300) for 1 minute, at 37°C. The trypsin was inactivated with 13.5ml of
MEF medium, and 5ml were transferred to a 75cm2 flask. The medium was toped-up to
15ml and the flask was placed in a 37°C incubator for 1-3 days or until confluent.
2.1.4 Inactivation of MEFs
Inactivation of MEFs was performed by treating -80% confluent 75cm2 flasks with 5ml of
10IJg/mi mitomycin-c (SIGMA: M4287) dissolved in MEF medium, for 2.5h. After that,
mitomycin-c was aspirated and the cells were washed 3 times in 15ml of PBS. They were
then treated with 1.5ml 0.05% trypsin for 3-5 minutes, at 37°C. The trypsin was inactivated
with 8.5ml of MEF medium, and the cell suspension was centrifuged at 200xg for 5 minutes.
Following centrifugation, the supernatant was aspirated and the cells were re-suspended in
10ml of fresh MEF medium. 201J1were removed to perform a cell count, and the cells were
centrifuged again at 200xg for 5 minutes. Cells were then seeded in 75cm2 flasks coated
with 0.1% gelatin (SIGMA: G9391), at a density of 4.8 x 106 cells per flask, and placed in a
37°C incubator.
2.1.5 Harvesting conditioned medium from MEFs
After inactivation with mitomycin-c, MEFs were allowed at least 4 hours to attach to the
surface of the flasks. The MEF medium was then aspirated and replaced with 25m I of BGK
medium. The flasks were placed in a 37°C incubator to allow conditioning of the medium. ~4
hours later, the medium was collected and replaced with 25ml of fresh BGK. The harvested
conditioned medium was supplemented with FGF (11J1/ml)and was used to maintain hESC
cultures. Conditioned medium collection was repeated every 24 hours, for 7 days.
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2.1.6 Growth and passage of hESCs on Matrigel coated surfaces
Growth and culture of hESCs on Matrigel™ coated flasks was performed as described in
Denning et al. (2006). Coating was performed by adding 5ml of Matrigel™ (BD Biosciences:
354234), diluted by 1:100 in DMEM medium, per 25cm2 flask and treating for 1 hour, at r.t.
Coated flasks were stored at 4°C for up to 2 weeks.
Vials of hESCs, of the cell line HUES7 (HUES Facility, Harvard University, Cambridge;
Cowan et al. 2004), were removed from liquid nitrogen and mixed with 10ml of BGK
medium. The cell suspension was centrifuged at 160xg for 4 minutes. Following
centrifugation, the supernatant was removed, and the cells were re-suspended in 5ml of
MEF conditioned medium and transferred to a Matrigel™ coated 25cm2 culture flask (NUNC:
163371). Cells were then placed in a 37°C incubator until confluent, with daily changes of
MEF conditioned medium. Once the flask was confluent, the MEF conditioned medium was
aspirated, the cells were washed with 5ml of PBS, and then treated with 0.5ml of 0.05%
trypsin for 1 minute, at 37°C. The trypsin was inactivated with 5.5ml of BGK medium, and
2ml were transferred to a 20ml Universal tube for a 1 in 3 passage. The cells were
centrifuged at 160xg for 4 minutes. The supernatant was then aspirated, the cells were re-
suspended in 5ml of MEF conditioned medium, and transferred to a Matrigel™ coated
25cm2 flask. The flask was stored in a 37°C incubator, with daily changes of MEF
conditioned medium. hESCs were passaged routinely every 48h.
The genetically modified hESC line, HOGN, (gifted by Dr. Christine Mummery, Leiden
University Medical Centre, The Netherlands) was cultured as described above for HUE~7
cells. This line carried a gene targeted insertion of an IRES-GFP-IRES-Neo cassette
immediately after the endogenous OCT4 gene. The cassette was able to support
expression of GFP protein and provide resistance Neomycin under the control of the
endogenous OCT4 promoter (Braam et al. 2008b).
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2.1.7 hESC differentiation through embryoid body (EB) formation by
forced aggregation
The protocol used for hESC differentiation was adapted from Burridge et al. (2007). In a
70% confluent 25cm2 culture flask, the MEF conditioned medium was aspirated and the
cells were washed with 5ml of PBS. The cells were then treated with 0.5ml of 0.05% trypsin
for 1 minute, at 37°C. The trypsin was inactivated with 4.5ml of BGK medium, and the cell
suspension was transferred to a 20ml Universal tube. 201-11were removed to perform a cell
count, and the cells were centrifuged at 160xg for 4 minutes. The cells were then re-
suspended in MEF conditioned medium and seeded in 96-well V-bottom plates (NUNC:
249662) at a density of 10,000 cells per well. The plate was centrifuged at 950xg for 5
minutes, and placed in a 37°C incubator for 2 days, after which a medium change was
performed with fresh MEF conditioned medium.
A further two days later (i.e. on day 4 of differentiation), the EBs formed were transferred
from the V-bottom plates to 20ml Universal tubes, where the MEF conditioned medium was
replaced with DIFF medium. EBs were then transferred to untreated 90mm Petri dishes and
stored in a 3rC incubator for 8 days (i.e. up to 12 of differentiation). The EBs were
detached from the bottom of the Petri dishes daily, by pipetting, while the medium was
replaced with fresh DIFF medium every 3-4 days. Following this treatment, EBs were
transferred to untreated 96-well U-bottom plates (NUNC: 262162), at a density of one EB
per well. The plates were stored in a 37°C incubator for up to 10 days. The medium was
replaced by 1501-11of fresh DIFF medium every 3-4 days.
The EBs were finally transferred to 20ml Universal tubes and frozen at -80°C to be used for
molecular biology analyses, or cultured further to derive cell lines of differentiated cells. For
analysis of differentiation into the three embryonic germ layers, EBs were seeded onto glass
chamber slides on day 21 of differentiation, and fixed using 4% PFA in order to be used for
immunofluorescence staining.
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2.1.8 Derivation of human fibroblast cell-lines from hESCs
After culture of EBs in 96-well U-bottom plates for -10 days (i.e. day 22 of differentiation),
EBs were transferred to a 20ml Universal tube and centrifuged at 200xg for 5 minutes.
Following centrifugation, the supernatant was aspirated and the EBs were treated with 2ml
of 0.05% trypsin for 3 minutes, in a 37°C water bath. The EBs were then vortexed and
trypsin was inactivated with 18ml of DIFF medium. The EBs were centrifuged again as
before, the supernatant was aspirated, the EBs were re-suspended in 10ml of DIFF
medium, and were transferred to a 90mm culture dish (NUNC: 150350) which was placed in
a 37°C incubator for 2 days to allow EB attachment to the plates. The medium was then
replaced with 10ml of fresh DIFF medium and the EBs were allowed to grow for a further 2
days. After this, the EBs were washed with 10ml PBS and visible cell clumps were removed
by aspiration. Remaining cells were treated with 1.5ml 0.05% trypsin for 3 minutes. The
trypsin was inactivated with 8.5ml of differentiation medium, and the cells were transferred
to a 20m I Universal tube to be centrifuged for 5 minutes, at 200xg. The pellet was re-
suspended in 5ml differentiation medium and the cells were seeded in a 25cm2 culture flask.
Once the cells were confluent, they were passaged in a 1:3 split, while a portion was
cryopreserved in DMSO for future use.
2.1.9 Generation of clonal cell lines from hESC-derived fibroblasts
A confluent flask of hESC-derived fibroblasts grown in DIFF medium was trypsinised by
treatment with 1ml of 0.05% trypsin for 3 minutes, at 37°C. The trypsin was inactivated with
4ml of DIFF medium, and cells were transferred to a 20m I Universal tube for centrifugation
at 200xg for 5 minutes. The supernatant was then aspirated, and the cells were re-
suspended in 5ml of DIFF medium. Cells were then seeded in 96-well flat-bottom plates
(NUNC: 167008) at a density of 20 cells per plate, and a total volume of 100IJI per plate. The
plate was placed in a 37°C incubator for 4 days, after which a medium change was
performed with fresh DIFF medium. The medium was replaced every 48h for a further 10
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days, after which the plates were scanned to identify wells containing proliferating
fibroblasts. The cells in each well were considered to represent clonal lines originating from
single cells. Each clonal line was expanded in culture and cryopreserved in DMSO for future
experiments.
2.1.10 Growth and culture of primary fibroblast lines
The BJ neonatal foreskin fibroblast line (kind gift by Dr. Ramiro Alberio, The University of
Nottingham) and the adult skin fibroblast line SUKE (gift by Dr. David Brook, The University
of Nottingham) were used in this thesis for comparison to hESC-derived fibroblasts. BJ
fibroblasts were originally derived by the group of Dr. J.R. Smith (Baylor College Medical
School, Houston) and are now available from the American Type Culture Collection
(Product no.: CRL-2S22). SUKE fibroblasts were isolated by the lab of Dr. D. Brook. Both
lines had a normal diploid karyotype.
BJ and SUKE fibroblasts were cultured in differentiation (DIFF) medium, as described
previously for hESC-derived fibroblasts (Section 2.1.8). Once a 2Scm2 flask of cells was
confluent, the DIFF medium was aspirated and the cells were washed with Sml of PBS.
They were then treated with 1ml of O.OS%trypsin for 3 minutes, at 37°C. The trypsin was
inactivated with Sml of DIFF medium, and 2ml were transferred to a 20ml Universal tube for
a 1 in 3 passage. The cells were centrifuged at 200xg for S minutes. The supernatant was
then aspirated, cells were re-suspended in Sml of DIFF medium, and transferred to a 2Scm2
flask which was stored in a 3rC incubator. The medium was replaced every 48h and the
cells were passaged every 3-4 days.
2.1.11 Growth and passage of Human Embryonic Kidney cells
Human Embryonic Kidney (HEK) cells of the cell line HEK2931T17 (American Type Culture
Collection: CRL-11268; Graham et al. 1977; Harrison et al. 1977) and the clonal HEK293
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line BL 15 (kindly gifted by Dr. David Darling, King's College London; Nesbeth et al. 2006)
were removed from liquid nitrogen and were mixed with 10ml of HEK293 medium. The cell
suspension was centrifuged at 200xg for 5 minutes. Following centrifugation, the
supernatant was removed, and the cells were re-suspended in 5ml of HEK293 medium and
transferred to a 25cm2 culture flask. They were then placed in a 37°C incubator for 2 days or
until confluent. Once the flask was confluent, the medium was aspirated and the cells were
washed with 5ml of PBS. They were then treated with 1ml of 0.05% trypsin for 1 minute, at
37°C. The trypsin was inactivated with 4ml of HEK293T medium, and 1ml was transferred to
a clean 25cm2 flask, for a 1 in 5 passage. The flask was placed in a 37°C incubator for 2
days or until confluent.
The culture medium for BL 15 cells was supplemented with 2.5jJg/ml Puromycin and
Blasticidin (SIGMA; P8833 and 15205, respectively) to maintain clonal selection.
2.1.12 Toxicity testing for the antibiotic G418
hESCs and hESC-derived fibroblasts were seeded in 6-well plates (NUNC: 152795) at a
density of 40,000 cells per well, and were grown in 2.5ml of conditioned or DIFF medium,
respectively. Wells were coated with Matrigel™ (section 2.1.6) prior to seeding of hESCs. 24
hours following cell seeding, the medium was replaced with fresh conditioned or DIFF
medium, which was supplemented with the antibiotic G148 (SIGMA; A1720), at
concentrations varying from 0 to 800 jJg/ml. This was repeated daily for 5 days, and the
percentage cell survival at each G418 concentration was calculated on the final day based
on total cell counts.
2.1.13 Calculation of population doubling time
hESCs and hESC-derived fibroblasts were seeded in 6-well plates at a density of 200,000
cells per well, and were grown in 2.5ml of conditioned or DIFF medium, respectively. Wells
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were coated with Matrigel™ (section 2.1.6) prior to seeding of hESCs. When confluent, the
cells were passaged as described in section 2.1.6 for hESCs and section 2.1.8 for hESC-
derived fibroblasts. The number of cells per well was calculated by total cell counts, and the
cells were re-seeded in fresh 6-well plates at a density of 200,000 cells per well. This was
repeated for a total of 6 passages, after which population doubling times were estimated
based on Denning et al. (2006). The equations used to calculate population doubling times
were based on cumulative population doubling and cumulative time in culture, as shown
below.
Cumulative population
doubling Sum
Log10(fold increase in cell number per passage)
Population doubling
time (hours)
Cumulative time in culture
Cumulative population doubling
2.1.14 Live cell staining for the surface antigen TRA-1-81
Immunofluorescence staining for the hESC surface marker TRA-1-81 was performed based
on Lowry et al. (2008), using live cells that were attached to culture surfaces. A
phycoerythrin (PE) conjugated anti-human TRA-1-81 antibody (eBioscience; 12-8883-80)
was diluted by 1:100 in MEF conditioned medium and filtered-sterilised through a Millex-GV 4
0.221Jm/4mm filter unit (Millipore: SLGV004SL). Cells were then incubated with the diluted
antibody for 20 minutes, in a 37°C incubator, in the dark. Following incubation, the antibody
was removed and cells were washed twice with MEF conditioned medium. Fluorescence
staining with TRA-1-81 antibody was assessed within 1 hour of antibody removal, under a
Nikon ECLIPSE TE2000-S inverted microscope.
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2.1.15 Oil red-O staining
Oil-red 0 staining for adipocyte detection was performed with help from Dr. David Anderson
using cells fixed in 4% paraformaldehyde, for 20 minutes. Following fixation, the cells were
washed in 60% isopropanol and then treated with 0.2% Oil-red 0 (SIGMA; 0-0625; diluted
in 60% isopropanol) for 10min, at room temperature. Oil-red 0 was washed off with distilled
water and images were captured under a Nikon ECLIPSE TE2000-S bright field inverted
microscope.
2.2 CELL MANIPULATION BY LlPOFECTION AND VIRAL TRANSDUCTION
2.2.1 Buffers and solutions
All buffers and solutions were autoclaved before use.
Table 2.2- Buffers and solutions used for lipofection and viral transduction
Buffer Component w/v or v/v Supplier Product number
NaGI 1.6g SIGMA SS886
KGI 0.076g SIGMA PS40S
2x HBS pH7.S Na2HP04 0.02g SIGMA SS136Glucose 0.2g SIGMA G7021
HEPES 1.0g SIGMA H1016
SDW to 100ml SIGMA W3S00
HEPES 0.119g SIGMA H1016
2.SM GaGI2pH7.S GaGI2 13.88g SIGMA G4901
SDW to SOml SIGMA W3S00
2.2.2 hESC lipofection with siRNAs
In a confluent 25cm2 culture flask of hESCs, MEF conditioned medium was aspirated and
the cells were washed with 5ml of PBS. They were then treated with 0.5ml of 0.05% trypsin
for 1 minute, at 37°C. The trypsin was inactivated with 4.5ml of BGK medium, and the cell
suspension was transferred to a 20m I Universal tube. 201-11were removed to perform a cell
count, and the cells were centrifuged at 160xg for 4 minutes. The cells were then re-
suspended in MEF conditioned medium and seeded in 24-well plates (NUNC: 143982) at a
density of 10,000 cells per well. Cells were placed in a 37°C incubator for 24 hours, after
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which MEF conditioned medium was replaced by O.Sml of OptiMEM I (GIBCO: 3198S)
containing 1.SIJI of the cationic lipid reagent Lipofectamine-2000 (Invitrogen: 11668-027),
and 2.SIJI of 20IJM stock siRNA against the gene of interest. The transfection was allowed to
occur for 4 hours, in a 37°C incubator, after which OptiMEM was replaced by O.Sml of fresh
MEF conditioned medium. The cells were further incubated at 37°C and were collected in
1.Sml Eppendorf tubes at 24, 48 and 72 hours after transfection, by lysis with 3S01J1RLT
buffer (QIAGEN RNeasy Kit: 74014). The cells were snap-frozen immediately on dry ice and
were stored at -80°C. All lipofections included a negative control sample which received no
treatment (Untreated), as well as a sample which was treated with lipid but no siRNA (Lipid
control).
Table 2.3- Invitrogen Stealth Select siRNAs used for lipofection of hESCs
HSS102859
DNMT1 NM_OO1379.1 HSS102860
HSS10286
HSS141868
NM_153759.2
DNMT3A NM_175629.1 HSS141869
NM_022552.3
HSS141870
2.2.3 HEK293 cell lipofection with plasmid DNA
In a confluent 2Scm2 culture flask, the HEK293 medium was aspirated and cells were
washed with Sml of PBS. They were then treated with 1ml of O.OS%trypsin for 2 minutes, at
37°C. The trypsin was inactivated with 4ml of HEK293 medium, and the cell suspension was
transferred to a 20ml Universal tube. 20IJI were removed to perform a cell count, and the
cells were centrifuged at 200xg for S minutes. Cells were then re-suspended in HEK293
medium and seeded in 6-well plates at a density of S,OOOor 10,000 cells per well. Plates
were placed in a 37°C incubator for 24 hours, after which HEK293 medium was replaced by
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2ml of OptiMEM I containing a cationic lipid reagent (Lipofectamine-2000, Lipofectamine-
LTX; Invitrogen: 15338-100, GeneJammer; STRATAGENE: 204130, or FuGENE HD;
Roche: 04709691001) and plasmid DNA. The transfection was allowed to occur for 4 hours,
at 37°C, after which OptiMEM was replaced by 2ml of fresh HEK293 medium. The cells
were grown for 24 hours at 37°C, they were photographed under bright-field and
fluorescence light, and were finally prepared for FACS analysis. All lipofections included a
negative control sample which received no treatment (Untreated), as well as a sample
treated with lipid but no DNA (DNA control).
2.2.4 Transduction with lentivirus produced in HEK293/T17 cells
HEK293 cells were seeded in a 175cm2 flask at a density of 5 million cells per flask, in a
total of 20m I of HEK293 medium. 24 hours later, the HEK293 cells were transfected as
described in section 2.2.3, using Lipofectamine-2000, 66.7j..lg of a lentiviral transfer plasmid,
(e.g. pLVTHM; Addgene: 12247), 50j..lg of the lentiviral packaging plasmid psPAX2
(Addgene: 12260) and 20j..lgof the envelope plasmid pMD2.G (Addgene: 12259). Formation
of lentiviral particles in HEK293 cells was allowed to occur for 48 hours, after which the
culture medium was collected and filtered through a 0.2j..lm filter unit. The virus-containing
medium was then concentrated by approximately 75-fold using centrifugation at 4000xg, for
20 minutes, in Amicon Ultra-15 Centrifugal Filter Units 100NMWL (Millipore; UCF910008).
200j..l1of fresh concentrated virus was used to transduce 50,000 target cells, seeded in 6-
well plates 4-6 hours prior to lentiviral transduction. Transduction was carried out in a total of
2ml of appropriate medium for each cell type, in the presence of 8j..lg/ml hexadimethrine
bromide (Polybrene) solution (SIGMA: H9268). The medium was replaced with fresh culture
medium 24 hours later, and the cells were maintained as described before until needed for
further analysis.
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2.2.5 Transduction with lentivirus produced in BL15 cells
BL15 cells were cultured in antibiotic-free medium supplemented with 100l-lM of Biotin
(SIGMA; P2165), for 48 hours prior to their use for generation of lentiviral particles. BL 15
cells were seeded on gelatine coated 90mm culture dishes at a density of 6 million cells per
dish, in Biotin-supplemented HEK293 medium. 24 hours later, BL 15 cells placed in 7ml of
OptiMEM medium supplemented with 10% FBS and 100l-lM Biotin, for 1 hour at 37°C, and
were then transfected as described in section 2.2.3, using 601-11of Lipofectamine-2000, 10l-lg
of a lentiviral transfer plasmid (e.g. pLVTHM), 7.51-1gof the lentiviral packaging plasmid
psPAX2, and 31-1gof the envelope plasmid pM02.G. After 5-6 hours, BL 15 cells were
carefully washed three times with serum-free HEK293 medium, supplemented with 1mM
sodium pyruvate (SIGMA; S8636), and were stored in this medium, at 37°C. Virus-
containing culture media were collected in 50ml Universal tubes at 12 and 24 hours
following transfection and were stored at -80°C until a final collection at 48 hours following
transfection was performed.
All virus-containing media where then thawed in cold water and were filter-sterilised through
a 0.21-1mfilter unit. They were then pH adjusted to a pH of 7.7, using 100mM NaOH (SIGMA;
S8045), and were precipitated by incubation with 60mM CaCb (SIGMA; C4901) for 30
minutes, in a 37°C water bath. Following formation of white precipitates, the tubes were
centrifuged at 4000xg for 5 minutes, and the pellet was re-suspended in virus buffer (50mM
NaCI, 100mM EOTA in SOW), at 1/1Oth of the original volume prior to precipitation. The virus
was then concentrated further using streptavidin paramagnetic beads (Promega; Z5481),
which were mixed with the precipitated virus at a 1:1 ratio and incubated on a roller for 2.5
hours, at r.t. Following incubation, the bead-bound virus was washed twice in OIFF medium
and was finally re-suspended in OIFF medium, at ~ the original volume. The virus was used
to transduce cells at a multiplicity of infection (MOl) of 5 units, in the presence of 8l-1g/ml
Polybrene solution.
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2.2.6 Formation of iPSCs from hESC-derived fibroblasts
hESC-derived fibroblasts grown in DIFF medium were seeded in 6-well plates, at a density
of 50,000 cells per well, and were transduced with lentiviral particles 4-6 hours later. For
virus produced in HEK293T cells (section 2.2.4), 200IJI of viral particles prepared with each
transfer plasmid; pSin-EF2-0CT4-Pur (Addgene: 16579), pSin-EF2-NANOG-Pur (Addgene:
16578), pSin-EF2-S0X2-Pur (Addgene: 16577), and pSin-EF2-LlN28-Pur (Addgene: 16580;
Yu et al. 2007b) were added to each well, in a total volume of 3ml. For virus produced in
BL 15 cells (section 2.2.5), cells were transduced at an MOl of 5 for each of the viruses
mentioned above.
hESC-derived fibroblasts were trypsinised (section 2.1.8) at 48 hours following lentiviral
transduction and were seeded onto inactivated MEF feeder cells. From then on, they were
cultured in BGK medium, supplemented with 10ng/ml FGF, with daily medium changes.
Seven days later, the BGK medium was replaced with MEF conditioned medium,
supplemented with 10ng/ml FGF. Daily medium changes were performed with fresh MEF
conditioned medium, supplemented with 10ng/ml FGF, until day 18-23 post-transduction,
when emerging iPSC colonies where expanded in culture using manual dissection
procedures (section 2.2.7) and were finally adapted to culture on Matrigel (section 2.1.6).
2.2.7 Growth and passage of iPSCs by manual dissection
iPSCs were derived as colonies on mitotically inactivated MEFs (see section 2.1.4) and
were maintained in BGK medium, with daily medium changes. Colonies were dissected
under a Leica MZ12.5 stereomicroscope, using a 0.190-0.210mm micro-dissecting glas's
knife (STEM CELL CUTTING TOOL: Vitrolife;14601). Colony pieces of 100-2001Jm in
diameter were transferred to a fresh culture dish seeded with mitotically inactive MEFs, and
were incubated in a 37°C incubator with daily medium changes for a further 2-5 days, until
they were ready for the next passage.
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2.3 KARYOTYPE ANALYSIS
To prepare cells for karyotype analysis, sub-confluent exponentially growing cultures of
hESCs or iPSCs were treated for 60 minutes, at 37°C, with the anti-mitotic agent
KaryoMAX® Colcemid™ (Invitrogen; 15212012) diluted to a final concentration of 100ng/ml
in MEF conditioned medium. The KaryoMAX containing medium, together with any floating
cells, was collected in a 20ml Universal tube. Attached cells were harvested by treatment
with 0.05% trypsin, as described in section 2.1.6, and were added to the same 20ml
Universal tube as before. Following centrifugation at 300xg for 5 minutes, the cell pellet was
re-suspended by slow drop-wise addition of hypotonic 0.6% sodium citrate solution (Fisher
Scientific; S/3320), while vortexing at 1800rpm. Incubation in hypotonic solution was then
carried out for 20 minutes, at r.t., after which the cells were pelleted by centrifugation at
300xg for 5 minutes. The cells were fixed by drop-wise addition of fixative solution
(methanol acetic acid mix at a 5: 1 ratio), while vortexing at 1800rpm. Cells were then stored
at -20°C, ready for G-banding analysis. G-banding was performed by Mr. Nigel Smith
(Nottingham City Hospital, UK), based on guidelines from the International System for
Human Cytogenetic Nomenclature (ISCN, 2005). 30 metaphase spreads were analysed for
each sample.
2.4 FLOW CYTOMETRY
2.4.1 Analysis of GFP expression
Cells grown in 6-well plates were washed in 2ml PBS and then trypsinised for 5-6 minutes,
at 37°C. Trypsin was inactivated with 5ml of 10% FBS in PBS per well, and the suspende,d
cells were transferred to 15ml Universal tubes to be centrifuged at 200xg for 5 minutes. The
supernatant was then aspirated and the cell pellet was re-suspended in 1ml of 10% FBS in
PBS. The cells were mixed well by pipetting and transferred to glass test tubes
(SARSTEDT; 55.476.005) for flow cytometry analysis which was performed by staff of the
Flow Cytometry Facility in Queen's Medical Centre, Nottingham.
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2.4.2 Analysis of protein expression
Cells were harvested by treatment with 0.05% trypsin, and were fixed by incubation in 600IJI
of 4% PFA in PBS (SIGMA; P-6148) for 15 minutes, at r.t. For staining of non-surface
antigens, the cells were treated with 200IJI of 0.5% Triton X-100 in PBS (SIGMA; T-8532) for
15 minutes, at r.t. They were then centrifuged at 300xg for 5 minutes and the pellet was re-
suspended in primary antibody, diluted at an appropriate concentration in 5% FBS in PBS
(Table 2.13). Following a 20 minute treatment in primary antibody, at r.t., the cells were
washed with 10ml of 5% FBS and centrifuged as before. The samples were wrapped in
aluminium foil and the pellet was re-suspended in AlexaFluor488 secondary antibody
(Invitrogen; A 11001), diluted at a 1:200 ratio in 5% FBS. The cells were incubated in
secondary antibody for 20 minutes, at r.t., and were then washed in 10ml of 5% FBS. Cells
were centrifuged for a final time at 300xg, for 5 minutes, and the pellet was re-suspended in
0.5ml of 5% FBS, ready for flow cytometry analysis.
2.4.3 Cell cycle analysis
Cells were harvested by treatment with 0.05% trypsin, and were re-suspended in 10 ml
PBS. They were then centrifuged at 160xg for 4 minutes, and the pellet was re-suspended
by drop-wise addition of ice-cold PBS. The cells were centrifuged as before and fixed by
drop-wise addition of ice-cold 70% ethanol, while vortexing at 1800rpm. Cells were stored in
fixative solution at 4°C for 24 hours, and were then centrifuged at 160xg for 4 minutes. The
pellet was re-suspended in staining solution, which consisted of 0.2% Tween-20 (SIGMA;
P5927), 250IJg/mi RNase A (SIGMA; R4642) and 10IJg/mi propidium iodide (SIGMA;
P4170) in PBS. Following a 30-minute incubation in staining solution, at r.t., the samples
were transferred to glass test tubes which were wrapped in aluminium foil to avoid bleaching
of propidium iodide. Cell cycle analysis was performed using an FC500 Flow Cytometer
(Beckmen Coulter). Propidium Iodide was excited at 488nm and emission data was
collected at 620nm. The data was analysed using Cylchred software, version 1.0.2.
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2.4.4 Analysis of flow cytometry results
Flow cytornetry analysis was performed using a Coulter Altra Flow Sorter, unless otherwise
stated. The cytometer was set to count 50,000 cells per sample, and results were evaluated
on WinMDI software, version 2.9. To analyse the results, the linear functions of the cells'
forward scatter (FS Lin) were initially plotted against those of the side scatter (SS Lin) as
shown in Figure 2.1.i. Healthy cells were selected (coloured red in Figure 2.1.ii) on these
plots, and cell debris (coloured black in Figure 2.1.ii) was excluded from further analysis of
marker expression (Figure 2.1.iii). Analysis of marker expression was performed by plotting
the Log10 function of its expression levels against the events/cells counted by the flow
cytometer. Quantification of % expression was performed relative to a negative control
sample (Untreated or GFP negative), whose expression level was set to 1%, in order to
account for cell auto-fluorescence.
i. ~. ..' , ii.
c
:.:::;
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c
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Figure 2.1- Scatter plots for flow cytometry analysis
Following collection of data from a flow cytometer, analysis was performed using WinMDI 2.9 software,
where i. the linear functions of the forward scatter (FS Lin) and side scatter (SS Lin) were plotted against each
other. ii. Healthy cells were selected (region highlighted in red) and iii. cell debris was excluded from further
analysis.
2.5 MOLECULAR BIOLOGY ANALYSIS
2.5.1 Buffers and solutions
All buffers and solutions were autoclaved before use.
69
PhD Thesis
Elena Matsa
School of Clinical Sciences
The University 0/Nottingham
Chapter 2- Materials and Methods
Table 2.4- Buffers and solutions used in protocols for molecular analysis
Buffer Component w/v or v/v Supplier Product number
3M sodium . Sodium acetate 61.S2g SIGMA S2889
acetate pHS SOW to 250ml N/A N/A
Tris Base 108g Fisher Scientific BPE152-1
10x TBE pH8 Boric acid SSg_ SIGMA B1934
EOTA 7.44g SIGMA E5134
SOW to1L N/A N/A
Agarose gel Bromophenol Blue 125mg SIGMA B6126Glycerol 60ml SIGMA G6376loading buffer
Water to 100ml SIGMA W4502
2.5.2 Total RNA extraction from animal cells
Total RNA was extracted from animal cells using the QIAGEN RNeasy Mini kit (QIAGEN:
74104), according to the manufacturer's instructions, on pg25-30 of the RNeasy Mini
Handbook. Optional steps 3b, 9 and DNase (QIAGEN: 79254) digestion were performed.
RNA was eluted in 301J1of sterile distilled water, precipitated using glycogen precipitation
(Invitrogen: 1OB14-01 D), and stored at -BO°C. All experiments included an RNA negative
control sample, in which no cells were added, to assess contamination of the RNA
extraction reagents. RNA was quantified using a NanoDrop ND1000 spectrophotometer,
and was considered to be of adequate quality if the ratio of light absorption at 260nm to that
at 2BOnm (260/2BO) was between 1.B-2.2 (Glasel 1995). A single absorption peak at 260nm
also indicated good quality RNA preparation.
2.5.3 cDNA synthesis
cDNA was synthesised using the First Strand cDNA Synthesis kit (GE Healthcare: 279261-
01). 100ng mRNA were mixed with RNase-free water in a final volume of BIJI, and were
.
heated to 65°C for 10 minutes. Samples were then placed on ice and mixed with 11J1of
random hexamer primers pd(N)6, 11J1OTT solution, and 51J1Bulk First-Strand cDNA reaction
mix (all supplied in the First Strand cDNA Synthesis kit). Samples were heated to 37°C for 1
hour, after which they were placed on ice and mixed with B51J1of RNase-free water. All
experiments included a Reverse Transcriptase (RT) negative control, in which the 51J1of
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Bulk First-Strand cDNA reaction mix were substituted by 51-11of water, and a cDNA negative
control in whioh the RNA template was replaced by water.
2.5.4 Real-time peR
21-11of cDNA synthesised using the First Strand cDNA synthesis kit (section 2.5.3) were
mixed with 101-11of 2x TaqMan Universal PCR Mastermix (Applied Biosystems: 4324018)
and 11-11of the appropriate TaqMan Gene Expression Assay, in a final volume of 201-11.The
reactions were set-up in ABI-PRISM® 96-well Optical Reaction Plates (Applied Biosystems:
4306737), which were sealed with Optical Adhesive Covers (Applied Biosystems:
43609954) after sample addition. The plates were centrifuged at 300xg for 2 minutes, and
the PCR was run in an Applied Biosystems 7500 Fast Real-Time PCR System. The results
were analysed based on the b.b.Ct method of relative quantification (Livak and Schmittgen
2001), using 7500 Fast System SDS V2.0 software (Applied Biosystems).
Table 2.5- TaqMan Gene Expression Assays used for Real-Time peR
Gene Ref. Seq. ABI cat. no./Ref Primer Primer sequence (5'~3')
F GAAGGTATTCAGCCAAAC
OCT4 NM_002701 Liedtke et al. 2007
R CTTAATCCCAAAAACCCTGG
F GCAATGGTGTGACGCAGAAG
NANOG NM_024865 - R GGCATCCCTGGTGGTAGGA
Probe CCCAGCCTTTACTC
SOX2 NM_003106.2 HsOl053049_sl - -
LlN28 NM_024674.4 Hs00702808_sl - -
KLF4 NM 004235.4 Hs00358836 ml - -
REX1 NM 174900.3 Hs00399279 ml - -
P4HB NM 000918.3 Hs00168586 ml - -
NM_175848.1
DNMT3B NM_175849.1 HsOl003405 ml - -
NM_175850.1
_
NM 006892.3
DNMTl
NM_001379.2 Hs00945900_g1 - -
NM 001130823.1
-
NM_153759.2
DNMT3A NM 175629.1 HsOl027166_ml - -_
NM 022552.3
DNMT3L NM_175867.i Hs00203536_ml - -
NM 013369.2
HPRT NM 000194.1 Hs99999909 ml - -
185 - Hs99999901 51 - -
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2.5.5 Gene expression analysis by RT-peR
PCR reactions were set in a final volume of 251J1.Each sample contained 2.51J1of 10IJM
primers, 2.51J1of 10x PCR buffer containing 1.5mM MgCI2 (QIAGEN: 1005479), 2.51J1of
2.5mM dNTPs (Invitrogen: R725-01), 0.1251J1of Hot Start Taq Polymerase (QIAGEN:
1007837), and 21J1of cDNA. Additional MgCI2 (QIAGEN: 1005482) was added according to
the primers used (Table 2.6). The reactions were set up in a thermal cycler (TECHNE TC-
412), with initial denaturation occurring at 95°C for 5 minutes, followed by repeated cycles
with denaturation at 95°C for 1 minute, annealing at a primer depended temperature for 30
seconds, and synthesis at 72°C for 1 minute. The cycle number varied according to the
primers used (Table 2.6). A final synthesis step was set at 72°C for 5 minutes. All reactions
included a negative control where cDNA was substituted by 21J1of water. 10IJI of amplified
PCR products were analysed by agarose gel electrophoresis (section 2.5.6) and the rest
were stored at -20°C.
2.5.6 Agarose Gel Electrophoresis
Molecular grade agarose (Invitrogen: 15510-027) was mixed with 1x TBE buffer to give the
percentage gel of choice. The suspension was heated in a microwave oven to dissolve the
agarose and, once cooled to -60°C, O.4lJg/ml ethidium bromide (SIGMA: E1510) was
added. The agarose was then poured into a clean gel-casting tray and was allowed to set
for 30-45 minutes. Once set, it was placed in an electrophoresis trough containing 1x TBE
buffer with O.4lJg/ml ethidium bromide. 10IJI of sample, together with 21J1of gel loading
buffer, were loaded in each well. Gels were run at 100V for -60min, after which they wer~
visualised using a UV transilluminator (Fujifilm; LAS4000). Band sizes were estimated using
appropriate DNA ladders that were run along with the samples, and were quantified using
AIDA V.4.15 2D densitometry software (Raytek Scientific Ltd).
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2.5.7 DNA gel extraction and purification
PCR amplification products were extracted using the QIAquick Gel Extraction kit (QIAGEN:
28704) according to the manufacturer's instructions, pg25-26 of the QIAquick Spin
Handbook. DNA was eluted in 301J1of elution buffer or sterile distilled water, quantified using
a NanoDrop spectrophotometer (NanoDrop ND-1000), if necessary, and stored at -20°C.
2.5.8 DNA extraction from animal cells
DNA was extracted from animal cells using the QIAGEN DNeasy Blood and Tissue kit
(QIAGEN; 69504), according to the manufacturer's instructions, pg25-27 of the DNeasy kit
Handbook. Optional steps 1c, and RNase A (QIAGEN: 19101) treatment were performed.
DNA was eluted in 100IJI of AE Buffer, and step 8 was omitted. If necessary, DNA was
precipitated using ethanol and Pellet Paint co-precipitant (Novagen; 69-049-3). DNA was
quantified using a NanoDrop ND1000 spectrophotometer, and stored at -20°C for future use.
2.6 DNA METHYLATION ANALYSIS
2.6.1 Bisulfite conversion of DNA
Bisulfite conversion of DNA was performed according to Kim et al. (2007). 1IJg of genomic
DNA, extracted as described in section 2.5.8, was digested in a total volume of 251J1for 16
hours, in a 37°C oven, with an appropriate restriction enzyme according to the gene
analysed (Table 2.7). The digested DNA was denatured by incubation at 100°C, for 5
minutes and then immediately placed on ice to avoid re-annealing of the DNA. The DNA
was then mixed with 2.51J1of freshly prepared 3M NaOH (SIGMA; S8045) and incubated at
37°C for 20 minutes. During this incubation period, 3.8g of sodium bisulphite (BDH
Chemicals: 103564D) were eluted in 5.5 ml of water (SIGMA; W4502) and 1.5ml of 2M
NaOH, all the while being kept in dark conditions. 110mg of hydroquinone (SIGMA: H9003)
were also dissolved in 1ml of water by heating at 55°C, for 10 min. The dissolved
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hydroquinone and bisulphite solutions were mixed together, and each DNA sample was
treated with 2701-11of the freshly prepared mixture. The samples were kept in the dark,
layered with 2001-11of mineral oil (SIGMA; M5310) and placed on a 55°C heat clock for 5
hours, to allow bisulfite conversion of the DNA. Following incubation, the mineral oil was
carefully removed, and the bisulphite treated DNA was added to 2ml sterile tubes
(Eppendorf; 0030 120.094) containing 6001-11of water, 901-11of 3M sodium acetate pH5
(SIGMA; S2889) and 2.51-11of Pellet Paint co-precipitant. 9001-11of isopropanol were then
added to each tube, and mixed well by pipetting. The samples were centrifuged in a desk-
top centrifuge, at maximum speed for 20 minutes. The resulting DNA pellets were washed in
8001-11of 70% ethanol and centrifuged as before, for 5 minutes. The supernatants were
carefully removed, and pellets were air-dried for 10 minutes. The pellets were then re-
suspended in 501-11of water, and the samples were desulfonated by addition of 51-11fresh 3M
NaOH. The reaction was completed by incubation at 37°C for 15 minutes, and the DNA was
purified using the QIAquick PCR purification kit (QIAGEN; 28104) according to the
manufacturer's instructions, pg19-20 of the QIAquick Spin Handbook. The DNA was eluted
in 331-11of water, and stored at -20°C for future use.
2.6.2 Bisulfite peR
Bisulfite PCR was performed in a final volume of 251-11,consisting of 0.1251-11Platinum Taq
(Invitrogen; 10966), 61-11of 51-1Mforward and reverse primers (Invitrogen), 2.51-11of 10x
Reaction buffer (Invitrogen; 10966), 1.251-11of 2.5mM dNTPs (Invitrogen; R72501), Xoptimal
MgCI2 (Invitrogen), and 11-11of bisulfite converted DNA (section 2.6.1). The PCR cycling
conditions were 95°C for 10 min followed by 40 cycles of; 95°C for 1min, Xoptimal "C for
1min, 72°C for 1min) and a final extension step at 72°C for 10min. Optimal conditions for
each primer set are shown in Table 2.7. Bisulfite PCR primers were designed using
MethPrimer software (Li and Dahiya 2002) or were previously published as described in
Table 2.7.
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2.6.3 Bisulfite sequencing
.
PCR products from bisulfite PCR (section 2.6.2) were separated by agarose gel
electrophoresis and purified using the QIAquick gel extraction kit (QIAGEN; 28704),
according to the manufacturer's instructions, pg25-26 of the QIAquick Spin handbook.
Sequencing analysis was performed using primers depicted by an asterix (*) in Table 2.7, by
staff of the DNA sequencing Lab, Queen's Medical Centre, The University of Nottingham.
Sequencing results were analysed as shown in Figure 2.2.
TGGGTTGAGGG TATTATGTGTT ATTATTGCGTT TTGAGCGTTTA GGAGGCGTTGT
'Y 'Y ... 'Y ...
o Unmethylated ® T> C et T= C 0 C> T • Methylated
Figure 2.2- Key for determining the methylation state of CpG sites in direct bisulfite sequencing
Thymidine (Tl peaks in CpG dinucleotides indicated unmethylated DNA, cytosine (C) peaks indicated
methylated DNA. Overlapping T and C peaks in individual CpG sites were regarded as preferentially
unmethylated if T>C, semi-methylated if T=C, and preferentially methylated if C>T.
2.6.4 Methylation-specific peR (MSP)
MSP (Herman et al. 1996) was performed as described in section 2.5.5, for 40 cycles, using
21J1of bisulfite converted genomic DNA (sections 2.5.8 and 2.6.1). DNA was amplified using
primers specific to both methylated and un-methylated DNA for each gene, as shown in
table Table 2.9. As positive control, a reference sample was methylated in vitro using SssI
methylase enzyme (NEB: M0226S). For this, 11J1of S-adenosy-L-methionine (SAM) was
added into 191J1of RNase/DNase free water, to a final concentration of 16001JM. The
reaction was performed in a total volume of 201J1,with 1IJg of genomic DNA, 21J1of 10X
buffer, 11J1of SssI methylase, 21J1of diluted SAM and 10IJI of RNase/DNase free water. In
vitro methylation was performed at 37°C for 2 hours, at the end of which the enzyme was
inactivated at 60°C for 20 minutes. Methylated DNA was purified using the QIAquick PCR
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purification kit according to the manufacturer's instructions. Following PCR amplification, the
samples were. resolved and imaged in a 2% agarose gel, as described before (section 2.5.6)
2.6.5 Combined bisulfite restriction analysis (COBRA)
PCR for COBRA (Xiong and Laird 1997) was performed as described in section 2.5.5, for 40
cycles, using 21-11of bisulfite converted genomic DNA (sections 2.5.8 and 2.6.1). Primers and
conditions used for PCR amplification are shown in Table 2.10. Following PCR, the products
were digested with appropriate restriction enzymes, as described in Table 2.8. All enzymes
were purchased from NEB. Digests were performed at 37°C, for 12 hours, in final volume of
251-11,using 1.51-11of the buffer recommended by the manufacturer for each restriction
enzyme, 0.51-11of restriction enzyme, 81-11of PCR product, and RNase! DNase free water
(SIGMA: W-4502). Following restriction digest, the samples were resolved and imaged in a
3% agarose gel, as described before (section 2.5.6)
Table 2.8- Restriction enzymes used for digestion of PCR products in COBRA analysis
Gene Restriction NEB Catalogue Number
enzyme
TP73 promoter Actl R0598S
PEG10 BstUI R0518S
Acil R0551S
PEG1 Acll R0598S
HpyCH41V R0619S
SLC22A18 BstUI R0518S
CDKN1C HpyCH41V R0619S
KvDMR1
BstUI R0518S
HpyCH41V R0619S
tGF2 DMRO
HpyCH41V R0619S
Acil R0551S
GTL2 CpG2 Actl R0598SHpyCH41V R0619S
SNRPN Acil R0551S
NESP55DMR Actl R0598S
GNAS1 XLas Acil R0551S
BstUI R0518S
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2.6.6 Genomic DNA digestion with methylation specific enzymes
.
Digests with the methylation specific enzyme McrBC (NEB; M0272S) were performed in a
final volume of 251..11,using 1.51..11of NEBuffer 2, 0.151..1110mg!ml BSA, 0.151..11of 100mM GTP,
and RNase! DNase free water (SIGMA: W-4502). 11..11of restriction enzyme was used to
catalyse the digestion of O.4lJg of genomic DNA (section 2.5.8). The digests were performed
at 37°C, for 12 hours. The enzyme was then heat-inactivated at 65°C, for 5 minutes, and
samples were run on a 1% agarose gel, as described in section 2.5.6.
2.7 CARRIER CHROMATIN IMMUNOPRECIPITATION (cChIP)
Cell pellets for cChlP analysis were collected and sent to The University of Birmingham, UK,
where cChlP was performed with help from Dr. Laura O'Neil. cChlP was carried out as
described in O'Neill et al. (2006), with D.me/anogaster SL2 cells being used as co-
precipitants for human cells. Nuclei were released by homogenization in a Dounce all-glass
homogenizer with a 'tight' pestle using two strokes. Chromatin of satisfactory quality
(predominantly but not exclusively mononucleosomal with minimal subnucleosomal
fragments), was used for ChiP with antibodies against H3K27me3, H3K9me2, H3K4Ac and
H3K4me3. DNA fractions precipitated with each antibody were analyzed using radioactive-
PCR (O'Neill L et a/. 2006). Primers and conditions for PCR are in shown in Table 2.11.
Table 2.11- Primers and PCRconditions used for radioactive-PCR
Gene Accession Primer Primer sequence (5' .......3') Annealing
number name temp.f'c
OCT4 NM_OO2701
F TTCCCCTTCCACA
58R GGGAGAGAGGGGTTGAGT
NANOG NM_024865
F TGTCTTCAGGTTCTGTTGCTCGGT
58R CGTCTACCAGTCTCACCAAGGCCA
- F TTAAGTACCCTGCACCAAAAASOX2 NM_OO3106 R GGGGATACAAAGGTTTCTCA 58
REX1 NM_174900.3
F CACCATGCCTGGCT AATTTT
58R CTGTCGTCCCAGCACTTTG
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2.8 IMMUNOHISTOCHEMISTRY
2.8.1 Solutions
All solutions, apart from 4% PFA which was stored at -20°C, were made fresh for each
experiment and were dissolved by placing on a roller for at least 20 minutes, at room
temperature.
Table 2.12- Buffers and solutions used for immunofluorescence staining
Buffer Component w/v or v/v Supplier Product number
4% PFA PFA 4g SIGMA P-6148PBS 100ml GIBCO 14190
8% goat serum Goat serum 8ml SIGMA G9023PBS 92ml GIBCO 14190
8% rabbit serum Rabbit serum 8ml SIGMA R9133PBS 92ml GIBCO 14190
0.1% Triton X-100 Triton X-100 101J1 SIGMA T-8532PBS 990IJI GIBCO 14190
Goat serum 0.5ml SIGMA G9023
1% serum wash buffer Tween-20 50IJI SIGMA P-5927
PBS 49.5ml GIBCO 14190
2.8.2 Cell preparation for immunofluorescence staining
Cells from confluent culture flasks were washed with PBS, trypsinised and centrifuged to
obtain a cell pellet. The pellets were re-suspended in an appropriate medium, and cells
were seeded in 8-chamber glass slides (NUNC: 177402) at a density of 1.7x104
cells/chamber. The slides were placed in a 37°C incubator for 2-3 days. Once they were 70-
80% confluent, the cells were fixed by treatment with 2001-11of 4% PFA per chamber, for 20
minutes at room temperature. The PFA was aspirated, cells were washed twice in 2001-11
PBS per chamber and were then stored at 4°C until needed for staining. To ensure good
quality staining, the slides were used within one week of cell fixation.
2.8.3 Immunofluorescence staining
Cells fixed in 4% PFA were removed from 4°C and were washed twice in PBS, for 5 minutes
at room temperature. Cells were then incubated in 100jJi of permeabilisation solution (0.1%
TritonX-100 in PBS), for 15 minutes at room temperature, and were washed again in PBS
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as before. Following permeabilisation, the cells were incubated in blocking solution (8% goat
serum in PBS for antibodies raised in mouse or rabbit, 8% rabbit serum for antibodies raised
in goat; Table 2.13), for 1 hour at room temperature, and were then washed once in PBS,
for 5 minutes, at r. t. After this, cells were incubated in primary antibody diluted in 2% goat
or rabbit serum, overnight at 4°C. The following day, cells were washed 4 times in 1% serum
wash buffer, for 10 minutes at r.t., incubated in 1OO~Isecondary antibody diluted in 2% goat
or rabbit serum (Table 2.13), for 1 hour at r.t, and washed again in 1% serum wash buffer as
before. The chambers were finally removed from the glass slides, a small amount of
Vectashield Mounting Medium with DAPI (Vector Laboratories: H-1200) was placed over the
area where each chamber used to be, and a glass coverslip was placed over the glass
slides. The slides were sealed with nail varnish and were stored at 4°C, in the dark. Image
acquisition was carried out using a Nikon ECLIPE 90i Fluorescence Microscope, a
Hamamatsu 1394 ORCA-285 Digital Camera and Volocity 5 Improvision software.
Table 2.13- Antibodies used for immunofluorescence staining
Primary antibody Supplier Dilution Secondary Supplier Dilution
antibody
OCT4 Santa Cruz; SC-5279 1:200
SSEA4 Millipore; MAB4304 1:50
TRA-1-81 Millipore; MAB4381 1:50
FSA Abcam; ab11333 1:750
P4HB Abcam; ab44971 1:50 goat anti-mouse Invitrogen; 1:400
~-III-tubulin COVANCE; MMS-435P 1:1000
AlexaFluor® 633 A21052
AFP SIGMA; A8452 1:1000
Cardiac SIGMA; A7811 1:800
a-actinin
DNMT1 NEB; M0231S 1:100
DNMT3A Abeam; ab4897 1:400 1:400
DNMT3L Abeam; ab3493 1:200 goat anti-rabbit Invitrogen; .LlN28 Abeam; ab462020 1:1500 AlexaFluor® 633 A21071
REX1 Abcam; ab50828 1:50
Cardiac Troponin-l Spectral Diagnostics; 1:1000 1:200PA-1010
SOX2 R&D Systems; AF2018 1:200
NANOG R&D -Systems; AF1997. 1:50 rabbit anti-goat Invitrogen; 1:400
DNMT3B Santa Cruz; SC-10236 1:250 AlexaFluor® 568 A11079
KLF4 . R&D Systems; AF3640 1:100 1:200
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2.8.4 Haematoxylin staining
Immunohistochemical analysis by haematoxylin staining was performed as described
previously (Burridge et al., 2007), with kind help from Miss Maria Barbadilio-MGnoz. EBs
were pelleted, fixed with 4% PFA for 15 minutes, washed twice in PBS, and set in 1%
agarose. EBs were then processed overnight, in a Shandon Excelsior tissue processor
(Thermo scientific), and embedded in paraffin wax (Tissue-Tek II embedding wax). Wax
blocks were sliced in 5IJm sections, using a microtome, and slices were affixed to clean
glass slides (SuperFrost Plus, Menzel-Glaser: J1800AMNZ). The slices were de-waxed by
treatment with Bond Dewax solution (Leica: AR9222), rehydrated through an ethanol/water
gradient, stained with Harri's-Haematoxylin (VWR: 95057-858), and finally mounted with
DePEX mounting medium (VWR: 10140-638). Staining was performed using BOND-MAX
system and reagents (Leica). Image acquisition was carried out using a Nikon ECLIPE 90i
Microscope and Volocity 5 Improvision software.
Table 2.14- Antibodies used for EB haematoxylin staining
Primary Supplier Dilution Secondary Supplier Dilution
antibody antibody
NANOG R&D Systems; AF1997 1:100
SOX2 R&D Systems; AF2018 1:600
Brachyury (T) R&D Systems; AF2085 1:200 Bond Polymer Leica; DS9800Refine Detection
KLF4 R&D Systems; AF3640 1:100
1:200
DNMT3B Santa Cruz; SC-10236 1:1000
OCT4 Santa Cruz; SC-5279 1:200
TRA-1-81 Millipore; MAB4381 1:200 HRP anti-goat Vision BioSystems;IgG DS9800
REX1 Abcam; ab50828 1:50
2.9 WESTERN BLOTTING
2.9.1 Buffers and solutions
Table 2.15- Sample Lysis buffer for protein extraction from animal cells
Reagent Supplier Final cone. Mass / volume
Tris Base pH 7.5 Fisher Scientific; BP1S2-1 SOmM Sml of SOOmM
NaF SIGMA; 57920 50mM 5ml of 500mM
B-glycerophosphate SIGMA; G6376 50mM 2.sml of 1M
Sodium orthovanadate SIGMA; S6508 10mM 500ul of 1M
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Triton X-100 SIGMA; T8s32 1% (v/v) SOOul
Water SIGMA; W4S02 36.5ml
Table 2.16- 2x SOSsample buffer for protein loading onto acrylamide gels
Reagent Supplier Final cone, Mass / volume
Tris Base pH 6.8 Fisher Scientific; BP1s2-1 100mM 1ml of 1M
OTT Fisher Scientific; BPl72-s 200mM 2ml of 1M
SOS SIGMA; L4390 4%w/v 2mlof20%
Glycerol SIGMA; G6376 20% w/v 2ml of 100%
Bromophenol Blue SIGMA; B6126 0.2% w/v 1mlof2%
Water SIGMA; W4S02 - 10ml
Table 2.17- Resolving and Stocking gels for polyacrylamide gel electrophoresis
Reagent Supplier 6% Resolving gel 5% Stocking gel
SOW SIGMA; W4S02 7.9ml 3.42sml
30% acrylamide Severn Biotechnology; 202100-05 3ml 830J..l1
1.5M Tris pH 8.8 Fisher Scientific; BP1s2-1 3.8ml -
1M Tris pH 6.8 Fisher Scientific; BP1s2-1 - 630J..l1
10% SOS SIGMA; L4390 rsou: SOJ..l1
10%APS Fisher Scientific; BP179-100 rsou: SOJ..l1
TEMEO Fluka Biochemika; 87689 12J..l1 sJ..l1
Table 2.l8-l0x Electrophoresis buffer for western blotting
Reagent Supplier Final cone, Mass / volume
Tris Base Fisher Scientific; BP1s2-1 0.2M 30.3g
Glycine SIGMA; 241261 1.92M 144g
SOS SIGMA; L4390 sOmM 109
SWO - - to 1L
Table 2.19- lOx Transfer buffer for western blotting
Reagent Supplier Final cone. Mass / volume
Tris Base Fisher Scientific; BP1s2-1 0.2sM 36.3g
Glycine SIGMA; 241261 2.4M 181.2sg
SWO - - to 1L
2.9.2 Protein extraction from animal cells
Cell Iysates were prepared from animal cells by treatment with sample Lysis buffer (Table
2.15), which was supplemented with 1mM PMSF (SIGMA; 93482) and Protease Inhibitors
(Roche; 11873 580 001) immediately before use. 10IJI of Lysis buffer were used per 1
million cells, and incubation was allowed to occur for 5 minutes, on ice. The samples were
then centrifuged at 800xg for 5 minutes, at 4°C, and the supernatants were transferred to
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clean Eppendorf tubes. Pelleted insoluble membranes and genomic material were
discarded. Protein samples were quantified via the Bradford assay using an Eppendorf Bio
Photometer, and were then mixed with 1x volume of 2x SOS sample buffer (Table 2.16),
which had previously been heated to 95°C on a heating block. The samples were placed on
a 95°C heating block for 5 minutes to denature proteins for polyacrylamide gel
electrophoresis, and were finally stored at -20°C.
2.9.3 Polyacrylamide gel electrophoresis
6% polyacrylamide resolving gels were prepared as described in Table 2.17, in an
omniPAGE Mini vertical gel electrophoresis system (Cleaver Scientific; VS100). TEMEO
was added to the gel immediately before casting into the tank. The gel was layered with
isopropanol so that it set evenly. After 15 minutes, the isopropanol was washed away. An
appropriate comb was placed on top of the resolving gel, and stacking gel was used to form
the wells. The stacking gel was allowed to set for 15 minutes, after which the combs were
removed and the gels were assembled in the tank. 750ml of 1x electrophoresis buffer were
added to the tank and the gels were loaded with 30j..Jgof protein per well. 6j..J1of pre-stained
protein marker (NEB; P7708) were added to one of the wells to determine protein size. The
gels were run at 125V for 90 minutes, or until the dye front reached the bottom.
2.9.4 Protein transfer to nitrocellulose membrane and immunoblotting
10x Transfer buffer (Table 2.19) was diluted 1:10 and supplemented with 20% methanol, to
make 1x Transfer buffer. 0.45j..Jm Hybond-ECL Nitrocellulose membrane (Amersham
Biosciences; 7040096), as well as 3M blotting paper were cut in 8x8cm pieces and were
soaked in 1x Transfer buffer for 15 minutes. The polyacrylamide gels were removed from
the electrophoresis tanks and disassembled. The electrophoretically separated proteins
were transferred to the nitrocellulose membrane by a wet transfer system, in 2L of 1x
Transfer buffer. The transfer was allowed to occur for 70 minutes, at 11OV.
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Following transfer, the membranes were incubated in blocking solution (5% skimmed milk in
PBS) for 1 hour, at r.t., and were then treated with primary antibody diluted to the
appropriate concentration (Table 2.20) in 0.02% Tween-20 in PBS (PBS-T), for 12 hours, at
4°C, on a rocking platform. The primary antibody was removed and the membranes were
washed 3x in PBS-T for 5 minutes per wash, at r.t. They were then incubated in secondary
antibody (Table 2.20) diluted in PBS- T, for 1 hour at r.t., on a rocking surface. The
membranes were washed as before, and developed using the EZ-ECLTM
chemiluminescence detection kit for HPR (Biological Industries; 20-500-120), according to
the manufacturer's instructions. Imaging was performed using a LAS4000 system (Fujifilm),
and protein expression was quantified using AIDA V.4.15 2D densitometry software.
Table 2.20- Antibodies used for western blotting
Primary Supplier Dilution Secondary Supplier Dilutionantibody antibody
a-Tubulin Calbiochem; CP06 1:2000 HPR anti- Cell Signalling; 7076 1:200mouse
ONMT1 NEB; M0231S 1:2000 HPR anti- Cell Signalling; 7074 1:200
ONMT3A Abcam; ab4897 1:200 rabbit
2.10 BACTERIAL CLONING
2.10.1 Buffers and Media
All buffers and media were autoclaved before use
Table 2.21- Composition of buffers media used for bacterial cloning
Buffer / Component w/v or v/v Supplier ProductMedium number
LB broth
LB broth powder 6.25g Fisher Scientific BPE1426
SOW 250ml N/A N/A
LB broth powder 6.25g Fisher Scientific BPE1426
LB agar Agar 3.75g Fisher Scientific BPE1423
SOW 250ml N/A N/A
Potassium acetate 100mM Fluka BioChemika 60035
Oligo annealing
, HEPES pH 7.4 30mM SIGMA H-1016buffer
Magnesium acetate 2mM Fluka BioChemika 63052
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2.10.2 Restriction Enzyme Digestion
All digests were performed in a final volume of 251JI,using the buffer recommended by the
manufacturer for each restriction enzyme and RNase! DNase free water (SIGMA: W-4S02).
O.SIJIof restriction enzyme were used to catalyse the digestion of 1IJg DNA. The digests
were performed at 37°C, for 2 hours. All digest products were passed through QIAquick Gel
Extraction columns, even if not electrophoresed on an agarose gel. This was done to ensure
separation of fragments excised by restriction digestion form the remaining plasmid.
2.10.3 Oligo cloning into plasm ids
Single stranded complementary oligos were mixed at a 1:1 concentration (21J1each) and
were added to 481J1of annealing buffer. In order to anneal to each other, the oligos were
heated to 9SoC for 4 minutes, then to 70°C for 10 minutes, and were finally left to cool down
to room temperature. 1 or 31J1of annealed oligos were then mixed with 1IJg plasmid DNA,
which had been digested with restriction enzymes compatible to the oligo ends. Following
this, oligos were ligated into the plasmid using O.SIJIligase enzyme (Quick Ligation Kit; NEB:
M2200S). Ligation was allowed to occur for S minutes at room temperature and was
followed by transformation of competent E. coli bacterial cells.
2.10.4 Transformation of E.coli DH5a competent cells
LB agar was melted in a microwave oven and left to cool down to SO°C. SOmg!ml ampicillin
were added to the agar which was then aliquoted to 90mm Petri dishes. The agar was left to
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set for -20 minutes at room temperature, and was then placed in a 37°C oven for 1 hour.
SOIJI E.coli Subcloning Efficiency DHSa Competent Cells (Invitrogen: 1826S-017) were
thawed on ice, and mixed with 1IJg plasmid DNA. The cells were incubated on ice for 30
minutes, heat-shocked at 42°C for 4S seconds and finally placed on ice for 3 minutes. They
were then mixed with 200IJI SOC medium and placed in a 37°C shaking incubator for 1
hour. When the cells were removed from the shaking incubator, they were spread on LB
agar which was set in 90mm Petri dishes, using a sterile technique. The dishes were
inverted and placed in a 37°C oven for at least 16 hours.
The following day, single bacterial colonies were picked from the Petri dishes, added to 2ml
SOC medium (supplemented with SOmg/ml ampicillin) in 20ml Universal tubes, and placed
in a 37°C shaking incubator for up to 12 hours. A mini-prep of the amplified DNA was
performed after this (section 2.10.S). If a DNA midi-prep was required (section 2.10.S),
single bacterial colonies were added to 1ml SOC medium in 20ml Universal tubes, and
placed in a 37°C shaking incubator for S-6 hours. Following this, the cell suspension was
added to a further 40ml of SOC medium, and placed in the shaking incubator overnight.
2.10.5 Plasmid purification by Mini, Midi and maxi preps
Plasmid Midi and Maxi-preps were performed using the QIAfilter Plasmid Midi or Maxi Kit
(QIAGEN: 12243 and 12262 respectively), according to the manufacturer's instructions,
pg16-20 of the QIAfilter Plasmid Purification Handbook, onwards from step 4. After
precipitation (step 14), samples were eluted in 100IJI of sterile distilled water for midi-preps
and 330IJI for maxi-preps, and placed on a 6SoC heat-block for 1S minutes. They were then
quantified using a NanoDrop spectrophotometer and stored at -20°C.
Mini-preps were performed using the QIAprep Spin Mini Prep Kit (QIAGEN: 27104),
according to the manufacturer's instructions, pg22-23 of the QIAprep Miniprep Handbook.
Samples were eluted in SOIJIof sterile distilled water in the final step.
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2.11 STATISTICAL ANALYSIS
Numerical results are presented as mean values of experimental replicates, ± the standard
error of the mean, as calculated using Microsoft Excel 2007. Statistical analysis was
performed using NeSS 2007 software for Windows v7.1.15. Initially, the Kolmogorov-
Smirnov test was performed on all data to determine whether the datasets were normally
distributed. Since none of the data presented here were normally distributed (p>0.05), non-
parametric analysis was used to statistically compare the data. The Kruskal-Wallis H test
was used for analysis of non-parametric independent data-groups, with the null hypothesis
(Ho) that there was no significant difference between the median values of the samples
analysed, and alternative hypothesis (Ha) that the median values differed between samples.
Tests were performed at a significance level of 0.05. Where a statistically significant result
(p<0.05) was returned, the Ho was rejected and pair-wise comparisons using the Mann-
Whitney's U test were performed to identify the samples that caused rejection of Ho.
Differences between sample distributions in each experiment were also demonstrated using
non-parametric box plots (Figure 2.3; Appendix IV; Williamson et al. 1989; Donnelly 1992).
•
+----- Upper value
+----- Upper quartile
+----- Median value
+----- Lower quartile
+----- Lowervalue
•
• +----- Outlying values
Figure 2.3- Box plot graph
A box plot graph shows the lowest and highest observations/values in a sample, the median value, the lowest
25% and highest 25% of observations (lower and upper quartiles), outlying observations, as well as the
dispersion and skewness of the data. The box plot makes no assumption about the distribution of the data
and is, therefore, a non~parametric plot.
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3 GENERATION OF A SINGLE-GENOTYPE MODEL CELL
SYSTEM FOR TH.E INVESTI,G,ATION OF PHENOTYPE
TRANSI:TION MECHANISMS
3.1 INTRODUCTION
To achieve the aims of this project, a model cell system was generated, by using cultures of
the HUES7 hESC line as the starting point from where fibroblast and iPSC lines were
derived. All cell lines in the model system shared the same genotype, hESCs and iPSCs
were cultured using the same method,
Differentiation and fibroblast cells were derived and
iPSCs
cultured using the same protocol. This
hESCs hESC-Fibroblasts
was performed in order to eliminate
iPS-Fibroblasts genotype and culture-induced variation
among cell lines of the model system
Differentiation and enable unbiased characterisation of
the epigenetic mechanisms associated with transcription factors that are key in regulating
phenotype transition from a pluripotent to a fibroblast differentiated state. This chapter
describes the generation and characterisation of the single-genotype model cell system.
3.1.1 hESC differentiation into fibroblasts
Fibroblast cells synthesise and organise connective tissue in a number of adult organs,
including the skin (dermis; He et al. 2007). The ease of their isolation from the human body
using non-invasive skin biopsies (Rittie and Fisher 2005) has made fibroblasts an attractive
differentiated lineage for reprogramming by over-expression of defined TFs (see Table 3.2).
Using in vitro-derived fibroblasts as a reprogramming starting point represents an
appropriate model for patient-derived primary cells, which would ease the transfer of
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experimental findings to potential clinical application. hESCs were, thus, differentiated to
fibroblasts in this thesis.
3.1.1.1 Method used for fibroblast derivation
Fibroblasts are a very diverse cell type and can arise either from the mesenchyme tissue or
the ectoderm through epithelial to mesenchymal transition (Dennis and Charbord 2002;
Kalluri and Neilson 2003). In vitro, cells with a fibroblast-like morphology (spindle-like long,
flat cells with elongated nucleus) can be derived from hESCs by 1-3 passages following
differentiation via EB formation, in the absence of a specific growth factor (Xu et al. 2004).
Fibroblast differentiated cells were derived in this thesis using forced aggregation of 10,000
hESCs in untreated V-bottom 96-well plates (Burridge et al. 2007). This differentiation
method was chosen as it is cost effective and enables formation of EBs with a defined size
(section 1.2.4.1), which was necessary to standardise differentiation procedures and enable
direct comparison between fibroblasts derived from hESCs and iPSCs.
3.1.1.2 Characterisation of hESC-derived fibroblasts
In order to confirm the identity of hESC and iPSC-derived fibroblasts, appropriate fibroblast-
specific markers had to be used. However, since fibroblasts are a very diverse cell-type,
showing slightly different characteristics in each organ they reside (e.g. skin, liver, muscle,
kidney, lungs) identification of appropriate fibroblast-specific markers is a difficult task
(Annunen et al. 1997; Oh et al. 2004; He et al. 2007).
Phenotype characterisation of hESC-derived fibroblasts has included staining with a range
of human mesenchymal stem cell (hMSC) surface markers, such as CD29 (integrin-~1),
CD44 (surface glycoprotein), CD71 (transferring receptor), CD90 (Thy-1) and CD106
(VCAM-1; Pittenger et al. 1999; Xu et al. 2004; Stojkovic et al. 2005). Vimentin and prolyl-4-
hydroxylase B (P4HB) have also been used to characterise hESC-derived fibroblasts (Wang
et al. 2005); vimentin is a marker detected in a number of cells with mesenchymal origin,
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and can also be found in astrocytes, Sertoli cells, and vascular smooth muscle (Moll et al.
1982), while P4HB is a cytoplasmic marker involved in collagen formation (Kivirikko et al.
1989) that has only been detected, thus far, in fibroblast cells (Annunen et al. 1997; Oh et
al. 2004; He et al. 2007). Therefore, aside from P4HB, the markers used to characterise
ESC-derived fibroblast cells have a broad specificity.
Surface markers, such as 1B10 (also known as fibroblast surface antigen, FSA) and AS02,
have been used to characterise primary fibroblast cells and eliminate contaminating
fibroblasts from other thymic epithelial and thyrocyte cell cultures (Esterre et al. 1992;
Saalbach et al. 1996; Saalbach et al. 1997; Saalbach et al. 1998). Of these, only FSA is
commercially available, but has not been studied in hESC-derived fibroblasts. Therefore, the
most appropriate fibroblast-specific markers for use in this thesis were P4HB and, possibly,
FSA.
3.1.2 Differentiation of hESCs and iPSCs to the three embryonic germ
layers
The ability of hESCs and TRA-1-81 positive iPSCs to differentiate to the three embryonic
germ layers; endoderm, mesoderm and ectoderm, was assessed by in vitro differentiation in
this thesis. In vitro differentiation has been used in several studies to confirm pluripotency of
hESCs (Shamblott et al. 1998; Reubinoff et al. 2000; Odorico et al. 2001), but has a
disputed stringency because it does not demonstrate in vivo differentiation (Maherali and
Hochedlinger 2008). Formation of tissue representative of the three germ layers in
teratomas (Thomson et al. 1998; Reubinoff et al. 2000) is thought to be a more stringer'lt
test, because differentiation is demonstrated in vivo (see Table 3.1). However, teratoma
formation does not test the ability of cells to promote normal development (Jaenisch and
Young 2008). It is also a non-quantitative test, that requires expert skills (Daley et al. 2009),
whose stringency has somewhat been challenged from evidence that teratoma
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characteristics vary greatly according to the type of tissue used to drive them (Miura et al.
2009). On the-other hand, in vitro differentiation is simpler and allows quantification of germ
layer formation by real-time PCR (Mahlstedt et al. 2009). The ability to demonstrate
formation of beating cardiomyocytes by in vitro differentiation also contradicts the argument
that this method does not show formation of functional cell types (Jaenisch and Young
2008). For these reasons, in vitro differentiation was the method of choice in this study for
demonstrating formation of the three embryonic germ layers from hESCs and iPSCs.
Table 3.1- Methods used to test the developmental potential of mouse and human pluripotent cells
(adapted from Jaenischand Young 2008)
Species Assay Experimental approach limitations
In vitro Differentiation of cultured cells followed by assay Differentiation not in vivo
~
differentiation for the expression of cell-type specific markers
c:
QI
'" Injection into immunodeficient mice results in111 ::J Doesnot demonstrate theE 0 Teratoma tumour formation that demonstrates
::l E ability for normalJ: formation differentiation into various cell types and
lineages development
Chimera Injection into host blastocyst demonstrates Autologous cells in
formation ability to support normal development chimera may complement
for defects in injected cells
QI Doesnot account for
'"
Germline::l Ability to generate functional germ cells epigenetic defects that0 contribution
~ could affect development
Tetraploid Injection into a 4n blastocyst which cannot Most stringent test, but
complementation contribute to somatic lineages results to embryo does not assessability to
composed exclusively by injected cells form trophectoderm
3.1.3 Methods and cell types used to generate iPSCs
Since 2006, several methods other than retroviral transduction have been employed to
achieve over-expression of the four "iPSC factors" (OCT4, SOX2 and either KLF4 and c-
MYC or NANOG and LlN28, summarised in Table 3.2). These methods either aimed in
improving the efficiency of iPSC generation (Ientiviral transduction) or eliminate the risk of
insertional mutagenesis due to retroviral or lentiviral DNA integration into the host-genome
(adenoviral transduction, use of plasmids, transposons, episomal vectors and recombinant
proteins). However, integration-free techniques have suffered from very low reprogramming
efficiencies, or limited success in hESCs compared to mESCs (Table 3.2).
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Several differentiated cell types, other than fibroblasts, have been used to generate iPSCs,
including stomach, liver, cord blood, and mature B cells (Aoi et al. 2008; Hanna et al. 2008;
Haase et al. 2009). Nevertheless, iPSCs generated from different cell-types show
differences in their transcriptional profiles, mostly due to residual expression of donor cell-
type specific genes (Ghosh et al. 2010). Transcription factor-induced reprogramming has
also crossed the human and mouse species barriers, as it was used successfully to
generate iPSCs from swine, rat and monkey fibroblasts (Liu et al. 2008a; Liao et al. 2009a;
Roberts et al. 2009; Wu et al. 2009b), opening further possibilities for disease modelling
(Esteban et al. 2010).
3.1.3.1 iPSe-generation system used in this thesis
One of the aims of this thesis was to investigate the mechanisms associated with
reactivation of key pluripotency genes during the formation of iPSCs. Early reprogramming
time-points had to be analysed, in order to study the epigenetic changes associated with the
transition of cell phenotype from a differentiated to a pluripotent state. To increase the
possibility of detecting these changes, the most efficient method available for the generation
of iPSCs from fibroblast cells, i.e. lentiviral transduction, (Table 3.2) was used in this study.
Since the use of iPSCs generated in this study was restricted to research purposes,
avoiding integration of viral DNA into the host genome was of a lesser significance. At the
point when this method was selected, lentivirus-mediated generation of iPSCs had only
been achieved using over-expression of the TFs OCT4, NANOG, SOX2 and LlN28 (Yu et
al. 2007b). Therefore, these four factors were used instead of the OCT4, SOX2, KLF4 and
c-MYC TF combination (Ok ita et al. 2007). A protocol for efficient genetic modification using
lentiviral vectors had to be established before generating iPSCs, since neither lentiviral
transduction nor iPSC formation had been performed in our lab previous to this thesis.
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Table 3.2- Strategies used for iPSe generation
0= OCT4, S= SOX2, K= KLF4, C= c-MYC, N= NANOG, L= LlN28, E= embryonic, F= foetal, NB= newborn, A= adult
Vector Transgenes Cell type Efficiency (%) References
Meissner et al. 2007; Wernig et al.
MEFs 0.01-0.5 2007; Huangfu et al. 2008a; Okita
et 01.2008
Hepatocytes 1-3
Aoi et al. 2008OSKC Gastric epithelia 1-3
B cells 0.01-0.1 Hanna et al. 2008
~-cells 0.1-0.2 Stadtfeld et al. 2008a
Retrovirus Neural stem cells 3-5 Eminli et al. 2008; Kim et al. 2008b
MEFs 0.001-0.01
Huangfu et al. 2008a; Nakagawa et
al. 2008; Wernig et al. 2008a
OSK
Hepatocytes 0.5-1 Aoi et al. 2008
0.1-1 Kim et al. 2008b
GI OKC or OSC 0.1-1 Eminli et al. 2008; Kim et al. 2008bVI Neural stem cells
::J OK or OS 0.1-0.2 Kim et al. 2008b0
s 0 0.014 Kim et al. 2009c
Lentivirus OSKC MEFs 0.03-1 Brambrink et al. 2008; Stadtfeld et
al. 2008b; Shao et al. 2009
Adenovirus
MEFs 0
Stadtfeld et al. 2008cOSKC
Hepatocytes 0.001-0.0001
Plasmid OSKC MEFs 0.001-0.0001 Okita et al. 2008
Lentivirus + Cre OSKC Dermal fibroblasts (A) N/A Chang et al. 2009a
Plasm ids + Cre OSKC 0.001-0.0001 Kaji et al. 2009
piggyBac OSKCL 0.01 Woltjen et al. 2009; Yusa et al.
transposon OSKC MEFs 0.005 2009
Transient
OSKC N/A Okita et al. 2008; Gonzalez et al.transfection 2009; Okita et al. 2010
Protein OSKC 0.00006 Zhou et al. 2009
Dermal fibroblasts (F,
0.001-0.01 Takahashi et al. 2007; Dimos et al.OSKC NB,A)
Bone marrow MSCs N/A
2008; Park et al. 2008a
Retrovirus OSK Fibroblasts (NB, A) 0.001-0.01 Huangfu et al. 2008b; Nakagawa et
OS Fibroblasts (NB) 0.001-0.004 01.2008
OK
Neural stem cells
0.01 Hester et al. 2009
0 0.004 Kim et al. 2009b
c: OSNL Dermal fibroblasts (E, 0.01-0.1 Yu et al. 2007b; Ebert et al. 2009III OSN or OSL NB, A) 0.0001-0.001E Lentivirus
::J OSNL Cord blood 0.0003-0.03 Haase et al. 2009
:J: OSKC Keratinocytes 0.00001 Carey et al. 2009
Lentivirus + Cre
OSKC
Fibroblasts (A) 0.01 Soldner et al. 2009OSK 0.005
Episomal vectors
OSCKNL & Foreskin fibroblasts
N/A Yu et al. 2009SV40LT (NB)
Protein OSKC Fibroblasts (NB) 0.001 Kim et al. 2009a
Minicircle-DNA OSNL
Adult adipose stem
0.005 Jia et al. 2010 .
cells
3.1.3.2 Genetic modification of human cells by lentiviral transduction
Viruses are parasitic organisms, highly evolved in their ability to transduce host cells, and
can therefore efficiently deliver target DNA within them (Patil et al. 2005). Adenoviruses,
retroviruses, and adeno-associated viruses have been used both in research and clinical
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trials to transduce host cells (reviewed in Somia and Verma 2000; Patil et al. 2005).
However, retroviral-based vectors are one of the most desirable tools for transgene delivery
as they enable transduction of some of the most resistant cell lines (Garton et al. 2002;
Merten 2004). Retroviruses are single-stranded RNA viruses which replicate by transducing
host cells and reverse transcribing their genome into double-stranded DNA that becomes
integrated into the host genome in a random location (Nisole and Saib 2004). Viral RNA is
transcribed along with the host genome during the lifetime of the cell, thus enabling new
viral particles to be assembled within host cells in a capsid and membranous envelope
(Blesch 2004). The basic retroviral genomic organisation consists of a packaging signal (41),
3' and 5' long terminal repeats (LTRs) that contain promoter, enhancer and viral integration
sequences, and the poly-proteins gag, pol and env which are required for viral replication
and packing (Figure 3.1; Somia and Verma 2000).
A subfamily of retroviral vectors, known as lentiviruses, has been shown to possess several
advantages over other family members. Lentiviruses are capable of infecting both dividing
and non-dividing cells, their genome shows high resistance to transcriptional silencing once
integrated into the host genome, they have low immunogenicity (reviewed by Park 2007)
and can accommodate the use of many ubiquitous or tissue-specific promoters (Follenzi
and Naldini 2002; Georgiades et al. 2007). Their basic genomic organisation is similar to
that of other retroviruses, but they also possess several accessory genes, such as vit, vpr,
vpu, net, tat and rev, some of which are crucial for replication and pathogenesis
(Buchschacher and Wong-Staal 2000). Lentiviruses can be engineered to avoid an immune
response by the host genome through removal of their non-essential regulatory genes
(Blesch 2004), something that also allows for safer experimentation with lentiviruses. Based
on the number of non-essential genes removed from their genome, lentiviral vectors are
categorised to 1st, 2nd, and 3rd generation systems, with increasing safety being introduced
at each generation (Blesch 2004).
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Lentiviral particles can be assembled in vitro by transfection of HEK293 cells (known as a
"viral-packaging cell line") with three plasmids; a packaging, a transfer, and an envelope-
coding plasmid (Figure 3.1.8; Naldini et al. 1996). Essential viral genes are divided among
these three plasm ids so that the viral particles generated in HEK293 cells are replication
defective (Somia and Verma 2000). This measure improves the safety of experimentation
with lentiviruses further. Once packaged, the viral particles are titered form HEK293 cells
and used for transduction experiments, to generate stable transgenic cell lines (Suter et a/.
2006; Xia et a/. 2008).
A Assembly of genome
into viral particle
/
env
B
Promoter/enhancer &
integration seq.
Core proteins Reverse
transcri ptase
Viral envelope
Transferplasmid
Selectable marker
(e.g. neo)
/
Packaging plasmid Envelope plasmid
S'
"-
Could be
manipulated to
determine
target cell type
Could be replaced by
viral or cellular promoters \ 1 I
.->.
• • •
HEK293
fI packaging cell line
....._--------------------~.--/f ...,-.=---------
e"y".
..
, c::I
I all
Replicationdefective
viral particles
Figure 3.1-ln vitro assembly of lentiviral particles
A. Basicgenome organisation of retroviral and lentiviral vectors, consisting of two long terminal repeats (L1R)
on either end of the genome, a ljJ (psi) sequence; necessary for genome assembly into viral particles, and gag,
pol and env genes; required for viral replication and packaging. B. Construction and packaging of viral particles
in a HEK293 "packaging cell line". The viral genes are divided in separate vectors in order to enable the
generation of replication defective viral particles (Adapted from Somia and Verma 2000).
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3.1.4 Chapter Aims and Objectives
The aim of this chapter was to generate the cell types involved in the model system
described in Figure 1.1. For this purpose, the following objectives had to be met:
* Establish and characterise cultures of two hESC lines; HUES? and the clonal variant
HOGN, which carried an OCT4-targeted IRES-GFP-IRES-Neo cassette and would
enable identification of endogenous OCT4 reactivation during iPSC formation
* Differentiate the two hESC lines into fibroblast-like cells
* Assess for the ability of putative fibroblast-specific markers to distinguish between
fibroblasts and progenitor or other differentiated cells mesodermal lineage
* Confirm the phenotype of hESC-derived fibroblast cells
* Establish optimised protocols for efficient lentiviral transduction of hESC-fibroblasts
and hESCs
* Generate and characterise iPSCs from hESC-fibroblasts, using lentivirus-mediated
over-expression of human OCT4, NANOG, SOX2 and LlN28
* Differentiate iPSCs to fibroblast cells
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3.2 RESULTS
3.2.1 Culture and phenotype assessment of HUES7 hESCs
HUES? hESCs (Cowan et al. 2004) were adapted, in our to lab, to feeder-free Matrigel™
culture in MEF conditioned medium (Denning et al. 2006). Cells were typically maintained in
culture at low passages (passages 20 to 32) following their derivation from human embryos,
in order to minimise karyotype instability and accumulation of mutations in the DNA,
observed upon extended culture of many hESC lines (Draper et al. 2004; Baker et al. 200?;
Spits et al. 2008). During this period, HUES? cells appeared healthy (densely packed cells
with angular cell walls, low cell death; Figure 3.2.C), and were typically passaged by 1:3
splits every 48 hours. The karyotype of HUES? cells was normal (46,XY) at passage 22,
according to analysis performed by Mr Nigel Smith, Nottingham City Hospital. In order to
assess the ability of HUES? to form derivatives of the three embryonic germ layers, cells
were differentiated via EB formation by forced aggregation. EBs were seeded onto glass
chamber slides on day 21 of differentiation, and fixed using 4% PFA in order to be used for
immunofluorescence staining. Figure 3.3 demonstrates differentiation into ectoderm
(expression the neural marker ~-III-tubulin), endoderm (expression of the foetal kidney
marker alpha-feto protein, AFP), and mesoderm (presence of a-actinin positive, beating
cardiomyocytes; Carpenter et al. 2003; Zeng et al. 2004).
Figure 3.2- Culture of HUES7 hESCs
Bright field images of passage 22 HUES7 cells grown on a feeder-free Matrigel™ surface in MEF-conditioned
medium, A. 8h, B. 24h and C. 48h following a 1:3 split. Scale bar represents tooum.
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Figure 3.3- Karyotype and pluripotency of HUES7 hESCs
A. HUES7 cells grown on Matrigel had a normal 46,XY karyotype at passage 22. B. Differentiation of HUES7
cells to cell types representative of the three germ layers; ectoderm, mesoderm and endoderm indicated their
pluripotent potential. Protein expression was captured using the Cy3 channel, while the overlay represents a
merge of the DAPI (nuclear staining) and Cy3 channels. Scale bars represent 641lm.
3.2.2 Culture and phenotype assessment of HOGN hESCs
A transgenic HUES7 line, modified to carry gene targeted insertion of an IRES-GFP-IRES-
Neo cassette immediately after the endogenous OCT4 gene (Figure 3.4.A), was kindly
provided for this study by Dr. Christine Mummery, Leiden University Medical Centre, The
Netherlands (Braam et a/. 2008b). In their undifferentiated state, the genetically modified
cells, referred to as HOGN for HUES7-0CT4-GFP-Neomycin, were GFP positive (Figure
3.4.B) and showed resistance to neomycin (Figure 3.7; Braam et al. 2008b). HOGN were
reported to have a normal karyotype after transfection and clonal growth (Braam et al.
2008b), but during culture scale-up, cells showed trisomy 12 and addition of chromosomal
material to the small arm of chromosome 21, believed to have originated from chromosome
17 (Figure 3.4, Figure 3.6.C). Nevertheless, cells could differentiate to the three embryonic
germ layers (Figure 3.4, Figure 3.6.0) and were used for further experiments as they
comprised a good control system to monitor the expression of endogenous OCT4 during
differentiation and fPSCS generation.
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Figure 3.4- Culture, karyotype and pluripotency assessment of HOGN hESCs
A. Representation of the IRES-GFP-IRES-Neo cassette inserted downstream of the endogenous OCT4 locus in
HUES7cells, to create the HOGNcell line (Braam et al. 2008b) P= promoter. B. Bright field and fluorescence
images of HOGN cells at passage p+8, on day 2 following a 1:3 split. Scale bars represent 100~m. C.
Differentiation of HOGN to cell types representative of the three germ layers; ectoderm, endoderm and
mesoderm. Protein expression was captured using the Cy3 channel, while the overlay represents a merge of
the DAPI (nuclear staining) and Cy3 channels. Scale bars represent 64~m. D. HOGN carried an abnormal
47,XY,+12,add(21)(p1) karyotype. Redboxes highlight the karyotype abnormalities.
3.2.3 Derivation and characterisation of hESC-fibroblast lines
3.2.3.1 Derivation of fibroblasts from HUES7 hESCs
Fibroblast-like cells were derived from HUES7 cells, as described in sections 2.1.7 and
2.1.8. As shown in Figure 3.5, EBs trypsinised and plated onto 90mm culture dishes
appeared to have the characteristic spindle-like morphology of fibroblasts (Stojkovic et pl.
2005) by passage 2. The formed line was named HUES7-Fib. HUES7-Fib cells were
cultured in DIFF medium, and passaged by 1:3 splits every 72 hours. They maintained this
regular split interval for 20 passages following their derivation, after which their growth rate
became slower. For this reason, HUES7 -Fib were only used for characterisation or iPSe
experiments within 15 passages following their derivation.
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Figure 3.5- Culture of HUES7-derived fibroblasts
Bright field images of A. an embryoid body (EB), 4 days following forced aggregation of 10,000 HUES7 cells, B.
HUES7-Fib on day 1 following trypsinisation and plating of EBs, C. HUES7-Fib at passage 2, 2 days after a 1:3
split and D. HUES7-Fib at passage 2, 3 days after a 1:3 split. Scale bar represents 100~m.
3.2.3.2 Derivation of fibroblasts from HOGN hESCs
HOGN were also differentiated into a fibroblast cell line, which was passaged at the same
intervals as HUES7-Fib. During differentiation, HOGN EBs gradually lost expression of GFP
protein (Figure 3.6.A-D); from day 12 onwards, GFP expression was lost in the outgrowths
of attached EBs, and became undetectable by day 20 of differentiation, depicting silencing
of endogenous OCT4. HOGN-Fib were GFP negative (Figure 3.6.E) and showed decreased
resistance to neomycin compared to undifferentiated HOGN cells (Figure 3.7).
Figure 3.6- Culture of HOGN hESCsand HOGN-derived fibroblasts (HOGN-Fib)
Bright field and fluorescence images of A. EBs on day 4, B. day 10, C. day 14 and D. day 20 following forced
aggregation of HOGNcelis. E. HOGN-Fib cells at passage 2, 3 days after a 1:3 split. Scale bars represent
100~m.
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3.2.3.3 Neomycin resistance of HOGN and HOGN-Fib cells
To assess neomycin resistance in HOGN and HOGN-Fib cells, a sensitivity test was
performed using the neomycin analogue G418, also known as Geneticin (Davies and
Jimenez 1980). Cells were treated with the antibiotic reagent for 6 days, at concentrations
varying from 0 to 800IJg/ml. At the end of this treatment, total cell counts were performed for
each sample, and the percentage of surviving cells at each G418 concentration was
calculated relative to the untreated control (OlJg/ml) for each cell type. The genetically
unmodified HUES7 and HUES7 -Fib cells were sensitive to G418 at all concentrations tested
(Figure 3.7). HOGN cells treated with 501Jg/ml, 100IJg/mi and 200IJg/mi of G418 showed
survival at 100%, 78.3% and 77.5%. In contrast, HOGN-Fib treated with 50-2001Jg/ml
showed survival at less than 60%. Since pluripotent HOGN cells could tolerate G418
treatment at concentrations up to 2001Jg/ml, while differentiated HOGN-Fib cells were
sensitive to G418 at concentrations of 50IJg/mi or higher, it was decided that 50IJg/mi of
G418 could be used in future experiments for the generation of iPSCs from HOGN-Fib. This
way, emerging iPSC colonies reactivating endogenous OCT4 and the IRES-GFP-IRES-Neo
cassette, would be selected against non-reprogrammed or incompletely reprogrammed cells
lacking OCT4 expression and Neomycin resistance.
3.2.3.4 Expression of pluripotency markers in HUES7-Fib and HOGN-Fib
In order to confirm that HUES7-Fib and HOGN-Fib had down-regulated the expression of
hESC-specific markers, such as OCT4, NANOG, SSEA4 and TRA-1-81 (Kannagi et al.
1983; Andrews et a/. 1984; Adewumi et al. 2007; Lanctot et a/. 2007b), immunofluorescence
staining was performed using antibodies raised against these markers. As shown in Figure
3.8, the pluripotent HUES7 and HOGN lines expressed all four markers tested, in contrast to
the differentiated lines HUES7 -Fib and HOGN-Fib.
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Figure 3.7- Effect of G418 treatment on the survival of HOGN, HUES7, HOGN-Fib and HUES7-Fib
Bright field images of A. HOGN and HUES7, and B. HOGN-Fib and HUES7-Fib cells treated with varying
concentrations of G418, ranging from 0 to 800 ug/rnl, Histograms of % cell survival in C. HOGN and HUES7,
and D. HOGN"-Fib and HUES7-Fib cells treated with varying concentrations of G418, as shown in A. and B. Scale
bars represent lOOllm.
• HOGN
• HUES7
106
PhD Thesis
Elena Matsa
School of Clinical Sciences
The University of Nottingham
o 50 100 200 400 800
G418 conc. (~ml)
Chapter 3- Generation of a model cell system for the investigation of human pluripotency
OCT4 OVERLAY NANOG OVERLAY
- -
-
1"""""1
-
.0
u::
r!.
Vl
lLJ
:::>
:J:
Z
\!J
o
:J:
.0
u;
Z
\!J
o
:J:
SSEA4 OVERLAY TRA-1-81 OVERLAY
r-,
Vl
lLJ
:::>
:J:
.0
u::
r!.
Vl
lLJ
:::>
:J:
Z
\!J
o
:J:
.0
u::
Z
\!J
o
:J:
Figure 3.8- Expression of pluripotency-associated markers in hESC-derived fibroblasts
Expression of OCT4, NANOG, SSEA4 and TRA-,181 in HUES7, HUES7-Fib, HOGN and HOGN-Fib cells, as
determined by immunofluorescence staining. Marker expression was captured using the Cy3 channel (red),
while the overlay represents a merge of the DAPI (nuclear staining) and Cy3 channels. Scale bars represent
641lm.
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3.2.4 Expression of fibroblast markers in HUES7 -Fib and HOGN-Fib
In order to confirm the fibroblast phenotype of HUES7-Fib and HOGN-Fib, expression of
putative fibroblast markers was assessed in these lines. A survey of the literature indicated
P4HB and FSA to be possible fibroblast-specific markers (Singer et al. 1989; Esterre et al.
1992; Wang et a/. 2005; He et al. 2007) since most other markers used to identify fibroblast
cells cross-react with additional types of cells, or fibroblast precursors (section 3.1.1).
3.2.4.1 Culture and characterisation of primary fibroblast lines
To test these antibodies for their specificity in staining fibroblast cells, the commercially
available human newborn foreskin fibroblast line BJ (referred to as BJ-Fib) and the adult
skin fibroblast line SUKE (referred to as SUKE-Fib) were used as positive controls. Both
lines were cultured as described in section 2.1.11, had the characteristic spindle-like
morphology of fibroblasts (Figure 3.9.A), and lacked expression of the pluripotency markers
OCT4, NANOG, SSEA4 and TRA-1-81 (Figure 3.9.0). Both lines stained uniformly for the
putative fibroblast specific markers P4HB and FSA (Figure 3.9.B&C).
3.2.4.2 Testing the specificity of putative fibroblast-specific markers
To determine cross-reactivity with other lineages, the anti-P4HB and FSA antibodies were
used to stain mouse neural stem cells (mNSCs) and mouse mesenchymal stem cells
(mMSCs). These cells were considered to be appropriate "negative" controls, since
fibroblasts are thought to arise from the mesenchyme tissue or from ectoderm via epithelial
to mesenchymal transition (Dennis and Charbord 2002; Kalluri and Neilson 2003). Slides of
fixed mMSCs and mNSCs were kindly provided for this experiment by Dr. Virginie Sottile,
School of Clinical Sciences, The University of Nottingham. Mouse embryonic fibroblasts
(MEFs) were also included in the analysis, to determine whether the antibodies cross
reacted with mouse cells. As a further control, beating clusters (heterogeneous populations
comprising of cardiomyocytes and fibroblasts, Figure 3.1O.A) derived from HUES7 cells
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Figure 3.9- Culture and characterisation of the patient fibroblast lines BJ and SUKE
A. Bright field (BF) images of the fibroblast lines BJ (passage33, 3 days following a 1:3 split) and SUKE (passage
14, 3 days following a 1:3 split). Immunofluorescence analysis of B. P4HB, C. FSA and D. pluripotency-
associated marker expression in BJ and SUKE fibroblasts. Target protein expression was captured using the
Cy3 channel, while the overlay represents a merge of the DAPI (nuclear staining) and Cy3 channels. Scale bars
represent 641lm.
were dissociated (Burridge et al. 2007) and attached to glass slides (section 2.8.2.); since
cardiomyocytes originate from the mesoderm (Beqqali et al. 2006), the same germ layer
that gives rise to mesenchyme tissue and fibroblasts, they acted as a stringent negative
control and should not react with fibroblast antibodies. The cardiac-specific marker troponin-
Iwas used to confirm the identity of cardiomyocytes (Figure 3.10, FITC staining).
Both the BJ and SUKE primary fibroblast lines stained uniformly for P4HB and FSA (Figure
3.10). No staining was observed in HUES7, or potential fibroblast precursors (mMSCs a~d
mNSCs). MEFs did show staining for both markers, confirming species cross reactivity of
the antibodies. However, many cells in the MEF population lacked expression of P4HB and
FSA, perhaps not unexpectedly, since these heterogeneous cell lines were prepared from
whole mouse embryos (section 2.1.2.). Furthermore, the mesoderm-originating human
cardiomyocytes did not stain for either P4HB or FSA, in contrast to the surrounding
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fibroblast-like cells, which were stained with both markers. These results showed that P4HB
and FSA were not expressed in potential fibroblast precursors (mMSCs and mNSCs) or in
cells originating from the same embryonic germ layer as fibroblasts (cardiomyocytes). Their
high and uniform expression levels in the commercially available human newborn foreskin
fibroblast line BJ and the adult skin fibroblast line SUKE inferred that P4HB and FSA can be
used as fibroblast-specific markers.
A B P4HB OVERLAY c FSA OVERLAY
Figure 3.10- Determining the specificity of putative fibroblast-specific antibodies
A. Phase contrast images of human BJ and SUKE fibroblasts (BJ-Fib and SUKE-Fib), a beating cluster (circled in
dotted line) containing human cardiomyocytes,·mouse embryonic fibroblasts (MEFs), mouse mesenchymal
and neural stem cells (mMSC and mNSC), and HUES7 hESCs. Expression of the fibroblast-specific markers B.
P4HB and C. FSA in the cell populations shown in A., as determined by immuno-fluorescence staining. Target
protein expression was captured using the Cy3 channel (red), while the overlay represents a merge of the
DAPI (nuclear staining), FITC (cardiac troponin-I) and Cy3 channels. Scale bars represent 321..lm.
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3.2.4.3 Expression of fibroblast markers in hESCs and their fibroblast derivatives
HUES?, HOGN, HUES?-Fib and HOGN-Fib were then assessed for the expression of
P4HB and FSA antigens. The pluripotent lines HUES? and HOGN lacked both these
markers, whereas expression was detected in HUES? -Fib and HOGN-Fib (Figure 3.11).
Expression of FSA was uniform across the population of the two fibroblast lines, but a
proportion of cells lacked expression of P4HB, both in the HUES?-Fib and HOGN-Fib
populations. This, perhaps, suggested that cytoplasmic P4HB was a more stringent marker
for identifying fibroblast cells than the surface antigen FSA.
A P4HB OVERLAY B FSA OVERLAY
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Figure 3.11- Expression of fibroblast-specific markers in hESC-derived fibroblasts
Expression ot the fibroblast-specific markers A. P4HB and B. FSA in HUES7, HUES7-Fib, HOGN and HOGN-Fib
cells, as determined by immuno-fluorescence staining. Marker expression was captured using the Cy3 channel
(red), while the overlay represents a merge of the DAPI (nuclear staining) and Cy3 channels. Scale bars
represent 641lm. . ,
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3.2.5 Generation of clonal hESC-fibroblast lines expressing P4HB
Having shown that the HUES? -Fib and HOGN-Fib lines did not consist of uniform cell
populations, attempts were made to produce pure fibroblast lines that could be used for
reprogramming experiments. This was considered necessary in order to eliminate the
possibility that reprogrammed cells in future experiments would originate from
undifferentiated or precursor cells residing in the HUES?-Fib and HOGN-Fib lines.
After unsuccessful attempts to sort live HUES? -Fib cells based on FSA expression, using
FACS and magnetic-bead separation (data not shown), a single-cell cloning strategy was
adopted. HUES?-Fib and HOGN-Fib were seeded in 96-well plates at a density of 20 cells
per plate, since this density was previously shown mathematically to provide the highest
number of single vs. mixed cell clones per plate (Ma and Wells 2004). Eight clonal lines
were expanded and analysed for both HUES?-Fib and HOGN-Fib. Lines showing the
highest enrichment in P4HB expression by immunofluorescence (Figure 3.12) were
expanded further in culture and analysed by flow cytometry to confirm the percentage of
P4HB positive cells in their populations. Two clonal lines from HUES? -Fib and HOGN-Fib
exhibited P4HB expression of between 90-96%, (Figure 3.12). This was a considerable
enrichment compared to the starting populations of HUES?-Fib and HOGN-Fib, which
showed a 41% and 2?% expression of P4HB, respectively.
Despite having generated clonal lines of the HUES? -Fib and HOGN-Fib populations, these
were not used to generate iPSCs. This was due to their extremely slow proliferation rate
(cells reached proliferative arrest after 2-3 passages), which did not allow the necessary
scale-up of cultures prior to their use for iPSC generation. Clone 4 of HUES?-Fib (referred
to as HUES?-Fib CI4), remained proliferative until passage 4 and was pelleted in order to be
used in comparison to HUES?-Fib in molecular biology analyses (chapter 4).
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3.2.6 Establishing a lentiviral system for efficient transduction of hESCs
and hESC-derived fibroblasts
Following derivation and characterisation of fibroblast lines from HUES7 and HOGN, it was
necessary to establish an efficient protocol for lentiviral transduction of these cells in our
laboratory. The protocol would be used to enable reprogramming of fibroblasts into iPSCs
(section 3.2.7), and to introduce shRNAs for the manipulation of epigenetic characteristics in
fibroblasts and hESCs (chapter 5). A flow chart of the parameters tested to establish an
optimised protocol is presented in Figure 3.13.
·HEK293 transfection
• Effect of HEK293density on virus production
Effect of viral volume on
transduction efficiency
• Virus harvesting time
• Virus storage conditions
• Effect of polybrene on cellular up-take of virus
• Enrichment of virus concentration using
Amicon-Ultra columns
Figure 3.13- Flow chart representation of experiments performed to optimise the lentiviral transductibn
system
Parameters involved in lentiviral transduction were varied in order to derive a protocol for efficient virus
production, concentration and up-take by target cells. The parameters tested included the method of HEK293
cell transfection and seeding density, the virus harvesting time and storage conditions, the effect of polybrene
treatment on cellular up-take of virus, and the concentration of viral particles using Amicon-Ultra columns. All
conditions were tested at a range of viral volumes (O-12001l1),to determine the most efficient protocol for
lentiviral transduction.
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3.2.6.1 Assessing different methods to achieve efficient transfection of HEK293 cells
To optimise HEK293 transfection, the fluorescence reporter plasmid pGFP-IRES-£!.uromycin
(pGIP) was used as a positive control (kindly gifted by Dr. Austin Smith, The University of
Cambridge, UK) (Figure 3.14).
Figure 3.14- Map of the pGIP plasmid
The fluorescence plasmid pGIP, used to optimise lentiviral transduction. This
plasmid supports expression of enhanced GFP (eGFP) protein from the
potent pCAGpromoter.
Four cationic lipids were tested for their efficiency in transfecting HEK293 cells with pGIP.
Each lipid was tested in duplicate at a 1:1, 2: 1 and 3: 1 lipid to DNA ratio. Negative controls
included an untreated sample, as well as a sample treated with plasmid DNA but no lipid.
The experiment was performed two times. The percentage of GFP positive cells was
determined by flow cytometry analysis, and representative plots for each sample are shown
in Figure 3.15.A. Transfection with GeneJammer was very inefficient at all lipid:DNA ratios
tested (% GFP+ cells being 1.9%±O.16 to 2.2%±0.45, Figure 3.15.8). FuGENE HO,
Lipofectiane-2000 and Lipofectamine-L TX showed similar transfection efficiencies at the 3: 1
ratio (83.1 %±14.5, 79.7%±14.9 and 81.8%±17.6, respectively). FuGENE was 17% more
efficient than Lipofectamine-2000 (75.1 %±11.3) and 29% more efficient than Lipofectamine-
.
LTX (66.0%±33) at the 2: 1 ratio. Less efficient transfection was observed at the 1:1 ratio
(Lipofectamine-2000; 60%±O.5, Lipofectamine-L TX; 29.3%±18.9 and FuGENE; 9.6%±4.3).
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Figure 3.15- Testing the ability of different lipid vectors to transfect HEK293 cells
A. Bright field and fluorescence images of HEK293 cells transfected with pGIP plasmid, using either
Lipofectamine-2000 (Lipo-2000), GeneJammer, Lipofectamine-LTX (Lipo-LTX) or FuGENE HD as a cationic lipid
transfection vehicle. Flow cytometry data of the total cells examined (Fe scatter plot) as well as gating of the
positive fluorescent populations (Fe) are shown. B. Histogram representing the % fluorescence in HEK293 cells
shown in A., as determined by flow cytometry. Error bars represent standard error. Scale bars represent
lOOllm.
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Lipofectamine-2000 and -LTX gave the highest transfection efficiencies at the 1:1 ratio,
which is important due to the high cost of these lipid reagents. To refine HEK293
transfection further, cell number was reduced from 10,000 to 5,000 since this has been
associated with improved transfection (Braam et al., 2008a). Based on flow cytometry
analysis, treatment with Lipofectamine-2000 allowed higher transfection efficiencies with
pGIP, compared to Lipofectamine-LTX (98.9% and 76.9% respectively; Figure 3.16). It was,
therefore decided that 31-11of Lipofectamine-2000 would be used at the 1:1 lipid:DNA ratio to
transfer 31-1gof plasmid DNA to 5,000 HEK293 cells. Smaller or bigger scale transfections
were performed according to these ratios.
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Figure 3.16- Refining lipid transfection of HEK293 cells
Bright field and fluorescence images of HEK293 cells transfected with pGIP plasmid using either
Lipofectamine-LTX (Lipo-LTX) or Lipofectamine-2000 (Lipo-2000). Flow cytometry data of the total cells
examined (Fe scatter plot) as well as gating of the % fluorescent populations (Fe) are shown. Scale bars
represent lOOllm.
3.2.6.2 Evaluating viral transduction
Plasmid combination from a 2nd generation viral system (section 3.1.3.2) was used to
generate Ientivlral particles. The plasm ids used were; the GFP reporter-transfer plasmid
pLVTHM, the packaging plasmid psPAX2 and the envelope plasmid pMD2.G (Figure 3.17).
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A B c
pLVTHM
l1085bp
cPPT
3'LTR
Figure 3.17- Maps of plasmids used to optimise lentiviral transduction
A. The fluorescence reporter lentiviral plasmid pLVTHM. B. The lentiviral packaging plasmid psPAX2.C. The
lentiviral envelope plasmid pMD2G. pLVTHM supports expression of eGFP protein under the eukaryotic
elongation factor la (EFla). This plasmid also carries HIV-llong terminal repeats (LTRsLan HIV-l psi (tjJ) pack,
a central polypurine tract (cPPT)sequence responsible for HIV nuclear import, and a woodchuck hepatitis
post-translational regulatory element (WPRE),shown to improve transgene expression and viral titres (Klein et
al. 2006). psPAX2and pMD2.G carry the viral genes gag, pal and VGV-G, which are essential packaging of viral
particles.
The ability to lentivirally transduce three cell types was tested. These cell lines were; 1)
HUES? -Fib, since they would be used in reprogramming experiments to derive iPSCs, 2)
HUES?, since these were going to be used to study the effect of DNMT knock-down in
pluripotent cells (chapter 5) and 3) HEK293, as a positive control because they are relatively
easy to culture and genetically modify (Thomas and Smart 2005). In optimisation
experiments (outlined in Figure 3.13), each cell line was transduced with varying volumes of
viral supernatants, ranging from 0 to 12001-11.Bright field and fluorescence images of all cells
were captured at ?2 hours post transduction (PTO), after which the cells were trypsinised
and prepared for analysis of GFP expression by flow cytometry. The percentage of GFP
positive cells was calculated relative to the untreated control sample (01-11of virus) for each
cell type.
Treatment with increasing volumes of viral supernatant resulted in higher percentage cell
transduction, with HEK293 proving to be the most easy to transduce cell line (Figure 3.18).
Doubling the number of HEK293 cells used to generate viral particles (1.5 million instead of
0.?5 million cells) increased transduction efficiency (Figure 3.18), indicating an increased
overall production of virus from HEK293 cells. The results for subsequent optimisation
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experiments, outlined in Figure 3.13, are presented in Table 3.3. Based on these results, it
was decided that viral-supernatants would be collected on day 2 post-transfection of
HEK293 cells, and used fresh. Polybrene solution, previously shown to improve viral up-
take of target cells (Davis et al. 2002), did not increase transduction efficiency in HEK293 or
HUES? cells, but did improve transduction of HUES?-Fib. Therefore, it was only be used
when transducing fibroblast cells.
Table 3.3- Experiments performed to improve lentiviral transduction of HEK293, HUES7 and HUES7-Fib
Parameter Variables
% Transduction (12001l1 of virus)
HEK293 HUES7 HUES7-Fib
HEK293 density
0.75 million 71.0 17.3 19.1
1.5 million 79.7 19.6 39.0
Virus harvesting
day 2 PTF 69.0 25.1 49.0
day 4 PTF 26.B 5.5 17.1
time
day 6 PTF 11.5 1.5 1.2
Virus storage
Fresh 69.0 25.1 49.0
Fridge (4°C) 51.0 6.9 15.1
conditions
Frozen (-BO°C) 42.2 4.6 9.1
Polybrene
Oug/rnl 90.B 61.3 63.5
Bug/rnl B1 49.7 B1.s
3.2.6.3 Viral concentration with Amicon-Ultra centrifugal filter units
With 12001-11approaching the highest volume physically possible to use for viral transduction
of 5,000 target cells seeded in 24-well plates, it was necessary to concentrate viral
supernatants to enable transduction with higher volumes. Amicon-Ultra centrifugal filter units
with a 100kDa nominal molecular weight limit (NMWL; Sena-Esteves et al. 2004) were used
to concentrate 15ml of viral supernatants by approximately ?5-fold, to a final volume of
2001-11.The centrifugation process did not result in loss of viral particles, since corresponding
volumes of non-concentrated (1.5ml) and concentrated virus (201-11)were shown' to
transduce cells with the same efficiency, which was close to 100% for all cell lines tested
(Figure 3.19). The use of Amicon-Ultra units opened the possibility of infecting a larger
number of cells, and improving experimental through-put.
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Chapter 3- Generation of a model cell system for the investigation of human pluripotency
3.2.7 Formation of iPSCs from hESC-derived fibroblasts
3.2.7.1 Testing the lentiviral plasm ids used to generate iPSCs
Before attempting to generate iPSes from hESe-derived fibroblasts, the lentiviral plasm ids
intended to be used for this purpose were tested to determine whether they could support
expression of each iPSe factor individually, in HUES7 -Fib. Four lentiviral transfer plasm ids
were used, each carrying cDNA of human OCT4, NANOG, SOX2 or LlN28 (Addegene; Yu
et al. 2007b; Figure 3.20). The plasmids formed part of a 2nd generation lentiviral system,
and were used in conjunction with the packaging and envelope plasm ids psPAX2 and
pMD2.G. Six days following lentiviral transduction of HUES7-Fib, cells were fixed in 4% PFA
and immunofluorescence was used to detect expression of the four iPSe factors (Figure
3.21). HUES7-Fib that were not transduced with virus, or were transduced with the pLVTHM
GFP control lentivirus, did not express any of the four iPSe factors. In contrast, cells
transduced with lentivirus carrying transgene sequences of human OCT4, NANOG, SOX2
and LlN28, expressed these proteins in approximately 60-80% of cells (visual estimation).
Thus, all four plasm ids were able to produce functional lentiviral particles, which supported
expression of the transgenes they were carrying.
A B c o
Figure 3.20- Maps of transfer plasm ids used to generate iPSCs
Lentiviral transfer plasm ids carrying cDNA for A. OCT4, B. SOX2, C. NANOG and D. LlN28, based on the pSin-
EF2-IRES-Puro backbone vector. pSIN-EF2-IRES-Puro has HIV-1 LTRs and an HIV-1 tjJ packing signal. It also has a
cPPT element assisting in virus nuclear import, and a Rev-responsive element (RRE) which facilitates nuclear
export of RNA molecules and supports their stability and translation. The transgenes are expressed under an
EF1a promoter and are followed by an IRESsequence, allowing expression of the puromycin resistance gene
under the same promoter.
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A NV GFP OCT4 SOX2 NANOG lIN28
B OCT4 OVERLAY SOX2 OVERLAY NANOG OVERLAY lIN28 OVERLAY
Figure 3.21- Protein expression of the four iPse factors lentivirally transduced into HUES7-Fibroblasts
A. Bright field images and B. immunofluorescence analysis of HUES7-Fib cells transduced with lentivirus over-
expressing GFP, OCT4, SOX2, NANOG or LlN28. For immunofluorescence analysis target protein expression
was captured using the Cy3 channel, while the overlay represents a merge of the DAPI (nuclear staining), and
Cy3 channels. NV = no virus. Scale bars represent 641lm.
3.2.7.2 Generation of iPSCs using fibroblasts derived from HOGN cells
Initially, the HOGN-Fib line was used to generate iPSCs, as described in section 2.2.6. On
day 8 post-transduction (PTO), the first ESC-like colonies were detected in culture (Figure
3.22.8). Colonies considered to represent putative iPSCs had defined borders, and
consisted of densely packed cells with angular cell walls. These colonies grew bigger over
time and expressed GFP protein from day 18 PTO (Figure 3.22.0), due to reactivation of the
OCT4 targeted IRES-GFP-IRES-Neo cassette.
G418 treatment (50lJg/ml) was applied from day 12 until day 16 of reprogramming, with the
aim of selecting against non-reprogrammed or incompletely reprogrammed cells. However,
.
this did not prove very effective, perhaps due to the low level resistance of HOGN-Fib cells
to the antibiotic G418 (Figure 3.7), or due to reactivation of endogenous OCT4 in some
incompletely reprogrammed colonies. On day 21 PTO, putative iPSe colonies were selected
based on hESC-like morphology and expression of GFP. They were manually dissected and
expanded in culture, and were finally adapted to feeder-free culture on Matrigel with trypsin
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passaging. Compared with culture as colonies, monolayer cultures on Matrigel with trypsin
passaging facilitate downstream molecular analysis, homogeneous EB formation, and direct
comparison to the HOGN hESC line which was also cultured on Matrigel. HOGN-iPSCs
transferred to Matrigel maintained GFP expression (Figure 3.22.F).
Figure 3.22- Generation of HOGN-iPSCs
Bright field and fluorescence images of iPSC colonies on A. day 0 B. day 8 C. day 10 D. day 18 and E. day 20
after transduction with lentiviruses over expressing OCT4, NANOG, SOX2, and LlN28. F. Bright field and
fluorescence images of HOGN-iPSCs cultured on Matrigel at passage 2, 2 days after a 1:3 split. Scale bars
represent 1001lm.
3.2.7.3 Characterisation of HOGN-iPSCs
In order to assess the ability of HOGN-iPSCs to form derivatives of the three embryonic
germ layers, cells were differentiated via EB formation. On day 21 of differentiation, EBs
.
were seeded onto glass chamber slides, fixed using 4% PFA and analysed by
immunofluorescence staining as described in section 3.2.1. Figure 3.23 demonstrates
differentiation into ectoderm, endoderm, and mesoderm derivatives. Cells expressed the
hESC markers OCT4, NANOG, SSEA4 and TRA-1-81, as determined by
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immunofluorescence, and lacked expression of the fibroblast markers P4HB and FSA
(Figure 3.24).
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Figure 3.23- Germ layer formation in HOGN-iPSCs
Differentiation of HOGN-iPSCs to cell types representative of the three germ layers; ectoderm, endoderm and
mesoderm. Protein expression was captured using the Cy3 channel, while the overlay represents a merge of
the DAPI (nuclear staining) and Cy3 channels. Scale bars represent 64(lm.
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Figure 3.24- Expression of pluripotency-associated and fibroblast-specific markers in HOGN-iPSCs
Immunofluorescence analysis of OCT4, NANOG, SSEA4, TRA-1-81, P4HB and FSA expression in HOGN-iPSCs.
Marker expression was captured using the Cy3 channel, while the overlay represents a merge of the DAPI
(nuclear staining) and Cy3 channels. Scale bars represent 64(lm.
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3.2.7.4 Generation of iPSCs from fibroblasts derived from HUES7 cells
Having validated the reprogramming process and seen the morphology of putative iPSC
colonies, reprogramming of HUES?-Fib cells lacking a reporter system to detect reactivation
of endogenous genes was then attempted. Live staining with the hESC-surface marker
TRA-1-B1 (Lowry et al. 200B) was used to identify emerging colonies, since this was shown
to be one of the most reliable markers for identification of true iPSCs in vitro (Chan et al.
2009). hESC-like colonies were identified from day 11 PTO (Figure 3.25.8), and increased
in size and number in the following days until, on day 21 post-transduction, they were
dissected and expanded on MEF-feeders. Colony counts on day 21 PTO revealed that the
overall reprogramming efficiency of HUES? -Fib cells was 0.1±%0.01. HUES? -iPSC colonies
were adapted to culture on Matrigel surfaces after? passages on MEF feeders.
Figure 3.25- Generation of HUES7-iPSCs
Bright filed images of iPse colonies on A. day 0 B. day 11 C. day 13 and D. day 20 after transduction with
lentiviruses over-expressing the four iPse factors. On B. day 11 and C. day 13 post-transduction, in vitro
staining of iPse colonies for the hESe-specificsurface antigen TRA-1-81 was performed and visualised in the
ey3 channel (red). E. HUES7-iPSescultured on Matrigel at passage 2, 3 days after a 1:3 split. Scale bars
represent 100~m.
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3.2.7.5 Characterisation of HUES7-iPSCs
Differentiation of HUES7-iPSCs to' endoderm and ectoderm derivatives was shewn by
immunefluerescence staining, as described in section 3.2.7.3 (Figure 3.26.A). Formation of
mesoderm derivatives was shewn by adipecyte Oil-red 0 staining (Figure 3.26.B), since
beating cardiemyecytes were net detected in differentiated HUES7-iPSCs. Mesederm
formation from HUES7-iPSCs was also confirmed by expression of the early mesoderm
marker Brachyury (Vidricaire et al. 1994), threugh immuno-histochemical and real-time PCR
analysis of d10 EBs (data net shewn). HUES7-iPSCs had a nermal46,XY karyotype (Figure
3.26.C), and expressed the pluripetency markers OCT4, NANOG, SSEA4 and TRA-1-81
(Figure 3.27). Cells lacked expression of the fibroblast markers P4HB and FSA. (Figure
3.27)
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Figure 3.26- Germ layer formation and karyotype analysis in HUES7-iPSCs
A. Differentiation of HUES7-iPSCs to cell types representative of ectoderm and endoderm. Protein expression
was captured using the Cy3 channel, while the overlay represents a merge of the DAPI (nuclear staining) and
Cy3 channels. B. Bright field images of adipocytes derived from HUES7-iPSCs and stained with Oil-red o.
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Figure 3.27- Expression of pluripotency-associated and fibroblast-specific markers in HUES7-iPSCs
Immunofluorescence analysis of OCT4, NANOG, SSEA4, TRA-1-81, P4HB and FSA expression in HUES7-iPSCs.
Marker expression was captured using the Cy3 channel, while the overlay represents a merge of the OAPI
(nuclear staining) and Cy3 channels. Scale bars represent 64~m.
3.2.7.6 Morphology of incompletely reprogrammed colonies
During reprogramming of HOGN-Fib and HUES7 -Fib lines, numerous colonies other than
the hESe-like putative iPSe colonies emerged. These usually appeared earlier than
putative iPSe colonies (day 6 for HOGN-Fib and day 8 for HUES7-Fib), and were
considerably more abundant. Their morphology could be categorised in two classes; large
colonies composed of loose rounded cells (Type I, Figure 3.28.A), and smaller colonies
composed of compacted granular cells (Type II, Figure 3.28.8). Notably, neither of these
colony-types stained positively for the hESe-surface marker TRA-1-81 (Figure 3.28).
Figure 3.28- Incompletely reprogrammed colonies observed during reprogramming of HUES7-Fib
Incompletely reprogrammed colonies emerging during induction of HUES7-Fib to form iPSCs. Incompletely
reprogrammed colonies were either A. large in size and composed of loose cells (Type I), or B. smaller in size
and composed of granular cells (Type II). Both colony types appeared more frequently and earlier than iPSC
colonies, but lacked expression of the TRA-1-81 hESC-surface marker. Scale bars represent 100~m.
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3.2.7.7 Differentiation of HOGN-iPSCs to fibroblasts
In order to evaluate whether fibroblast-derived iPSCs could re-differentiate to fibroblasts,
HOGN-iPSCs were differentiated through the same method previously used for HUES? and
HOGN cells (section 3.2.3). EBs strongly expressed GFP protein on day 4 of differentiation
(Figure 3.29.A), but this was gradually lost until it became completely undetectable by day
18 (Figure 3.29.E). The resulting cell line (referred to as HOGN-iPS Fib) lacked GFP
expression, but also lacked the characteristic spindle-like morphology of fibroblast cells
(Figure 3.29.F). Differentiation was repeated twice, with fibroblasts having the same
rounded morphology both times.
HOGN-iPS Fib did not express the hESC markers NANOG, SSEA4 and TRA-1-81, but did
express OCT4. Lack of GFP expression in HOGN-iPS Fib (Figure 3.29) suggested that the
OCT4 expression detected by immunofluorescence staining was driven by the lentiviral
transgene, which failed to become silenced. Cells also lacked expression of the fibroblast
marker, P4HB. Together with the rounded morphology of HOGN-iPS Fib cells (Figure 3.29),
these observations suggested that the HOGN-iPS Fib line did not consist of fibroblasts.
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Figure 3.29- Differentiation of HOGN-iPSCs to fibroblasts
Bright field and fluorescence images of EBs on A. day 4 B. day 8 C. day 10 D. day 16 and E. day 18 of
differentiation. F. Bright filed and fluorescence images of HOGN-iPS Fib at passage 3, 2 days following a 1:3
split. Scale bars represent 1001lm.
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Figure 3.30- Expression of pluripotency-associated and fibroblast-specific markers in HOGN-iPS Fib
Immunofluorescence analysis of OCT4, NANOG, SSEA4, TRA-1-81, P4HB and FSA expression in HOGN-iPS Fib.
Marker expression was captured using the Cy3 channel, while the overlay represents a merge of the OAPI
(nuclear staining) and Cy3 channels. Scale bars represent 641lm.
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3.2.7.8 Differentiation of HUES7-iPSCs to fibroblasts
HUES?-iPSQs were also differentiated into a fibroblast cell line, with the same method
previously used for HUES?, HOGN and HOGN-iPSCs. The resulting cell line did show the
characteristic spindle-like morphology of fibroblasts (Figure 3.31), but had reduced
proliferation rates compared to HUES?-Fib. The cells reached proliferative arrest by
passage 4-6. Nevertheless, they expressed the fibroblast markers P4HB and FSA, and had
down-regulated expression of OCT4, NANOG, SSEA4 and TRA-1-81 (Figure 3.32).
Figure 3.31- Differentiation of HUES7-iPS to fibroblasts
Bright filed images of EBs on A. day 8 and B. day 18 of differentiation. C. HUES7-iPS fibroblasts (HUES7-iPS Fib)
at passage 1, 3 days following trypsinisation and plating of EBs. Scale bar represents 100~m.
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Figure 3.32- Expression of pluripotency-associat.ed and fibroblast-specific markers in HUES7-iPS Fib
Immunofluorescence analysis of OCT4, NANOG, SSEA4, TRA-1-81, P4HB and FSA expression in HUES7-iPS Fib.
Marker expression was captured using the Cy3 channel, while the overlay represents a merge of the DAPI
(nuclear staining) and" Cy3 channels. Scale bars represent 64~m.
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3.3 DISCUSSION
In this chapter, hESC cultures of the HUES? and OCT4-GFP targeted HOGN lines were
characterised and differentiated in vitro to generate fibroblast-like cells. The fibroblasts
lacked expression of pluripotency markers, but did express P4HB and FSA; two markers
shown to specifically detect fibroblasts in this study. P4HB was only expressed in a subset
of hESC-derived fibroblasts, in contrast to clonal lines derived from these cells that showed
90-96% expression of P4HB. Unfortunately, due to proliferative arrest, the clonal lines were
not used in reprogramming experiments. Instead, they were pelleted for use in gene
expression and epigenetic analyses (chapter 4). Since lentiviral transduction had not been
performed previously in our lab, a protocol for efficient genetic manipulation by lentiviral
transduction was established and then used to reprogram hESC-derived fibroblasts to
iPSCs. Reprogrammed cells were successfully differentiated to all three embryonic germ
layers, and showed silencing of fibroblast-specific markers as well as reactivation of hESC-
specific markers. iPSCs were further differentiated to fibroblasts to complete generation of
the model cell system, described in Figure 1.1.
3.3.1 Culture and characterisation of hESCs
hESCs of the HUES? and OCT4-GFP reporter line, HOGN, expressed the hESC-specific
makers OCT4, NANOG, SSEA4 and TRA-1-81 (Figure 3.8), and could differentiate to cell-
types representative of the three embryonic germ-layers; endoderm, ectoderm and
mesoderm (Figure 3.3 and Figure 3.4). Formation of beating cardiomyocytes indicated that
hESCs could derive functional differentiated cell types (section 3.1.2). HUES? hESCs had a
normal karyotype when cultured on Matrigel™ surfaces with MEF conditioned medium and
trypsin passaging (Figure 3.3). HOGN had trisomy of chromosome 12 and addition of
chromosome 1? material to the small arm of chromosome 21 (Figure 3.4). When the HOGN
cell line was generated by (Braam et al. 2008b) cells were reported to have normal
karyotype after transfection with the OCT4-GFP targeting plasmid and clonal growth.
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However, trisomy of chromosome 12 was detected in a sub-set of cells during culture scale-
up (Braam et al. 2008b), and as a result, HOGN cultures used for this thesis also had an
abnormal karyotype. Karyotype abnormalities involving chromosomes 12, 17q and 20q 11,
accumulate frequently in cultures of hESCs (Draper et al. 2004; Spits et al. 2008) and are
speculated to confer a proliferative advantage to hESCs by increasing the dosage of
pluripotency-associated genes such as NANOG, which is located on chromosome 12 (Clark
et al. 2004; Draper et al. 2004). Despite their abnormal karyotype, HOGN were used to
derive fibroblasts, and subsequently iPSCs, since their OCT4-GFP reporter system was
valuable for distinguishing between fully and partially reprogrammed iPSC colonies, which
were being derived for the first time in our lab.
3.3.2 Derivation and characterisation of hESC-fibroblast lines
In this project, fibroblast-like cells were generated from the OCT4-GFP reporter line, HOGN,
and the genetically unmodified line, HUES7 (section 3.2.3.). Fibroblasts from both lines
were cultured by regular split intervals for approximately 15 passages (45-60 days), after
which they begun to senesce. Senescence is not uncommon for in vitro cultured primary
fibroblasts (Hayflick and Moorhead 1961; Goldstein 1990), which show limited proliferative
capacity related to telomere shortening (Allsopp and Harley 1995). It is also not uncommon
for ESC-derived cells since telomere shortening due to reduced human telomerase reverse
transcriptase (h TERn expression begins upon differentiation of hESCs (Lebkowski et al.
2001; Xu et al. 2001). hESC-derived fibroblasts were previously shown to proliferate in
culture for 40-55 days (Xu et al. 2004), in line to results from this study. Genetic modification
involving hTERT over-expression could extend the life-span of hESC-derived fibroblasts by
at least twice (Xu et al. 2004).
Fibroblasts derived from the OCT4-GFP reporter line, HOGN, were sensitive to treatment
with G418 at concentrations of 50IJg/ml or higher (Figure 3.7). Since 50IJg/ml were not toxic
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to undifferentiated cells, it was decided that this concentration would be used in
reprogramming experiments using HOGN-Fib as a "parent cell-line", in order to select
against partially reprogrammed cells that had not reactivated the expression endogenous
OCT4. This was in agreement with the concentration of G418 used in Yu et al. (200?b), who
employed the same lentiviral system used here for iPSC generation. Worth noting is that
HOGN-Fib did not show detectable expression of OCT4 or GFP proteins (Figure 3.6), but
had increased resistance to G418 compared to HUES?-Fib (Figure 3.?). This suggested
that HOGN-Fib expressed OCT 4 at residual levels or that some cells within the HOGN-Fib
population remained undifferentiated. Latent undifferentiated cells have previously been
observed in populations of differentiated mESCs, and are increasingly common in lines with
karyotype abnormalities (Enseat-Waser et al. 2009), such as the HOGN line. Staining with
the fibroblast-specific marker P4HB confirmed that both the HUES? -Fib and HOGN-Fib
populations consisted of cells other than fibroblasts, while the percentage of non-fibroblast
cells was -15% higher in HOGN-Fib compared to HUES? -Fib (Figure 3.12). In contrast to
P4HB, FSA expression was detected in most cells within the HOGN-Fib and HUES?-Fib
populations (Figure 3.11), suggesting that P4HB was a more stringent fibroblast-specific
marker than FSA. This is in accordance to studies that have reported FSA expression in
other mesodermal lineages (e.g. macrophages and peripheral monocytes; Singer et al.
1989).
3.3.3 Lentiviral transduction of hESCs and hESC-fibroblasts
One of the aims of this chapter was to generate a protocol for efficient lentiviral transduction
of hESCs and hESC-derived fibroblasts, since this had not been performed previously in our
lab. Despite the availability of lentiviral transduction protocols in the literature (Kutner et al.
2009), it was important to determine the parameters that allowed efficient transduction with
the type of second generation plasm ids used in this thesis (VSV-G pseudotype; Burns et al.
1993; Zhou et al. 2003). Also, it was important to improve the efficiency of available
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transduction protocols, which often result in the generation of low titre viral supernatants
(D'Costa et. al. 2001). After testing a number of parameters involved in the process (Figure
3.13), an optimised protocol was established that allowed close to 100% transduction of
target cell lines (section 3.2.6). This protocol was published in Braam et al. (2008a), a paper
describing methods for efficient genetic modification of hESCs. The protocol used
centrifugal Amicon-Ultra filter units for the concentration of viral supernatants (Figure 3.19),
which have been shown to result in higher lentiviral particle titres and recovery efficiencies
compared to other techniques, such as ultra-centrifugation or anion exchange
chromatography (Sena-Esteves et al. 2004), which are more elaborate and time-consuming
processes (Tiscornia et al. 2006; Kutner et al. 2009). Also, the virus was used fresh to
transduce target cells, since storage at 4 or -80°C decreased transduction efficiency by -20-
40% (Table 3.3). This is often ignored by other studies who recommend freezing the virus
despite observing up to 50% losses in viral transduction due to repeated freeze-thaw cycles
(Seyer et al. 2002). Collection of virus-containing medium from HEK293 cells at time-points
after day 2 post transfection (Le. day 4 and 6 post-transfection) resulted in a 20-58%
decrease in transduction efficiency. This effect was consistent with findings from previous
papers (Geraerts et al. 2006) and was likely to be related to the short life-time of lentiviral
particles (19h±0.2; Chilton and Le Doux 2008), or to increasing deficiency in metabolic
energy of the virus-producing cell-line HEK293 (Cynthia et al. 2003; Elias et al. 2003) and
loss of plasmid expression following cell divisions of HEK293 cells (Geraerts et al. 2006).
3.3.4 Formation of iPSCs from hESC-fibroblast lines
Lentiviral-mediated over-expression of the four pluripotency-associated genes, OCT4,
NANOG, SOX2 and LlN28, was used in this study to induce reprogramming of hESC-
derived fibroblasts to iPSCs (section 3.2.7). This method was originally described by the
group of Dr. James Thomson (Yu et al. 2007b), who also pioneered the isolation of hESCs
from blastocyst embryos (Thomson et al. 1998).
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Fully reprogrammed HOGN-iPSes were identified based on expression of GFP protein,
which indicated reactivation of endogenous OCT4 (Figure 3.22). HUES7-iPSes were
identified by live cell staining with the surface marker TRA-1-B1 (Figure 3.25), previously
shown to be the most reliable marker for early in vitro selection of bona fide iPSes from
genetically unmodified "parent" cells (section 1.B.1.1, Figure 1.11). Incompletely
reprogrammed type I and type II colonies lacked TRA-1-B1 expression (Figure 3.2B),
supporting the notion that TRA-1-B1 is a powerful marker for early in vitro identification of
bona fide iPSe colonies (Chan et al. 2009).
During reprogramming of HOGN-Fib, putative iPSe! hESe-like colonies were first observed
on day B PTO, which was 3 days earlier to colony detection during HUES7-Fib
reprogramming (day 11 PTO). It is possible that the karyotypically abnormal HOGN-Fib
cells, carrying an extra copy of the pluripotency gene NANOG, had a "reprogramming
advantage" relative to HUES7-Fib that had a normal karyotype. Appearance of HUES7-
iPse colonies was detected on day 11 PTO. This was similar to reprogramming of IMR90
human foetal fibroblasts by lentiviral transduction of "iPSe factors", where iPSe colonies
were detected on day 12 PTO (Yu et al. 2007b), but was earlier compared to
reprogramming of neonatal fibroblasts using retroviral vectors, where iPSe colonies were
detected on 15 day PTO (Hotta et a/. 2009). The overall efficiency of colony formation from
HUES7 -Fib was 0.1±%0.01, consistent with other studies using lentiviral transduction to
over-express the four "iPSe factors", and 10 to 100-fold more efficient compared to studies
using retroviral transduction (Table 3.2) which is more prone to silencing by the host
genome (section 3.1.3.2). An iPSe generation efficiency of 0.1% was at the higher end of
the range reported by previous studies who used lentiviral transduction of OCT4, NANOG,
SOX2 and LlN28 (Table 3.2), and is consistent with the advantageous use of hESe-derived
fibroblasts as an "iPSe parent-line", instead of the more terminally differentiated foetal,
neonatal or adult fibroblasts (Park et al. 200Bc; Laurent et al. 2010).
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The iPSC-generation method used in this thesis served the purpose it was chosen for, i.e.
the efficient derivation of reprogrammed cells that would enable the study of epigenetic
changes associated with key pluripotency genes and the transition of cell phenotype from a
differentiated to a pluripotent state.
3.3.5 Derivation and characterisation of iPSe-fibroblast lines
HUES7-iPS were successfully differentiated to P4HB positive fibroblasts (Figure 3.32),
demonstrating that they could "circle-back" to the same cell-type they were derived from
when the same differentiation protocol was applied. This showed that hESCs and iPSCs
shared similar differentiation potentials. However, HOGN-Fib differentiation resulted in the
generation of P4HB negative cells which lacked the characteristic spindle-like fibroblast
morphology. The persistent expression of OCT4 in HOGN-iPS Fib (Figure 3.30) could be
responsible for the unexpected morphology of HOGN-iPS Fib. It is likely that HOGN-iPS
were differentiated towards endoderm lineages, since OCT4 over-expression in hESCs has
been shown to promote up-regulation of markers indicative of endoderm derivatives
(Rodriguez et al. 2007). Repression of lentiviral transgene expression is an important
characteristic of fully reprogrammed iPSCs (Akitsu Hotta 2008). Even though HOGN-iPS
could differentiate to the three embryonic germ layers (Figure 3.23) and expressed all
pluripotency-markers analysed (Figure 3.24) their inability to differentiate to the cell-type
they were derived from (i.e. to fibroblasts) indicates that HOGN-iPSCs might not have been
fully reprogrammed. Despite the karyotype and phenotype abnormalities, cells of the HOGN
model system were used in chapter 4 to study the epigenetic mechanisms associated with
expression of pluripotency associated genes, in order to determine whether any differences
existed between the HOGN and the HUES7 model systems.
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4 EXPRESSION AND EPIGENETIC REGULATION OF
PLURIPOTENCY GENES IN CELLS OF THE MODEL SYSTEM
4.1 INTRODUCTION
In chapter 3, hESC-fibroblasts, iPSCs and iPSC-fibroblasts were all derived from the same
hESC line, generating a model system of cells having the same genotype but different
phenotypes. In this chapter, the aim was to link the transcriptional basis associated with the
change of cell phenotype from a pluripotent to a fibroblast differentiated state to its
regulation by the epigenome. Thus, some of the epigenetic mechanisms associated with
key pluripotency-associated genes in cells of the model system, but also during transition
between phenotypes, were investigated. The genes involved in this analysis were OCT4,
NANOG, SOX2 and LlN28; used to generate iPSCs, as well as KLF4; a TF at the top of the
ESC transcriptional hierarchy and necessary for self-renewal in ESCs (section 1.3.2), and
DNMT3B and REX1; two TFs that are dispensable for self-renewal in ESCs but necessary
for normal differentiation (Table 1.1).
4.1.1 Transcriptional regulation of pluripotency-associated genes by
epigenetic modifications
It is documented that TFs at the top of the transcriptional hierarchy in mouse and human
ESCs interact with each other and also with themselves to auto-regulate their expression
(sections 1.3.2 & 1.8.2). However, no comprehensive information is available about the
epigenetic states of pluripotency associated genes in ESCs or in differentiated cell
phenotypes. This section tries to collect the currently available information regarding, the
epigenetic regulation of pluripotency genes in mouse and human cells.
4.1.1.1 OCT4
Oct4 is the best characterised pluripotency gene in terms of its epigenetic regulation (Table
4.1). The Oct4 promoter is active and unmethylated at the DNA level in mouse and human
138
PhD Thesis
Elena Matsa
School of Clinical Sciences
The University of Nottingham
Chapter 4- Expression and epigenetic regulation of pluripotency genes
ESCs (Deb-Rinker et al. 2005a; Brunner et al. 2009). Histone de-methylation at H3K9,
catalysed by Jmjd 1a and Jmjd2c, and methylation at H3R 17 & 26, catalysed by CARM 1, are
also associated with the active Oct4 promoter in mESCs and are thought to contribute to the
maintenance of a euchromatic state at the promoter region (Loh et al. 2007; Wu et al.
2009a). Silencing of Oct4 during differentiation (Figure 4.1) has been associated with
enriched G9a-mediated H3K9me, which is recruited to the Oct4 promoter following binding
of the germ-cell nuclear factor (GCNF; Feldman et al. 2006; Epsztejn-Litman et al. 2008).
H3K9me also recruits binding of heterochromatin protein 1 (HP1), which is thought to
promote heterochromatinisation and repression of the Oct4 promoter (Gu et al. 2006). Oct4
is believed to then be stably silenced by recruitment of Dnmt3a and 3b which catalyse de
novo DNA methylation, several days after histone methylation has taken place (Feldman et
al. 2006; Gu et al. 2006; Li et al. 2007c). Recruitment of Dnmt3a and 3b is facilitated by
binding of the methyl-binding protein 3 (MBP3, core component of the nucleosome
remodelling and de-acetylase (NuRD) complex) to the Oct4 promoter while it is still un-
methylated (Xue et al. 1998; Gu et al. 2006). During differentiation, the pluripotency
regulating gene Oct4 also loses the activating histone marks, H3K9Ac, K3K14Ac and
H3K4me (Feldman et al. 2006; Gu et al. 2006) .
•
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Figure 4.1-"Model for Oct4 heterochromatinisation during differentiation of mESCs
Germ-cell nuclear factor (GCNF)binds the Oct4 promoter at the retinoic acid receptor element (RARE).This
brings about binding of G9a, which catalyses H3K9methylation, and of histone de-acetylase (HDAC)enzymes,
which catalyse removal of H3K4 & Kl4 acetylation. Heterochromatin protein 1 (HPl) then binds H3K9me
residues. Finally, Dnmt3a and 3b are recruited to the Oct4 promoter to catalyse de novo DNA methylation.
AC= histone acetylation, Me= histone methylation, open lollipops = un-methylated DNA, red lollipops=
methylated DNA (Feldman et al. 2006).
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Upon reprogramming to iPSCs, Oct4 becomes de-methylated via, thus far, unknown
mechanisms (Takahashi et al. 2007). H3K9 methylation or association with other histone
modifications or histone and chromatin modifying enzymes has not been analysed in the
Oct4 promoter of iPSCs. It is possible that re-activation of Oct4 expression during iPSC
formation could be facilitated by protein sumoylation and phosphorylation. These two
epigenetic modifications have been shown to affect Oct4 expression in mESCs, with
sumoylation promoting Oct4 stability, DNA binding and transcriptional activity (Wei et al.
2007), and phosphorylation promoting Oct4 homo- and hetero-dimerisation that in turn
support transcriptional activity by auto-regulatory feed-back loops (Saxe et al. 2009). In
hESCs, expression of OCT4 at the levels required to sustain pluripotency (Niwa et al. 2000;
Rodriguez et al. 2007) is thought to be regulated by the ubiquitin ligase, WWP2, which can
directly interact with OCT4, resulting in ubiquitilation and degradation of OCT4 by the 26S
proteosome (Xu et al. 2009b). Ubiquitilation is also thought to form part of the OCT4 auto-
regulatory circuit, perhaps antagonising phosphorylation to maintain OCT4 expression at
appropriate levels (Xu et al. 2009b).
Even though the epigenetic regulation of Oct4 has been characterised more than other
pluripotency-factors, most information available comes from studies of the mouse gene. The
only information available regarding the transcriptional regulation of the human gene is that
it is hypomethylated at the DNA level in hESCs, hECs and iPSCs and is associated with
H3K4m3, K3K9Ac and H3K36me3 in hECs, whereas it is hypermethylated in differentiated
lineages and is associated with repressive histone marks H3K9me and/or H3K79me3
(Table 4.1).
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Table 4.1- Epigenetic modifications and enzymes associated with OCT4
TSS= Transcription start site, EC= embryonic carcinoma cell, EG= embryonic germ cell, MSC= mesenchymal
stem cell, Me;;: DNA methylation. Histone modifications are on histone 3 (H3), unless otherwise stated. Red=
silencing mark, maroon= silencing enzyme, green= activating mark, purple= activating enzyme, black= mark
not associated with transcriptional activity, += active transcription, X= inactive transcription (Pan et al. 2006;
Barrand and Collas 2009; Hemberger et al. 2009; Masui 2010; Table 1.3)
Cell type Transcription Core promote
Proximal
Distal enhancerOCT4
enhancer
TSS, No CpG island OCT/SOX site
ICM, ESCs,EGs + - Me no-Me
Epiblast, ECs,
+ - no-Me Me
EpiSCs
CI.I
de-K9me3 (Jmj1a, Jmjd2C), K4me3 (MLL, Paflc), R17&26me3'"::J ECs, ESCs +0 (CARM1), K9&14Ac, Euchromatin (Chd1)
~
Differentiated Me (Dnmt3a &3b), K9me2&3 (G9a-
x -
cells EHMTl), Heterochromatin (HP1)
iPSCs + - de-Me
ESCs + - no-Me
ECs + K9Ac, K4me2&3, - K4me2&3, K9Ac, K36me3
Neurons x Me
c
111 Me, K9me, K79me3,E Adipose MSCs x Me, K9me, K79me3 -
::J K36me3
:I:
Adult fibroblasts x Me, K9me, K79me3 - Me, K9me, K79me3
Keratinocytes x Me, K9me - Me, K9me,
iPSCs + - de-Me
4.1.1.2 NANOG
The regulation of NANOG expression has not been characterised to the same extent as
OCT4. Available information from the literature is summarised in Table 4.2. The
transcriptional activity of this pluripotency regulator in mouse and human ESCs is
associated with an unmethylated promoter at the DNA level (Deb-Rinker et al. 2005a;
Meissner et a/. 2008). In hECs, NANOG is also associated with the activating histone marks
H3K9Ac and H3K36me3 (Barrand and Collas 2009). In differentiated cell types, the Nanog
promoter becomes associated with increased DNA methylation (especially in the OCT/SOX
.
binding site), possibly through collaboration between Dnmt3a and Dnmt3b in mouse cells
(Chen et al. 2003; Farthing et a/. 2008), as well as with H3K9 and K27 methylation, which
are believed to promote heterochromatlnisation and silencing of this pluripotency gene
(Barrand and Collas 2009). However, mechanistic details of how these epigenetic
modifications occur are unknown and the human gene is poorly studied.
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Table 4.2- Epigenetic modifications and enzymes associated with NANOG
Abbreviations and colour coding same as in Table 4.1
Differentiated
r::
!'Cl
E
::l
J:
Adipose MSCs,
Adult fibroblasts,
4.1.1.3 SOX2
x
x
K9me, K27me3
Transcriptional activity in Sox2 has been associated with increased CARM1-catalysed
H3R16 and R17 methylation in the mouse, and with increased H3K9Ac in human ECs
(Table 4.3). In differentiated cell types, SOX2 becomes associated with the repressive
histone marks H3K27me3 and H3K9 in human cells (Barrand and Collas 2009), and also
with DNA methylation in mouse cells; a region 2.7kb upstream from the Sox2 TSS,
containing two POU binding sites, was found to be hyper-methylated in MEFs, brain, kidney
and germ cells compared mESCs Imamura et al. 2006. Furthermore, a region 3.5kb
downstream the Sox2 TSS, containing an OCT/SOX biding site, was shown to be slightly
more methylated in MEFs, brain and kidney than mESCs (Imamura et al. 2006). Some
SOX2 hyper-methylation has been observed in human gastric cancer cells (Otsubo et al.
2008), but not in healthy human cells.
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Table 4.3- Epigenetic modifications and enzymes associated with SOX2
Abbreviations and colour coding same as in Table 4.1
Core Proximal Distal
Coding regionSOX2 Cell type Transcription promoter enhancer enhancer
TSS
POU site OCT/SOX siteCpG island
no-Me - no-Me no-Me
ESCs +
R17&26me3 (CARM1), Chd1QI -
1/1
::J Germ cells x no-Me - Me no-Me0
s MEFs, brain &
x no-Me - Me Mekidney cells
ECs + K4me2&3, K9Ac,
K4me2&3, H9Ac,
-
K36me3
c
11) Adipose MSCs, - K9me, K27me3,E
Adult fibroblasts x K9me, K27me3, K79me3 K79me3::J -
:I:
Keratinocytes x K9me, K27me3 - K9me, K27me3
Gastric cancer x Me - -
4.1.1.4 KLF4
Very little information is available about the epigenetic regulation of KLF4. This pluripotency-
associated gene was found to be hyper-methylated in cancer cells, in a region located -156
to -39 to the TSS (Wei et al. 2006; Yong Gu et al. 2007) and more recently, in the CpG
island of medulloblastoma cells (Nakahara et al. 2010). The KLF4 TSS is also
hypermethylated in hESC-derived fibroblasts and neonatal fibroblasts relative to hESCs,
however, the exact region analysed is not well documented (Laurent et al. 2010). Even
though KLF4 can interact with HAT (e.g. p300) and HDAC (e.g. HDAC5) enzymes (Yoshida
et al. 2008; Evans et al. 2010), association of histone or chromatin modifying enzymes with
the KLF4 promoter has not been characterised to date. At the post-transcriptional level,
KLF4 is negatively regulated by miRNA-145 (Xu et al. 2009c).
4.1.1.5 LlN28
LlN28 methylation has been observed in somatic tumour cells (Dansranjavin et al. 2009),
but not in healthy cells. In fact, down-regulation of LlN28 upon differentiation of human
mesenchymal stem cells (hMSCs) to osteoblasts and adipocytes was shown to occur
through a methylation independent pathway (Dansranjavin et al. 2009), suggesting that
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aberrant DNA methylation could be a cancer-cell specific mechanism for gene inactivation.
No other epigenetic modifications have been associated with LlN28 at the transcriptional
level. At the post-transcriptional level, Lin28 expression is negatively regulated by miR-125b
(Iin-4) and miR-125a, which interact with the micro-RNA responsive elements miREO,
miRE1 and miRE2 found in the 3' UTR of Lin28, and also by miRNAs of the let-7 family,
which are themselves negatively regulated by Lin28 and DNA methylation (Johnson et al.
2005; Wu and Belasco 2005; Brueckner et al. 2007; Johnson et al. 2007; Newman et al.
2008; Viswanathan et a/. 2008; Chang et al. 2009b).
4.1.1.6 DNMT3B
DNMT3B has two alternative promoters, both of which lack a TATA-box close to the TSS
and contain clusters of binding sites for the TF Sp1, especially at the proximal enhancer
region (Yanagisawa et al. 2002). Binding of Sp1 and Sp3 TFs to the DNMT3B promoter,
positively regulates DNMT3B transcriptional activity (Jinawath et al. 2005). In mouse cells,
Dnmt3b associates with several enzymes of the epigenetic machinery (e.g. HP1, Ezh2 and
HDAC1) to repress the expression of target genes (reviewed by Hemberger et al. 2009).
However, other than regulation by the TFs Sp1 and Sp3, mechanisms that have an impact
on its own expression have not been characterised.
4.1.1.7 REX1
Rex1 is highly expressed in mESCs, mECs and hESCs (Shi et al. 2006; Adewumi et al.
2007). Upon differentiation, Rex1 undergoes similar step-wise silencing to Oct4 in mESCs,
.
and becomes associated with increased H3K9me and HP1 binding, which promote
heterochromatinisation of its promoter (Feldman et al. 2006). The REX1 promoter is also
unmethylated in hESCs and iPSCs, but hyper-methylated in human dermal fibroblasts and
hECs (Takahashi et al. 2007). However, differentiation of hESCs into fibroblasts was not
associated with an increase in promoter DNA methylation (Yeo et a/. 2007).
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Overall, the mechanisms that regulate the expression of key pluripotency genes are not well
understood; and have mostly been characterised in mouse or cancer cells. Also, most
studies suffice in characterising either pluripotent or differentiated cell phenotypes, resulting
in poor understanding of how gradual changes occur in gene expression and epigenetic
modifications. Therefore, as well as investigating end point phenotypes of cell-types
comprising the model system generated in chapter 3, this chapter aimed to analyse several
time-points during the transition from pluripotent (hESCs, iPSCs) to fibroblast differentiated
phenotypes, and vice-versa from fibroblasts to iPSCs. This chapter focused on analysing
the epigenetic modifications most abundantly associated with regulatory regions of
pluripotency genes, which were; DNA methylation, H3K9Ac and H3K4me3, H3K9me and
H3K27me3.
4.1.2 Chapter Aims and Objectives
The aim of this chapter was to analyse the expression and epigenetic regulation of the
pluripotency-associated factors OCT4, NANOG, SOX2, KLF4, LlN28, REX1 and DNMT3B,
in cells of the model system (Figure 1.1, Chapter 3). To achieve this aim, the following
objectives had to be met:
* Determine the gene (real-time PCR) and protein (immunofluorescence) expression
levels of pluripotency-associated factors, in hESCs, iPSCs and derived fibroblasts
* Analyse DNA methylation and histone modifications in key regulatory regions of
pluripotency factors, in hESCs, iPSCs and derived fibroblasts
* Investigate the timing and pattern of pluripotency-gene inactivation durinq
differentiation, and reactivation during reprogramming to iPSCs
* Analyse the timing and pattern of DNA methylation changes and histone
modifications associated with pluripotency genes during differentiation, and during
reprogramming to iPSCs
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4.2 RESULTS
4.2.1 Expression of pluripotency factors in cells of the model system
The first aim of this chapter was to study the expression of the pluripotency-associated
factors OCT4, NANOG, SOX2, KLF4, LlN28, REX1 and DNMT3B (sections 1.3.2, 1.3.4 and
4.1.1) in hESCs, iPSCs and derived fibroblasts. As controls, this investigation included the
clonal fibroblast line, HUES7-Fib CI4 (section 3.2.5), the neonatal fibroblast line, BJ, and the
adult fibroblast line, SUKE. This would establish whether any differences existed in gene
expression between these, potentially, more differentiated fibroblast phenotypes and the
heterogeneous hESC-fibroblasts. Expression of the fibroblast-specific marker P4HB (section
3.2.4.2) was also analysed, in order to compare the relationship between expression of
pluripotency-associated and lineage commitment genes.
4.2.1.1 Selecting primers for gene expression analysis by real-time peR
Real-time PCR analysis was performed using TaqMan® assays for SOX2, LlN28, KLF4,
DNMT3B, REX1 and P4HB (Applied Biosystems, Table 2.5). TaqMan® assays for SOX2
and LlN28 specifically amplified the endogenous genes, avoiding detection of lentiviral
transgenes. Commercially available TaqMan® assays for OCT4 and NANOG were not able
to distinguish between the true genes and their numerous pseudogenes (Takeda et al.
1992; Booth and Holland 2004). Therefore, a set of primers for OCT4 that could distinguish
between the true OCT4 transcript and its pseudogenes, as well as between endogenous
OCT4 and the transgene, were used in this study (Liedtke et al. 2007). However, the
location and amplicon size of these primers did not permit TaqMan® probe design, leadinq
to the use of SYBR-Green based real-time PCR analysis for OCT4. A TaqMan® based
assay for NANOG was designed in our lab for this experiment, by Mr. Jayson Bispham
(Bispham and Young, unpublished data), using Primer Express® software. The primers
could distinguish between the true NANOG transcript and its eleven pseudogenes
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(Appendix Ill), but it was not possible to also distinguish between the endogenous gene and
the transgene.
4.2.1.2 Gene expression analysis by real-time peR
Real-time PCR analysis was performed with help from Mr. Jayson Bispham and Dr. Roger
McGillvray. In the pluripotent cell lines; HUES?, HUES?-iPS, HOGN, and HOGN-iPS,
expression of all pluripotency factors was detected, with the exception of REX1, which failed
to become re-activated in HUES?-iPS (Figure 4.2 and Figure 4.3). HUES?-iPS and HOGN-
iPS expressed OCT4, SOX2, KLF4, REX1 and ONMT3B at lower levels, compared to
HUES? and HOGN, as shown in Table 4.4. KLF4 was expressed in all samples analysed,
and was considerably high in SUKE fibroblasts (RQ= 2.52±C.42) (Figure 4.2 and Figure
4.3). NANOG was detected in both HUES?-iPS Fib and HOGN-iPS Fib, but other
pluripotency genes were not expressed in fibroblast cells. The fibroblast specific marker
P4HB showed reduced expression in all pluripotent samples compared to fibroblasts. This
was more evident in the HUES? model system (3 to 5-fold higher expression in fibroblasts,
Figure 4.2), whereas in the HOGN system differences were more subtle «C.5-fold higher
expression in fibroblasts, Figure 4.3). The clonal line HUES?-Fib C14, showed the highest
P4HB expression (RQ= 8.14±C.51).
Table 4.4- Differences in expression of pluripotency factors between hESCsand iPSCs
Expression in hESCswas considered to represent 100% (RQ= 1). Expression in iPSCs is presented relative to
hESCs,with "-"depicting lower expression and "+" depicting higher expression.
Gene HUES7 vs HUES7-IPS HOGN vs. HOGN-iPSRQ value % difference p-value RQ value % difference p-value
OCT4 0.42+0.11 - 58 0.42 0.28+0.07 -72 0.02
NANOG 2.19±0.17 + 119 0.03 0.88±0.18
- 12 0.20
SOX2 0.26+0.01 - 78 0.00 0.38+0.02
- 62 0.00
KLF4 0.36±0.16 - 64 0.00 0.65±0.06 - 35 0.03
LlN28 0.64+0.05 - 36 0.15 0.96+0.06 -4 0.63
REX1 0.001±0.00 -100 0.00 0.32±0.06 - 68 0.00
DNMT3B 0.32±0.04 - 68 0.15 0.56±0.01 - 44 0.15
P4HB 0.64±0.01 - 46 0.00 0.71±0.04 - 29 0.63
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Figure 4,2- Gene expression of pluripotency and fibroblast-specific markers in the HUES7model system
Expressionof OCT4, NANOG, SOX2, KLF4, LlN28, REX1, DNMT3B and P4HB in the HUES7model system and in
control fibroblast lines, as determined by quantitative real-time peR. Error bars represent standard deviation,
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Figure 4.3- Gene expression of pluripotency and fibroblast-specific markers in the HOGNmodel system
Expression of Oa4, NANOG, SOX2, KLF4, LlN28, REX1, DNMT3B and P4HB in the HOGN model system, as
determined by quantitative real-time peR. Error bars represent standard deviation.
4.2.1.3 RT-peR primers to distinguish transgene from endogenous gene expression
Silencing/ repression of lentiviral transgenes is considered to be important for the generation
of fully reprogrammed iPSes (Maherali and Hochedlinger 2008). Although investigation by
real-time peR gave information about the relative expression of "iPSe factors" in cells of the
model system, it was .unclear whethe~ transgenes were silenced. RT-peR primers were,
therefore, designed to distinguish between total expression of the iPSe factors (endogenous
& lentiviral transgene), from either endogenous or lentiviral expression (Figure 4.4). Figure
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4.5 shows validation of each set of "distinguishing" primers; products from the total (T)
primer set- were detected in HUES? and transgene plasmid DNA, endogenous (E)
expression was only detected in HUES? cells, and lentiviral (L) transgene expression was
detected in plasmid DNA. HUES?-Fib, 8J-Fib, SUKE-Fib, MEFs, and the clonal line HUES?-
Fib el4 showed no amplification with any primer set.
Start codon (ATG) Stop codon (TGA)
L
ntiviral eDNA
T J
I
.( IRES u
Start codon (ATG) Stop codon (TGA)
Figure 4.4- Design of primers distinguishing endogenous, lentiviral and total expression of iPSe factors
RT-peR primers to detect expression from the endogenous (E) locus of OCT4, NANOG, SOX2 and LlN28 were
designed so that the reverse primer was located on the 3' untranslated region (UTR) of the mRNA/cDNA, a
feature that the lentivirally (L) inserted copies of the genes lacked. Instead, the reverse primer for detecting
the lentiviral transcripts was designed on the IRES sequences, which directly followed the stop codons of
target genes in the viral inserts. To detect the total (T) expression of target genes, i.e. from both the
endogenous and lentiviral loci, the reverse primers were designed in regions 5' to the stop codons, which
were present in both transcripts. The forward primers were shared between all reverse primers for each gene.
4.2.1.4 RT-peR analysis to distinguish transgene from endogenous gene expression
Both HUES? -iPSes and HOGN-iPSes showed reactivation of the four iPSe factors from the
endogenous loci, as well as silencing of lentiviral transgenes, especially for SOX2, NAtyOG
and LlN28 (Figure 4.5). Some residual expression was observed for the OCT4 transgene in
HUES?-iPS, which was however, down regulated upon differentiation to fibroblasts. HUES?-
iPS Fib showed down regulation of. the four iPSe factors from the endogenous loci.
Unexpectedly, P9R with the L primer set in HOGN and HOGN-Fib detected a peR product.
Since neither line was transduced with an OCT4 lentivirus, it is likely that detection of a peR
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product with the L primer represents expression from the OCT4-targeted IRES-GFP-IRES-
Neo cassette (Figure 3.5.A). Sequence alignment showed that the L primer set would
amplify the same product from the OCT4 transgene and the OCT4-IRES-GFP-IRES-Neo
locus. HOGN-iPS and HOGN-iPS Fib showed a strong PCR product when amplified with
the OCT4 L primer set, perhaps from accumulation of expression from both the endogenous
OCT4-IRES-GFP-IRES-Neo and transgene loci. Since endogenous OCT4 expression was
largely down regulated in HOGN-iPS Fib compared to HOGN-iPS, it is likely that protein
expression detected by immunofluorescence in HOGN-iPS Fib (Figure 3.30) originated from
failure to down regulate the OCT4 transgene. Some residual expression of endogenous
NANOG was also detected in HOGN-iPS Fib, which could be due to the aneuploid
karyotype of these cells (trisomy of chromosome 12, where NANOG resides, Figure 3.4.B).
4.2.1.5 Protein expression analysis by immunofluorescence staining
In order to determine whether gene expression correlated to protein expression,
immunofluorescence staining was performed for all the markers analysed by real-time PCR
(section 4.2.1.2.). OCT4, NANOG, SOX2, LlN28, REX1 and DNMT3B proteins were
detected in the pluripotent lines HUES7, HUES7-iPS, HOGN and HOGN-iPS, with the
exception of REX1, which was not detected in HUES7-iPSCs (Figure 4.6-4.9), correlating to
TaqMan® PCR data (Figure 4.2 and Figure 4.3). Also, corresponding to the results obtained
by real-time PCR, KLF4 protein expression was detected in all samples analysed (Figure
4.7 and Figure 4.9). Pluripotency-associated factors were not detected in fibroblast lines
tested (Figure 4.6-4.9), in contrast to P4HB and FSA. As shown before (Figure 3.30),
HOGN-iPS Fib were an exception, since they expressed OCT 4 and lacked P4HB.
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4.2.2 DNA methylation analysis in cells of the model system
To determine the epigenetic mechanisms that are associated with pluripotency genes in
their active and silenced states, DNA methylation analysis was performed, using direct
sequencing of bisulfite PCR products (sections 2.6.1, 2.6.2 and 2.6.3).
4.2.2.1 Selecting primers for DNA methylation analysis by bisulfite PCR
Bisulfite PCR primers for LlN28, KLF4 and P4HB were designed within CpG islands
(-500bp regions with CG content 2:55%; Takai and Jones 2002), located in their promoter
regions (Figure 4.10, Table 2.7). OCT4 and NANOG lack CpG islands in their promoters, so
primers were chosen to span their OCT/SOX binding sites (-2,207 to -2, 192bp and -336 to -
321 bp upstream of the transcriptional start site, TSS), previously shown to be unmethylated
in hESCs, and hyper-methylated in differentiated hESC-derived fibroblasts and neonatal
foreskin fibroblasts (Wernig et al. 2007; Yu et al. 2007b; Park et al. 2008c). Based on similar
evidence, REX1 primers were chosen to span part of the CpG island in its promoter region
(Takahashi et al. 2007). For DNMT3B, primers spanned the 5' end of its CpG island and
were located -496 to -839 downstream of Sp1 and Sp3 binding sites, previously shown to
regulate DNMT3B at the transcriptional level (Jinawath et al. 2005). SOX2 primers were
designed based on a study performed in mESCs and germ cells (Imamura et al. 2006), and
spanned three different SOX2 regulatory regions; the CpG island (-302 to +153bp from the
TSS), the POU binding site (-4,476 to -4,1 03bp) and the OCT/SOX binding site (+3,548 to
+3,891bp).
4.2.2.2 DNA methylation analysis by bisulfite PCR
Following PCR amplification, DNA methylation analysis was performed by bisulfite
sequencing, and the results were scored as described in section 2.6.3. LlN28, KLF4,
DNMT3B and P4HB were "not informative", since they did not show differential DNA
methylation between the cell lines analysed (Figure 4.10 and data not shown). The same
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was true for the POU binging site and CpG island of SOX2. However, the OCT/SOX binding
site of SOX2 was found to be differentially methylated between populations tested; the four
CpG sites within this region were unmethylated in the HUES?, HUES?-iPS, HOGN and
HOGN-iPS samples, and hypermethylated in all fibroblast samples (Figure 4.11). Similar
patterns to SOX2 were observed in the OCT/SOX binging sites of OCT4 and NANOG, and
the CpG island of REX1 (Figure 4.11). Once more, HOGN-iPS Fib were an exception, since
they were hypomethylated in OCT4 and SOX2. HOGN-iPS Fib irregularities could be due to
their abnormal karyotype and phenotype (section 3.2.??). Also, perhaps not unexpectedly,
all CpG dinucleotides of the REX1 CpG island were heavily methylated in HUES? -iPS,
which were previously shown to lack REX1 expression (Figure 4.2 and Figure 4.6).
A SOX2 {NM_003106.3} B LlN28 {NM_024674.4}
3q26.3-q27_--l!oIi'--- _
-4,47~ \:4,103 -30;; \_+ 153
lp36.11
-110) ~200
c KLF4 {NM_004235.4} o DNMT3B (NM_175848.1)
+ 1,705to-
20ql1.2
-18,17~ \-17,753
9q31---
+ 803) \_+ 310
-34~ \-515
POU Binding site
o Spl site
00 OCT/ SOX Binding Site
• CpGlsland
.. TSS
E P4HB (NM_000918.3)
+ 117to-
17q25 -----
Figure 4.10- Non-informative genes and regions analysed by bisulfite sequencing
The regions shown here were analysed by bisulfite sequencing but were not found to be differentially
methylated in hEse, iPSeand fibroblast populations
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Figure 4.11- DNA methylation analysis in cells of the HUES7 and HOGN model systems
Bisulfite analysis performed by direct sequencing in key regulatory regions of the endogenous OCT4, NANOG,
SOX2 and REXl genes in the HUES7 and HOGN model systems, and control fibroblast lines. Regulatory regions
were unmethylated or hypo-methylated in hESCsand iPSCs, and hyper-methylated in fibroblast lines.
4.2.3 Histone modification analysis in cells of the model system
Chromatin immunoprecipitation (ChiP) analysis for a selected group of histone rnodificajions
was performed in key regulatory regions of the pluripotency genes OCT4, NANOG, SOX2
and REX1, which were found to be "informative" for DNA methylation (section 4.2.2.2). Cell
pellets were collected in our lab and taken to Birmingham University, where cChlP analysis
was performed with the help of Dr. Laura O'Neill. The histone modifications analysed were;
H3K27me3, H3K9me2, H3K4me3 and H3K9Ac (section 4.1.1).
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Activating histone marks (H3K9Ac and K3H4me3) were enriched relative to repressive
marks (H3K2?me3 and K3K9me2) in the undifferentiated HOGN and HUES? cells (Figure
4.12). In HOGN-Fib and HUES? -Fib, presence of activating marks was reduced, while the
repressive marks H3K2?me3 and H3K9me2 were enriched, especially for OCT4, NANOG
and SOX2 in HUES?-Fib and REX1 in HOGN-Fib (11.22±1.321). REX1 was not analysed in
cells of the HUES? model system, since this gene was not reactivated following
reprogramming of HUES?-Fib (Figure 4.2 and Figure 4.6). Only OCT4 and SOX2 re-
established high levels of H3K9Ac and H3K4me3 in HOGN-iPS, but OCT 4 also had high
levels of H3K9me2. Activating marks, and especially H3K9Ac, remained high in the OCT4
and SOX2 promoters of HOGN-iPS Fib, which also lacked DNA methylation, as shown
before (Figure 4.11). NANOG showed considerable enrichment of H3K9me2 in HOGN-iPSC
Fib (13.28±4.35).
Overall, pluripotent HOGN and HUES? cells showed enrichment for activating histone
marks which were reduced in differentiated HOGN-Fib and HUES?-Fib. OCT4, NANOG,
SOX2 and REX1 active and silenced states showed direct correlation to H3K4me3 and
H3K9Ac, while silencing was associated with the repressive marks H3K2?me3 and
H3K9me2. However, these observations did not correspond to those for HOGN-iPSCs and
HOGN-iPS Fib, perhaps due to deregulation of the epigenetic machinery by the
reprogramming process, or due to incomplete reprogramming of HOGN-iPSCs. ChiP
analysis in HUES?-iPS, HUES? iPS-Fib and control fibroblast lines, as well as additional
pluripotency-genes is continuing in the lab.
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Figure 4.12- cChlP analysis in the HOGN model cell system
cChlPanalysis performed with the help of Dr. LauraO'Neill in regions of the endogenous OCT4, NANOG, SOX2
and REXl genes in the HOGNmodel system. DNA was immunoprecipitated with anti-H3K27me3, H3K9me2,
H3K9Ac and H3K4me3 antibodies, prior to amplification with gene-specific primers using radioactive-PCR.
Enrichment of each histone modification was measured by 2D densitometry and was calculated relative to a
pre-immune control sample.
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Figure 4.13- cChlP analysis in HUES7 and HUES7-Fib
cChlP analysis performed in regions of the endogenous OCT4, NANOG, and SOX2 genes in the HUES7and
HUES7-Fib.DNAwas immunoprecipitated with anti-H3K27me3, H3K9me2, H3K9Acand H3K4me3 antibodies,
prior to amplification with gene-specific primers using radioactive-PCR. Enrichment of each histone
modification was measured by 2D densitometry and was calculated relative to a pre-immune control sample.
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4.2.4 Epigenetic regulation of gene silencing during differentiation
Pluripotency associated factors were expressed in the hESC lines, HUES7 and HOGN, and
silenced in hESC-derived fibroblasts (section 4.2.1). Active states were associated with
DNA hypo-methylation and enrichment of activating histone marks (H3K9Ac and
H3K4me3), while silenced states were associated with hyper-methylation, and reduced
H3K9Ac and H3K4me3 (sections 4.2.2 and 4.2.3). To investigate the timing and order by
which these epigenetic changes occur, HUES7 hESCs were differentiated via EB formation
and pellets were collected at two-day intervals during the differentiation process. TaqMan®
real-time PCR and Haematoxylin immunohistochemical staining were used to study the
gene and protein expression profiles of pluripotency-associated factors during differentiation
(Figure 4.14, Figure 4.15), which were compared to DNA methylation analysis performed by
bisulfite sequencing (Figure 4.16).
4.2.4.1 Gene expression analysis during differentiation of hESCs
Expression of pluripotency associated and fibroblast-specific genes was investigated in
HUES7 cells, from day 0 to day 16 of differentiation. Real-time PCR analysis indicated that
gene expression during differentiation followed four distinct patterns (Figure 4.14). The first
pattern involved initial up-regulation of gene expression, followed by decline to minimal
levels. This trend was exemplified by OCT4, which relative to day 0 of differentiation
increased by 4-fold on day 2 (RQ= 4.05±2.62) and by 7.5-fold on day 4 (RQ= 7.49±3.61)
(Figure 4.14). Thereafter, expression was down-regulated by 4-fold on day 6 (RQ=
1.92±O.85) compared to day 4, until it became almost undetectable by day 12. Si!l1ilar
profiles were seen for SOX2, LlN28, REX1 and DNMT3B, although some differences were
observed in onset and degree of down-regulation (Figure 4.14).
The second trend was characterised by immediate down-regulation of gene expression, as
observed for NANOG (Figure 4.14). On day 0 and day 2 of differentiation NANOG
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expression was high (RQ= 1±0.12 and 0.93±0.48, respectively), but was down-regulated by
33% on day 4 (RQ = 0.67±0.11), and by 91% on day 6 (RQ = 0.09±0.005), becoming
undetectable by day 12 of differentiation. The third trend was represented by KLF4, which
showed initial up-regulation between days 0-6 of differentiation (day 6 RQ= 5.9±1.9),
followed by decline to sustained levels (Figure 4.14). Between days 8-16, KLF4 expression
was maintained at -2.5-fold higher levels compared to undifferentiated cells on day O.
The final trend was that exhibited by the fibroblast-specific marker P4HB, whose expression
was constant between days 0-6 of differentiation, and was up-regulated from day 8 (RQ =
1.7±0.11). Up-regulation of this fibroblast-specific gene coincided with the down-regulation
of pluripotency genes, and especially down-regulation of REX1 and LlN28.
4.2.4.2 Protein expression analysis during differentiation of hESCs
Immunohistochemical analysis using haematoxylin staining was performed with kind help
from Miss Maria Barbadilio-MGnoz in order to detect protein expression of pluripotency-
associated factors during differentiation of HUES7 -EBs. EBs collected at 2-day intervals
were stained with TRA-1-81, OCT4, NANOG, SOX2, KLF4, REX1 and DNMT3B antibodies.
Protein expression was reduced from day 14 of differentiation for OCT4, NANOG, SOX2,
REX 1 and DNMT3B (Figure 4.15). Expression of the hESC-surface marker TRA-1-81 was
down-regulated 4 days earlier (day 8 of differentiation), while KLF4 expression appeared
constant at all time points analysed (Figure 4.15). Protein down-regulation for OCT4,
NANOG, SOX2, REX1 and DNMT3B was delayed by 6-8 days relative to gene down-
regulation (Figure 4.14).
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Figure 4.14- Expression of pluripotency-associated and fibroblast markers during differentiation of HUES7
Real-time peR analysis of OCT4, NANOG, SOX2, L1N28, KLF4, REX1, DNMT3B and P4HB expression at 2-day
intervals during differentiation of HUES7cells via EB formation. Error bars represent standard deviation.
Experiments performed in'collaboration with Mr. JaysonBispham and Dr. RogerMcGilvray.
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Figure 4.15- Protein expression of pluripotency-associated markers in HUES7-EBs
Sections of EBs collected at 2-day intervals during differentiation of HUES7, and stained for the pluripotency-
associated markers OCT4, NANOG, SOX2, TRA-1-81, KLF4, REX1 and DNMT3B. Scale bar represents lOOllm
4.2.4.3 DNA methylation analysis during differentiation of hESCs and iPSCs
Material from the same cell samples analysed by real-time PCR in section 4.2.4.1, was
evaluated here by bisulfite sequencing to determine the dynamics of DNA methylation
changes during differentiation. Analysis was performed in key regulatory regions of OCT4,
.
NANOG, SOX2 and REX1 (section 4.2.2.2.) and also included samples collected at 2-day
intervals during differentiation of HUES? -iPSCs.
Methylation in the CpG sites examined increased gradually during differentiation of HUES?
and HUES? -iPS.Cs, both in terms of the amount of methylation on individual CpGs and the
number of CpGs that became hypermethylated (Figure 4.16).
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Figure 4.16- Bisulfite analysis in differentiating HUES7 and HUES7-iPSCs
Bisulfite analysis performed by direct sequencing in regions of the endogenous OCT4, NANOG, SOX2 and REXl
genes in differentiating HUES7 and HUES7-iPSCs.
For OCT4, increased methylation was observed from day 6 of differentiation, corresponding
to the beginning of gene down-regulation (Figure 4.14). For NANOG, DNA methylation in
HUES? EBs appeared from day 2 of differentiation, and considerably increased by day 4
(Figure 4.16), which also correlated with timing the gene down-regulation (Figure 4.14).
Methylation in SOX2 was detected from day 10 (Figure 4.16), suggesting that gene down-
regulation, evident from day 6 of differentiation (Figure 4.14), was initiated by a mechanism
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other than DNA methylation. The timing of DNA methylation events for OCT4, NANOG and
SOX2 was similar during differentiation of HUES7 and HUES7-iPSCs. Expression of REX1
in HUES7 was also closely associated to the levels of DNA methylation in its CpG island.
CpGs were hypermethylated on days 0 and 2 of differentiation compared to day 4 (Figure
4.16), when REX1 expression was highest (Figure 4.14). DNA methylation gradually
increased from day 6, when REX1 expression begun to gradually decrease. In iPSC-EBs,
all CpGs were methylated from the earliest time-point analysed (day 4), associated with
failure of REX1 to become reactivated and hypo-methylated in HUES7-iPSCs (Figure 4.2
and Figure 4.11).
4.2.5 Endogenous pluripotency-gene reactivation during iPSe formation
4.2.5.1 Formation and time-point collection of iPSCs
Generation of lentiviral particles that could support over-expression of the four iPSC factors;
OCT4, NANOG, SOX2 and LlN28, was performed as described in section 2.2.5, using BL15
(Biotin-Lenti clone 15) cells instead of HEK293T cells (kind gift from Dr. David Darling,
King's College London; Nesbeth et al. 2006). These cells covalently link free-biotin to the
extracellular domain of the cell-surface receptor, LlLNGFR (low-affinity nerve growth factor
receptor). Thus, the envelopes of lentiviral vectors generated are tagged with biotin and
have high affinity for streptavidin paramagnetic particles, something that facilitates both the
concentration of lentiviral supernatants (by >4500-fold) and the ease of virus production in
large scale. The protocol for lentiviral transduction using BL15 cells was generated in our
lab in collaboration with Dr. Emily Dick.
HUES7-Fib were induced to form iPSCs by lentiviral transduction with human OCT4,
NANOG, SOX2 and LlN28. Reprogramming was allowed to occur for 18 days, and cell
pellets were collected at 2-day intervals. HUES7-Fib started showing morphological
changes on day 8 PTO, when incompletely reprogrammed colonies begun to emerge
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(Figure 4.17.E&F). Putative iPSC colonies appeared from day 11 PTO, and grew in size
number over the following days (Figure 4.17.A-D). Cells transduced with the pLVTHM GFP-
control virus did not show a change in morphology (Figure 4.17. G).
Figure 4.17- Time course collection of HUES7-iPSCs
Bright field images of iPse colonies on A. day 11 B. day 14 C. day 16 and D. day 18 after transduction with
lentiviruses over expressing OCT4, NANOG, SOX2 and LlN28. Incompletely reprogrammed colonies of E.Type I
and F. Type II, emerging during induction of hESe-derived fibroblasts to form iPSes. G. Negative control
sample, on day 18 of reprogramming. Arrows represent putative iPSecolonies on day 11 of reprogramming.
Scalebars represent lOOllm.
4.2.5.2 Analysis of endogenous gene reactivation during generation of iPSCs
Using pellets collected in section 4.2.5.1, cDNA was synthesised from 1j.Jg of total RNA,
which was diluted to 50j.J1prior to its use in RT-PCR (modified from section 2.5.3). PCR
amplification was performed for 40x cycles. Primers specific to endogenous OCT4, NANOG,
SOX2 and LlN28 (Table 2.6; Figure 4.4), were used to detect re-activation of these genes
during iPSC generation. Quantification of gene expression was performed by 20
densitometry, using AIDA software (section 2.5.6), and plotted relative to HUES7 cells. Any
expression detected in the untreated control (d18 GFP; Figure 4.17) was subtracted from
other samples, so that only changes brought about due to transduction with "iPSC factors"
would be accounted for.
Endogenous pluripotency genes were reactivated from day 8-10 during iPSC formation
(Figure 4.18). In NANOG and SOX2 PCR, non-specific products were detected (arrow-
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marked upper bands were true product, lower bands were non-specific). The non-specific
SOX2 bands were due to expression of mouse transcripts from MEF feeders (Figure 4.19)
whereas non-specific NANOG peR bands were likely to represent pseudogenes. OCT 4
expression was detected in all samples, either due to residual gene expression or
amplification of pseudogenes (Figure 4.18).
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Figure 4.18- Reactivation of endogenous iPse factors during reprogramming of HUES7-Fib
A. Gel electrophoresis analysis following RT:PCRwith primers specific for the endogenous OCT4, NANOG,
SOX2 and LlN28 genes, in HUES7-iPStime-course samples. Black arrows represent products of the expected
size for NANOG and SOX2. B.-E. Quantification of gene expression by 20 densitometry. Gene expression is
presented relative to the HUES7sample, following subtraction of any expression in the untreated (d18 GFP)
control.
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Figure 4.19- RT-peR analysis of endogenous SOX2 expression
Gel electrophoresis following RT-PCRanalysis with primers specific to endogenous SOX2, in HUES7, HUES7-Fib,
MEFs, and HUES7-Fib on day 12 of reprogramming. Black arrow points to the true SOX2 product. Non-specific
bands of smaller size than the true SOX2 product were observed in MEFs and on day 12 of reprogramming.
4.2.5.3 Epigenetic modifications during iPSe generation
Since the first putative iPSC colonies were identified on day 11 of reprogramming (based on
live staining with TRA-1-81), this was the first time-point when colonies could be isolated by
manual dissection in order to analyse the epigenetic modifications associated with
endogenous pluripotency gene activation. On day 11 PTO, HUES7-iPSC colonies had
already become hypomethylated in regulatory regions of endogenous OCT4 and NANOG
(Figure 4.20.A). Unfortunately, DNA from day 11 colonies was not enough return a PCR
product for SOX2 or REX1. cChlP analysis showed that OCT4, NANOG and SOX2
regulatory regions were enriched with the activating histone mark H3K4me3 (Figure 4.20.8).
Investigating the DNA de-methylation and histone modification changes that occur during
earlier time-points of reprogramming to iPSCs would be important to unravelling the
pathways that induce re-activation of endogenous pluripotency genes. However, due to the
heterogeneity of iPSC time-course samples (sections 4.2.5.1 and 4.2.5.2), direct bisulfite
sequencing (section 2.6.3) was unlikely to detect any DNA de-methylation events taking
place. Clonal sequencing (as described in Kim et al. 2007) needed to be performed on a
large number of clones, in order to calculate the % de-methylation occurring in the
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promoters of pluripotency factors at each time-point during reprogramming. These
experiments are still ongoing in the lab.
A OCT4 (NM_002702.4) NANOG (NM_024865.2)
·336to-321 c:__
12p13.31 00 _t----
/~
eooe:!XXX)
- 2,207 to -2,192 c:__
6p21.31 00 _1----
-7 1.2,077
B OCT4 NANOG SOX2 0 Unmethylated
6 6 6
• Methylated
5 5 0 C>T5 @S S S T> C
--
4 -<; 4 -<; 4 et C=Te e e
.... .... ....
• Unreadc: c: c:Q) 3 Q) 3 Q) 3E E E 00 OCT/ SOX Binding Site..c: ..c: ..c:
u 2 u 2 u 2..::: ..::: ..:::
•
c: c: c: CpG IslandUJ UJ UJ
1 1 1
~ TSS0 0 0
H3K27me3 H3K4me3 H3K27me3 H3K4me3 H3K27me3 H3K4me3
Figure 4.20- Bisulfite sequencing and ChiP analysis in HUES7-iPSC colonies on day 11 of reprogramming
A. Bisulfite sequencing and B. cChlP analysis performed in regions of endogenous OCT4, NANOG, and SOX2 in
HUES7-iPSC colonies, on day 11 during reprogramming. DNA was immunoprecipitated with anti-H3K27me3,
and H3K4me3 antibodies, prior to amplification with gene specific enzymes using radloactlve-Pt'R. Enrichment
of each histone modification was measured by 2D densitometry and was calculated relative to a pre-immune
control sample.
4.3 DISCUSSION
In this chapter, iPSCs generated form HUES7-derived fibroblasts were shown to express
the pluripotency associated markers OCT4, NANOG, SOX2, LlN28, REX1 and DNMT3B,
albeit at lower levels compared to hESCs. iPSCs showed down-regulation of lentiviral
transgenes, a trait considered important to complete the reprogramming process.
Expression of the master pluripotency regulators OCT4, NANOG and SOX2 was inversely
related to the levels of DNA methylation found in their OCT/SOX binding sites, while the
same was true for DNA methylation in the CpG island of REX1. The histone modifications,
H3K9Ac and H3K4me3, were directly related to gene expression in hESCs and hESC-Fib.
During differentiation of hESCs and iPSCs, DNA methylation in the pluripotency genes
analysed was found to increase gradually, both in the number of CpGs that became
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methylated and in the amount of methylation on individual CpGs. The timing of DNA
methylation events coincided with gene silencing and showed similar dynamics between
hESCs and iPSCs. Pluripotency genes were silenced during days 6-8 of differentiation and
were reactivated from days 8-10 of reprogramming.
4.3.1 Expression of pluripotency-genes in cells of the model system
4.3.1.1 Gene and protein expression analysis
Real-time PCR showed that most pluripotency genes analysed were active in hESCs and
iPSCs, and silenced in fibroblast lines (Figure 4.2, 4.3 and 4.6), which was consistent with
current literature (sections 1.3.3 and 1.3.4). Expression of pluripotency factors in iPSCs was
in some cases significantly lower than in hESCs (Table 4.4), something that is often
observed between different hESC lines (section 1.7.1; Abeyta et al. 2004). It is, therefore,
plausible that iPSCs acquired a different "pluripotency state" compared to hESCs (Rossant
2008). Importantly, all pluripotency genes analysed were reactivated to a similar level in
iPSCs (within 25-60% of their levels in hESC), indicating that the relative and not the
absolute expression levels of pluripotency factors might be the determining factor to
acquiring a pluripotent state. This also suggests that a minimum threshold level of
pluripotency-gene expression could exist, over which cells can acquire an ESC-like
phenotype (MacArthur et al. 2008). KLF4 was expressed in all cell lines analysed (Figure
4.2, 4.3 and 4.6), consistent with studies reporting wide-spread tissue specificity for this
marker (Garrett-Sinha et al. 1996; Shields et al. 1996; Aasen et al. 2008). Some unexpected
results were observed for REX1, which failed to become re-activated in HUES7-iPSCs, and
for NANOG, which was detected in both HOGN- and HUES7-iPSC fibroblasts. These two
events are discussed below.
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4.3.1.2 NANOG real-time peR
NANOG expression was unexpectedly detected by real-time PCR in HOGN and HUES7-
iPSC fibroblasts, likely due to residual expression from both the endogenous locus and the
lentiviral transgene since the NANOG real-time PCR assay could not distinguish between
them (section 4.2.1.1). Detection from both loci could also account for the increased
expression of NANOG in HUES7-iPSCs (Figure 4.2). Nevertheless, NANOG gene
expression in HOGN-iPS Fib was not enough to be detected by immunofluorescence at the
protein level (Figure 4.6.C). NANOG protein was also absent in HUES7-iPSC Fib (Figure
4.6.A), despite gene expression levels appearing to be higher than in HUES7 (Figure 4.2).
Closer investigation of the real-time PCR raw data revealed that the seemingly increased
expression of NANOG detected by relative quantification (RQ) using the LlLlCt method
(Yuan et al. 2008), was not due to increased expression of NANOG mRNA, but due to
reduced expression of the reference gene 18S. The LlLlCt method of relative quantification
assumes that expression of the reference gene is constant in all samples analysed (Livak
and Schmittgen 2001), and bases relative quantification on the difference between
expression of the target and reference genes, with the target-gene expression being the
only variable. Therefore, reduced expression of the reference gene, 18S, in HUES7-iPS Fib
skewed the calculation of RQ values. Quantification of NANOG expression using the house-
keeping gene HPRT had similar results to quantification with 18S, since HPRT was also
detected at reduced levels in HUES7-iPS Fib compared to other samples analysed (data not
shown).
Reduced expression of reference genes in HUES7 -iPS Fib could be due to their slow
proliferation rate (section 3.2.7.8), something that has been shown to affect cellular
metabolism and, thus, expression of house-keeping genes (Thellin et a/. 1999; Ullmannova
and Haskovec 2003). 18S and HPRT are routinely used as real-time PCR internal controls
in our lab and by other groups (reviewed in Bustin 2000; Dheda et al. 2004; Huggett et al.
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2005), but perhaps a more appropriate house-keeping gene for this specific experiment
would have been GAPDH, as it exhibits constant expression levels in senescent fibroblasts
(Zainuddin et al. 2008). Nevertheless, RT-PCR analysis confirmed that endogenous
NANOG expression was down-regulated in HUES7-iPS Fib (Figure 4.5).
4.3.1.3 REX1 re-activation not required to induce pluripotency
In the HUES7 model cell system, iPSCs expressed a range of pluripotency associated
markers, including OCT4, SOX2, NANOG, KLF4, as well as SSEA4, TRA-1-81, DNMT3B
and LlN28 (sections 3.3.6.6 and 4.2.1). They had a normal karyotype and were able to
exhibit pluripotency by in vitro differentiation to cell-types representative of all three germ
layers (Figure 3.27). Despite this, they failed to reactivate REX1 (Figure 4.2 and Figure 4.7),
a downstream regulator in the pluripotency network (section 1.3.4). Disruption of Rex1 in
mESCs was previously shown to have no effect in cell morphology, self-renewal properties,
and Oct4, Sox2 and Nanog expression, but did impair differentiation into visceral endoderm
(Masui et al. 2008). Moreover, knock-out or over-expression of Rex1 in mESCs were able to
enhance or reduce responsiveness to retinoic acid-induced differentiation, respectively
(Masui et al. 2008; Scotland et al. 2009). Based in these observations, Rex1 is believed to
playa role in inhibiting differentiation rather than actively maintaining pluripotency in ESCs.
ChiP sequencing analysis by Kim et al. (2008a) showed that Rex1 targets in mESCs are
similar to those of c-Myc, and have a role in cell metabolism rather than developmental
processes. Also, Rex1 targets show decreased levels of the repressive histone mark
H3K27me3, something that suggests a role of Rex1 in gene activation (Kim et al. 2008a).
Therefore, Rex1 could be inhibiting differentiation by activating differentiation antagonists. In
this thesis, it has been shown that human somatic cells do not require REX1 to induce and
maintain pluripotency, challenging the role of this gene as a pluripotency-marker. The exact
role of REX1 in the determination of cell phenotype remains poorly understood, and merits
further investigation.
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4.3.1.4 Transgene silencing
RT-peR analysis confirmed that lentivirally-inserted transgenes were silenced in iPSes and
iPSe-fibroblasts, both in the HOGN and HUES? model systems. An exception was the
OCT 4 transgene, whose expression was detected in HOGN-iPS and HOGN-iPS Fib,
possibly due to accumulation of expression from both the transgene and endogenous
OCT4-IRES-GFP-IRES-Neo loci (section 4.2.1.4). High expression of iPS transgenes has
been shown to ablate iPSe differentiation (Brambrink et al. 2008), correlating with the
abnormal phenotype of the HOGN-iPS Fib which maintained high expression levels of the
OCT4 transgene (Figure 4.5 and Figure 4.6).
Low levels of residual OCT4 transgene expression were also observed in HUES?-iPS and
HUES? -iPS Fib. This was not dissimilar to previously published data from groups who used
the same lentiviral system used here to generate iPSes (Yu et al. 200?b), or from groups
using retroviral vectors, which are believed to undergo silencing more easily than
lentiviruses (Dimos et al. 2008; Park et al. 2008b). Residual expression from the OCT4
transgene did not affect the ability of HUES? -iPSes to differentiate to the three embryonic
germ layers and generate P4HB positive fibroblasts (Figure 3.26 and Figure 3.31),
consistent with other studies showing that residual transgene expression did not impair
iPse formation, maintenance and directed differentiation (Papapetrou et al. 2009).
4.3.2 DNA methylation analysis in cells of the model system
4.3.2.1 "Non-informative" promoter regions
LlN28, KLF4, DNMT3B and P4HB did not show differential methylation between pluripotent
and differentiated cells, even though primers for bisulfite peR were designed within epG
islands in their promoters (section 4.2.2.2). This indicated these genes were regulated by
mechanisms other than DNA methylation, or that their DNA methylation regulatory regions
were not the ones analysed. DNMT3B primers for bisulfite peR were originally intended to
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span the Sp1 and Sp3 binding sites located in the DNMT3B promoter, which were shown to
regulate expression of DNMT3B at the transcriptional level (Jinawath et al. 2005). However,
bisulphite PCR primers designed to this region were not successful in amplifying a product
of the correct size (data not shown). Re-designed primers that could amplify a product of the
expected size did not span the Sp binding sites, but were instead located -496 to -839bp
downstream, something that could have affected detection of differential DNA methylation
for DNMT3B.
Lack of differential methylation for LlN28 was in agreement to current literature, showing
that this gene remained unmethylated upon differentiation of hMSCs to osteoblasts and
adipocytes, and was down-regulated through a methylation independent pathway
(Dansranjavin et al. 2009). KLF4 methylation at the TSS has been shown to increase in
hESC-derived fibroblasts compared to undifferentiated hESCs (Laurent et al. 2010), an
observation that comes in contrast to results from this study, which showed no differential
methylation in the KLF4 CpG island located in close proximity (+310 to +803) to the TSS
(Figure 4.10). This difference could be due to analysis of non-overlapping regions within the
KLF4 promoter by Laurent et al. (2010) and this thesis, or due to the use of alternative
methods to derive hESC-fibroblasts (spontaneous monolayer differentiation vs. EB
formation), and differences in genotype (WA09 vs. HUES7) and culture conditions (StemPro
vs. KSR/bFGF MEF-conditioned medium) between the hESC lines used by Laurent et al.
(2010) and this thesis. Notably, differences in the method used to differentiate mouse and
human ESCs have previously been shown to result in variation of OCT 4 and NANOG DNA
methylation (Yeo et al. 2007), and differential regulation of Oct4 repression by the NuRD
chromatin remodelling complex component; Mbd3 (Kaji et al. 2006). The developmental
context in which gene regulatory mechanisms are analysed is thus thought to influence the
outcome and interpretation of experimental results (Young and Denning 2007).
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4.3.2.2 Genes with differentially methylated regulatory regions
Short stretches of CpG sites in the OCT/SOX binding sites of OCT4 and NANOG were
previously shown to be unmethylated in pluripotent and differentiated cell lines (sections
4.1.1.1 and 4.1.1.2). These findings were in agreement to the results obtained here, where
hESCs and iPSCs were hypomethylated relative to derived fibroblasts, as well as neonatal,
adult and clonal fibroblast lines (Figure 4.11). SOX2 was also differentially methylated
between human pluripotent and fibroblast lines (Figure 4.11). This is, to our knowledge, the
first report of differential SOX2 methylation between human non-cancerous cell-types.
Interestingly, all three master regulators of pluripotency analysed by bisulfite PCR (OCT4,
NANOG and SOX2) showed differential methylation in their OCT/SOX binding sites,
perhaps unravelling a common regulatory mechanism between them. Methylation of the
OCT/SOX binding site could be inhibiting interaction among OCT4, NANOG and SOX2,
thus preventing auto-regulatory feedback loops (Chen and Zhong 2008) and serving as a
mechanism contributing to gene down regulation during differentiation.
The CpG island of REX1 showed similar differential methylation to OCT4, NANOG and
SOX2 (Figure 4.11). This was consistent with observations that REX1 is hypermethylated in
foetal and adult fibroblast cells and hypomethylated hESCs and iPSCs (Takahashi et a/.
2007). However, it was contradictory to studies showing that this gene was not
hypermethylated upon hESC differentiation (Yeo et a/. 2007). Considering the findings from
Takahashi et al. (2007) and this study, it is likely that findings from Yeo et al. (2007) were
due to analysis of a different region within the REX1 promoter, or due to the methodology
used for hESCs culture and differentiation (culture by Yeo et a/. (2007) was on MEF feeders
and differentiation by EB suspension culture in non-adhesive surfaces).
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4.3.3 Carrier chromatin immunoprecipitation
Even though details about the epigenetic mechanisms that regulate Oct4 expression in the
mouse have been characterised more extensively than other pluripotency-genes (Feldman
et al. 2006; Epsztejn-Litman et al. 2008), little is known about the precise mechanisms that
regulate this gene in human cells. Using chromatin immunoprecipitation analysis, an attempt
was made to determine the histone modifications associated with key pluripotency genes in
hESCs, hESC-fibroblasts, iPSCs and iPS-fibroblasts. Characterisation was performed in
cells of the HOGN model system, as well as in HUES? and HUES?-Fib (Figure 4.12).
HOGN and HUES? showed high enrichment for the activating marks H3K9Ac and
H3K4me3 (especially for OCT4, NANOG and REX1) that were lost when the cells were
differentiated into fibroblasts. This was consistent with findings that H3K9Ac associates with
OCT4, NANOG and SOX2 in mESCs and hECs, and that these genes lose H3K9Ac and
H3K4me in differentiated lineages (Barrand and Collas 2009). HOGN-iPSCs and HOGN-iPS
Fib did not show the same patterns of histone modifications as HOGN and HOGN-Fib,
perhaps due to deregulation of the epigenetic machinery by the reprogramming process, or
due to partial reprogramming of HOGN-iPSCs caused by persistent expression of the OCT4
lentiviral transgene (Figure 3.30).
4.3.4 Epigenetic regulation of gene silencing during differentiation
4.3.4.1 Gene expression analysis during differentiation of hESCs
The pluripotency factors OCT4, NANOG, SOX2, LlN28, DNMT3B, and REX1 show high
expression levels in ESCs and are usually down-regulated to almost undetectable levels in
differentiated cell types (Richards et al. 2004; Boyer et al. 2005; Adewumi et al. 200?;
Viswanathan et al. 2008). Here, the exact timing and pattern by which these genes are
down-regulated was investigated during differentiation of hESCs via EB formation. Four
patterns of gene expression were observed during differentiation, as shown in Figure 4.14
1?8
PhD Thesis
Elena Matsa
School of Clinical Sciences
The University of Nottingham
Chapter 4- Expression and epigenetic regulation of piuri potency genes
and Figure 4.21. Initial up-regulation of the pluripotency genes OCT4, SOX2, LlN28, REX1,
DNMT3B and KLF4 could have been due to a paracrine effect brought about by the forced
aggregation of hESCs to form EBs or because the genes are necessary to initiate
differentiation towards certain lineages (e.g. OCT4 up-regulation leads to endoderm
differentiation; Rodriguez et al. 2007, and SOX2 is expressed in neural progenitors;
Zappone et al. 2000). This effect was also observed by Viswanathan et al. (2008), who
studied the expression of LlN28 during hESCs differentiation via EB formation. OCT4
expression in the same study showed immediate decline, but was not analysed prior to day
5 of differentiation.
P4HB
KLF4
OCT4, SOX2, L1N28,
REX1, DNMT3B
NANOG
dO d2 d4 d6 dB dlO d12 d14 d16
Figure 4.21- Gene expression trends observed during hESCs differentiation
Four expression trends were observed during differentiation of hESCs via EB formation. OCT4, SOX2, L1N28,
REX1, DNMT3B; initial up-regulation followed by decline, NANOG; immediate decline, KLF4; initial up-
regulation followed by decline to sustained levels, P4HB; up-regulation. Y-axis represents relative expression
but is not drawn to scale.
NANOG expression did not show initial up-regulation (Figure 4.14), and together with
DNMT3B, it was one of the first genes to become down-regulated upon differentiation
(Figure 4.22). Down-regulation of LlN28 and REX1 was delayed relative to OCT4, NANOG,
SOX2 and DNMT3B, and coincided with up-regulation of the fibroblast marker, P4HB.. This
correlates with the idea that LlN28 and REX1 are downstream regulators of the pluripotency
transcription-factor network necessary to suppress the expression of miRNAs and lineage
commitment genes that promote differentiation (section 1.3.4). Delayed down-regulation
kinetics of Lin28 relative to Oct4 and Nanog have also been observed by Viswanathan et al.
(2008).
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Figure 4.22- Timing of gene repression during hESCsdifferentiation
NANOG and DNMT3B were the first genes to become down-regulated during differentiation of HUES7 hESCs,
followed by SOX2, OCT4, LlN28 and REX1. Stars highlight the expression of NANOG, KLF4 and P4HB, which
showed different patterns to other genes (Figure 4.21). V-axis represents relative expression but is not drawn
to scale.
4.3.4.2 DNA methylation analysis during differentiation of hESCs and iPSCs
Bisulfite sequencing results are usually performed on individual DNA clones, and are scored
by either open (unmethylated) or dark (methylated) circles, with CpGs only considered to be
methylated if T is absent (section 2.6.3; Wernig et al. 2007; Yu et al. 2007b; Park et al.
2008c). However, analysing individual DNA clones for several time-points during
differentiation, and repeating this for several genes, would be a cumbersome task for this
study. Instead, DNA methylation analysis was performed by direct sequencing of whole
PCR products, and scoring bisulfite sequencing results with open, dark, half-filled and
partially filled circles (section 2.6.3), something that enabled detailed recording of DNA
methylation changes during differentiation. This method could discriminate between an
increase in the number of CpG sites that became methylated across the whole cell
population, and an increase in the proportion of cells that were methylated at each CpG
(Figure 4.16, Figure 4.23). A similar 5-category scoring system was recently used in a
-
whole-genome next-generation sequencing study by Laurent et al. (2010) to account for
DNA methylation differences between hESCs, fibroblast derivatives and neonatal
fibroblasts.
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Results from section 4.2.4.3 showed that DNA methylation in the promoters of OCT 4,
NANOG and REX1 began to increase at the same time as transcriptional repression was
initiated during differentiation (Figure 4.14 and Figure 4.16), indicating that DNA methylation
might be significant for gene repression. SOX2 methylation was detected four days following
gene down-regulation, suggesting that other mechanisms might be necessary to initiate
gene silencing. DNA methylation in SOX2 might be necessary to stabilise rather than initiate
gene silencing, similar to Oct4 gene silencing in the mouse, which is initiated by histone
modifications and stably repressed by DNA methylation (see section 4.1.1.1). This is to our
knowledge the first study correlating the changes in gene expression to DNA methylation
during differentiation in non-cancerous cells (Deb-Rinker et al. 2005a). NANOG was the first
pluripotency factor to become down-regulated and methylated during hESC differentiation,
suggesting a significant role of this gene in initiating changes in the hESC transcriptional
machinery that are necessary for phenotype transition from a pluripotent to a differentiated
state.
OCT4
DNA methylation
REXl
DNA methylation
HUES7 d2 d4 dG d8 dlO d12 d14 dlG HUES7-Fib HUES7 d2 d4 dG d8 dlO d12 d14 dlG HUES7-Fib
SOX2 DNA methylation NANOG
Protein DNA methylation
H3K9Ac
H3K4me3
H3K27me3
HUES7 d2 d4 dG d8 dlO d12 d14 dlG HUES7-Fib HUES7 d2 d4 dG d8 dlO d12 d14 dlG HUES7-Fib
Figure 4.23- Relationship between gene and protein expression to DNA methylation
DNA methylation in OCT4 and REXl was observed after the initial up-regulation in gene expression observed
during hESCdifferentiation, and coincided with the beginning of gene down-regulation. NANOG, the only gene
to show an immediate decline in gene expression during differentiation, also showed the earliest signs of DNA
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methylation in its promoter. SOX2 transcriptional down-regulation preceded DNA methylation by four days. A
change in protein expression was detected several days following gene down-regulation for all pluripotency
factors analysed. V-axis is not drawn to scale.
4.3.5 Reactivation of endogenous pluripotency factors during iPSe
formation
Reactivation of the endogenous pluripotency factors, LlN28, NANOG, SOX2 and OCT 4,
was observed from days 8-10 PTO, during reprogramming of HUES?-Fib to iPSCs (Figure
4.18 and Figure 4.24). This shows that all four iPSC factors are reactivated with similar
kinetics, and are equally necessary for the formation of iPSCs. However, these results
should be interpreted with caution since RT-PCR primers for each gene could be amplifying
the template cDNA with different efficiencies. Apart from NANOG, whose real-time PCR
primers did not distinguish between the endogenous gene and the lentiviral transgene, gene
expression analysis could be repeated by real-time PCR, where primers work with a similar
amplification efficiency (Livak and Schmittgen 2001).
- 0(T4
- NANOG
- SOX2
- LlN2B
Figure 4.24- Reactivation of endogenous
pluripotency genes during iPse formation
All endogenous pluripotency factors analysed were
detected between days 8-10 during deprogramming
of HUES7-Fib to iPSe. V-axis represents relative
expression but is not drawn to scale.
dO d2 d4 d6 dB dlO d12 d14 dlB
Reactivation of endogenous pluripotency factors in our experiments was observed 3-6 days
earlier than previously reported (Brambrink et a/. 2008; Stadtfeld et al. 2008b; section
1.8.1.3). However, other studies used flow cytometry to determine protein re-activation,
which is likely !o be detectable at later stages compared to mRNA expression (Short et al.
2005). Considering the population doubling time of HUES? cells (30-42 hours; Denning et
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al. 2006) and the appearance of putative iPSC colonies from d11 PTO, which consisted of
-10 cells each (Figure 4.17.Al, it was calculated that HUES7 -Fib were reprogrammed -3
days before colony appearance, which would coincide with the timing of endogenous gene
re-activation. This suggests that reactivation of endogenous pluripotency genes is what
enables a change in phenotype from a differentiated to an ESC-like state.
DNA methylation and histone modification analysis using iPSC colonies on day 11 PTO
revealed that repressive epigenetic marks (DNA hyper-methylation and H3K27me3) were
removed by this time-point, reinforcing their role in regulating the expression of pluripotency-
associated genes. This is the earliest time-point of epigenetic analysis reported to date,
during iPSC generation, while analysis of even earlier time-points is continuing in our
laboratory.
4.3.6 Future work
Strong inverse relationship was observed between expression of the pluripotency-
associated factors OCT4, NANOG, SOX2 and REX1 and the amount of DNA methylation in
key regulatory regions (sections 4.2.1, 4.2.2, 4.2.4). This suggested that DNA methylation
acts as a mechanism for gene silencing, but in order to establish a more direct link, these
experiments could be followed by knock-down studies of DNMTs in hESCs. Delayed or
absent hyper-methylation of pluripotency factors during differentiation would confirm the
involvement of DNA methylation in gene silencing and provide information about which
DNMT enzymes are more important for the process. Similar experiments have been
performed in mESCs, but have focused on Oct4 and Nanog expression (Jackson et a/.
2004; Li et al. 2007c), while investigation in hESCs has not been performed.
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5 INVESTIGATING THE EFFECT OF DNMT KNOCK-DOWN ON
CELL PHENOTYPE AND INDUCED PLURIPOTENCY
5.1 INTRODUCTION
In chapter 4, DNA methylation analysis highlighted that key regulatory-regions of
pluripotency factors were unmethylated or hypo-methylated in pluripotent cells and hyper-
methylated in differentiated fibroblast cells. DNA methylation was also shown to gradually
become enriched as hESCs and iPSCs were differentiated by EB formation. These results
suggested that expression of the pluripotency factors under investigation was closely related
to DNA methylation. This chapter aimed to investigate whether the timing of piuripotency
gene re-activation during reprogramming of differentiated cells, and the overall
reprogramming efficiency, could be manipulated by altering the levels of DNA methylation.
Considering the abnormal karyotype involved in the HOGN model cell system (Figure 3.4),
experiments in this chapter were focused on the HUES? model system.
5.1.1 Manipulation of DNA methylation through DNMT knock-down
Even though treatment with the chemical 5-aza-cytidine (5-aza) can reduce global DNA
methylation and improve the generation of iPSCs from mouse fibroblasts (Huangfu et al.
2008a; Mikkelsen et al. 2008), this method was not used here as it is highly toxic to hESCs
(Allegrucci et al. 200?) and shows several side-effects, such as DNA damage and cell cycle
arrest in differentiated cells (Liao et al. 200gb). In the absence of a DNA de-methylase
enzyme in humans (section 1.5.2.4), reduction of DNA methylation in this chapter was
performed via knock-down of DNA methyltransferase enzymes, using RNA interference
(RNAi) technologies. This approach also offered the advantage of identifying which DNMT
enzyme had the most profound effect on the efficiency of iPSC generation and the re-
activation of endogenous pluripotency factors, thus potentially providing mechanistic details
into the regulation of pluripotency-gene expression.
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5.1.2 RNA interference
RNA interference (RNAi) is a mechanism for gene silencing that was used here to knock-
down the expression of DNA methyltransferase enzymes. RNAi occurs naturally in most
eukaryotic organisms as a defence mechanism against viral invasion and transposon
expansion, and to mediate post transcriptional regulation (reviewed by Jinek and Doudna
2009). At least 30% of human genes are regulated at the post-transcriptional level by RNAi,
reflecting the significance of this mechanism in maintaining genome integrity, and regulating
metabolic processes, growth and differentiation (Lewis et al. 2005). RNAi has also recently
been shown to hold an important role in maintaining pluripotency in hESCs and in
reprogramming somatic cells to iPSCs (Ji and Tian 2009; Mallanna and Rizzino 2010).
RNAi is typically initiated in the presence of double-stranded RNAs within cells (Figure 5.1),
which promote the RNase III-like enzyme, Dicer, to bind to and cleave the double stranded
sequences into non-coding small RNA duplexes of -20-30bp in length, either in the form of
short-interfering RNAs (siRNAs) or micro-RNAs (miRNAs; reviewed by Sontheimer and
Carthew 2005). In the cytoplasm, small RNAs form a bond with the RNA-induced Silencing
Complex (RISC, composed of enzymes of the Argonaute family), which causes the double
stranded small RNAs to unwind and subsequently bind to a homologous endogenous
mRNA sequence, causing mRNA degradation, translation inhibition and thus, gene silencing
(Figure 5.1; Hutvagner and Simard 2008). Small RNAs of the siRNA family are thought to
cause degradation of endogenous mRNAs by endonucleolytic cleavage, while the miRNA
family repress mRNA translation by removal/shortening of the mRNA poly(A) tails (process
known as de-adenylation) which destabilises mRNAs and causes their degradation
(Giraldez et al. 2006; Wu et al. 2006; McDaneld 2009). Small regulatory siRNAs and
miRNAs in eukaryotic organisms can also lead to target gene silencing via
heterochromatinisation of DNA through DNA methylation and histone modifications (e.g.
H3K9 and H3K27; Gonzalez et al. 2008; Carthew and Sontheimer 2009).
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The efficiency by which RNAi enables degradation of endogenous mRNA is influenced by
the accessibility and secondary structure of the mRNA as well as by the length and base-
pair complementarity of the functional intermediates, siRNAs or miRNAs, to the endogenous
mRNA (Pei and Tuschl 2006; Shao et al. 2007). Even though siRNAs associate with target
RNAs that contain a perfectly complementary sequence (reviewed by Jinek and Doudna
2009), miRNAs usually base-pair imperfectly with target RNAs (Filipowicz 2005; Jinek and
Doudna 2009). The critical region for miRNA target recognition and RISC complex binding is
located between 2-8bp from the 5' end ("seed" sequence; Doench and Sharp 2004;
Brennecke et al. 2005). Due to the short length of the miRNA seed sequence, siRNAs can
also sometimes act as miRNAs when base-pairing imperfectly, and can thus potentially
cause specific degradation or translational repression of endogenous off-target mRNAs
(Saxena et al. 2003).
Nevertheless, RNAi is now a well established tool for experimental post transcriptional gene
silencing, and its natural occurrence within cells distinguishes it from other nucleic-acid
silencing technologies, such as anti-sense oligonucleotides and ribozymes (reviewed by
Kurreck 2003). For research purposes, siRNAs can be produced by chemical synthesis, in
vitro transcription or digestion of dsRNA using recombinant Dicer, and in vivo expression of
siRNA duplexes as short hairpin RNAs (shRNAs) from plasm ids, or viral vectors (Scaringe
2001; Calegari et al. 2002; Donze and Picard 2002; Paddison et al. 2002; Sui et al. 2002).
Although chemically synthesized siRNAs are very efficient and readily introduced into most
types of cells using cationic-lipid transfection, electroporation or microinjection tools
(Menendez et al. 2005), they can only produce a transient gene knockdown effect (Vallier et
al. 2004). In vitro transcription or digestion of dsRNA using recombinant Dicer, are cost
effective tools for siRNA synthesis, but also present several disadvantages such as low
product purity, low specificity, and variable efficiency (reviewed by Whitehead et al. 2009).
One of the best available tools for RNAi is the expression of shRNAs, from retroviral or
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lentiviral vectors (Paddison and Hannon 2003). Several groups have reported long-term
gene sileneing using these vectors (Szulc et al. 2006; Kappel et a/. 2007).
Repe at-associ ate d
transcripts
(centromeres,
transposons), viral
RNAs, gene-
pseudogene
duplexes, shRNAs,
experimentally
introduced dsRNAs,
Nucleus
::::.::::
Cytoplasm
AG02
Argonaute
Passenger-sf rand ~TT1I::i'rirTT
cleavage L.........................
Passenger-strand
ejection
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Figure 5.1- The RNA interference (RNAi) pathway
Double stranded RNAs (dsRNA) are processed by Dicer enzyme into 19-30bp long short-interfering RNAs
(siRNA, left panel) or micro-RNA (miRNA, right panel). Association with the RNA-induced silencing complex
(RISC) unwinds siRNAs or miRNAs into single-stranded molecules and mediates degradation of endogenous
mRNA by endonucleolytic cleavage (siRNAs) or removal of the poly-A tails from their 3'UTRs (miRNAs; Jinek
and Doudna 2009).
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In order to achieve DNA methyltransferase knock-down in this chapter, transient knock-
down by lipofection of chemically synthesised siRNAs was initially tested to screen several
commercially available siRNAs and select those that best induced knock-down of their
target genes. To study the long-term effects of DNA methyltransferase knock-down on cell
phenotype and induced pluripotency, the most efficient siRNAs were subsequently cloned
into lentiviral vectors and were stably expressed in host cells in the form of shRNAs, taking
advantage of the lentiviral vectors' ability to avoid transcriptional silencing by the host
genome (section 3.1.3.2)
5.1.3 DNA methyltransferase depletion in differentiated cells
Disruption of DNMTs in human and mouse ESCs has little effect in the maintenance of
pluripotency characteristics and self-renewal ability, but affects differentiation and silencing
of pluripotency associated genes such as Oct4 and Nanog (section 1.6.2.7; Chen et al.
2003; Hattori et al. 2004; Jackson et al. 2004; Li et al. 2007c). However, disruption of
DNMTs in differentiated cells has more severe effects; knock-out of Dnmt1 or 3b in MEFs
can result in p53-mediated cell death, de-methylation of repetitive elements, aberrant
expression of imprinted, cell cycle control, DNA repair and tissue-specific genes, premature
senescence and karyotype instability (Table 5.1; Jackson-Grusby et al. 2001; Dodge et al.
2005). In human cancer cells (HCT116), loss of DNMT1 was associated with reduced
proliferation rates or mitotic arrest at G1-S phase (Chen et al. 2007), and decreased DNA
methylation in centromeric regions and tumour suppressor genes (Rhee et al. 2000).
These effects were enhanced with combined knock-out of DNMT1 and 38, where a 95%
reduction in global DNA methylation was observed (Rhee et al. 2002). Single knock-out of
DNMT38 in human cancer cells had more modest effects than DNMT1 single knock-out
(Table 5.1). Collectively, these data suggest that DNMTs, and especially DNMT1, have a
significant role in the proliferation and karyotype stability of differentiated cells. Dnmt3a
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knock-out was shown to have no effect in the maintenance of global DNA methylation,
imprinting stability and expression of tumour suppressor genes in mouse cells (Dodge et al.
2005).
Considering data from the literature, the effects of DNMT1, but not DNMT3A, knock-down
on proliferation, cell-cycle progression, global DNA methylation, and DNA methylation at
imprinted and tumour suppressor genes were tested in this chapter, prior to the use of
fibroblast cells in reprogramming experiments to generate iPSCs.
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Figure 5.2- Phenotypic effects of DNMTl manipulation in mammalian cells
Relative levels of DNMTl expression are shown on the Y-axls, with 100% depicting normal DNMTllevrls and
0% representing DNMTl knock-out. The severity of reduced DNMTl expression on cell phenotype increases as
the level of down-regulation increases. Outcomes associated with the known DNMTl role as a maintenance
methyltransferase are shown above the graph, whereas non-canonical functions of DNMTl are shown below
the graph (Brown and Robertson 2007).
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Table 5.1- Roles of DNA methyltransferase enzymes in differentiated cells
KO= knock-out, DKO= double knock-out
Cell type Gene Treatment Effect Papers
p53 dependent cell death, hypo-methylation of
repetitive elements (lAP, L1, G7e), aberrant
Jackson-
Dnmtl KO expression genes involved in imprinting (Tdag, Xist, Grusby et al.
H19, Ig12, GrblO, Peg3), cell cycle control, DNA 2001
repair, lineage specification and mobilisation of
retroelements
MEFs
Dnmt3a No effect on processes studied
p53 dependent cell death, premature senescence,
KO partial loss of global DNA methylation, genome Dodge et al.Dnmt3b
instability (aneuploidy & polyploidy, chromosome 2005
breaks and fusions)
Dnmt3a-3b DKO Same as DNMT3B KO
Mouse
Hypo-methylation of H19 & Nnat promoters &
Pituitary Dnmtl
RNAi by reactivation of Nnat. Differential expression of 91 Dudley et al.
siRNA genes involved in induction of apoptosis, signal 2008
Adenoma
transduction, and developmental processes
90% decrease in methyltransferase activity, hemi-
methylation in 20% ofCpGs (a-SAT, L1, MLH1,
Rhee etal.
DNMTl KO CDKN2A), slower proliferation rate, inactivation of 2000;ChenG2/M checkpoint, severe mitotic defects (broken
etal.2007
chromosomes, anaphase bridges). Cell death during
mitosis or at tetraploid G1
Increased cell death, decreased methylation activity,
Robert et al.
Human DNMTl
RNAi by global genomic hypo-methylation, hypo-methylation
2003;Spada
colorectal
siRNA and reactivation of tumour suppressor genes
etal.2007
CDKN2A and MLHl
cancer
<13% decrease in methyltransferases activity, <3%(HCT1l6)
DNMT38 KO reduction in global DNA methylation, modest hypo-
methylation at Sat-2 sequences
Rhee etal.Growth suppression, near loss of methyltransferase
2002; Karpf
activity, >95 % global hypo-methylation, hypo-
and Matsui
DNMTl-38 KO methylation at repeat sequences (Sat-2 & Alu), 2005
tumour suppressor and imprinted genes (TlMP-3,
IGF2 & p16), genomic instability, chromosomal
translocations
Inhibition of cell proliferation & induction of cell
DNMTl death. Hypo-methylation in cancer-related genes
Human CDKN2A, ASSF1A, HTLF, RUNX3, AKAP128. lung eta/.gastric
DNMT38 No effect on processes studied 2007
cancer
RNAi by No synergistic effect in de-methylation or gene
DNMTl-38 .
siRNA reactivation
Human
lung
DNMTl
Increased expression of cell-cycle regulating genes Milutinovic
carcinoma p21 and 81K et 01.2004
HEK293
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5.1.4 Chapter Aims and Objectives
This chapter aimed to establish a closer link between the expression of pluripotency-
associated genes and DNA methylation by testing whether knock-down of DNMT enzymes
would enable easier gene re-activation and/or increased formation of iPSCs during
reprogramming. To achieve this aim, the following objectives had to be met:
* Determine the expression levels of each DNMT in hESC-derived fibroblasts
* Use RNAi technologies (siRNAs), to test transient knock-down of the most highly
expressed DNMTs in hESC-derived fibroblasts (DNMT1 and 3A) and then induce
stable knock-down using lentivirally expressed shRNAs
* Study the effects of DNMT1 knock-down on pluripotency maintenance and
differentiation, population doubling time, cell cycle progression, imprinting stability,
and methylation of tumour suppressor genes
* Investigate whether DNMT1 and/or 3A knock-down could affect the reactivation of
endogenous pluripotency genes during reprogramming and/or result in increased
formation of iPSC colonies.
5.2 RESULTS
5.2.1 Expression of DNA methyltransferases in HUES7 and HUES7 -Fib
Four DNA methyltransferase enzymes have been detected in human cells (section 1.5.2.2).
These are the maintenance methyltransferase DNMT1, and the de novo methyltransferases
DNMT3A, DNMT3B and DNMT3L. In order to determine which of these enzymes to target
for knock-down, their expression levels in hESC-derived fibroblasts were determined by
real-time PCR and immunofluorescence staining. Real-time PCR analysis showed that the
de novo methyltransferases DNMT38 and DNMT3L were almost undetectable in HUES?-
Fib cells (Figure 5.3.A). The same was true for the fibroblast line, BJ-Fib, which was
included as a control in this experiment. DNMT3A was detected in fibroblast lines, but at
lower levels than in HUES? cells (5?% lower in HUES?-Fib, 94% lower in BJ-Fib). The most
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abundant DNMT in fibroblast cells was the maintenance methyltransferase DNMT1, but was
still expressed at 21-25% lower levels than in HUES? Immunofluorescence staining
confirmed the findings of real-time PCR; all DNMTs were expressed at high levels in HUES?
cells (Figure 5.4.A), DNMT3B and DNMT3L were almost undetectable in HUES?-Fib, and
DNMT3A was expressed at lower levels compared to HUES? (Figure 5.4.B). Gene and
protein expression analysis suggested that DNMT1 and DNMT3A should be targeted for
knock-down in HUES? -Fib.
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Figure 5,3- Gene expression of DNA methyltransferases in HUES7, HUES7-Fib and BJ-Fib cells
Real-time peR analysis of DNMTl, 3A, 38 and 3L expression in HUES7, HUES7-Fib and 8J-Fib. Error bars
represent standard error.
5.2.2 Knock-down of the DNA methyltransferase DNMT1
5.2.2.1 siRNA-mediated transient knock-down of DNMT1
Commercially available siRNAs against human DNMT1 were tested to determine which one
would enable the highest gene knock-down (KD; Figure 5.5). All siRNAs had 100%
complementarity to endogenous mRNA and were located within the coding region (siRNA
859; exon 16, siRNA 860; exon 30 and siRNA 861; exon 6). Cells were treated with each
siRNA, as well as with combination of all siRNAs together. DNMT1 expres~ion was
assessed by real-time PCR at 24, 48 and ?2 hours following transfection with siRNAs.
Results were quantified relative to a control sample, treated with the cationic lipid
Lipofectamine-2000 but no siRNA (lipid control). Each siRNA was referred to by using the
three last digits of its manufacturer's product number (Table 2.3). Tests were performed
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using HUES7 cells, since protocols for siRNA transfection of this line were well established
in our lab by previous colleagues (section 2.2.2).
All siRNAs tested were able to reduce DNMT1 expression by 50-85% (Figure 5.5). KO with
siRNAs 860, 861, and combination of all siRNAs was at its lowest 24 hours post-transfection
and increased at 48 and 72 hours, while siRNA859-mediated KO showed the reverse
pattern. Overall, siRNAs 859 and 860 enabled the highest KO for DNMT1 (85% KO, RQ=
0.15±0.002, p=O.OO and 72% KO, RQ= 0.28±0.013, p=O.OO). No statistically significant
synergistic effect was observed in the presence of all three siRNAs, relative to siRNA860
(p= 0.04 at 24h, p=0.23 at 48h and p=0.09 at 72h).
A Untreated Lipid control siRNA859 siRNA860 siRNA861 AlisiRNAs
B
siRNA mediated DNMTl knock-down in HUES7cells
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Figure 5.5- siRNAmediated knock-down' of DNMTl in HUES7cells
A. Bright field images and B. real-time peR analysis of DNMTl expression in HUES7 cells transfected with
siRNAs against DNMTl at 24, 48 and 72 hours post transfection. Error bars represent standard error. Scale
bars represent 1001lm.
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5.2.2.2 Design of shRNA oligos for stable knock-down of DNMT1
Gene knock-down by siRNA mediated pathways has a transient effect on down-regulating
expression of target genes (Vallier et al. 2004). Stable DNMT1 KO in HUES7 and HUES7-
Fib was introduced by lentiviral delivery of short hairpin RNA (shRNA) oligos. shRNA
sequences were based on siRNAs 859 and 860, shown to cause the highest knock-down of
DNMT1 (section 5.2.2.1). shRNAs were designed by synthesising oligos containing two
repeats of the siRNA sequences (one 5' to 3' and the other its reverse complement), that
were separated by a loop forming sequence (Figure 5.6.A). The loop contained an Xbal
restriction site to facilitate screening (Figure 5.6.C), while half-sites for Mlul and Cia! were
included at the ends of the oligos to enable cloning into the lentiviral plasmid pLVTHM
(Figure 5.6.8). Successful cloning was confirmed by sequencing analysis (data not shown).
A non-targeting (NT) shRNA was purchased from SIGMA (SHC002), as an insert into the
backbone vector TRC1/1.5 pLKO.1-puro. With help from Dr. David Anderson, the NT
shRNA insert was sub-cloned into pLVTHM between its Mlul and Cia I restriction sites
(Figure 5.6.8), and used as a negative control, instead of scrambled or reverse shRNA
sequences (Cortina et al. 2007; Wang et al. 2008a). The NT shRNA was designed by the
manufacturer to have at least a 4-5 base mismatch with any human transcript and could,
thus, activate the RISC complex and RNAi pathways without causing knock-down of any
known gene.
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5.2.2.3 shRNA-mediated knock-down of DNMT1
Both HUES7 and HUES7-Fib cells were transduced with pLVTHM-based lentivirus that
expressed NT, 859 and 860 shRNAs (Figure 5.7.A&B). Cells were collected at 72 hours
PTO and used in real-time PCR analysis, which was performed relative to the NT shRNA
control sample. In both HUES7 and HUES7-Fib, shRNA 859 caused a higher DNMT1 KO
(64% KO, RQ= 0.36±0.027, p=0.02 and 81% KO, RQ= 0.19±0.012, p=0.02), compared to
shRNA 860 (24% KO, RQ= 0.76±0.051, p=0.02 and 48% KO, RQ= 0.62±0.050,. p=0.01;
Figure 5.7.C&O), Doubling the viral volume did not improve the levels of DNMT1 knock-
down (data not shown). Based on these results, shRNA 859 was used in all subsequent
experiments involving DNMT1 knock-down,
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Figure 5.7- shRNA-mediated knock-down of DNMTl in HUES7 and HUES7-Fib
Bright field and fluorescence images of A. HUES7 and B. HUES7-Fib cells with no virus (NV), or transduced with
lentivirus carrying NT shRNA, or shRNAs 859 and 860 against DNMTl, at 72 hours post transduction. C.&O.
Quantitative real-time peR analysis of DNMTl expression in the populations shown in A. and B. Error bars
represent standard error. Scale bars repre.sent 1001lm.
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5.2.2.4 Stable-knock-down of DNMT1
Followinq transduction with shRNA-expressing lentivirus, HUES7 and HUES7-Fib cells were
cultured in triplicate flasks for five passages. During this time, cell counts were performed at
each passage to calculate growth curves, and cell pellets were collected to determine the
levels of DNMT1 mRNA and protein KO. Real-time PCR was performed using all three
replicates of each sample, but these were pooled for Western blot analysis in order to
provide enough material for protein extraction.
HUES7 and HUES7-Fib lines carrying DNMT1 KO remained brightly fluorescent for 5
passages (Figure 5.8.A&8), indicating persistent expression of lentiviral genes. They had
population doubling (PO) times of 41.22 h/PD and 36.62 h/PD (Figure 5.8.C&D), none of
which was significantly different to their respective NT shRNA controls (p=O.63 for HUES7
and p=O.08 for HUES7-Fib).
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Figure 5.8- Population doubling time in HUES7 and HUES7-Fib cells with stable DNMTl knock-down
Bright field and fluorescence images of A. HUES7 and B. HUES7-Fib cells transduced with lentivirus carrying
shRNA859 against DNMTl, at passages 0; 1, 3 and 5 after transduction. Dot-plot analysis of the cumulative
population doublings between passages 1 and 5, in C. HUES7 and D. HUES7-Fib cells transduced with no virus,
lentivirus carrying NT shRNA or shRNA859 against DNMTl. Error bars represent standard error. Scale bars
represent 1001lm.
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Real-time peR analysis over 5 passages PTO showed that DNMT1 expression remained
39-51%.lower in KO HUES? and HUES?-Fib lines, compared to the NT shRNA controls at
passage 5 (p<0.05; Figure 5.9). ONMT1 protein expression was reduced by 28.5-38% in KO
lines (Figure 5.10).
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Figure 5.9- DNMTl gene expression in HUES7 and HUES7-Fib cells with stable DNMTl knock-down
Real-time peR analysis of DNMTl expression in cells transduced with lentivirus carrying shRNA8S9 against
DNMTl between passages 1 to S is shown relative to the starting populations of HUES7 (A) and HUES7-Fib (B),
cells with no virus (NV) or transduced with lentivirus carrying NT shRNA, for S passages. Error bars represent
standard error.
A c <l: 8 c0 0 <l:tl.Q'+=i III Z tl.O~ III:::l Zc ro
.... a:: c ro :::l
',p "S s ..c ._ - L- a::
....a. III DNMTl shRNA +-' :::J ._ ..c DNMTl shRNA....0.> IIIBl~ 0 f- 200 f-Z Z Vl a. Z Z
pO pS pS pI p2 p3 p4 pS pO pS pS pI p2 p3 p4 pS
C
120
c: 100
0
'iii
80IIIQj
...
Q, 60x
Qj
c: 40
'iii
...
0 20
...
Q,
'#. 0
Starting NV
population pS
HUES7
NT shRNA DNMTl
pS shRNA pS
DNMTl
a-tubulin
0
120
c: 100
0
'iii 80III
Qj
...
Q, 60x
Qj
c: 40
'iii
...
200
...
Q,
'#. 0
Starting
Population
HUES7-Fib
NV NT shRNA DNMTl
pS pS shRNA
Figure 5.10- DNMTl protein expression in HUES7 and HUES7-Fib cells with stable DNMTl knock-down
Western blot analysis of DNMTl expression in cells transduced with lentivirus carrying shRNA8S9 against
DNMTl between passages 1 to S is shown- relative to the starting populations of HUES7 (A) and HUES7-Fib (B),
cells with no virus (NV) or transduced with lentivirus carrying NT shRNA, for S passages, C. D. Histograms
representing the % expression of DNMTl protein in the samples shown in A, and B, Protein expression was
normalised to the NT shRNA sample,
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5.2.3 The effect of DNMT1 knock-down on cell cycle progression
HUES? .and HUES?-Fib carrying ONMT1 KO were cultured up to passage 1? PTO, in order
to give enough time for the KO to affect DNA methylation (Jackson et al. 2004). At passage
1?, cells maintained GFP expression and ONMT1 KO (Figure 5.11), while they had not up-
regulated de novo ONMT expression (data not shown). Cell cycle analysis was performed
as described in section 2.4.3. No considerable differences in the percentage of cells at each
stage of the cell cycle were observed between the HUES? control and KO lines (Figure
5.12). However, in the HUES?-Fib ONMT1 KO sample, the number of cells in G1 phase was
reduced by 14%, and was increased by 12% in S phase. This indicated that DNMT1 knock-
down could be delaying cell cycle progression at S phase.
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Figure 5.11- Expression of DNMTl at passage 17 post-transduction with shRNA859
A. Bright field and fluorescence images of HUES7 and HUES7-Fib cells, 17 passages following DNMTl KD. B.
Quantitative real-time peR analysis of DNMTl expression, 17 passages following KD in HUES7 and HUES7-Fib
cells. The starting population represents HUES7 cells at passage p+O. Error bars represent standard error.
Scale bars represent lOOllm. NV= no virus
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Figure 5.12- Cell cycle analysis by flow cytometry in HUES7 and HUES7-Fib with stable DNMTl knock-down
Cell cycle analysis was performed by flow cytometry, using propidium iodide (PI) to stain DNA. A. The
percentage of cells at stages Gl, S or G2 of the cell cycle was determined by Cylchred software. Blue= total cell
distribution, red= cells at Gl and G2, green= cells at S phase. The results from A. were represented graphically
using histograms for B. HUES7 and C. HUES7-Fib cells. The starting population represents HUES7 cells at
passage p+O. NV = no virus.
5.2.4 Differentiation of hESCs with stable DNMT1 knock-down
In order to determine whether HUES? with DNMT1 KO maintained the ability to form the
three embryonic germ layers, cells at passage 1? PTO were differentiated via EB formation.
Even though EB diameters varied between the NV, NT shRNA and KO samples (Figure
5.13), their differences were not statistically significant (day 4: p=0.09 and day 8: p=0.98).
Derivatives of the three embryonic germ layers were identified in the control NV and NT
shRNA lines (data not shown), as well as in the DNMT1 KO line (Figure 5.13),
demonstrating that DNMT1 KO did not affect pluripotency in HUES? cells.
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Figure 5.13- EB formation and differentiation of HUES7 ONMTl KO cells into the three germ layers
A. Histogram representing the average diameter of EBs on day 4 and 8 during differentiation of HUES7 cells
with no virus (NV), NT shRNA or shRNA859 against DNMTl. B. Differentiation of HUES7 cells carrying
shRNA859 against DNMTl into cell-types representative of the three germ layers; ectoderm, endoderm and
mesoderm. Protein expression was captured using the Cy3 channel, while the overlay represents a merge of
the DAPI (nuclear staining) and Cy3 channels. Scale bars represent 641lm.
5.2.5 DNA methylation analysis in cells with DNMT1 knock-down
HUES? and HUES?-Fib carrying stable KD of DNMT1 showed normal population doubling
times, while pluripotent HUES? cells maintained the ability to differentiate to the three
embryonic germ layers. KD of DNMT1 in differentiated HUES? -Fib cells affected
progression of the cell cycle at S phase. In this section, the effects of DNMT1 KD on DNA
methylation were investigated.
5.2.5.1 Global methylation of genomic DNA
Global levels of DNA methylation were analysed using restriction digestion with the
methylation specific enzyme McrBC (section 2.6.6; Spada et al. 200?). This enzyme can
only recognise and cut methylated DNA (Sutherland et al. 1992; Gowher et al. 2000; Zhou
et al. 2002). Undigested control samples (U), showed thick DNA bands at the top of agarose
gels, while digested products (D) formed DNA smears (Figure 5.14). In HUES? and EBs,
DNMT1 KD did not affect global DNA methylation. However, in HUES?-Fib DNMT1 KD
202
PhD Thesis
Elena Matsa
School a/Clinical Sciences
The University 0/Nottingham
Chapter 5- Effect of DNMT knock-down on cell phenotype and induced pluripotency
cells, a thicker undigested band was observed at the top of the DNA smear (circled in red,
Figure 5.14). This band was of similar size to undigested (U) DNA, and was absent from the
digested (D) samples in NV and NT shRNA controls, indicating reduced global DNA
methylation due to DNMT1 KD in HUES7 -Fib.
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Figure 5.14- Genomic DNA digest with the methylation sensitive enzyme McrBC
Gel electrophoresis of genomic DNA following restriction digest with the enzyme McrBC, which specifically
digests methylated DNA. HUES7, EBs and HUES7-Fib cells with a stable DNMTl knock-down, as well as their
respective no virus (NV) and NT shRNA controls, were used for the experiment and were run both undigested
(U) and digested (D) with McrBC enzyme. The starting population represents HUES7 cells at passage p+O.
5.2.5.2 DNA methylation in imprinted genes
Genomic DNA digestion with McrBC showed a reduction in global DNA methylation of
HUES7-Fib, but gave little information about the genes affected. Considering the role of
DNMT1 in imprinting and genome stability (section 5.1.3), the methylation status of
imprinted and tumour suppressor and genes were analysed more closely. Since a large
number of tumour suppressor and imprinted genes have been identified in the human
genome, this study investigated those found to be most unstable in ESC and cancer studies
(Esteller and Herman 2002; Kim et al. 2007; Rugg-Gunn et al. 2007).
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DNA methylation analysis of imprinted genes was performed with kind help from Dr. Kee-
Pyo Kim, using combined bisulfite restriction analysis (COBRA). PCR products were
digested with enzymes that could only cut at their recognition sites if DNA was methylated.
Therefore, undigested DNA represented loss of DNA methylation (Figure 5.15). HUES? -Fib
PCR products for PEG10, digested with the enzyme Bstul, showed different band patterns
compared to HUES? and EB samples (heavier bottom bands, Figure 5.15). The same was
observed when IGF2 DMRO products were digested with HpyCH41V and Acil, indicating
tissue specific DNA methylation (Moore et al. 199?; Okabe et al. 2003; Tsou et al. 2003) in
HUES?-Fib. DNMT1 KO EBs showed GTL2 CpG2 hypo-methylation (heavier top
undigested band with HpyCH41V digest). Reduced methylation was also observed in the
HUES?-Fib DNMT1 KO sample for GNAS1 XLas (heavier top undigested band), and
NESP55 DMR (loss of digested bands). Off-target effects, possibly owing to lentiviral
transduction or activation of the RNAi pathway (Jackson and Linsley 2004; Fedorov et al.
2006; Morris and Rossi 2006), were observed for NESP55 DMR in the NT shRNA and
DNMT1 KO HUES?, and for KvDMR1 (HpyCH4IV digestion) in the NV shRNA and DNMT1
KO HUES? -Fib.
COBRA repeated at passage 30 PTO showed similar results to analysis at passage 1? PTO
(data not shown and Figure 5.15). Bisulfite sequencing analysis confirmed the DNMT1 KD-
induced hypo-methylation observed by COBRA in GTL2 CpG2, NESP55 DMR and GNAS
XLas (data not shown).
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Figure 5.15- COBRA analysis of imprinted genes in cells with DNMTl knock-down
Gel electrophoresis of PCRproducts from COBRA. HUES7, EBs and HUES7-Fib cells with a stable DNMTl knock-
down, as well as their respective no virus (NV) and NT shRNA controls, were used for this experiment and
were run both undigested (U) and digested (D) with appropriate methylation-dependent restriction enzymes.
The starting population represents HUES7 cells at passage p+O. Red boxes/ arrows= samples/bands showing
decreased DNA methylation, green boxes/ arrows= samples/bands showing tissue-specific DNA methylation
5.2.5.3 DNA methylation in tumour suppressor genes
Methylation specific PCR (MSP) analysis was performed in ten tumour suppressor genes,
with kind help from Dr. Kee-Pyo Kim. In this type of PCR, gene specific primers were
designed to detect bisulfite-converted methylated (M) or unmethylated (U) DNA (Table 2.9).
In vitro methylated HUES? were included in the investigation, to confirm primer specificity.
Products from this sample were only detected with the methylated (M) primer set (Figure
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5.16). The ten tumour suppressor genes studied were mostly unmethylated in the HUES?
starting-population, and in the NV controls of HUES?, EBs and HUES?-Fib (Figure 5.16).
The cell cycle regulating gene p16 (Lukas et al. 1995), was hyper-methylated in ONMT1 KO
HUES?, and to a lesser extent, in ONMT1 KO EBs. However, methylation was not present
in HUES?-Fib KO cells. TlMP-3, a gene involved in inhibiting degradation of the extra-
cellular matrix (Gomez et a/. 199?), was hyper-methylated in HUES?-Fib compared to
HUES? and EBs, with the highest methylation observed in the NV HUES?-Fib control. Off-
target effects, possibly owing to lentiviral transduction or activation of the RNAi pathway,
were observed for TIMP-3 in NT shRNA HUES? and ONMT1 KO EBs, and for GATA4 in NT
shRNA EBs and HUES?-Fib. Overall, very little instability was detected by MSP. p16 was
the only gene to show a ONMT1 KO-specific response.
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Figure 5.16- MSPanalysis of tumour suppressor genes in cells with DNMTl knock-down
Gel electrophoresis of peR products from MSPusing primers specific for methylated (M) or unmethylated (U)
tumour suppressor genes. HUES7,EBsand HUES7-Fibcells with a stable DNMTl knock-down, as well as their
respective no virus (NV) and NT shRNA controls, were used for the experiment. The starting population
represents HUES7cells at passage p+O. As a further control, HUES7at p+O were in vitro methylated via
treatment with the SssI methyltransferase and were included in the analysis to conform the specificity of U
and M primer sets.
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5.2.5.4 DNA methylation in pluripotency genes following DNMT1 knock-down
Bisulfite. sequencing analysis was performed in differentiated HUES7-Fib, to determine
whether DNMT1 KO had affected DNA methylation in the pluripotency-associated genes
OCT4, NANOG, SOX2 and REX1 (section 4.2.2.2). However, bisulfite sequencing showed
no differences in DNA methylation between the DNMT1 KO HUES7 -Fib and control samples
(Figure 5.17). The possibility that DNMT1 could confer an advantage to endogenous gene
reactivation when the cells were found in a "reprogramming environment", i.e. upon
transduction of with lentiviruses over-expressing the four iPS factors, still existed.
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Figure 5.17- Bisulfite sequencing within endogenous iPSegenes in HUES7-Fibcells with DNMTl knock-down
Bisulfite analysis performed by direct sequencing in regions of the OCT4, NANOG, SOX2 and REXl genes in
HUES7-Fibcells with stable DNMTl knock-down, as well as in their respective no virus (NV) and NT shRNA
controls.
5.2.6 Knock-down of the de novo DNA methyltransferase DNMT3A
.
5.2.6.1 Transient knock-down of DNMT3A
Since HUES7-Fib also expressed the de novo DNA methyltransferase, DNMT3A (Figure 5.3
and Figure 5.4), KO of this gene was performed as described in section 5.2.2 for DNMT1. A
set of three commercially available siRNAs against human DNMT3A were tested for their
ability to reduce gene expression (Figure 5.18). All siRNAs were had 100% complementarity
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to endogenous mRNA and were located within the coding region (siRNA 868; exon 14,
siRNA 869; exon 18 and siRNA 870; exon 23). siRNAs 868 and 870 enabled the highest
knock-down for DNMT3A (81% KO, RQ= 0.19±0.015, p=O.OO and 89% KO, RQ=
0.11 ±0.012, p=O.OO; Figure 5.18). No significant synergistic effect was observed in the
presence of ali three siRNAs, relative to siRNA 870 (p=0.48 at 24h, p= 0.00 at 48h and
p=1.00 at 72h).
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Figure 5.18- siRNA mediated knock-down of DNMT3A in HUES7
A. Bright field images and B. real-time peR analysis of DNMT3A expression in HUES7 cells transfected with
siRNAs against DNMT3A at 24, 48 and 72 hours post-transfection. Error bars represent standard error. Scale
bars represent ioou-.
5.2.6.2 shRNA-mediated knock-down of DNMT3A
To enable stable DNMT3A KO, shRNAs were designed as described in section 5.2.2.2,
based on the sequences of siRNAs 868 and 870 (Figure 5.19.A). Oligonucleotide
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sequences were cloned into the lentiviral plasmid, pLVTHM (Figure 5.19.B), between its
MluI and Cia I restriction sites. Successful cloning was confirmed by digest with the enzyme
XbaI and by sequencing (Figure 5.19.C and data not shown). Both HUES7 and HUES7-Fib
were transduced with lentivirus carrying shRNAs 868 and 870. Real-time PCR analysis was
performed relative to the NT shRNA control, and showed that shRNA 868 caused the
highest DNMT3A KO (65% KO in HUES7, RQ= 0.45±0.03, p=O.OOand 30% KO in HUES7-
Fib, RQ= 0.70±0.02 p=0.34; Figure 5.20). Doubling the viral volume did not improve the
levels of DNMT3A KO (data not shown). Even though there was no significant difference in
the KO caused by shRNAs 868 and 870 in HUES7-Fib (p= 0.27), it was decided that shRNA
868 would be used in all subsequent experiments involving DNMT3A KO, as it caused the
highest KO in HUES7 cells (p=0.03; Figure 5.20).
A
MluI XbaI CIaI
868 5' CGCGTCCCCAGCGCACAAGAGAGCGGCTGGTGTTCtAGAGACACCAGCCGCTCTCTTGTGCGCTTTTTTGGAAAT 3' F
3' AGGGGTCGCGTGTTCTCTCGCCGACCACAAGaTCTCTGTGGTCGGCGAGAGAACACGCGAAAAAACCTTTAGC 5' R
MluI XbaI CIaI
870 5' CGCGTCCCCCCCTGTGATGATTGATGCCAAAGTTCtAGAGACTTTGGCATCAATCATCACAGGGTTTTTGGAAAT 3' F
3' AGGGGGGGACACTACTAACTACGGTTTCAAGaTCTCTGAAACCGTAGTTAGTAGTGTCCCAAAAACCTTTAGC 5' R
B c
Xbal - 5942 - TCTAG_A
Clal- 5686- ATCG_AT
Xbal-5645 -T'CTAG_A
Mlul -5611-A'CGCG T
pLVTHM
DNMT3A shRNA
11160bp
DNMT3A shRNA 280bp
Figure 5.19- Cloning DNMT3A shRNAs into lentiviral transfer plasmids
A. shRNA sequences specific to human DNMT3A. Green= restriction enzyme overhangs, black= siRNA
sequences, red= loop sequence, purple and light blue= hairpin forming sequences B. Map of the lentiviral
transfer plasmid pLVTHM after cloning DNMT3A shRNAs between its ClaI and MluI restriction sites. Cloning
the DNMT3A shRNAs into the plasmid created a second XbaI restriction site. C. Gel electrophoresis of plasmid
DNA following a restriction digest with the enzyme XbaI, used to positively identify clones with the DNMT3A
shRNA inserts.
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Figure 5.20- shRNA mediated knock-down of DNMT3A in HUES7 and HUES7-Fib
Bright field and fluorescence images of A. HUES7 and B. HUES7-Fib cells transduced with no virus (NV) or with
lentivirus carrying either NT shRNA, or shRNA 868 or 870 against DNMT3A, at 72 hours post transduction.
C.&O. Real-time peR analysis of DNMT3A expression in the populations shown in A. and B. Error bars
represent standard error. Scale bars represent 1001lm.
5.2.6.3 Stable knock-down of DNMT3A in HUES7 -Fib
The untreated NV control HUES? -Fib line, previously cultured in parallel to the ONMT1 KO
HUES?-Fib line, was transduced with DNMT3A shRNA lentivirus to generate a DNMT3A KO
line (Figure 5.22). Previously established HUES?-Fib ONMT1 KO cells were also
transduced with DNMT3A lentivirus, to generate a double-KO (OKO) line. Two weeks later,
expression of ONMT1 and ONMT3A was assessed by real-time peR and Western blotting
(Figure 5.21), which showed a 24-32% reduction in ONMT1, both at the gene and protein
levels, and a 22-40% reduction in ONMT3A gene and protein levels. No up-regulation of the
de novo ONMTs, ONMT3B and ONMT3L, was observed in response to ONMT1 and
ONMT3A KO, but the OKO line showed a 40% reduction in ONMT3B expression (RQ=
0.60±0.008; Figure 5.21.A).
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Figure 5.21- Stable DNMTl and DNMT3A knock-down in HUES7-Fib
A. Real-time peR and B.&C. Western blot analysis of DNMT expression in HUES7-Fib cells carrying knock-down
of DNMTl and/or DNMT3A, as well as in the control HUES7-Fib lines NV and NT shRNA. Protein and gene
expression were quantified relative to the NT shRNA control sample.
5.2.7 Generation of iPSCs from hESC-derived fibroblasts carrying
DNMT1 and DNMT3A knock-down
ONMT1 and ONMT3A KO HUES7 -Fib were induced to form iPSCs by lentiviral transduction
with human OCT4, NANOG, SOX2 and LlN28 (section 2.2.7). Reprogramming was allowed
to occur for 18 days PTO, with pellets from each sample being collected at 2-day intervals,
as outlined in Figure 5.22. Generation of lentiviral particles was performed as described in
section 4.2.5.
HUES7-Fib that were transduced with the four iPS factors started showing morphological
changes on day 8 PTO, when incompletely reprogrammed colonies begun to emerge
(section 4.2.5.1). Live TRA-1-81 staining performed on day 11 PTO allowed detection of
potential iPSC colonies in all samples, apart from the ONMT1 KO sample (data not shown).
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Putative iPSC colonies grew in size and number over the following days until, on day 18
PTO, TRA-1-81 staining was repeated (Figure 5.23.A-F). Colony counts were performed in
4 replicates of each sample and showed that, relative to the iPS- and NT shRNA-controls,
there were 82%±8.97 more TRA-1-81 positive colonies in the ONMT3A KO sample (Figure
5.23.G). Formation of TRA-1-81 positive colonies was reduced by 40%±11.49 in ONMT1 KO
cells, and by 22%±5.05 in OKO cells. The same results were obtained when TRA-1-81
staining was performed on day 25 PTO (data not shown). Overall, ONMT1 KO decreased
reprogramming efficiency, while ONMT3A KO improved it.
- 2 weeks dO d2 d4 d6 d8 dlO d12 d14 d16 dIS
0............... 0 ~
DNMT3A KD
No virus Untreated control
iPScontrol
NTshRNA
NTshRNA NTshRNA & GFPcontrol
DNMTl KD
DNMTl & 3A DKD
Figure 5.22- Experimental plan for iPse generation from HUES7-Fib with DNMTl and DNMT3A knock-down
Previously established HUES7-Fib lines with DNMTl knock-down were transduced with lentiviral particles
expressing shRNAs against DNMT3A, to generate a double knock-down fibroblast line. No virus (NV) HUES7-
Fib cells were also transduced with the same lentiviral particles. All lines were cultured in parallel for 2 weeks
and were then transduced with the four iPS factors (dO). During the reprogramming process, cell pellets from
each sample were collected at two day intervals for the following 18 days, in order to be used for molecular
analysis. KD = knock-down, DKD = double knock-down. Black circles represent lentiviral transduction. Scale
bars represent lOOllm.
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Figure 5.23- Live TRA-1-81 staining on day 18 during iPSC formation
Bright field, GFPfluorescence (green) and Cy3 fluorescence (red) images of A. untreated, B. iPS and C. NT
shRN!\ control samples, as well as D. DNMTl, E. DNMT3A and F. double knock-down samples, on day 18 of
reprogramming. Cy3 fluorescence represents live cell staining with a phycoerythrin (PE)conjugated anti-TRA-
1-81 antibody. G. Histogram representing the % colony counts in each sample, on day 18 of reprogramming.
Colonies were counted based on TRA-l-Bl expression. Results were normalised to the NT shRNA control
sample. NT = non-targeting, KD= knock-down, DKD= double knock-down. Scalebars represent 100~m.
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5.2.8 Effect of DNMT1 and DNMT3A knock-down on the reactivation of
endogenous pluripotency genes during iPSe generation
RT-peR analysis was performed using samples collected as described in section 5.2.7.
(Figure 5.22). cONA synthesis was carried out as described in section 4.2.5.2. Primers
specific to endogenous OCT4, NANOG, SOX2 and LlN28 (Figure 4.4), and the human de
novo ONMTs, DNMT3A, 3B and 3L (Table 2.6), were used to detect re-activation of these
genes during iPSe generation. Any expression detected in the untreated control (Figure
5.22) during quantification of gene expression by 20 densitometry, was subtracted from the
respective time-point collection of other samples, so that only changes brought about due to
transduction with "iPSe factors" would be accounted for.
5.2.8.1 LlN28, NANOG, DNMT3L and SOX2
LlN28 was expressed at residual levels in day 0 fibroblasts, i.e. prior to lentiviral
transduction (Figure 5.25), and in days 14 and 18 PTO of the untreated control, when
fibroblast cell number increased, depicting residual LlN28 expression in fibroblasts. In iPS-
and NT shRNA-control cells transduced with "iPSe factors", LlN28 was detected from day
6-8 PTO (Figure 5.25), while in ONMT1 and/or 3A KO cells, it was detected from day 4 PTO,
but ONMT3A KO cells expressed LlN28 at 8-27% higher levels compared to other samples.
Earlier reactivation in ONMT3A KO cells was also observed for NANOG and DNMT3L, with
some differences in the level and timing of reactivation (Figure 5.26 and Figure 5.27). SOX2
expression was detected from day 8-10 PTO and was highest in ONMT3A KO cells from day
10 PTO (Figure 5.28).
5.2.8.2 OCT4, DNMT3B and DNMT3A
peR products for OCT 4, DNMT3B and DNMT3A were observed in all samples analysed.
This was expected for DNMT3A(Figure 5.3 and Figure 5.4), while for DNMT3B, peR
products in day 0 samples and early reprogramming were accounted for by residual
DNMT3B expression in fibroblasts (Figure 5.24). As mentioned before, to quantify gene
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expression changes brought about due to transduction with "iPSe factors", any expression
detected in the untreated control was subtracted from the respective time-point collection of
other samples. Increased endogenous OCT4 expression was detected from day 6-10 PTO.
In ONMT3A KO cells, OCT4 showed delayed onset (day 12), but was expressed at 15-40%
higher levels compared to other samples by day 18 PTO, (Figure 5.29), while DNMT38 was
reactivated from day 8-14 PTO, and was expressed at 30-40% higher levels in ONMT3A KO
cells by day 18 PTO (Figure 5.30). DNMT3A expression showed an overall 30-60% increase
during iPSe formation (Figure 5.31). A 12-37% KO was observed in ONMT3A KO cells, on
days 0-10 PTO, and in the double knock-down sample, especially on days 2-6 PTO. By day
18 PTO, DNMT3A was expressed at 15-50% higher levels in ONMT3A KO cells, perhaps
owing to the increased formation of TRA-1-81 positive colonies, which were likely to express
DNMT3A at higher levels than non-reprogrammed cells (Figure 5.31; Stadtfeld et al. 2008b).
Overall, RT-peR analysis enabled earlier detection (by 2-4 days) of the pluripotency-
associated factors NANOG, LlN28 and DNMT3L during reprogramming of HUES7 -Fib with
ONMT3A KO (Figure 5.26, Figure 5.25 and Figure 5.27). OCT4, SOX2, DNMT38 and
DNMT3A were not detected at earlier time-points in this sample but did show the highest
expression levels by day 18 PTO (Figure 5.28-Figure 5.31), possibly owing to the increased
formation of iPSe colonies (Figure 5.23).
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Figure 5.24- RT-PCR analysis of DNMT3B expression in fibroblast lines
Gel electrophoresis following RT-PCR analysis with primers specific to human DNMT3B, in the fibroblast lines
HUES7-Fib, HUES7-Fib C14,BJ-Fib, SUKE-Fib and MEFs, and in the hESC line HUES7.
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Figure 5.25- Endogenous LiN28 reactivation during iPse formation from HUES7-Fib with ONMTl & 3A KO
Gel electrophoresis and histogram representation of endogenous LlN28 expression during reprogramming of
HUES7-Fib cells carrying knock-down of ONMTl and/or ONMT3A. These samples were reprogrammed in
parallel to untreated and NT shRNA control samples. Band quantification was performed by 20 densitometry,
relative to the HUES7 sample. Subtraction of any expression in untreated control was performed prior to
quantification. NT = non-targeting, KO = knock-down, OKO = double knock-down
216
PhD Thesis
Elena Matsa
School of Clinical Sciences
The University of Nottingham
Chapter 5- Effect of DNMT knock-down on cell phenotype and induced pluripotency
o N
"0 "0
«
z
0
"
"0
(f) 'E
0 N
"'"
co tu Ul 0::::::> co 0CD co .,.... .,.... .,.... .,.... a::"0 "0 "0 "0 "0 "0 I Cl.
--
-
...Untreated control
iPS control
NTshRNA
ONMT1 KO
ONMT3A KO
ONMT1 & 3A OKO
140
• Untreated120
c: • iPScontrol
0 100·iii
• NTshRNAIII
CII
• DNMTl KD... 800-
X
• DNMT3A KDCII 60CII
• DNMTl & 3A DKDe
CII 40bD
'* 20
0
dO d2 d4 d6 d8 d10 d12 d14 d18 HUES7
NANOG
Figure 5.26- Endogenous NANOG reactivation during iPSeformation from HUES7-Fibwith ONMTl & 3A KO
Gel electrophoresis and histogram representation of endogenous NANOG expression during reprogramming
of HUES7-Fibcells carrying knock-down of ONMTl and/or ONMT3A. These samples were reprogrammed in
parallel to untreated and NT shRNA control samples. Black arrows represent peR products of the expected
size. Band quantification was performed by 20 densitometry, relative to the HUES7sample. Subtraction of any
expression in untreated control was performed prior to quantification. NT = non-targeting, KO= knock-down,
OKO= double knock-down
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Figure 5.27- DNMT3L reactivation during iPse formation from HUES7-Fib with ONMTl & 3A KO
Gel electrophoresis and histogram representation of DNMT3L expression during reprogramming of HUES7-Fib
cells carrying knock-down of ONMTl and/or ONMT3A. These samples were reprogrammed in parallel to
untreated and NT shRNA control samples. Band quantification was performed by 20 densitometry, relative to
the HUES7 sample. Subtraction of any expression in untreated control was performed prior to quantification.
NT = non-targeting, KO = knock-down, OKO = double knock-down
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Figure 5.28- Endogenous SOX2 reactivation during iPSeformation from HUES7-Fibwith ONMTl & 3A KO
Gel electrophoresis and histogram representation of endogenous SOX2 expression during reprogramming of
HUES7-Fibcells carrying knock-down of DNMTl and/or DNMT3A. These samples were reprogrammed in
parallel to untreated and NT shRNA control samples. Black arrows represent peR products of the expected
size. Band quantification was performed by 2D densitometry, relative to the HUES7sample. Subtraction of any
expression in untreated control was performed prior to quantification. NT = non-targeting, KD = knock-down,
DKD= double knock-down
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Figure 5,29- Endogenous OCT4 reactivation during iPSeformation from HUES7-Fibwith DNMTl & 3A KD
Gel electrophoresis and histogram representation of endogenous OCT4 expression during reprogramming of
HUES7-Fib cells carrying knock-down of ONMTl and/or ONMT3A. These samples were reprogrammed in
parallel to untreated and NT shRNAcontrol samples. Band quantification was performed by 20 densitometry,
relative to the HUES7 sample. Subtraction of any expression in untreated control was performed prior to
quantification. NT = non-targeting, KO = knock-down, OKO = double knock-down
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Figure S.30-0NMT38 reactivation during iPse formation from HUES7-Fibwith ONMTl & 3A KO
Gel electrophoresis and histogram representation of DNMT38 expression during reprogramming of HUES7-Fib
cells carrying knock-down of DNMTl and/or DNMT3A. These samples were reprogrammed in parallel to
untreated and NT shRNA control samples. Band quantification was performed by 2D densitometry, relative to
the HUES7 sample. Subtraction of anv expression in untreated control was performed prior to quantification.
NT = non-targeting, KD = knock-down, DKD = double knock-down
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Figure 5.31- DNMT3A reactivation during iPSeformation from HUES7-Fibwith ONMTl & 3AKO •
Gel electrophoresis and histogram representation of DNMT3A expression during reprogramming of HUES7-Fib
cells carrying knock-down of DNMTl and/or DNMT3A. These samples were reprogrammed in parallel to
untreated and NTshRNAcontrol samples. Band quantification was performed by 2D densitometry, relative to
the HUES7sample. NT = non-targeting, KD= knock-down, DKD= double knock-down
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5.3 DISCUSSION
In this chapter, HUES? and HUES?-Fib lines carrying DNMT1 and/or DNMT3A KD were
generated. HUES? with 40-55% DNMT1 KD showed no reduction in global DNA
methylation, were able to differentiate into the three embryonic germ layers, and had normal
population doubling times and cell cycle progression. In contrast, HUES?-Fib with 35-40%
DNMT1 KD showed reduced global DNA methylation, and delayed cell cycle progression at
S phase. These changes were accompanied by hypo-methylation in the cell cycle regulating
gene, p16, and the imprinted genes, NESP55 DMR and GNAS XLas. DNMT1 KD in
HUES?-Fib reduced the efficiency of iPSe generation (p= 0.02), while KD of DNMT3A
increased reprogramming efficiency by >80% (p= 0.02) and enabled earlier reactivation of
endogenous NANOG, LlN28 and DNMT3L during iPSe formation.
5.3.1 Expression of DNMTs in hESCs and hESCs-fibroblasts
DNMT1 was expressed at high levels in HUES? as well as in HUES?-Fib and BJ-Fib (Figure
5.3 and Figure 5.4). This is in accordance to available literature, which identifies DNMT1 as
the most abundant DNMT in a variety of cell types (Robertson et al. 1999). DNMT3B was
almost undetectable in HUES?-Fib and BJ-Fib, but was highly expressed in HUES?,
consistent with its role in establishing DNA methylation patterns during early development
(section 1.5.1.3) and its high expression observed in human and mouse ESes (Okano et a/.
1998; Okano et al. 1999; Xie et al. 1999). DNMT3A was also detected at higher levels in
HUES? compared to HUES?-Fib and BJ-Fib. Nevertheless, HUES?-Fib and BJ-Fib
expressed DNMT3A at higher levels than DNMT3B, in accordance to data supporting that
DNMT3A was readily detected in human somatic tissues, while DNMT3B was almost
undetectable (Robertson et al. 1999). Perhaps due to their more terminal differentiation
state (Park et al. 2008c) the foetal fibroblasts, BJ, expressed DNMT3A at lower levels
compared to the hESes-derived fibroblasts, HUES?-Fib (Figure 5.3).
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5.3.2 Knock-down of DNMT1 in HUE57 and HUE57 -Fib cells
Stable DNMT1 KO was achieved by shRNA-induced RNAi (sections 5.2.2.3 and 5.2.2.4).
Real-time PCR analysis at 72 hours PTO, showed a 64% KO of DNMT1 expression in
HUES7 (Figure 5.7), while at later passages, KO was reduced to 40-55% (Figure 5.9 and
Figure 5.11). In HUES7-Fib, ONMT1 KO was reduced even more dramatically between 72
hours PTO (81% KO, Figure 5.7) and later passages (35-40% KO, Figure 5.9 and Figure
5.11). Since lentivirally transduced cells remained brightly fluorescent at late passages
(Figure 5.11), indicating that the virus was not silenced, it is likely that reduced ONMT1 KO
was caused by the death of cells carrying the highest KO levels. This is consistent with data
supporting that ONMT1 depletion can lead to increased cell death, and has a more severe
effect on differentiated cells compared to pluripotent cells (Jackson-Grusby et al. 2001; Jung
et al. 2007; Spada et al. 2007). Residual ONMT1 expression in HUES7-Fib with ONMT1 KO
could explain why these cells remained proliferatively active for several passages (section
5.2.2.4), in contrast to differentiated cells carrying knock-out of ONMT1, which have been
reported to reach proliferative arrest resulting from complete loss of ONMT1 expression
(Brown and Robertson 2007).
5.3.2.1 Differentiation to the three embryonic germ layers
HUES7 cells carrying a stable 40-55% KO of ONMT1 were able to form EBs with similar
morphology and size to wild-type cells (Figure 5.13.A) and differentiate into all three
embryonic germ layers (Figure 5.13.B). This was in contrast to knock-out studies in mESCs
which showed that elimination of ONMT1 resulted in reduced differentiation ability (Jackson
et al. 2004). Normal differentiation in ONMT1 KO HUES7 could be due to differences in
gene regulation between mouse and human ESCs (section 1.6) or complementation of
ONMT1 activity by de novo ONMTs, which were highly expressed in hESCs (Figure 5.3 and
Figure 5.4), and have been shown to co-operate with ONMT1 to maintain DNA methylation
at the appropriate levels (section 1.5.2.3). Complementation of ONMT1 activity by de novo
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methyltransferases in pluripotent cells could also account for the unaltered levels of global
DNA methylation (Figure 5.14) and normal cell cycle progression (Figure 5.12) in DNMT1
KD HUES7 cells.
5.3.2.2 Cell cycle progression
DNMT1 KD HUES7-Fib had 12% more cells residing in S phase, compared to controls.
DNMT1 enzyme localises to replication foci as cells enter S phase of the cell cycle
(Leonhardt et al. 1992; Margot et al. 2001) in order to catalyse methylation of hemi-
methylated DNA (Figure 1.9). Therefore, lack of DNMT1 in HUES7-Fib KD cells could
explain their reluctance to progress past S phase of the cell cycle. This is in accordance to
studies in human cancer cells, showing defects in cell-cycle check points following DNMT1
down-regulation (Brown and Robertson 2007).
5.3.3 DNA methylation analysis in cells with DNMT1 knock-down
HUES7-Fib DNMT1 KD showed reduced DNA methylation in the imprinted genes NESP55
DMR and GNAS XLas (Figure 5.15), and the tumour suppressor gene, p16 (Figure 5.16).
NESP55 and GNAS XLas are encoded by the same gene (GNAS1) on chromosome 20q13
(Weinstein et at. 2001). However, they are oppositely imprinted and do not share a common
sequence due to alternative splicing and use of alternative promoters (Hayward et at. 1998;
Weiss et at. 2000; Bastepe et at. 2005). The two genes have been involved in endocrine
tumour formation, fibrous bone dysplasia and hereditary osteodystrophy (Weinstein et at.
2004). In normal tissue, the G protein a sub-unit (Gsa) encoded by GNAS XLas is involved
in stimulating cAMPI protein kinase A signalling, which inhibits fibroblast proliferation and
collagen synthesis (Weinstein et al. 2001; Zhang et al. 2004). Unfortunately, these two
imprinted genes did not carry informative (i.e. heterozygous) allele-specific single nucleotide
polymorph isms (SNPs) in HUES7 cells (Kim et al. 2007), and thus investigation of a change
in their allele-specific expression in response to DNMT1 KD was not possible. Nevertheless,
the de-methylation observed in GNAS XLas, could have contributed to the delayed S phase
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progression seen in DNMT1 KO HUES7 -Fib (Figure 5.12), since this gene is involved in
fibroblast proliferation. GTL2 CpG2 hypo-methylation in EBs with DNMT1 KO could indicate
some impairment towards differentiation, since GTL2 has been associated with myogenesis
and nervous system development (SChuster-Gassier et al. 1998; Fahrenkrug et al. 2000).
The tumour suppressor gene, p16, is an inhibitor of the cyclin dependent kinase, CDK4, and
it is involved in the cell cycle check-point responsible for allowing progression from the G1 to
S phase (prevents cells from entering S phase and holds them at G1 phase; Lukas et al.
1995). Self renewal in ESCs is supported by a short cell cycle, mostly due to a shortened
G1 phase (Becker et al. 2006) and, therefore, p16 methylation observed in DNMT1 KO
HUES7 and EBs could have been catalysed by de novo DNMTs, in order to repress p16
and prevent delays in transition from G1-S phase due to DNMT1 KO (Chen et al. 2007).
Lack of p16 methylation in DNMT1 KO HUES7-Fib could be due to the low expression of de
novo DNMTs observed in these cells. Studies in human cancer cells have shown p16
methylation to be unaffected following DNMT1 KO (Rhee et al. 2000), but become hypo-
methylated following double knock-out of DNMT1 and 3B (Rhee et al. 2002). This supports
the observation from DNMT1 KO HUES7-Fib; that both de novo and maintenance DNMTs
need to be expressed at reduced levels to enable p16 hypo-methylation. p16 hypo-
methylation could also have contributed to the abnormal cell cycle progression of DNMT1
KO HUES7-Fib (Figure 5.12).
Overall, knock-down of DNMT1 in pluripotent hESCs had no effect on the processes
analysed (cell-cycle progression, global DNA methylation, methylation at imprinted and
tumour-suppressor genes, and differentiation), whereas in differentiated cells, knock-down
caused a more severe change in phenotype. This is consistent with current literature
showing that DNMT1 depletion is detrimental to differentiated cells (reviewed by Brown and
Robertson 2007). Despite the changes in phenotype, HUES7-Fib with DNMT1 KO were
used in reprogramming experiments to address the question of whether DNA methylation
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catalysed by DNMT1 was involved in the repression of pluripotency gene expression in
fibroblasts.
5.3.4 Knock-down of the de novo DNA methyltransferase DNMT3A
Real-time peR analysis showed a 30% reduction in DNMT3A expression in HUES7-Fib, at
72 hours PTO (Figure 5.20) and at 2 weeks PTO (Figure 5.21), indicating that prolonged
DNMT3A KO did not cause increased cell death. This was in agreement to studies showing
that Dnmt3a knock-out in MEFs did not have an effect on cell death or cell cycle progression
(Dodge et al. 2005). Surprisingly, combined KO of DNMT3A and DNMT1 in HUES7-Fib,
reduced expression of the de novo methyltransferase, DNMT3B (Figure 5.21). Even though
a number of studies have analysed the effects of DNA methyltransferase KO in mouse and
human ESes and differentiated cells (Rhee et al. 2002; Hattori et al. 2004; Dodge et al.
2005; Tsumura et al. 2006; Li et al. 2007c), none have looked at the combined effect of
DNMT1 and 3A. Therefore, it is difficult to conclude whether reduction of DNMT3B
expression occurred stochastically, or was due to reduced DNMT1 and 3A expression, even
though interaction between DNMT enzymes (Pradhan and Esteve 2003) suggests that they
might be involved in regulating each-other's expression.
5.3.5 Reprogramming of hESC-derived fibroblasts carrying DNMT1 and
DNMT3A knock-down
Reprogramming of HUES7-Fib carrying DNMT1 knock-down resulted in a 40% decreased
iPse colony formation (Figure 5.23). This was unexpected, and in contrast to the hypothesis
that if DNA methylation associated with pluripotency-gene silencing occurs durinq early
time-points of HUES7 differentiation (section 4.2.4.3) it would only need to be maintained in
HUES7-Fib, a reaction likely to be catalysed by the maintenance methyltransferase,
DNMT1. It was also in contrast to studies in mouse cells showing that treatment with
siRNAs or shRNAs against DNMT1 could increase the efficiency of iPSe formation by
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enabling partially reprogrammed granular colonies, generated from MEFs, to become fully
reprogrammed (Mikkelsen et al. 2008). The inability of DNMT1 KD to increase the efficiency
of iPse formation in this thesis could reflect further differences between gene regulation in
mouse and human ESes. Alternatively, since the kinetics of iPSe generation were shown to
be directly related to the rate of cell division (Hanna et al. 2008), it is possible that
decreased formation of iPse colonies from DNMT1 KD HUES? -Fib was due to their
delayed progression through S phase of the cell cycle (Figure 5.12).
In contrast to DNMT1 KD, DNMT3A KD enabled increased formation of TRA-1-81 positive
colonies by day 18 PTD (Figure 5.23), which suggested that pluripotency gene silencing in
differentiated cells was associated with DNMT3A-mediated DNA methylation. Gene
expression analysis by RT-peR supported this hypothesis, since earlier detection of the
pluripotency associated factors NANOG, LlN28 and DNMT3L was observed during iPSe
generation from DNMT3A KD HUES?-Fib (Figure 5.32). OCT4, SOX2 and DNMT38 were
not detected at earlier time-points in this sample, indicating that DNMT3A-mediated
suppression acted in gene-specific mechanisms. Dnmt3a-mediated DNA methylation has
previously been shown to regulate Dnmt31 expression in mESes (Hu et al. 2008), perhaps
explaining the earlier re-activation of DNMT3L in HUES?-Fib DNMT3A KD cells (Figure
5.2?).
Dnmt3a has also been shown to catalyse methylation of Nanog and Oct4 during
differentiation of mESes (Li et al. 200?c), therefore establishing a link between expression
of these genes and Dnmt3a-mediated DNA methylation. Lack of OCT4 detection at earlier
time-points in response to DNMT3A KD in this study (Figure 5.29) could be due to
differences in regulation of gene expression between mouse and human cells, or due to
distortion of peR results by detection of pseudogene or residual OCT4 expression in all
samples (Figure 5.29). Future experiments analysing OCT4 expression during
reprogramming could be performed by using the OCT4 real-time peR primers which are
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specific to endogenous OCT4 and can distinguish between pseudogenes and the real
transcript.
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Figure 5.32- Endogenous gene reactivation during reprogramming of HUES7-Fib with ONMT3A KO
Expression of endogenous pluripotency genes during reprogramming of HUES7-Fib with ONMT3A KO (dotted
lines) compared to the NT shRNA control sample (solid lines). The pluripotency-associated genes NANOG,
L1N28 and DNMT3L were detected at earlier time-points in the DNMT3A KO sample, due to earlier reactivation
and/or increased overall efficiency of reprogramming to iPSCs. Stars are colour coded and represent the point
when gene expression in the ONMT3A KO sample became higher than the control. V-axis represents relative
expression but is not drawn to scale.
Earlier detection of LlN28 expression in response to DNMT3A KO was perhaps unexpected,
since this gene did not show differential methylation between pluripotent and differentiated
cells in previous experiments (section 4.2.2.2). RT-PCR results (Figure 5.25) suggested that
LlN28 expression could be regulated by DNA methylation in a different region to the one
analysed here, or even by other factors that are themselves regulated by DNA methylation.
Lin28 expression is negatively-regulated at the post-transcriptional level by miR-12$b, which
interacts with three miRNA responsive elements (MREs) found in its 3' UTR, and also by
miRNAs of the /et-7 family, which are themselves negatively regulated by Lin28 and DNA
methylation (section 4.1.1.5). Nevertheless, neither de-methylation of MREs or /et-7
transcribing -genes could explain the earlier detection of LlN28, since these were likely to
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result in decreased LlN28 expression. Further investigation is necessary to identify the DNA
methylation-dependent LlN28 regulator, without excluding the possibility that this regulator
might even be NANOG.
The effect of DNMT3A KD on the efficiency of iPSC generation and endogenous gene
reactivation has suggested that key pluripotency genes are regulated by DNA methylation
events that are maintained by the de novo methyltransferase DNMT3A in differentiated
cells, and has provided further mechanistic details into the regulation of gene expression
and iPSC generation.
5.3.6 Evidence supporting the stochastic model of iPSe generation
Current discussion has focused on whether iPSCs represent an elite subset of cells found in
differentiated populations that are competent for reprogramming (Elite model), or whether all
cells are capable of reprogramming but only a few manage to reach the target phenotype
(Stochastic model; Huang 2009; Yamanaka 2009). The Elite model has been somewhat
contradicted by the findings of Hanna et al. (2008) who were able to generate iPSCs from a
clonal population of B lymphocytes that exhibited genetic recombination of the globin locus,
characteristic of terminally differentiated cells. This showed that iPSCs could be derived
from a pure population of terminally differentiated cells, lacking any precursor of
undifferentiated cells that could have formed iPSCs if the elite model held true. Hanna et al.
(2009) also supported the argument that iPSC generation is a stochastic process by
demonstrating that monoclonal transgenic second generation B-cells, expressing all iPS
factors at the appropriate levels, could be reprogrammed to iPSCs with 92% efficiency after
being maintained in culture for 18 weeks, which indicated that all cells in a differentiated
population are capable of reprogramming.
Over-expression of the pluripotency-associated factors, Esrrb, TERT, or NANOG & LlN28 in
combination with the four iPSC factors, OCT4, SOX2, KLF4 and c-MYC (Liao et al. 2008;
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Park et al. 2008c; Feng et a/. 2009), as well as treatment of somatic cells with small
molecules that are capable of affecting DNA methylation and histone modifications (section
1.8.3.1) were able to improve the formation of iPSe colonies by several-fold, showing that
helping somatic cells acquire a transcriptional and epigenetic state more similar to that of
hEses improves the activation of the endogenous machinery necessary for acquiring and
maintaining pluripotency, and reinforcing the stochastic model of iPSe generation. DNMT3A
knock-down, performed in this study, also helped cells overcome one of the "barriers"
towards iPSe generation since it increased iPSe generation efficiency by >80%. This
observation strengthened the notion that reprogramming is a stochastic process amenable
to acceleration (Hanna et al. 2009; Yamanaka 2009), and has laid a foundation for further
improving reprogramming efficiency by targeting other epigenetic modifications regulating
the expression of key pluripotency genes.
Generation of iPSCsfrom clonal population
of term inaIly differentiated cells
Efficiency iPSCformation
corresponds to calculated number
of precursor cells within iPSCs
differentiated populations
®
-----------.+t------- ...0 Elitemodel
-~+__----.+,-------41• .---..0 Stochasticmodel
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Uptake &
appropri ate
expression of
iPSCfactors
92%of 2nd pS3, p16 or p19
generation B-cells knock-down
form iPSCs
Apoptosis Activating endogenous
transcriptional & epigenetic
pluripotency machinery
Differentiated cell
Additional pluripotency-
associated TFsor treatment
with chemicals
DNMT3A knock-down
Figure 5.33- Models of iPse generation
Two models have been proposed for the generation of iPses from differentiated cells; one is the Elite model,
which supports that only a subset of cells within differentiated populations are capable of reprogramming,
and the other is the Stochastic model, which supports that all differentiated cells are capable of
reprogramming. The low efficiency of iPSC generation in the Stochastic model is suggested to arise from the
inability of some differentiated cells to overcome "barriers" towards iPSe formation. Black diamonds & red
writing= "barriers" towards iPse formation/ evidence disproving Elite model, green writing= treatments used
to help cells overcome "barriers"/ evidence supporting Elite model. Improvement of iPSe generation following
DNMT3A has supported the hypothesis that reprogramming is a stochastic process, amenable to acceleration
(Hong et al. 2009; Kawamura et al. 2009; Li et al. 2009; Marion et al. 2009a; Utikal et al. 2009).
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5.3.7 Future work
DNA methylation catalysed by de novo DNMTs has been suggested as a possible
mechanism for viral gene silencing (Okano et al. 1999; He et al. 2005). Also, reactivation of
de novo DNMTs during iPSe generation was shown to be correlated to the timing of viral
transgene silencing (Stadtfeld et al. 2008b). It is, thus, possible that increased formation of
iPses from DNMT3A KO HUES7-Fib was not due to DNA de-methylation of endogenous
pluripotency factors, but due to delayed transgene silencing, previously shown to improve
the overall formation of iPSes (Brambrink et al. 2008). Unfortunately, studying the
inactivation of transgenes by RT-peR with lentivirus-specific primers (Figure 4.4) did not
show a reduction in transgene expression (data not shown), since the time-course iPSe
experiments were performed using whole-cell populations (section 5.2.7) which consisted of
reprogrammed cells as well as partially reprogrammed and non-reprogrammed ones. Future
experiments could, therefore, benefit from using drug-inducible iPSe vectors (Brambrink et
al. 2008; Stadtfeld et al. 2008b), to ensure their silencing upon removal of drug treatment.
Further controls should also be introduced to ensure that the phenotypes brought about
following treatment with shRNAs against DNMT1 and DNMT3A were not off-target effects of
the shRNAs due to imperfect base-pairing with miRNA seed sequences or with genomic
DNA (Sharp 2001). This could be performed by studying the effects of several shRNAs
against DNMT1 and 3A to show that the phenotypes were not specific to the shRNA
sequence but were due to degradation of their target mRNAs. To further rule out the
possibility of off-target effects, "genetic rescue" experiments could be performed where the
levels of DNMT1 or DNMT3A protein in knock-down samples would be restored by
functional protein, translated form a lentiviral or plasmid-inserted transgene carrying a silent
point-mutation that would escape base-pairing with shRNAs. Reversing/rescue of the knock-
down phenotype would verify that the effects observed it this thesis following treatment with
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shRNAs were specific to down-regulation of DNMT1 or DNMT3A protein and not due to off-
target effects of the shRNAs.
Finally, recent analysis of chromosome-wide DNA methylation patterns in iPSCs revealed
that although iPSCs and hESCs were clustered together based on their DNA methylation
signatures, iPSCs had slightly increased global DNA methylation at CpG sites compared to
hESCs (Deng et al. 2009). Moreover, imprinted genes such as H19, KCNQ10T1, PEG3,
GTL2 and IGF2 showed aberrant DNA methylation and allele-specific expression in iPSCs,
relative to the differentiated lines they were derived from (Pick et al. 2009). It would,
therefore, be of interest to investigate the epigenetic stability of iPSCs in the model system
generated in this study, to determine whether karyotype or culture-induced effects could
account for the differences observed by Deng et a/. (2009) and Pick et al. (2009) or whether
reprogramming by defined factors does affect epigenetic stability.
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6 GENERAL DISCUSSION
The aim of this thesis was to investigate the precise mechanisms by which key pluripotency-
associated transcription factors become activated or repressed in order to enable a change
in cell phenotype from a pluripotent to a fibroblast differentiated state, and vice-versa. In this
section, key findings from each chapter of this thesis are integrated and discussed in
relation to current literature, and new models for the regulation of key pluripotency-genes in
human cells are proposed. Also, methods for further investigation of these models are
described.
6.1 SINGLE-GENOTYPE HUMAN MODEL CELL SYSTEM
The epigenetic regulation of pluripotency-associated genes is poorly studied in human cells,
in contrast to mouse cells, where the mechanisms associated with the regulation of some
pluripotency-genes, e.g. Oct4, have been characterised in more detail (Figure 4.1; Feldman
et al. 2006; Epsztejn-Litman et al. 2008). However, differences in transcriptional profiles,
response to signalling molecules and chemical treatment (section 1.6) have shown that
mESCs might represent a different developmental stage to hESCs (Brons et al. 2007; Tesar
et al. 2007). These observations suggested that it was necessary to develop human models
for the investigation of gene-expression regulatory mechanisms involved in human
development and lineage specification. Also, differences between existing hESC lines, in
terms of the levels of pluripotency-gene expression and epigenetic characteristics that are
caused by genotype and culture-induced effects (reviewed by Allegrucci and Young 2007),
have suggested that these variables should be eliminated in order to avoid false
interpretation of experimental results when analysing gene regulatory mechanisms.
To reduce species or genotype and culture-induced variation, chapter 3 of this thesis
generated a single-genotype human model cell system, comprising of hESCs, iPSCs and
derived-fibroblasts. In this system, hESCs and iPSCs were cultured under similar conditions
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(feeder-free culture on Matrigel with MEF-conditioned medium and trypsin passaging;
Denning et al. 2006), and were differentiated using the standardised forced-aggregation
technique (Burridge et al. 2007). This approach enabled direct comparison between the
epigenetic characteristics of pluripotency-genes in the hESC and iPSC pluripotent states,
the hESC- and iPSC-fibroblast differentiated states, and the mechanisms employed by
hESCs and iPSCs induce differentiation. This strategy was advantageous to studies
comparing the epigenetic profiles of iPSCs, derived from patient fibroblasts, blood or
keratinocytes, to existing hESCs that have a different genotype to the iPSCs (Park et al.
2008a; Carey et al. 2009; Haase et al. 2009), and also to studies comparing the profiles of
iPSCs to the fibroblast lines they were derived from (Pick et al. 2009), without taking into
account that characteristics such as genomic imprinting can adopt tissue-specific DNA
methylation patterns (Moore et al. 1997; Okabe et al. 2003; Tsou et al. 2003). Through the
model cell system derived in this thesis, it emerged that iPSCs and hESCs have similar
DNA methylation profiles in key pluripotency-genes (Figure 4.11) and use the same DNA
methylation-associated mechanisms to transition to a fibroblast-differentiated state (Figure
4.16). Also, hESC and iPSC-fibroblasts reached similar DNA methylation states (Figure
4.11), showing that iPSCs can "circle" back to the same cell-phenotype they were derived
from. Findings from this thesis suggested that iPSCs serve as a good alternative model to
hESCs for the investigation of human pluripotency and associated gene-regulatory
mechanisms. However, to confirm these findings, further polyclonal or even clonal iPSC
lines generated form hESC-derived fibroblasts should be analysed, to ensure that
reprogramming consistently yields iPSCs with epigenetic characteristics similar to hESCs.
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6.2 PLURIPOTENCY-GENE EXPRESSION AND EPIGENETIC REGULATION
6.2.1 Temporal gene expression during differentiation and iPSe
formation
Repression/ silencing of the key piuripotency-associated transcription factors (TFs) can lead
to differentiation of pluripotent hESCs (section 1.3.3), while over-expression of the same
TFs can reprogram differentiated cells to a pluripotent ESC-like state (section 1.8.1).
Nevertheless, the temporal requirements of these transcription factors during differentiation
or reprogramming are poorly investigated in mouse or human cells, since most studies
focus on analysing gene expression in either the pluripotent or the differentiated cell states
(Adewumi et al. 2007). Very few studies have performed a time-course analysis of gene
expression during differentiation, and have focused on just 2-3 time-points (Dvash et al.
2004). To understand how the pluripotent phenotype becomes repressed or re-established
in human cells, a 2-day interval time-course analysis over a total of 16 or 18 days during
differentiation or iPSC-generation was performed in this thesis (Chapter 4).
Reactivation of the pluripotency-genes OCT4, NANOG, SOX2 and LlN28 was detected at
similar time-points (within 8-10 days) during fibroblast reprogramming to iPSCs, perhaps
due to the use of RT-PCR primers with dissimilar efficiencies (Figure 4.18). On the other
hand, TaqMan real-time PCR analysis during differentiation revealed that pluripotency-
genes became repressed at distinct time-points (Figure 4.14). NANOG was the first gene to
become repressed. Previous studies have shown that Nanog has a role in stabilising
pluripotency in mESCs (Chambers et al. 2007) and hESCs (Darr et al. 2006), therefore
supporting the observations from this thesis that NANOG down-regulation is important to
destabilise the pluripotent state and enable a transition in cell phenotype. Other genes, such
as DNMT3B, OCT4, SOX2, REX1 and LlN28 showed initial up-regulation during
differentiation; either due to a paracrine effect caused by EB formation, or because they
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were necessary to initiate differentiation towards certain lineages (Rodriguez et al. 2007;
Zappone et al. 2000). Earlier down-regulation of ONMT3B relative to OCT4 (Figure 4.14)
suggests that this de novo DNMT might not be involved in OCT 4 methylation during
differentiation of hESCs, in contrast to mESCs where Oct4 repression is associated with
Dnmt3b-catalysed DNA methylation (Biniszkiewicz et al. 2002; Chen et al. 2003). This
observation points towards distinct gene-regulatory mechanisms between mouse and
human cells. Down-regulation of pluripotency factors during differentiation is proposed to
follow a defined hierarchical pattern, based on the requirement of each factor in pluripotency
and lineage specification.
6.2.2 Regulation by DNA methylation
The exact mechanisms of how pluripotency-associated transcription factors become
activated or repressed are poorly understood, and are scarcely studied in human cells. This
thesis aimed at extending our understanding of these mechanisms and providing novel
information about how the pluripotent state is activated or repressed in human cells.
Chapter 4 of this thesis showed that the master pluripotency regulators OCT4, SOX2 and
NANOG had differential DNA methylation between pluripotent and fibroblast differentiated
cell lines in their OCT/SOX binding regions (Figure 4.11), suggesting a common regulatory
mechanism between them. This was also the first report for SOX2 differential methylation in
human non-cancerous cells, since other studies have reported that SOX2 was unmethylated
following hESC differentiation (Yeo et al. 2007). OCT/SOX binding sites are found in several
developmental-regulators (Sharov and Ko 2009) and are believed to have a significant role
in the auto-regulatory circuits of Oct4 and in the regulation of other pluripotency genes, such
as Fbx15 and Fgf4 (Okumura-Nakanishi et al. 2005). This study has shown that the
OCT/SOX binding site might also be involved in SOX2 auto-regulation. Identification and
epigenetic characterisation of this binding motif in further pluripotency-regulators could
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reveal further information about the significance of OCT/SOX motifs in developmental
processes.
In this thesis, NANOG, OCT4 and REX1 DNA methylation gradually increased during
differentiation of hESCs and iPSCs, and was associated closely with gene down-regulation
during differentiation (Figure 4.23). This observation showed that expression of NANOG,
OCT4 and REX1 was initiated by DNA methylation, a finding that comes in contrast to
studies from mESCs showing that Oct4 and Rex1 down-regulation is initiated by histone
modifications that are catalysed by the G9a histone methyltransferase (Feldman et al.
2006). Increase in SOX2 DNA methylation during differentiation was delayed relative to
gene down-regulation, suggesting that transcriptional repression was initiated by other
mechanisms (e.g. histone modifications or TF binding) and was possibly stabilised by DNA
methylation at later time-points, in a manner similar to the regulation of Oct4 in mESCs
(Epsztejn-Litman et al. 2008). Therefore, this thesis has highlighted that epigenetic
regulation of pluripotency-factors adopts gene-specific patterns in human cells, which are
likely to be distinct to the regulatory patterns of each gene in mouse cells.
6.2.3 Proposed model for the transcriptional regulation of pluripotency-
associated genes
Through this thesis, NANOG, OCT4 and REX1 expression has been inversely associated to
DNA methylation, which appears to initiate gene down-regulation during differentiation
(Figure 4.23). Improved NANOG reactivation during reprogramming of HUES7-Fib with
DNMT3A KD suggests that DNA methylation is a "dominant" silencing mechanism for this
gene, and might act by directly inhibiting TF binding to the NANOG promoter (Vaissiere et
al. 2008; Figure 1.7.8). Even though histone modifications are associated with the NANOG
gene (Figure 4.13) these might have a "secondary" role to DNA methylation. OCT4 down-
regulation could be initiated by DNA methylation during differentiation, but this gene showed
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no change in reactivation timing during reprogramming of HUES?-Fib with DNMT3A KO.
This suggests that OCT4 is regulated by additional mechanisms, e.g. repressive histone or
chromatin modifications that occur after DNA methylation has taken place (Figure 6.1).
SOX2 expression also showed no change in reactivation timing in cells with DNMT3A KO,
but in contrast to OCT4, down-regulation of SOX2 during differentiation was not initiated by
DNA methylation. This suggests that histone modification events (and possibly chromatin
remodelling) take place prior to DNA methylation in regulatory regions of this gene. REX1
showed initial up-regulation during differentiation and transcriptional repression coincided
with DNA hyper-methylation, showing that this gene could be regulated by mechanisms
similar to OCT4. ONMT3L, which was detected at earlier time-points during reprogramming
of DNMT3A KO HUES? -Fib could be regulated with similar mechanisms to NANOG, even
though further investigation regarding the methylation of ONMT3L during differentiation
should be carried out.
NANOG
DNMT3L? DNA
methylation
hES(s/iPS(s
OCT4
REX1? FibroblastsDNA
methylation
Histone modifications,
chromatin remodelling
SOX2
Histone modifications,
chromatin remodelling
DNA
methylation
LlN28
~~~~ DNA methylation inr factor X
Figure 6.1- Proposed models of the epigenetic regulation of pluripotency-genes in human cells
NANOG repression could be dominantly: regulated by DNMT3A-catalysed DNA methylation, whereas 0(T4
repression could be initiated by DNA methylation and further stabilised by histone and chromatin
modifications ..SOX2 repression is likely to be initiated by histone and/or chromatin modifications and stably
silenced by DNA methylation. Expression of LlN28 could be responsive to DNA methylation of "secondary"
transcription factors that in turn regulate LlN28 expression.
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6.2.4 Regulation by histone modifications
In chapter 4, the activating histone marks H3K9Ac and K3K4me3 were associated with
transcriptionally active OCT4, NANOG, SOX2 and REX1, while the silencing histone marks
H3K27me3 and H3K9me2 were associated with repressed transcriptional activity, in
agreement to data previously available from mouse or hEC studies (Barrand and Collas
2009). However, the timing when these events occurred during differentiation or
reprogramming has not been identified so far. Further analysis of histone modifications
associated with key pluripotency-genes is in progress and can reveal the precise
involvement of H3K9Ac, H3K4me3, H3K9me2 and H3K27me3 in the transition of cell
phenotype from a pluripotent to a fibroblast-differentiated state, and vice-versa.
To confirm these findings, enzymes responsible for catalysing these histone modifications
could also be targeted for knock-down or over-expression, in order to establish a direct link
between histone modifications and gene expression. Enzymes that could be targeted for
knock-down include the polycomb group (PcG) members SUZ12, EED and EZH2, which
catalyse the repressive histone mark H3K27me3, as well as the G9a methyltransferase that
catalyses H3K9me2 (reviewed by Kouzarides 2007). Over-expression studies could target
enzymes of the Trithorax group, which catalyse H3K4me3 methylation, or the HAT enzymes
p300, Tip60/p400 and GCN5 that are responsible for histone acetylation, an activating mark
associated with the promoters of OCT4, NANOG and SOX2 in hECs (Table 4.1-Table 4.3).
In addition to genetic modification experiments, investigation of the epigenetic
characteristics associated with pluripotency genes during cell-phenotype transition could
benefit from ChiP analysis, studying the association of enzymes of the epigenetic machinery
with pluripotency-factor regulatory regions. Together, this information would generate an
epigenetic "map" of the enzymes and types of modifications associated with pluripotency-
gene promoters, and indicate how these modifications affect pluripotency-gene expression
and cell phenotype.
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6.2.5 Regulation by chromatin remodelling enzymes
Chromatin remodelling (mobilising or displacing of nucleosomes) can also have important
consequences on transcriptional activity (see sections 1.5.1), and has been shown to act in
concert with histone modifications and TFs to regulate cell phenotype (Bonifer et al. 2008).
Chromatin remodelling enzymes, such as esBAF and Chd1, associate with Oct4, Sox2 and
Nanog in mESCs (Chen et al. 2008a; Ho et al. 2009a) and are thought to be necessary for
the maintenance of pluripotency and self-renewal (Gao et al. 2008; Van et al. 2008; Ho et al.
2009b). Moreover, Chd1 expression was found to be necessary for the formation of iPSCs
from MEFs (Gaspar-Maia et al. 2009). In effect, chromatin remodelling enzymes could also
be targeted for genetic modification, in order to test whether they could enhance the
reactivation of endogenous pluripotency genes during reprogramming and improve the
efficiency of iPSC generation, but also provide further insight into the precise molecular
mechanisms of cell phenotype determination.
6.2.6 Regulation by small molecules
Over-expression of pluripotency-associated TFs for the reprogramming of somatic cells to
iPSCs involves genetic modification of target cells, which often introduces the risk of
insertional mutagenesis due to integration of vector DNA into the host-genome (section
3.1.3; Scheper and Copray 2009). Other than generating non-integrating or excisable
vectors for the over-expression of exogenous TFs (Table 3.2), a number of efforts have
been made to completely eliminate the need for transgene over-expression by substituting
transgenes with small molecules. High content chemical screening has identified that iPSCs
can be generated when Sox2 and c-Myc transgenes are replaced by small molecules that
inhibit Tgf-[3 signalling (Ichida et al. 2009; Maherali and Hochedlinger 2009), whereas Klf4
could be replaced by the small molecule, kenpaullone, which stimulates Nanog expression
(Lyssiotis et al. 2009).
241
PhD Thesis
Elena Matsa
School of Clinical Sciences
The University of Nottingham
Chapter 6- General discussion
Further investigation into eliminating the need for transgene over-expression to generate
iPSCs could focus on the use of small molecules that affect the epigenetic characteristics
associated with key pluripotency-genes. Treating differentiated cells with small compounds
that alter epigenetic modifications has already been shown to increase the efficiency of
iPSC-generation (reviewed by Li and Ding 2009). However, most compounds tested to date
have a broad specificity and provide little information about the specific mechanisms of
iPSC generation. Future experiments could, therefore, use high content chemical screening
to investigate the effect of yet untested small molecules that target specific epigenetic
modifications (Table 6.1).
Small molecule screening is now amenable to investigation within our lab which was
recently equipped with a new robotic culture system (TECAN; Freedom Evo® 2000) that
can accommodate large-scale screening of chemical libraries. A collaboration has been
established between our lab and Dr. Tapas Kundu (Jawaharlal Nehru Centre for Advanced
Scientific Research, India) whose lab specialises in deriving and derivatising small
molecules from natural sources. Some of these molecules have been demonstrated to
possess histone modification abilities. For example, Sanguinarine, a plant root extract, has
been shown to specifically inhibit H3K4 and R17 methylation in vivo (Selvi et al. 2009b).
Equally, the compound TBBD, can inhibit CARM1-mediated H3R17 methylation (Selvi et al.
2009a) which has been detected at elevated levels in the Oct4 and Sox2 promoters of
mESCs (Wu et al. 2009a). Further small compounds that have the potential to affect cell
phenotype or iPSC generation are summarised in Table 6.1. Using new technologies and
effective collaborations can enable the identification of new small molecules that are able to
improve the formation of iPSCs or potentially alleviate the need for lentiviral transgenes
altogether, by facilitating activation of endogenous piuri potency-factors for the generation of
iPSCs.
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Table 6.1- Small molecules that have the potential to improve iPSegeneration
Compound Cell type Function References
Anacardic acid - p300 HAT & p300-CBP associated factor (PCAF) inhibitor
CTBP Balasubramanyam
(Anacardic acid - p300 HAT activator etal.2003
amide derivative)
Garcinol HeLa cells p300 HAT & PCAF inhibitor, with preference to p300 Balasubramanyam
- Prevents acetylation of p53 etal.2004
Curcumin
p300-CREB binding Causes 15-20% global DNA
Leukaemia cells protein (CBP) inhibitor hypo-methylation in MV4-11 Liu et al. 2009(MV4-11)
cells
LTK-13, 14 & 19 p300 inhibitors. Induce 70-80% de-acetylation in HeLa
HeLa cells cells, and up to 100% de-acetylation when used in Mantelingu et al.(Garcinol
Tcells combination with TSA or NaBu (HDAC inhibitors), and iG 2007
derivatives} (HAT inhibitor)
TBBD
HEK293T inhibits CARMi-mediated H3R17 methylation Selvi et al. 2009a(ellagic acid)
Panobinostat
Human acute HDAC inhibitor, can deplete the histone methyltransferase
Fiskus et al. 2009
leukaemia Ezh2
Rat liver, HeLa
intercalates with DNA and chromatin, causes chromatin
Sanguinarine aggregation, inhibits G9a-mediated H3K9me in vitro, and Selvi et al. 2009b
cells
histone acetylation, H3K4me and H3R17me in vivo
6.3 FINAL REMARKS
"Ground-state" pluripotency, i.e. the ability of ESCs to self-renew in an uncommitted state
and form all lineages in an adult organism when prompted by developmental signals or cell
culture environment (Smith 2009), depends on complex TF networks and epigenetic
modifications that are thought to be under transcription-factor regulation (Niwa 2007).
Findings from this thesis (summarised in Figure 6.2) have also shown that pluripotency-
regulating TFs are themselves controlled by epigenetic modifications, therefore showing that
transcription-factor and epigenetic regulation of gene expression are equally significant for
the determination of cell-phenotype.
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Differentiation
hESC
~ DNA methylation
~ H3K27me3 & H3K9me2
t H3K9Ac & H3K4me3
iPS
~ DNA methylation
~ H3K27me3 & H3K9me2
t H3K9Ac & H3K4me3 Differentiation
hESC-Fibroblasts
t DNA methylation
t H3K27me3 & H3K9me2
~ H3K9Ac & H3K4me3
iPS-Fibroblasts
t DNA methylation
Figure 6.2- Summary of thesis outcomes
Generation of model system comprising of hESCs, iPSCs, and derived fibroblasts, enabled unbiased
characterisation of pluripotency gene expression and epigenetic regulation
Studying the intermolecular gene-specific interactions that are at the heart of cell phenotype
transitions is important for understanding the complex processes of human development
and somatic cell reprogramming. Continued in-depth analysis of individual gene-regulation,
investigation of transcription-regulatory trends, as well as the search for new small
molecules that can regulate gene expression are all necessary to unravel such interactions.
This thesis has investigated the transition of cell phenotype form a pluripotent to a fibroblast
differentiated state in human cells, focusing on the epigenetic regulation of transcription
factors that enable phenotype changes. Through this investigation, new gene-specific
interactions have emerged which increase our understanding of transcriptional gene control
and provide the foundation for further improving reprogramming efficiency.
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Millipore (UK.) Ltd. httj;1:LLwww.millij;1ore.com
Nalge Nunc International httj;1:LLwww.nuncbrand.com
NanoDrop Technologies httj;1:LLwww.nanodroQ.com
New England Biolabs (UK), ltd. httj;1:LLwww.neb.uk.com
Nikon Ltd. httj;1:LLwww.euroj;1e-nikon.com
Promega UK Ltd httQ:LLwww.j;1romega.com
Qiagen, ltd. httj;1:LLwww .giagen .com
R&D Systems, Inc. httj;1:LLwww.rnds~stems.com
Raytek Scientific (UK), ltd. httj;1:LLwww.ra~tek.co.uk
Roche Diagnostics ltd. httj;1:LLwww.rocheuk.com
Santa Cruz Biotechnology, Inc. httj;1:LLwww .scbt.com
Sarstedt Ltd httj;1:LLwww.sarstedt.com
Sartorius (UK), ltd. httj;1:LLwww.sartorius.co.uk
Scientific Laboratory Supplies, Ltd. httj;1:LLwww.scientificlabs.eu
Sigma-Aldrich / Sigma-Genosys ltd. httQ:LLwww.sigmaaldrich.com
Thermo Electron Corporation httj;1Ilsac«. thermo.com
Vector Laboratories, ltd. httj;1:LLwww.vectorlabs.com
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Appendix IU- NANOG TaqMan Assay design
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Appendix IV-Statistical analysis
ApPENDIX IV - STATISTICAL ANALYSIS
Statistical analysis of non-parametric independent variables
Ho= Samples are drawn from independent populations with equal medians
Ha= Samples are drawn from independent populations with non-equal medians
Significance level = 0.05
CHAPTER4
Gene expression analysis by real-time PCR in the HUES7 and HOGN model systems
OCT4
Grouping Variable Sample Median Mean Standard error Probability Ho
value (p)
HUES7-Fib 25.9094 25.9094 1.35933 0.045500 R~ect
HUES7 HUES7-iPS 9.485979 9.400016 0.95263 0.423340 AccE!gt
Median= 9.287 HUES7-iPS Fib 18.39372 18.35008 0.78882 0.003948 RejectHUES7-Fib CI4 - - 0.002093 ReiectMean= 8.9678 -SUKE-Fib 28.8497 29.29636 1.052333 0.020137 RejectSt. error= 0.78481
BJ-Fib 27.06157 27.07187 0.639558 0.003948 Reiect
HOGN HOGN-Fib 24.37291 24.36013 0.2772017 0.003579 Reject
Median= 6.9618 HOGN-iPS 9.058858 8.923901 0.289626 0.023471 Reject
Mean= 7.5049
HOGN-iPS Fib 16.91208 17.21931 0.3117006 0.003579 RejectSt. error= 0.2772
NANOG
Grouping Variable Sample Median Mean Standard error Probability Ho
value (p)
HUES7-Fib 27.34122 27.02458 0.3736502 0.003948 Reject
HUES7 HUES7-iPS 14.23995 14.185 0.2848353 0.037373 Reject
HUES7-iPS Fib 15.01702 14.96467 0.2811683 0.200185 AccE!gtMedian= 15.453 HUES7-Fib CI4 27.23021 27.09966 0.3639324 0.003948 RejectMean= 15.4249 SUKE-Fib 25.42235 25.60737 0.2999439 0.003948 RejectSt. error= 0.37365
BJ-Fib 24.44486 24.23281 0.35131 0.003948 R~ect
HOGN HOGN-Fib 26.29628 26.61872 0.3388385 0.003948 Reject
Median= 15.921 HOGN-iPS 16.40458 16.33193 0.3335624 0.200185 Accept
Mean= 15.893
HOGN-iPS Fib 18.03669 18.15962 0.2882671 0.003948 RejectSt. error= 0.33884
SOX2
Grouping Variable Sample Median Mean Standard error Probability Ho
value (p)
HUES7-Fib 24.24765 24.07612 0.3285909 0.003948 RejectHUES7 HUES7-iPS 13.2709 13.29087 0.2064237 0.003948 Reject
HUES7-iPS Fib 17.14607 17.17515 0.171713 0.003948 Rej_ectMedian= 11.34035 HUES7-Fib CI4 24.86983 24.67653 0.3663152 0.003948 RejectMean= 11.38277 SUKE-Fib 22.61161 22.72109 0.4417535 0.003948 RejectSt. error= 0.32859
BJ-Fib 22.14886 22.08077 0.2706956 0.003948 Reiect
HOGN HOGN-Fib 21.55057 21.68957 0.2539824 0.003948 . Reject
Median= 11.2691 HOGN-iPS 12.35315 12.39261 0.1923115 0.003948 Reject
Mean= 11.19226
HOGN-iPS Fib 19.32827 19.47639 0.1847141 0.003948 RejectSt. error= 0.25398
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LlN28
Grouping Variable Sample Median Mean Standard error
Probability
Ho
value (p)
.. HUES7-Fib 25.37381 24.71629 0.4781346 0.006170 Reject
HUES7 HUES7-iPS 10.79433 10.81079 0.4113156 0.149541 Acce_f)t
HUES7-iPS Fib 18.48386 18.78631 0.4103148 0.003948 Reject
Median= 10.19753 HUES7-Fib CI4 24.97948 24.81719 0.4049484 0.003948 RejectMean= 10.18498 SUKE-Fib 22.24881 22.40644 0.5156769 0.003948 RejectSt. error= 0.436475
BJ-Fib 22.11683 22.1397 0.3208649 0.003948 Reject
HOGN HOGN-Fib 24.07357 24.0327 0.478122 0.003948 Reject
Median=10.41708 HOGN-iPS 10.36568 10.34997 0.3806755 0.630954 Accept
Mean=10.41699
HOGN-iPS Fib 18.00882 17.96105 0.3451578 0.003948 RejectSt. error= 0.478122
KLF4
Grouping Variable Sample Median Mean Standard error Probability Ho
value (p)
HUES7-Fib 24.43035 24.4866 0.1681287 0.149541 Acc~_t
HUES7 HUES7-iPS 26.18638 26.29413 0.0098057 0.003948 RE&ect
HUES7-iPS Fib 25.7019 25.7652 0.0087272 0.003948 RejectMedian=24.8657 HUES7-Fib CI4 26.71874 26.74418 0.0069024 0.003948 RejectMean=24.86371 SUKE-Fib 24.27029 24.25252 0.2276703 0.262332 Acc~tSt. error= 0.168128
BJ-Fib 23.36864 23.61779 0.2175693 0.003948 RE&ect
HOGN HOGN-Fib 28.42579 28.4423 0.1200987 0.003948 Reject
Median=25.47297 HOGN-iPS 26.02183 25.98255 0.1579745 0.037373 Reject
Mean=25.36978
HOGN-iPS Fib 25.56286 25.62783 0.1314173 0.336668 AcceptSt. error= 0.1287607
REX1
Grouping Variable Sample Median Mean Standard error Probability Ho
value (p)
HUES7-Fib 27.61343 27.61343 0.1586892 0.045500 Reject
HUES7 HUES7-iPS 23.54689 23.55304 0.139509 0.003948 RE&ect
Median=13.54009
HUES7-iPS Fib 26.11933 25.98291 0.3496676 0.006170 Reject
HUES7-Fib CI4 - -
- 0.002093 RejectMean=13.56946 SUKE-Fib - 0.002093 RejectSt. error= 0.1287607 - -BJ-Fib - -
- 0.002093 Reject
HOGN HOGN-Fib 22.26485 22.37518 0.1227456 0.003948 Reject
Median=13.18482 HOGN-iPS 14.81171 14.83772 0.0971701 0.003948 Reject
Mean=13.22766
HOGN-iPS Fib 23.31185 23.5101 0.2267205 0.003948 RejectSt. error= 0.122745
DNMT3B
Grouping Variable Sample Median Mean Standard error Probability Ho
value (p)
HUES7-Fib 23.85983 23.71037 0.7701713 0.003948 Reject
HUES7 HUES7-iPS 16.97787 17.00202 0.8062362 0.149541 Acc~t
HUES7-iPS Fib 23.94463 23.94288 0.7421852 0.003948 Reject
Median=15.4259 HUES7-Fib CI4 25.13584 25.19358 0.7318104 0.003948 • Reject
Mean=15.41022 SUKE-Fib 24.92129 24.91646 0.8540214 0.003948 RejectSt. error= 0.770171
BJ-Fib 25.23142 25.25573 0.8369006 0.003948 RE&ect
HOGN HOGN-Fib 24.93937 24.94041 0.1287607 0.003948 Reject
-
Median=14.92297 HOGN-iPS 15.88525 16.00218 0.7013581 0.149541 Accept
Mean=14.81762
HOGN-iPS Fib 21.70299 21.9302 0.7164029 0.003948 RejectSt. error=0.1287607
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P4HB
Grouping Variable Sample Median Mean Standard error
Probability Ho
value (p)
.. HUES7-Fib 16.80164 16.98019 0.1532458 0.003948 Reiect
HUES7 HUES7-iPS 19.63215 19.63598 0.0087511 0.006485 Reject
Median=19.061 HUES7-iPS Fib 17.52477 17.55824 0.1036741
0.003948 Reiect
HUES7-Fib CI4 16.68957 16.64437 0.1662038 0.003948 ReiectMean=19.09332 SUKE-Fib 17.38194 17.36285 0.0080103 0.003948 RejectSt. error=O .1532458
BJ-Fib 17.13778 17.10863 0.144398 0.003948 Reject
HOGN HOGN-Fib 16.56254 16.53767 0.2435509 0.003948 Reject
Median=17.65896 HOGN-iPS 17.95757 17.92071 0.1983235 0.630954 Accept
Mean=17.95032
HOGN-iPS Fib 17.2525St. error=0.243551 17.43817 0.2352213 0.037373 Reject
Box plots
OCT4 real-time PCR NANOG real-time PCR
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KLF4 real-time PCR
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DNMT3B real-time PCR
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CHAPTER 5
DNMT1 siRNA test at 24hpost-transduction (PTF)
REX1 real-time PCR
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P4HB real-time PCR
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Grouping Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 6.0635 6.05175 0.1247545 0.056747 Accept
shRNA 859 8.4775 8.516417 0.2346606 0.000032 Reject
Median=5.76 shRNA 860 6.947 6.8985 0.1102086 0.000041 Reject
Mean=5.693 shRNA 861 6.4645 6.614417 0.1471693 0.000999 Reject
St. error= 0.1287607 All shRNAs 6.2145 6.398334 0.1820952 0.008730 Reiect
shRNA 860 - - - 0.000053 Reject
-
shRNA 859 shRNA 861 - - - 0.000110 Reject
All shRNAs - - - 0.000747 Reject
shRNA 861 - - - 0.148915 Accept
shRNA 860 All shRNAs . - - - 0.039352 Reject
shRNA 861 All shRNAs - - - 0.453695 Accept
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DNMT1 siRNA test at 48h PTF
Grouping Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 5.609 5.797417 0.2672046 0.423656 Accept
shRNA 859 7.014 7.146 0.1998039 0.000268 Reject
Median= 5.091 shRNA 860 7.0145 7.048 0.2889399 0.003101 Reject
Mean= 5.429273 shRNA 861 6.83 6.807909 0.2187273 0.001152 Reject
St. error=0.279086 All shRNAs 7.6375 7.649167 0.2928873 0.000911 Reject
shRNA 860 - - - 0.622065 Acceot
shRNA 859 shRNA 861 - - - 0.278599 Accept
All shRNAs - - - 0.056188 Acceot
shRNA 860
shRNA 861 - - - 0.526237 Acceot
All shRNAs - - - 0.232823 Accept
shRNA 861 All shRNAs - - - 0.015861 Reject
DNMT1 siRNA test at 72h PTF
Grouping Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 5.225 5.883364 0.2535849 1.000000 Acceot
shRNA 859 6.98 7.031727 0.1752014 0.000357 Reject
Median= 5.758 shRNA 860 7.676 7.858182 0.3121224 0.000451 Reject
Mean= 5.79875 shRNA 861 7.367 7.343 0.2422117 0.001314 Reject
St. error= 0.242789 All shRNAs 8.4425 8.5745 0.280653 0.000747 Reject
shRNA 860 - - - 0.094041 Acceot
shRNA 859 shRNA 861 - - - 0.257354 Acceot
All shRNAs - - - 0.000911 Reject
shRNA 861 - - - 0.496757 Acceot
shRNA 860 All shRNAs - - 0.087532 Acceot-
shRNA 861 All shRNAs - - - 0.004222 Reject
Box plots
DNMT1 siRNA knock-down 24h DNMT1 siRNA knock-down 48h DNMT1 ·siRNA knock-down 72h
10.0 10.0 10.0
NV NT shRNA shRNA shRN,Il All
shRNA 859 860 861 shRNAs
NV NT shRNA shRNA shRN.e All
shRNA 859 860 861 shRNAs
NV NT shRNA shRNA shRNP All
shRNA 8S9 860 861 shRNAs
DNMT1 shRNA test in HUES7
Groupmg Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 1.376 1.402333 0.0841117 0.033895 Reject
Median= 0.9905 shRNA 859 2.276 2.3185 0.0087617 0.020921 Reject
Mean= 0.9485
1.3255 1.34075St. error= 0.0072842 shRNA 860 0.00677808 0.020921 Reject
shRNA 859 shRNA 860 - - - 0.019419 Reject
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ONMT1 shRNA test in HUES7-Fib
Grouping Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 1.7005 1.737 0.0055471 0.083265 Accept
Median= 1.931 shRNA 859 4.1895 4.2745 0.1335636 0.020921 Reject
Mean= 1.89525
St. error=0.005547 shRNA 860 2.626 2.5864 0.103667 0.014306 Reject
shRNA 859 shRNA 860 - - - 0.014306 Reject
Box plots
DNMT1 shRNA test HUES7 DNMT1 shRNA test HUES7-Fib
3.0 5.0
B Q
2.2 3.8
l- I-
0 0
"0 "0
1.3 g g 2.7
EJ cd ~
0.5 1.5
NV NT shRNA shRNA NV NT shRNA shRNA
shRNA 859 860 shRNA 859 860
Average population doubling time in HUES7
Grouping Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 2.489505 2.511947 0.1520136 1.000000 Accept
Median= 410
Mean= 418 01 KO 2.428959 2.339822 0.1646778 0.630954 AcceptSt. error= 0.038016
Average population doubling time in HUES7-Fib
Grouping Variable Sample Median Mean
Standard Probability value Ho
error (p)
NT NV 2.405848 2.437545 0.0079298 0.003948 Reject
Median= 2.004158
Mean= 1.969445 01 KO 2.111518 2.13713 0.00497418 0.077648 Accept
St. error= 0.007929
Box plots
Population doubling time HUES7 Population doubling time HUES7-Fib
3.2 3.0
C> C> 8.S .S:n z::J ::J0 2.7 0 2.5"0 "0C C0 ~-~"S "S Qc. c.8. 8.
Q) 2.1 Q) 2.1 ttC> C>~ ~Q) Q)> >« «
1.6 1.6
NV NT DNMTl NV NT DNMTl
shRNA shRNA shRNA shRNA
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ONMT1 knock-down over 5 passages in HUES7
Grouping Variable Sample Median Mean Standard Probability value Ho
error (p)
St. pop. 0.7524986 0.7269503 0.1127842 0.297107 Accept
NV 0.5061256 0.5117769 0.0807753 0.052197 Accept
NT2ml
01 p1 1.443258 1.377888 0.00897538 0.010515 Reject
Median= 0.9775534 01 p2 1.398708 1.394572 0.0079868 0.010515 Reject
Mean= 0.9025109 01 p3 1.346822 1.346822 0.0760126 0.010051 RejectSt. error= 0.0065212
01 p4 1.385432 1.385432 0.0075321 0.010051 Reject
01 p5 1.565179 1.546698 0.0069649 0.003948 Reject
ONMT1 knock-down over 5 passages in HUES7-Fib
Grouping Variable Sample Median Mean Standard Probability value Ho
error (p)
St. pop. 1.029093 0.9792709 0.0074206 0.055009 Accept
NV 0.7233315 0.9655633 0.1925243 1.000000 Accept
NT2ml 01 p1 1.567257 1.589732 0.0648887 0.010515 Reject
Median= 0.7381144 01 p2 1.71836 1.712582 0.0064423 0.010515 Reject
Mean= 0.7241271 01 p3 1.615713 1.812445 0.1687236 0.010515 RejectSt. error= 0.006059
01 p4 1.465883 1.502467 0.108835 0.010515 Reject
01 p5 1.445227 1.505657 0.008432 0.020137 Reject
Box plots
ONMT1 KO over 5 passages in HUES7 ONMT1 KO over 5 passages in HUES7
2.0 3.0
1.3 2.2
l-
o
"0
1.3
~
0.5
St. NV NT 01 01 01 01 01
pop pS pS pi p2 p3 p4. pS
St. NV NT 01 01 01 01 01
pop pS pS pI p2 p3 p4 pS
EB diameter on day 4 of differentiation
Grouping Variable Sample Median Mean Standard Probability value Hoerror (p)
NT
NV . 460 459.25 3.801618 0.000000 Reject
Median= 410
Mean= 418 01 KO 402.5 404.25 3.766848 0.091576 AcceptSt. error= 3.801618
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EB diameter on day 8 of differentiation
Grouping Vanable Sample Median Mean Standard
Probability value Ho
error (p)
NT
NV 410 412.25 7.062107 0.000023 Reject
Median= 350
Mean= 359 01 KO 357.5 355 7.387756 0.978155 AcceptSt. error= 7.062107
Box plots
EB diameter on d4 of differentiation EB diameter on d8 of differentiation
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ONMT3A siRNA test at 24h PTF
Grouping Variable Sample Median Mean Standard error Probability value Ho(p)
NT NV -1.0115 -1.0521 0.0745837 0.597843 Accept
shRNA 868 1.2505 1.3244 7.421379E-02 0.000076 Reject
Median=-1.1485 shRNA 869 1.291 1.329455 7.810625E-02 0.000049 Reject
Mean=-1.064583 shRNA 870 2.041 2.118818 8.583843E-02 0.000049 Reject
St. error= 0.0680853 All shRNAs 2.2465 2.2105 6.620421 E-02 0.000076 Reject
shRNA 869 - -
- 0.888000 Accept
shRNA 868 shRNA 870 - - - 0.000190 Reject
All shRNAs - - - 0.000157 Reject
shRNA 870 - -
- 0.000268 Reject
shRNA 869 All shRNAs - - 0.000108 Reject-
shRNA 870 All shRNAs - - - 0.481321 Accept
ONMT3A siRNA test at 48h PTF
Grouping Variable Sample Median Mean Standard error Probability value Ho(p)
NT NV -1.133 -1.119 5.234634E-02 0.969698 . Accept
shRNA 868 0.957 1.012727 4.870956E-02 0.000071 Reject
Median= -1.088 shRNA 869 1.302 1.260333 9.760004E-02 0.000169 Reject
Mean= -1.160364 shRNA 870 0.981 1.152182 9.840492E-02 0.000071 Reject
St. error= 0.004.7349 All shRNAs 1.667 1.792556 9.189751E-02 0.000169 Reject
shRNA 869 - - - 0.119361 Accept
shRNA 868 shRNA 870 - - - 0.669509 Accept
All shRNAs - - - 0.000169 Reject
shRNA 870 - - - 0.425031 Accept
shRNA 869 All shRNAs - - 0.019283 Reject-
shRNA 870 All shRNAs - - - 0.004385 Reject
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Appendix IV~Statistical analysis
DNMT3A siRNA test at 72h PTF
Grouping Variable Sample Median Mean Standard Probability value Ho
error (p)
NT NV -0.985 -1.1177 0.1468274 0.858955 Accept
shRNA 868 0.617 0.5790909 0.1171494 0.000280 Reject
Median= -1.1035 shRNA 869 0.3635 0.337875 0.1686702 0.000778 Reject
Mean= -1.2195 shRNA 870 0.642 0.479 0.1655051 0.001194 Reject
St. error= 0.164158 All shRNAs 0.417 0.44975 0.834625 0.000778 Reject
shRNA 869 - - - 0.247676 Accept
shRNA 868 shRNA 870 - - - 0.683604 Accept
All shRNAs - - - 0.408961 Accept
shRNA 869 shRNA 870 - - - 0.487453 AcceptAll shRNAs - - - 0.674424 Accept
shRNA 870 All shRNAs - - - 1.000000 Accept
Box Plots
DNMT3A siRNA knock-down 24h DNMT3A siRNA knock-down 48h DNMT3A siRNA knock-down 72h
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DNMT3A shRNA test HUES7
Grouping Variable Sample Median Mean Standard Probability value Ho
error (p)
NT NV -1.175342 -1.206225 0.0030582 0.067264 Accept
Median= -1.304644 shRNA 868 -0.1801643 -0.176369 0.0194891 0.006054 Reject
Mean= -1.318359
St. error= 0.003350 shRNA 870 -1.214071 -1.22894 0.0044583 0.220671 Accept
shRNA 868 shRNA 870 - - - 0.033895 Reject
DNMT3A shRNA test HUES7-Flb
Grouping Variable Sample Median Mean Standard Probability value Ho
error (p)
NT NV 1.759946 1.747541 0.0057709 0.563703 Accept
Median= 1.686086 shRNA 868 2.250748 2.219598 0.0371056 0.033895 Reject
Mean= 1.703564
St. error= 0.0321344 shRNA 870 2.156113 2.138145 0.0037232 0.033895 Reject
shRNA 868 shRNA 870 - - - 0.275234 Accept
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Appendix IV~ Statistical analysis
Box plots
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0.0
====
-0.5
I-
0
'0
-1.1
U e
-1.6
NV NT shRNA shRNA
shRNA 868 870
DNMT3A shRNA test HUES?-Fib
2.4
UEJ
21
I-
o
'0
1.7
1.4 +---~-~-----.---~---,
NV NT shRNA
shRNA 868
shRNA
870
iPS colony counts during reprogramming of HUES7-Fib with ONMT1 and ONMT3A knock-down
Grouping Variable Sample Median Mean Standard Probability value Ho
error (p)
NV 0 0 0 0.013874 RejectNT NV-iPS 70.5 72.75 3.010399 0.663117 Accept
Median= 72 01 KO 46 44 5.988705 0.020921 RE&ect3AKO 134.5 133.25 4.793659 0.020921 RejectMean= 73.25
01 & 3ASt. error= 1.692508
KO 55.5 73.25 3.039668 0.020165 Reject
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